STATUS EPILEPTICUS
STATUS EPILEPTICUS: MECHANISMS AND MANAGEMENT edited by Claude G. Wasterlain and David M. Treiman
THE MIT PRESS CAMBRIGE, MASSACHUSETTS LONDON, ENGLAND
© 2006 Massachusetts Institute of Technology All rights reserved. No part of this book may be reproduced in any form by any electronic or mechanical means (including photocopying, recording, or information storage and retrieval) without permission in writing from the publisher. MIT Press books may be purchased at special quantity discounts for business or sales promotional use. For information, please email
[email protected] or write to Special Sales Department, The MIT Press, 55 Hayward Street, Cambridge, MA 02142. This book printed and bound in the United States of America. Library of Congress Cataloging-in-Publication Data Status epilepticus : mechanisms and management / Claude G. Wasterlain and David M. Treiman, editors. p. cm. Includes bibliographical references and index. ISBN 0-262-23245-6 1. Epilepsy. 2. Convulsions. 3. Epilepsy—Treatment. 4. Convulsions—Treatment. I. Wasterlain, Claude G. II. Treiman, David M. RC372.S769 2006 616.8¢53—dc22 2005058405 10
9
8
7
6
5
4
3
2
1
CONTENTS
Preface
xi
Contributors
xiii
I
STATUS EPILEPTICUS: HISTORY, DEFINITION, CLASSIFICATION, AND EPIDEMIOLOGY 1
1
Historical Overview
2
Definition and Classification of Status Epilepticus C G. W and J W. C 11
3
Incidence and Causes of Status Epilepticus
4
Prognosis after a First Episode of Status Epilepticus D C. H, and W. A H 33
5
Epidemiology of Childhood Status Epilepticus
B S. M
3
R J. DL
17
G L,
S S
39
II STATUS EPILEPTICUS: CLINICAL PHENOMENOLOGY 53 6
Generalized Convulsive Status Epilepticus
D M. T
7
Simple and Complex Partial Status Epilepticus P T, B Z, and F A
55
69
v
8
Absence Status P T, B Z, and F A 91
9
The Two Faces of Electrographic Status Epilepticus: The Walking Wounded and the Ictally Comatose D G. F 109
10
Status Epilepticus in Infancy and Childhood R S 113
11
Nonconvulsive Status Epilepticus in Children: With Special Reference to Electrical Status Epilepticus During Slow-Wave Sleep Syndrome (ESES Syndrome) S O, Y Y, K K, and N N 125
12
Status Epilepticus in the Neonate
J Y. W, S K, and
E M. M
135
III STATUS EPILEPTICUS: BIOLOGICAL MARKERS R P. S
13
Physiologic Responses to Status Epilepticus
14
Clinical Neuropathology in Convulsive Status Epilepticus H-J M and G V 163
15
Neuron-Specific Enolase in Status Epilepticus C M. DG, A L. R, J C, C N H, P S. G, and S S 169
16
Brain Imaging in Status Epilepticus
T R. H
IV BASIC MECHANISMS: PATHOPHYSIOLOGY
vi
147 149
177
207
17
Self-Sustaining Status Epilepticus A M. M, H L, D E. N, L S, K W. T, A P V, R S, A N, and C G. W 209
18
Pathophysiology of Seizure Circuitry in Status Epilepticus M E K, and W A. S 229
19
Neuroanatomy of Status Epilepticus
20
Role of GABAA Receptors in Status Epilepticus J K 267
21
Physiologic Mechanisms of Inhibition and Status Epilepticus I S 281
A H
D C. MI,
239
R L. M and
22
Glutamate and Glutamate Receptors in Status Epilepticus and B S. M 295
23
Metabotropic Receptors in Status Epilepticus
B S. M
24
The Role of Adenosine in Status Epilepticus M D 315
D Y and
V BASIC MECHANISMS: BRAIN DAMAGE
A G. C
305
325
25
Excitotoxicity in Status Epilepticus L E. A. M. M, L C, C H, and R L S 327
26
Seizure-Induced Damage in the Immature Brain: Overcoming the Burden of Proof K W. T and R S 339
27
Metabolic and Circulatory Adaptations to Status Epilepticus in the Immature Brain A N and A P V 349
28
Excitotoxicity and Seizures in the Immature Brain
29
Age-Specific Mechanisms of Status Epilepticus and S L. M 371
30
Developmental Differences in Seizure Susceptibility and Hippocampal Vulnerability: Molecular Correlates L K. F and E F. S 379
31
Seizures and Neurotrophic Factor Expression C M. G 389
32
Behavioral Consequences of Status Epilepticus in the Immature Brain G L. H, R K, Z L, M R. S, and C E. S 399
P Mˇ
367
J Vˇ , R W,
H I. K and
VI BASIC MECHANISMS: EPILEPTOGENESIS
407
33
Late Consequences of Status Epilepticus J P L, A V S, and E A. C 409
34
Epileptogenic Effects of Status Epilepticus Y S, L S, A M. M, and C G. W
35
423
Hippocampal Reactive Synaptogenesis from Status Epilepticus G W. M 441
vii
VII THERAPEUTIC PRINCIPLES 36
Neuroprotective Strategies in Status Epilepticus
37
Generalized Convulsive Status Epilepticus: Principles of Treatment E F and C M. DG 481
38
Therapeutic Attitudes and Therapeutic Algorithms C G. W 493
39
Approach to the Management of Neonatal Status Epilepticus H Z. A-H and M J. P 503
40
Management of Status Epilepticus in Infants and Children P E, A A, I H, P G, and R S 515
VIII PHARMACOTHERAPY
D G. F
463
523
41
Benzodiazepines for Initial Treatment of Status Epilepticus B K. A 525
42
Phenytoin in the Treatment of Status Epilepticus
43
Phenytoin and Fosphenytoin F M. P 545
44
Phenobarbital in the Treatment of Status Epilepticus
45
Valproate S D, R A W, and K L. P 561
46
Other Pharmacologic Therapy for Refractory Status Epilepticus A G. S and R S. F 569
I E. L
539
R. E R and
IX THERAPEUTIC MANAGEMENT
viii
461
E F
589
47
Approaches to Treating Status Epilepticus Outside the Hospital J W. M and G D. A 591
48
The Treatment of Status Epilepticus Patients in the Emergency Setting E P. S 597
49
Critical Care of the Status Epilepticus Patient
T P. B
607
553
50
The Impact of Status Epilepticus on Health Care Delivery Systems: Quality of Care and Access B G. V 615
51
Status Epilepticus: The Future D M. T 621
Index
C G. W and
623
ix
PREFACE The demon possesses him many times during the middle watch of the night. —Sakikku cuneiform, 7th century .. Attacks are strung like red beads on a black cord of continuing unconsciousness. —William Lennox, 1960
L’état de mal épileptique, this most extreme manifestation of the sacred disease, is still a major medical emergency and a major unresolved therapeutic problem, with a mortality of 27% in adults and a formidable array of medical and neurological sequellae. We have learned to control the fever and many of the metabolic complications that were so often fatal in earlier times, yet this condition remains poorly understood and still extolls an unacceptably high price from its victims. The first large meeting on status epilepticus was the tenth “Colloque de Marseilles” in 1962, which emphasized electroclinical description and classification. The Santa Monica meeting in 1980 brought basic science into the clinical picture, and the second international Santa Monica meeting in 1997 focused on mechanisms and management. Interest in status epilepticus has exploded in the past 20 years: while Shorvon found 370 publications on status epilepticus from 1965 to 1978, a PubMed search reveals 4227 publications on status epilepticus since 1979, including 1761 in the past five years. Because more than 20 years have passed since the publication of the first multiauthored book on status epilepticus and more than 10 years have passed since Shorvon’s beautiful monograph, there was a need for a comprehensive review of the considerable progress made in the last decade. The current book attempts this daunting task, but because the field has expanded so much in the past 10 years, it focuses on the two areas in which progress has been most rapid, namely basic mechanisms and treatment. Coverage of other areas of the field of status epilepticus is selective, rather than comprehensive. In the area of basic mechanisms, we have seen the emergence of a concept of what status epilepticus is and how it differs from serial or grouped seizures. With this has come an understanding of some of the complications of status epilepticus at the molecular level, and this should eventually lead to improved therapy. Because of the realization that neuronal apoptosis and necrosis can be triggered very quickly and that status epilepticus–induced damage may be highly epileptogenic, treatment strategies today differ from those of yesteryear by their far greater sense of urgency, including prehospital administration of anticonvulsants whenever feasible and rapid induction of general anesthesia when seizures do not quickly abate with treatment. However, the number of agents available to treat status epilepticus has not kept pace with the rapid expansion of our therapeutic armamentarium for epilepsy. The book is divided equally between studies of basic mechanisms in animal models and clinical studies, so that one can go from the reductionist experiment that isolates a small component of status to the complex clinical situation in which that component is a small and interactive part of a large array. Hopefully, this marriage of basic and clinical science
xi
will provide a scientific rationale for our clinical decisions and will help develop therapeutic attitudes that are firmly grounded in pathophysiology. This book is aimed at the diverse medical groups that deal with status epilepticus in addition to the investigators who study it: emergency room physicians, intensivists, pediatricians, neurologists and pediatric neurologists, anesthesiologists, pharmacists, emergency room and intensive care unit nurses, and internists. We hope that it will bridge the gap between these disciplines and will renew interest in this complex clinical and experimental problem. We thank Barbara Blackburn and Richard Beaver for editorial assistance. We also thank the Veterans Health Administration’s Research Service and the National Institute of Neurological Diseases and Stroke for their support.
Claude G. Wasterlain and Kerry W. Thompson West Los Angeles, California David M. Treiman Phoenix, Arizona
xii
CONTRIBUTORS A-H, H Z. Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania A, B K. Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, California A, F Montreal Neurological Hospital and Institute, Montreal, Quebec, Canada A, G D. Department of Pharmacy, University of Washington, Seattle, Washington A, A Service de Neuropediatrie, Universite Paris VII Dennis-Diderot, Paris, France B, T P. Departments of Neurology, Surgery, Internal Medicine, The University of Virginia, Charlottesville, Virginia C, E A. Neurologia Experimental, UNIFESPEPM, São Paulo, SP, Brazil C, A G. Dept of Clinical Neurosciences, Institute of Psychiatry, Kings College, London, United Kingdom C, J W. Department of Neurology, Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California C, J Department of Neurology, Raul Carrea Institute for Neurological Research, Buenos Aires, Argentina C, L UNIFESP-EPM, Department of Physiology, São Paulo, SP, Brazil S, A V Neurologia Experimental, UNIFESP-EPM, São Paulo, SP, Brazil DG, C M. Department of Neurology, Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California DL, R J. Department of Neurology, Virginia Commonwealth University, Richmond, Virginia D, S Pharmacy Service, VA Greater Los Angeles Healthcare System, Los Angeles, California V, A P INSERM U.398, Strasbourg, France D, M Department of Pharmacology and Molecular Medicine, Faculty of Medicine and Human Biology, University of Auckland, Auckland, New Zealand E, P Service de Neuropediatrie, Universite Paris VII Dennis-Diderot, Paris, France F, E University of Alabama School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama F, R S. Department of Neurology, Stanford University School of Medicine, Palo Alto, California F, L K. Department of Neuroscience-Histology, New York College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, New York
F, D G. Experimental Neurology Laboratory, VA Greater Los Angeles Healthcare System, Sepulveda, California G, C M. Department of Neurobiology, University of California, Irvine, School of Medicine, Irvine, California G, P S. Department of Neurology, University of Southern California School of Medicine, Los Angeles, California G, P Service de Neuropediatrie, Universite Paris VII Dennis-Diderot, Paris, France H, C Department of Physiology, UNIFESPEPM, São Paulo, SP, Brazil H, A Neurology Department, Veterans Administration Greater Los Angeles Healthcare System, West Los Angeles, California H, W. A G.H. Sergievsky Center, Columbia University, New York, New York H, C N USC Epilepsy Program, University of Southern California School of Medicine, Los Angeles, California H, T R. Department of Neurology, Emory University, Atlanta, Georgia H, D C. G.H. Sergievsky Center, Columbia University, New York, New York H, G L. Center for Neuroscience at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire H, I Service de Neuropediatrie, Universite Paris VII Dennis-Diderot, Paris, France K, J Department of Neurology, University of Virginia, Charlottesville, Virginia K, M E University of Pennsylvania, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania K, R Center for Neuroscience at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire K, K Department of Child Neurology, Okayama University Medical School, Okayama, Japan K, S Division of Pediatric Neurology, David Geffen School of Medicine and Mattel Children’s Hospital, University of California at Los Angeles, Los Angeles, California K, H I. Departments of Molecular and Medical Pharmacology and Pediatrics, University of California at Los Angeles, School of Medicine, Los Angeles, California L, J P Departamento de Neurologia, UNIFESP-EPM, São Paulo, SP, Brazil L, I E. College of Pharmacy, University of Minnesota, Minneapolis, Minnesota
xiii
L, H Department of Neurology, Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California L, Z Department of Neurology, Medical College of Georgia, Augusta, Georgia L, G School of Public Health, Harvard University, Boston, Massachusetts M, R L. Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee Mˇ, P Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic M, G W. Division of Neurosurgery, Reed Neurological Research Center, University of California at Los Angeles, Medical Center, Los Angeles, California M, A M. Department of Neurology, Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California MI, D C. Institute for Neuroscience, Department of Psychology, Carleton University, Ottawa, Ontario, Canada M, H-J Epilepsy-Center Berlin, Evg. Krankenhaus, Königin Elisabeth Herzberge und VirchowKlinikum, Med. Fakultät der Humboldt-Universität, Berlin, Germany M, B S. GKT School of Biomedical Sciences, London, United Kingdom M, L E. A. M. UNIFESP-EPM, Department of Physiology, São Paulo, SP, Brazil M, J W. Departments of Neurology and Surgery, University of Washington, Seattle, Washingston M, E M. Section of Neurophysiology, Department of Neurology, Texas Medical Center, Houston, Texas M, S L. Department of Neurology, Albert Einstein College of Medicine, Bronx, New York N, D E. Department of Neurology, Geffen School of Medicine, University of California at Los Angeles, West Los Angeles, California N, A INSERM U 666, Faculte de Medecine, Strasbourg, France N, N Department of Child Neurology, Okayama University Medical School, Okayama, Japan O, S Department of Child Neurology, Okayama University Medical School, Okayama, Japan P, J. M Departments of Neurology and Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania P, K L. Neurology Service, Stroke Team, West Los Angeles Veterans Administration Medical Center, West Los Angeles, California P, F M. Neurology Service, Miami Veterans Administration Medical Center, Miami, Florida R, A L. Berlex Laboratories, Montville, New Jersey R, R. E Departments of Neurology and Psychiatry, International Center for Epilepsy, University of Miami, Miami, Florida S, R Departments of Neurology and Pediatrics, University of California, Los Angeles at School of Medicine, Los Angeles, California S, M R. Department of Neurobiology, Yale University School of Medicine, New Haven, Connecticut
xiv
S, S Department of Neurology, University of California, Irvine, School of Medicine, Long Beach, California S, S Epilepsy Management Center, Montefiore Medical Center, Bronx, New York S, Y National Utano Hospital, Ukyo-ku, Kyoto, Japan S, R P. Robert Stone Dow Chair of Neurology, Director of Neurobiology Research, Legacy Health Systems, Portland, Oregon S, E P. Department of Emergency Medicine, University of Illinois at Chicago, Chicago, Illinois S, R L UNIFESP-EPM, Department of Physiology, São Paulo, SP, Brazil S, E F. Department of Neuroscience and Neurology, Albert Einstein College of Medicine, Bronx, New York S, I School of Dentistry, University of California at Los Angeles, Los Angeles, California S, C E. Departments of Neurology and Pediatrics, University of Wisconsin, Madison, Wisconsin S, W A. Institute for Neuroscience, Department of Psychology, Carleton University, Ottawa, Ontario, Canada S, A G. The Queen’s Medical Center, Honolulu, Hawaii S, L Epilepsy Research Laboratory, University of California at Los Angeles, School of Medicine, West Los Angeles, California T, P Hopital Pasteur, Nice, France T, K W. Department of Neurology, University of California at Los Angeles, School of Medicine, Los Angeles, California T, D M. Department of Neurology, The Barrow Neurological Institute, Phoenix, Arizona V, G Institut of Neuropathology, von Bodelschwingh’sche Anstalten, Bielefeld, Germany Vˇ, J Department of Neurology, Albert Einstein College of Medicine, Bronx, New York V, B G. Department of Neurology, University of California at Los Angeles, Los Angeles, California W, R A Department of Neurology, Veterans Administration Greater Los Angeles Healthcare System, West Los Angeles, California W, C G. Department of Neurology, Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California W, J Y. Department of Pediatrics, David Geffen School of Medicine and Mattel Children’s Hospital, University of California at Los Angeles, Los Angeles, California W, R Department of Neurology, Albert Einstein College of Medicine, Bronx, New York Y, Y Department of Child Neurology, Okayama University Medical School, Okayama, Japan Y, D Department of Molecular Medicine & Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand Z, B Department of Sciences, Hopital du SacreCœur, Montreal, Quebec, Canada
I STATUS EPILEPTICUS: HISTORY, DEFINITION, CLASSIFICATION, AND EPIDEMIOLOGY
1
Historical Overview
.
Introduction This chapter provides a succinct historical review of our understanding of status epilepticus (SE). It begins with the clinical studies that led to the identification of the different forms of SE. It then takes up questions that have been addressed by experimental studies, and thereby provides an overview of the key themes of the book. In preparing this chapter I have benefited from information presented at the Marseille Colloquia (28, 56), from the volume that preceded this one (18), and especially from the book on SE by Simon Shorvon (73).
Early clinical history The earliest known medical description of epilepsy appears on tablet XXV–XXVI of the Sakikku cuneiform, 718–612 .. (38). It alludes to the unfavorable prognosis associated with multiple seizures in one night: “If the possessing demon possesses him many times during the middle watch of the night, and at the time of his possession his hands and feet are cold, he is much darkened, keeps opening and shutting his mouth, is brown and yellow as to the eyes . . . it may go on for some time, but he will die.” Today this possible fatal outcome is frequently emphasized as the primary feature differentiating repetitive or prolonged seizures from single seizures. The term état de mal first appeared in 1824 in the thesis of Louis Calmeil (8); the Anglo-Saxon latinized version, status epilepticus, appears in Bazire’s translation of Trousseau’s lectures (86). T-C S Trousseau (86) provided the first account of SE of the grand mal or tonic-clonic type, which drew attention to the evolving nature of the pattern of clinical seizures, a feature that suggested that something other than a simple repetition of tonic-clonic seizures was occurring. Trousseau also gave a clear account of petit mal status. Bourneville (5) provided a superb clinical account of tonicclonic status in which he described cardiovascular changes and the occurrence of hyperthermia. Hyperthermia as a characteristic of status, regardless of the etiology of the status, has since been widely recognized; in particular, it is associated with a poor neurologic outcome and cerebellar damage (clinically and at post mortem) (2). A series of 38 cases of SE was reported by Clark and Prout in 1903–1904 (17). They described the characteristic changes in seizure
expression associated with the transition from episodes of tonic activity alternating with coma to a stupor with loss of superficial and deep reflexes. Postmortem studies in seven patients revealed selective neuronal necrosis progressing to cell loss, most prominently in the second and third cortical laminae. They described the early appearance of chromatolytic changes (visible in Nissl preparations) of large pyramidal neurons in lamina III and the later neuronophagia and cell loss. L S Episodes of fugue were interpreted as epileptic by Charcot (16), and Hughlings Jackson (80) described prolonged episodes of psychomotor seizures. The proper recognition of limbic status came only after electroencephalography (EEG) became established in the 1940s. The definitive attribution of a fugue state to psychomotor SE was provided by Gastaut and colleagues in 1956 (28). Case histories of limbic status have been collected and reported in recent years (21, 84, 98). A study of the effects of blue mussel or domoate poisoning in 150 Canadians in 1987 (81) provided important insights into the clinical features and sequelae of prolonged limbic seizures, although the bilaterality of the pathology may be atypical for “spontaneous” limbic status. O F SE The nineteenth century also saw the classic description of West’s syndrome (94), with the clear recognition that repeated spasms could be a manifestation of sustained epileptic activity. Sustained focal cortical seizure activity was also recognized by Kojewnikoff (39) and is a feature of the encephalitic syndrome described by Rasmussen and colleagues (69). The EEG characterization of petit mal status with sustained spike-and-wave discharges at 2–3 Hz was provided by Lennox in 1945 (43).
Pathological consequences of generalized SE Pfleger in 1880 (64) observed discoloration (hortensia-like) of the amygdala and hippocampus in patients dying after SE and thought that vascular events associated with the seizure were causing local pathology. Clark and Prout’s observations (17) of the laminar cortical damage were the outstanding early contribution to the neuropathology of SE. Their observations of chromatolysis and neuronophagia were further documented by the German school of neuropathology. Spielmeyer (78) and
:
3
Scholz (70–72) described the acute neuronal cytopathology as “ischaemic cell change” and attributed it to vasospasm associated with the seizure. Descriptions of the pathology found in children dying shortly after prolonged febrile convulsions or SE slowly accumulated (1, 25, 60, 100) and showed the laminar cortical damage of Clark and Prout (17), cerebellar damage involving Purkinje cells, and a pattern of selective loss in the hippocampus similar to that recognized by Sommer in 1880 (77) as being a characteristic finding in institutionalized patients with severe generalized epilepsy. A link between hippocampal sclerosis and temporal lobe or psychomotor seizures was first described by Stauder in 1935 (79). The key observation linking the pathology of SE with the pathology of temporal lobe epilepsy came, however, from Alfred Meyer’s studies on the en bloc anterior temporal lobe specimens provided by Murray Falconer. In 1956, Cavanagh and Meyer (12) were the first to report that hippocampal sclerosis (or “mesial temporal sclerosis”) was the commonest specific pathological finding in complex partial seizures originating in the temporal lobe, and that the majority of such patients had experienced either a single episode of SE or complex febrile convulsions in late infancy or early childhood. This observation was emphasized by Falconer (24) and by Ounsted and colleagues (61) over the next 15 years, and has been confirmed in many studies since 1975 (7, 13, 14, 19, 37, 44, 45, 97). The hypothesis that a prolonged seizure in early life causes pathology in the hippocampus, amygdala, and piriform cortex that, over several years, leads to that temporal lobe becoming the focal source for complex partial seizures has become central to the thinking of many research groups and has received much experimental support (48). Limbic seizures induced by focal or systemic kainic acid provided the first experimental model of epileptogenesis secondary to SE (10, 26). Subsequently the systemic pilocarpine model (with or without lithium) was shown to induce spontaneous seizures more consistently (see discussion under Experimental Studies of SE). Electrically induced limbic SE can also lead to spontaneous seizures (58).
Classification of types of SE The clinical study of SE advanced little in the first half of the twentieth century. The application of EEG to the study of epilepsy was vigorously pursued in Marseille, and the Marseille Colloquia, convened by Henri Gastaut, provided an invigorating forum for the discussion of the pathophysiology of epilepsy and epileptic brain damage (56) and SE (31). The Xth Marseilles Colloquium, in 1962, was the first international meeting devoted to SE. It provided the first systematic classification of status (31). The definition of status proposed at that time (“a term used whenever a seizure per-
4
T 1.1 Clinical forms of status epilepticus État de (grand) mal Petit mal status EEG studies Infantile spasm EEG studies Epileptic fugue EEG studies Epilepsia partialis continua EEG studies Epileptic aphasia
Calmeil, 1824 (8) Trousseau, 1868 (86) Lennox, 1945 (43) West, 1841 (94) Gibbs and Gibbs, 1952 (32) Bright, 1831 (6) Charcot, 1889 (16) Gastaut et al, 1956 (28) Kojewnikoff, 1895 (39) Rasmussen et al, 1958 (69) Juul-Jensen and Denny-Brown, 1966 (36) Wieser et al, 1977 (96) Landau and Kleffner, 1957 (41)
sists for a sufficient length of time or is repeated frequently enough to produce a fixed or enduring epileptic condition”) was not innovative. The novel feature of the classification, however, was the proposal that there are as many types of SE as there are types of epileptic seizure. This was apparent from the case studies of that time in terms of clinical and EEG seizure type; that is, in addition to the classic tonic-clonic status (état de grand mal ) there was tonic status, myoclonic status, simple partial status, and complex partial status. A differentiation of status was also evident in terms of particular epilepsy syndromes and pathophysiologies (notably neonatal seizures, febrile seizures, and various childhood epilepsies, such as West’s syndrome, Landau-Kleffner syndrome), myoclonic status of coma, and the progressive myoclonic epilepsies. This broadening of the concept of SE greatly complicated discussion of the central issues of status. Clinical forms of SE are listed in Table 1.1.
The central conceptual issue of SE Is SE merely prolonged or repetitive seizures, or does something happen that makes it different in kind from the events associated with isolated seizures? Clearly, this question must be posed and answered for each and every type of SE. It is evident that tonic-clonic status has an evolutive pattern (in clinical and EEG terms) that is not shown by absence status or by epilepsia partialis continua. These three categories are also very different in terms of the associated pathologies. Generalized tonic-clonic status, hemispheric status, and limbic status would appear to have much in common, in that they all show an evolutive pattern that includes early increases in cerebral blood flow (CBF) and metabolic rate and later evidence of intracellular calcium accumulation and the onset of selective patterns of neuronal necrosis (ischemic cell change).
: , , ,
T 1.2 Transition from single seizure to status epilepticus: Experimental hypotheses Single seizure (1–15 minutes) Marked ionic shifts (Na+, K+, Ca2+, Cl-) and H2O redistribution. Metabolic enhancement (glycolysis, CMRO2, etc.) Delayed secondary effects (e.g., immediate early gene induction, endocrine activation, some neuroreceptor changes) Status epilepticus (transition at 15–90 minutes) Adenosine formation/release Failure of GABA-mediated inhibition Ca2+ loading of mitochondria Multiple enzyme activations (PLC, proteases, etc.) Multiple metabolic changes (poisoning of mitochondria, free radical generation) Metabotropic receptor effects (short and long term) IEGs–expression of neurotrophins, cytokines, etc. Receptor trafficking Electrical synchronization
For these syndromes, it appears likely that there is a similar answer to the question, What is the transition between the condition of a single seizure to the condition of SE? This question may have several answers, which may be congruent or not. Thus, an analysis based on clinical and EEG evidence may give a different time point from an answer based on neurochemistry, pharmacology, or cellular electrophysiology. It seems evident that satisfactory answers to these questions cannot be derived from clinical studies alone, and that animal experimental studies are required. Some of the key experimental hypotheses are listed in Table 1.2.
Experimental studies of SE Lennox and colleagues (42) and Zimmermann (99) reported some experiments on prolonged seizures induced in cats or kittens by metrazol, camphor, or thujone. Damage to cortical (laminae II and III) and cerebellar (Purkinje) neurons was described and thought to be related to hypoxia and hyperthermia (Purkinje cells). The experimental study of SE began in earnest, however, only 30 years ago, as suggested by the fact that the excellent volume, Experimental Models of Epilepsy, published in 1972 (68), does not have a chapter on models of SE. Spielmeyer (78) and his followers (70–72, 89) had emphasized the similarity, in terms of both the nature of the cellular degenerative changes and the pattern of selective vulnerability of epileptic or post-SE brain damage and ischemic/hypoxic brain damage, and concluded that the pathology after status was of an anoxic-ischemic type. Initially it was thought that vasospasm was part of the pathophysiology of epilepsy, but the direct observations of
Penfield and Jasper (63) showed that focal seizures were associated with a local enhancement of blood flow. This finding led to a greater emphasis on systemic respiratory and cardiovascular problems as potential factors contributing to brain damage. Thus, Meldrum and Brierley began a series of experiments in experimental primates (monkeys and baboons) with extensive physiologic monitoring, including arterial and cerebral venous blood gas measurements, during prolonged seizures induced by bicuculline or allylglycine (51–53). These studies showed that during the first 30 minutes of seizure activity, arterial pressure was elevated and cerebral venous oxygenation was enhanced. Body temperature rose, and blood glucose levels also tended to be elevated. Later, arterial pressure fell, blood glucose fell, and cerebral venous oxygen saturation returned to normal levels. The primary correlation with the occurrence of ischemic cell change in hippocampus and cortex was the duration of the seizure activity. Studies in paralyzed, ventilated baboons in which any systemic consequences of status were minimized (53) established that the duration of electrical seizure activity was the most important determinant of hippocampal pathology. Hyperpyrexia appeared to contribute to cerebellar damage, as indicated by experimental studies of hyperthermia and clinical observations in SE (2). The role of local electrical activity in initiating the process of acute neuronal necrosis was definitively established by the studies of Sloviter employing perforant path stimulation and examining the ipsilateral and contralateral hippocampus (74–76). A detailed historical analysis of the concept of activity-induced cell death in epilepsy has recently been published (47). Chapman and colleagues in 1977 (15) set up a similar model of SE induced by bicuculline in the rat, in which it was possible to measure regional CBF, and oxygen and glucose consumption and biochemical measurements of labile metabolites could be made by rapid freezing of the cerebral cortex. This model showed that there was a massive early increase in cerebral metabolic rate that initially was more than compensated for by increased CBF. The critical role of enhanced Ca2+ entry into neurons was emphasized by Meldrum and colleagues (22, 23, 33–35, 50, 51). Using the oxalate/pyroantimonate method for visualizing free calcium in electron microscopy, they showed a marked calcium loading of mitochondria focally in dendrites and in somata of selectively vulnerable neurons in the hippocampus. Such loading was evident at 30 minutes, becoming more severe in the following hours. Initially it was reversible, but when prolonged, it led to ischemic cell change. These findings have been reproduced in an in vitro model of hippocampal SE (62). The pathological consequences of limbic SE induced by kainate or pilocarpine have been widely studied since 1980 (3, 4, 9, 27, 59, 87, 88). In these models, damage to the
:
5
amygdala and the entorhinal and piriform cortices may be particularly prominent. Febrile convulsions were studied in kittens by Lennox and colleagues in 1954 (42), but modern experimental studies relating to the neonatal period and infancy were initiated by Wasterlain with studies of electroshock, then flurothyl and bicuculline in neonatal rats and subsequently in marmosets (20, 90–93). In the neonatal period, protein synthesis is impaired and growth is restricted, but the classic pattern of selective neuronal loss in the hippocampus is not seen. The lack of the characteristic hippocampal pathology when status is induced in neonatal rodents was subsequently confirmed for both the kainic acid model of limbic status (59) and the pilocarpine model (9, 67). Classic hippocampal damage can be induced from postnatal day 18 in both models. Vulnerability can sometimes be observed earlier than this, for example, at 15 days with perforant path stimulation in the rat (83, 84). SE induced by lithium-pilocarpine can, however, cause necrotic damage in the mediodorsal thalamus in 12-day-old rats (40). Hippocampal and medial temporal damage secondary to prolonged seizures induced by focal, intraventricular, or systemic kainate was shown to be followed, after a few weeks, by spontaneous limbic seizures (10, 26, 55, 59, 64). SE induced by systemic pilocarpine has, however, proved to lead to a more consistent pattern of spontaneous limbic seizures (9, 54, 87).
Therapy for SE Treatment in Europe in the nineteenth century involved blood-letting, trephining, application of ice to the skull or spinal cord, and the administration of a great variety of substances orally, subcutaneously, or rectally. By 1903, Clark and Prout (17) had concluded that trephining had a place only in posttraumatic SE and that venesection could be helpful if combined with intravenous (IV) saline, but the greatest benefit was obtained with an oral cocktail of morphine, opium, potassium bromide, and chloral hydrate, especially when given early or prophylactically, and that subcutaneous bromide was also useful. In the last 50 years the IV use of anticonvulsant agents has been reported to produce dramatic benefit in some cases. The use of IV paraldehyde was described by Whitty and Taylor in 1949 (95). The dramatic effect of IV phenytoin in children with SE was described by McWilliam in 1958 (46). In the early to mid1960s the effects of IV chlormethiazole (66) and diazepam (29, 57) were reported by French neurologists. The first full report of a controlled therapeutic trial yielding statistically significant results was published in 1998 (85). These studies concern elderly adults. We are still surprisingly ignorant of the optimal treatments in childhood, especially in the neonatal period.
6
Comment The study of SE has suffered a long period of neglect, and unfavorable clinical outcomes are still common. The problems have at last been defined and the tools for their experimental and clinical investigation are immediately to hand. It is to be hoped that this volume will be effective in guiding the appropriate studies. REFERENCES 1. Aicardi, J., and J. J. Chevrie. Convulsive status epilepticus in infants and children. Epilepsia 1970;11:187–197. 2. Aminoff, M. J., and R. P. Simon. Status epilepticus: Causes, clinical features and consequences in 98 patients. Am. J. Med. 1980;69:657–666. 3. Ben-Ari, Y. Limbic seizures and brain damage produced by kainic acid: Mechanisms and relevance to human temporal lobe epilepsy. Neuroscience 1985;14:375–403. 4. Ben-Ari, Y., E. Tremblay, O. P. Ottersen, and B. S. Meldrum. The role of epileptic activity in hippocampal and “remote” cerebral lesions induced by kainic acid. Brain Res. 1980; 191:79–97. 5. Bourneville, D. M. L’état de mal épileptique. In D. M. Bourneville, ed. Recherches cliniques et thérapeutiques sur l’épilepsie et l’hystérie. Compte-rendu des observations recueillies a la Salpêtrière. Paris: Delahaye, 1876. 6. Bright, R. Reports of medical cases, selected with a view of illustrating the symptoms and cure of diseases by a reference to morbid anatomy. London: Taylor, 1831:2. 7. Bruton, C. J. The Neuropathology of Temporal Lobe Epilepsy. Oxford, U.K.: Oxford University Press, 1988. 8. Calmeil, L. F. De l’épilepsie, étudiée sous le rapport de son siège et de son influence sur la production de l’aliénation mentale. Thesis, University of Paris, 1824. 9. Cavalheiro, E. A., J. P. Leite, Z. A. Bortolotto, W. A. Turski, C. Ikonomidou, and L. Turski. Long-term effects of pilocarpine in rats: Structural damage of the brain triggers kindling and spontaneous recurrent seizures. Epilepsia 1991; 32:778–782. 10. Cavalheiro, E. A., D. Riche, and G. Le Gal La Salle. Long-term effects of intrahippocampal kainic acid injection in rats: A method for inducing spontaneous recurrent seizures. Electroencephalogr. Clin. Neurophysiol. 1982; 53:581–589. 11. Cavalheiro, E. A., D. F. Silva, W. A. Turski, F. L. Calderazzo, Z. A. Bortolotto, and L. Turski. The susceptibility of rats to pilocarpine-induced seizures is age-dependent. Brain Res. 1987;465:43–58. 12. Cavanagh, J. B., and A. Meyer. Aetiological aspects of Ammon’s horn sclerosis associated with temporal lobe epilepsy. BMJ 1956;2:1403–1407. 13. Cendes, F., F. Andermann, and F. Dubeau. Early childhood prolonged febrile convulsions, atrophy and sclerosis of mesial structures, and temporal lobe epilepsy: An MRI volumetric study. Neurology 1993;43:1083–1087. 14. Cendes, F., F. Andermann, and P. Gloor. Atrophy of mesial temporal structures in patients with temporal lobe epilepsy: Cause or consequence of repeated seizures? Ann. Neurol. 1993;34:795–801.
: , , ,
15. Chapman, A. G., B. S. Meldrum, and B. K. Siesjö. Cerebral metabolic changes during prolonged epileptic seizures in rats. J. Neurochem. 1977;28:1025–1035. 16. Charcot, J. M. Clinical Lectures on the Diseases of the Nervous System (T. Savill, trans.). London: New Sydenham Society, 1889. 17. Clark, L. P., and T. P. Prout. Status epilepticus: A clinical and pathological study in epilepsy. Am. J. Insanity 1903;60:291– 306; 1904;60:645–675, 61:81–108. 18. Delgado-Escueta, A. V., C. G. Wasterlain, D. M. Treiman, and R. J. Porter, eds. Status Epilepticus: Mechanisms of Brain Damage and Treatment. Adv. Neurol. 1983:34. 19. Duncan, J. S., and H. J. Sagar. Seizure characteristics, pathology, and outcome after temporal lobectomy. Neurology 1987; 37:405–409. 20. Dwyer, B. E., and C. G. Wasterlain. Selective focal inhibition of brain protein synthesis during generalised bicuculline seizures in newborn marmoset monkeys. Brain Res. 1984;309: 109–121. 21. Engel, J., B. I. Ludwig, and M. Fetell. Prolonged partial complex status epilepticus. Neurology 1978;28:863–869. 22. Evans, M., T. Griffiths, and B. S. Meldrum. Early changes in the rat hippocampus following seizures induced by bicuculline or -allylglycine: A light and electron microscope study. Neuropathol. Appl. Neurobiol. 1983;9:39–52. 23. Evans, M. C., T. Griffiths, and B. S. Meldrum. Kainic acid seizures and the reversibility of calcium loading in vulnerable neurons in the hippocampus. Neuropathol. Appl. Neurobiol. 1984;10:285–302. 24. Falconer, M. A. Mesial temporal (Ammon’s horn) sclerosis as a common cause of epilepsy: Aetiology, treatment and prevention. Lancet 1974;2:767–770. 25. Fowler, M. Brain damage after febrile convulsions. Arch. Dis. Child. 1957;32:67–76. 26. Franck, J. E., and P. A. Schwartzkroin. Do kainate-lesioned hippocampi become epileptogenic? Brain Res. 1985;329: 309–313. 27. Fujikawa, D. G. The temporal evolution of neuronal damage from pilocarpine-induced status epilepticus. Brain Res. 1996; 725:11–22. 28. Gastaut, H., J. Roger, and A. Roger. Sur la signification de certaines fugues épileptiques: État de mal temporal. Rev. Neurol. 1956;94:298–301. 29. Gastaut, H., R. Naquet, R. Poiré, and C. A. Tassinari. Treatment of status epilepticus with diazepam (valium). Epilepsia 1965;6:167–182. 30. Gastaut, H. A propos d’une classification symptomatologique des états de mal épileptiques. In H. Gastaut, J. Roger, and H. Lob, eds. Les états de mal épileptiques. Paris: Masson, 1967;1–8. 31. Gastaut, H., J. Roger, and H. Lob, eds. Les états de mal épileptiques. Paris: Masson, 1967. 32. Gibbs, F., and E. Gibbs. Atlas of Electroencephalography. Vol 2. Cambridge, Mass.: Addison-Wesley, 1952. 33. Griffiths, T., M. C. Evans, and B. S. Meldrum. Intracellular calcium accumulation in rat hippocampus during seizures induced by bicuculline or -allylglycine. Neuroscience 1983;10: 385–395. 34. Griffiths, T., M. C. Evans, and B. S. Meldrum. Intracellular sites of early calcium accumulation in the rat hippocampus during status epilepticus. Neurosci. Lett. 1982;30:329–334. 35. Griffiths, T., M. C. Evans, and B. S. Meldrum. Status epilepticus: The reversibility of calcium loading and acute neuronal pathological changes in the rat hippocampus. Neuroscience 1984;12:557–567.
36. Juul-Jensen, P., and D. Denny-Brown. Epilepsia partialis continua. Arch. Neurol. 1966;15:563–578. 37. Kim, J. H., P. O. Guimaraes, M. Y. Shen, L. M. Masukawa, and D. D. Spencer. Hippocampal neuronal density in temporal lobe epilepsy with and without gliomas. Acta Neuropathol. (Berl.) 1990;80:41–45. 38. Kinnier Wilson, S. A., and E. H. Reynolds. Translation and analysis of a cuneiform text forming part of a Babylonian treatise on epilepsy. Med. Hist. 1990;34:185–198. 39. Kojewnikoff, A. Y. Eine besondere Form von corticaler Epilepsie. Neurol. Zentralb. 1895;14:47–48. 40. Kubová, H., R. Druga, K. Lakasiuk, L. Suchomelová, R. Haugvicová, I. Jirmanová, and A. Pitkänen. Status epilepticus causes necrotic damage in the mediodorsal nucleus of the thalamus in immature rats. J. Neurosci. 2001;21:3593–3599. 41. Landau, W. M., and F. Kleffner. Syndrome of acquired aphasia with convulsive disorder in children. Neurology 1957;7:523–530. 42. Lennox, M. A., W. A. Sibley, and H. M. Zimmerman. Fever and febrile convulsions in kittens: A clinical, electroencephalographic, and histopathological study. J. Pediatr. 1954;45:179–190. 43. Lennox, W. The petit mal epilepsies: Their treatment with tridione. JAMA 1945;129:1069–1073. 44. Mathern, G. W., T. L. Babb, B. G. Vickrey, M. Melendez, and J. K. Pretorius. Traumatic compared to non-traumatic clinical-pathologic associations in temporal lobe epilepsy. Epilepsy Res. 1994;19:129–139. 45. McMillan, T., G. E. Powell, I. Janota, and C. E. Polkey. Relationships between neuropathology and cognitive functioning in temporal lobectomy patients. J. Neurol. Psychiatry 1987;50:167–176. 46. McWilliam, P. K. A. Intravenous phenytoin sodium in continuous convulsions in children. Lancet 1958;2:1147–1149. 47. Meldrum, B. S. Concept of activity-induced cell death in epilepsy: Historical and contemporary perspectives. Prog. Brain Res. 2002;135:3–11. 48. Meldrum, B. S. First Alfred Meyer Memorial Lecture. Epileptic brain damage: A consequence and a cause of seizures. Neuropathol. Appl. Neurobiol. 1997;23:185–201. 49. Meldrum, B. S. Metabolic effects of prolonged epileptic seizures and the causation of epileptic brain damage. In F. C. Rose, ed. Metabolic Disorders of the Nervous System. London: Pitman, 1981:175–187. 50. Meldrum, B. S. Metabolic factors during prolonged seizures and their relation to nerve cell death. In A. V. DelgadoEscueta, C. G. Wasterlain, D. M. Treiman, and R. J. Porter, eds. Status Epilepticus: Mechanisms of Brain Damage and Treatment. Adv. Neurol. 1983;34:261–273. 51. Meldrum, B. S., and J. B. Brierley. Prolonged epileptic seizures in primates: Ischaemic cell change and its relation to ictal physiological events. Arch. Neurol. 1973;28:10–17. 52. Meldrum, B. S., R. W. Horton, and J. B. Brierley. Epileptic brain damage in adolescent baboons following seizures induced by allylglycine. Brain 1974;97:417–428. 53. Meldrum, B. S., R. A. Vigoroux, and J. B. Brierley. Systemic factors and epileptic brain damage: Prolonged seizures in paralysed artificially ventilated baboons. Arch. Neurol. 1973;29: 82–87. 54. Mello, L. E. A. M., E. A. Cavalheiro, and A. M. Tan. Circuit mechanisms of seizures in the pilocarpine model of chronic epilepsy: Cell loss and mossy fibre sprouting. Epilepsia 1993; 34:985–995.
:
7
55. Menini, C., B. S. Meldrum, D. Riche, C. Silva-Comte, and J. M. Stutzmann. Sustained limbic seizures induced by intraamygdaloid kainic acid in the baboon: Symptomatology and neuropathological consequences. Ann. Neurol. 1980;8: 501–509. 56. Morin, G., and H. Gastaut. Colloque sur les problèmes d’anatomie normale et pathologique posés par les décharges épileptiques. Acta Med. Belg. (Bruxelles) 1956. 57. Naquet, R., R. Soulayrol, G. Dolce, C. A. Tassinari, R. Broughton, and H. Loeb. First attempt at treatment of experimental status epilepticus in animals and spontaneous status epilepticus in man with diazepam. Electroencephalogr. Clin. Neurophysiol. 1965;18:424–427. 58. Nissinen, J., T. Halonen, E. Koivisto, and A. Pitkänen. A new model of chronic temporal lobe epilepsy induced by electrical stimulation of the amygdala in rat. Epilepsy Res. 2000;38:177–205. 59. Nitecka, L., E. Tremblay, G. Charton, J. P. Bouillot, M. L. Berger, and Y. Ben-Ari. Maturation of kainic acid seizurebrain damage syndrome in the rat. II. Histopathological sequelae. Neuroscience 1984;13:1073–1094. 60. Norman, R. M. The neuropathology of status epilepticus. Med. Sci. Law 1964;4:46–51. 61. Ounsted, C., J. Lindsay, and R. Norman. Biological Factors in Temporal Lobe Epilepsy. London: Heinemann, 1966: 1–135. 62. Pal, S., S. Sombati, D. D. Limbrick, and R. J. DeLorenzo. In vitro status epilepticus causes sustained elevation of intracellular calcium levels in hippocampal neurons. Brain Res. 1999;851:20–31. 63. Penfield, W., and H. Jasper. Epilepsy and the Functional Anatomy of the Human Brain. Boston: Little, Brown, 1954. 64. Pfleger, L. Beobachtungen über Schrumpfung und Sclerose des Ammonshorn bei Epilepsie. Allg. Zeitschr. Psychiatr. 1880; 36:359–365. 65. Pisa, M., P. R. Sanberg, M. E. Corcoran, and H. C. Fibiger. Spontaneously recurrent seizures after intracerebral injections of kainic acid in rat: A possible model of human temporal lobe epilepsy. Brain Res. 1980;200:481–487. 66. Poiré, R., P. Royer, M. Degraeve, and C. Rustin. Traitement des états de mal épileptiques par le “CTZ base” (dérivé de la fraction thiazolique de la vitamine B1): Etude électroclinique. Rev. Neurol. 1963;108:112–126. 67. Priel, M. R., N. F. Dos Santos, and E. A. Cavalheiro. Developmental aspects of the pilocarpine model of epilepsy. Epilepsy Res. 1996;26:115–121. 68. Purpura, D. P., J. K. Penry, D. M. Woodbury, D. B. Tower, and R. D. Walter. Experimental Models of Epilepsy. New York: Raven Press, 1972. 69. Rasmussen, T., J. Olszewski, and D. Lloyd-Smith. Focal seizures due to chronic encephalitis and epilepsy. Neurology 1958;8:435–445. 70. Scholz, W. The contribution of pathoanatomical research to the problem of epilepsy. Epilepsia 1959;1:36–55. 71. Scholz, W. Die Krampfschädigungen des Gehirns. Berlin: Springer, 1951. 72. Scholz, W. Über die Entstehung des Hirnbefundes bie der Epilepsie. Ztg. Ges. Neurol. Psychiatr. 1933;145:471–515. 73. Shorvon, S. D. Status Epilepticus: Its Clinical Features and Treatment in Children and Adults. Cambridge, U. K.: Cambridge University Press, 1994:1–382. 74. Sloviter, R. S. “Epileptic” brain damage in rats induced by sustained electrical stimulation of the perforant path. I. Acute
8
75.
76.
77.
78. 79. 80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90. 91. 92.
electrophysiological and light microscopic studies. Brain. Res. Bull. 1983;10:675–697. Sloviter, R. S., and B. P. Damiano. Sustained electrical stimulation of the perforant path duplicates kainate-induced electrophysiological effects and hippocampal damage in rats. Neurosci. Lett. 1981;24:279–284. Sloviter, R. S., E. Dean, A. L. Sollas, and J. H. Goodman. Apoptosis and necrosis induced in different hippocampal neuron populations by repetitive perforant path stimulation in the rat. J. Comp. Neurol. 1996;366:516–533. Sommer, W. Erkrankung des Ammonshornes als aetiologisches Moment der Epilepsie. Arch. Psychiatr. Nervenkr. 1880;10: 631–675. Spielmeyer, W. Die Pathogenese des Epileptischen Krampfes. Zeitschr. Ges. Neurol. Psychiatr. 1927;109:501–520. Stauder, K. H. Epilepsie und Schlafenlappen. Arch. Psychiatr. Nervenkr. 1935;104:181–211. Taylor, J. Selected Writings of Hughlings Jackson. Vol. 1. On Epilepsy and Epileptiform Convulsions. London: Hodder & Stoughton, 1931. Teitelbaum, J. S., R. J. Zatorre, S. Carpenter, D. Gendron, A. C. Evans, A. Gjedde, and N. R. Cashman. Neurologic sequelae of domoic acid intoxication due to the ingestion of contaminated mussels. N. Engl. J. Med. 1990;322:1781– 1787. Thompson, K., A. M. Holm, A. Schousboe, P. Popper, P. Micevych, and C. Wasterlain. Hippocampal stimulation produces neuronal death in the immature brain. Neuroscience 1998;82:337–348. Thompson, K., and C. Wasterlain. Partial protection of hippocampal neurons by MK-801 during perforant path stimulation in the immature brain. Brain Res. 1997;751: 96–101. Treiman, D. M., and A. V. Delgado-Escueta. Complex partial status epilepticus. In A. V. Delgado-Escueta, C. G. Wasterlain, D. M. Treiman, and R. J. Porter, eds. Status Epilepticus: Mechanisms of Brain Damage and Treatment. New York: Raven Press, 1983:69–81. Treiman, D. M., P. D. Meyers, N. Y. Walton, J. F. Collins, et al. A comparison of four treatments for generalized convulsive status epilepticus. N. Engl. J. Med. 1998;339: 792–798. Trousseau, A. Lectures on Clinical Medicine Delivered at the Hotel Dieu, Paris. Vol. 1 (P. V. Bazire, trans.). London: New Sydenham Society, 1868. Turski, L., C. Ikonomidou, W. A. Turski, Z. A. Bortolotto, and E. A. Cavalheiro. Review: Cholinergic mechanisms and epileptogenesis. The seizures induced by pilocarpine: A novel experimental model of intractable epilepsy. Synapse 1989;3:154–171. Tuunanen, J., T. Halonen, and A. Pitkänen. Status epilepticus causes selective regional damage and loss of GABAergic neurons in the rat amygdaloid complex. Eur. J. Neurosci. 1996;8:2711–2725. Veith, G. Anatomische Studie über die Ammonshornesklerose im Epileptikergehirn. Dtsch. Ztg. Nerv. 1970;197:293– 314. Wasterlain, C. G. Mortality and morbidity from serial seizures: An experimental study. Epilepsia 1974;15:155–174. Wasterlain, C. G. Recurrent seizures in the developing brain are harmful. Epilepsia 1997;38:728–734. Wasterlain, C. G., and T. E. Duffy. Status epilepticus in immature rats. Arch. Neurol. 1976;33:821–827.
: , , ,
93. Wasterlain, G. G., D. G. Fujikawa, L. Penix, and R. Sankar. Pathophysiological mechanisms of brain damage from status epilepticus. Epilepsia 1993;34:S37-S53. 94. West, W. J. On a peculiar form of infantile convulsions. Lancet 1841;1:724–725. 95. Whitty, C. W. M., and M. Taylor. Treatment of status epilepticus. Lancet 1949;2:591–594. 96. Wieser, H. G., H. P. Graf, C. Bernoulli, and J. Siegfried. Quantitative analysis of intracerebral recordings in epilepsia partialis continua. Electroencephalogr. Clin. Neurophysiol. 1977;44: 558–572. 97. Williamson, P. D., J. A. French, and V. M. Thadani. Characteristics of medial temporal lobe epilepsy. II. Interictal and ictal scalp electroencephalography, neuropsychological testing, neuroimaging, surgical results, and pathology. Ann. Neurol. 1993;34:781–787. 98. Wolf, P. Zur Klinik und Psychopathologie des Status Psychomotoricus. Nervenarzt 1970;41:603–610. 99. Zimmerman, H. M. The basis of convulsive attacks in children: An experimental study. N. Y. Pathol. Soc. 1959;35: 801–810. 100. Zimmerman, H. M. The histopathology of convulsive disorders in children. J. Pediatr. 1938;13:859–890.
:
9
2
Definition and Classification of Status Epilepticus
. .
Definition Status epilepticus (SE) is one of the few illnesses named not by the physicians who treated it but by the patients who suffered from it. The expression état de mal was coined by the patients at the Salpêtrière, the world’s first neurologic hospital, and reached the medical literature through the doctoral thesis of Louis Calmeil (6), then became latinized as status epilepticus in Bazire’s English translation of the 1867 lectures of Armand Trousseau in London (44). Although Trousseau and Bourneville (5) recognized the existence of stages in SE, and Clark and Prout (9) identified SE as being different from single epileptic seizures, the first attempt at a formal definition came at the 1962 Marseilles Colloquium, where Gastaut defined it as “epileptic seizures which are so frequently repeated and so prolonged as to create a fixed and enduring epileptic condition” (15). The definition and classification of SE were further refined by Gastaut in the World Health Organization’s 1973 publication, Dictionary of Epilepsy (18), in the 1974 Handbook of Clinical Neurology (35), and in the 1975 Handbook of Electroencephalography and Clinical Neurophysiology (20). Gastaut also proposed a formal classification of status epilepticus (Table 2.1) at the first Santa Monica meeting, in 1980 (12, 16). C B D SE Is SE simply a cluster of severe seizures, or is it a separate condition with its own unique pathophysiology? Trousseau expressed the uniqueness of SE as early as 1867: “In that form of status epilepticus when the convulsions are practically continuous, something specific happens which demands an explanation” (44). Indeed, recent experimental evidence strongly suggests that SE is a separate phenomenon and not simply a series of seizures. Seizure-like stimulation of some excitatory pathways in the brain easily triggers SE. Once it is established, stimulation can be stopped and seizures continue. Moreover, these self-sustaining seizures can be suppressed for hours with a synaptic blocker, yet when that blocker’s effects wane, the seizures return in the absence of any further stimulation, implying that self-sustaining SE is maintained by an underlying change in excitability (31). The transition from serial seizures to SE is modulated by neuropeptides, neurotrans-
mitters, and receptor trafficking (29–31), and anticonvulsants that are effective against serial seizures are often ineffective against established, self-sustaining SE (32). At the second Santa Monica meeting (37) there was a vigorous debate over the basis for defining and classifying SE. Many participants suggested definitions based on seizure durations ranging from 5 to 30 minutes. Others defined SE by the subject’s failure to recover consciousness before seizure recurrence. This criterion is retained in our definition, since it permits the inclusion of cases in which severe seizures are associated with long interictal intervals. Engel has proposed that SE is defined by the failure of normal mechanisms to terminate a seizure (14). A logical conclusion of that premise would be to define SE statistically, as a seizure duration that is clearly outside the range of “normal” seizure duration, for example 5 standard deviations (SD) removed from the mean. The definition of SE proposed later in the chapter is in accord with that line of thought. T C “I SE” Ever since Gastaut defined SE as a fixed and enduring epileptic condition, the medical literature has struggled to determine the minimal duration and severity of seizures that constitute SE. Simple as it may be, such a determination is essential to clinical trials and therapeutic guidelines. Some of the dilemmas created by these attempts at a more precise definition are discussed in Shorvon’s outstanding book (36) and are beyond the scope of this chapter. Yet we must recognize that seizures are rarely fixed, that the boundaries of what constitutes a seizure vary with the method of observation (e.g., electroencephalographic [EEG] or clinical), and that the most useful definition may vary with our main objective. For example, many epileptologists apply the treatment of status when faced with the admittedly unusual event of continuous generalized motor seizures lasting 5 minutes, which suggests that a seizure duration of 5 minutes meets their operational definition of SE. Reducing the definition of status to that extent, however, would enormously complicate epidemiologic studies by including in population studies a large number of patients who may not experience full-blown SE.
:
11
T 2.1 1983 classification of SE Primary Generalized Convulsive Status Tonic-clonic status Myoclonic status Clonic-tonic-clonic status Secondary Generalized Convulsive Status Tonic-clonic status with partial onset Tonic status Subtle generalized convulsive status Simple Partial Status Partial motor status Unilateral status Epilepsia partialis continua Nonconvulsive Status Absence status—typical or atypical Complex partial status
C B D B S D The duration of what is accepted as SE has been shrinking progressively, from 30 minutes in the guidelines of the Epilepsy Foundation of America’s Working Group on Status Epilepticus (51) to 20 minutes (2), and to 10 minutes in the Veterans Affairs (VA) cooperative trial on the treatment of SE (42). Most recently, Wasterlain (at the 1997 Santa Monica meeting), Lowenstein and Alldredge (25), Lowenstein, Bleck, and Macdonald (26), and Meldrum (33) have proposed an operational definition of SE that defines the time when severe seizures should be treated as SE. Those several authors have proposed that 5 minutes of continuous generalized convulsive seizures is sufficient to fulfill that criterion. Videotape-telemetry studies show that the mean duration of generalized convulsive seizures in adults ranges from 62.2 seconds (n = 120) to 52.9 ± 14 seconds (n = 50) (very close to the 1-minute estimate of Gastaut and Broughton [19]) for the behavioral manifestations and averages 59.9 ± 12 seconds for the EEG manifestations. None of those seizures lasted 2 minutes (21, 39). Therefore, the operational definition of SE as 5 minutes of continuous generalized convulsive activity is probably too conservative, since it defines status by a seizure duration that is 18–20 SD removed from the norm, restricting it to an extremely rare event. It might be more logical to treat with intravenous (IV) drugs after 2 minutes of continuous seizure activity (4–5 SD outside the norm), as proposed by Theodore and colleagues (39). However, in practice, there is essentially no difference between 2 and 5 minutes, since it takes more than 3 minutes to deliver the first IV injection. A definition of 5 minutes of continuous seizures has two advantages: first, it reconciles the definition of status with
12
the almost universal emergency room practice of treating those patients as if they had SE, and second, it places the definition of status far outside the norm for seizure duration, clearly indicating that something distinctly unusual and severe is occurring. However, we propose to call it impending status epilepticus, since not all such patients are in SE, and a significant proportion will stop seizing spontaneously in the next few minutes. The Richmond data provide support for this concept: more than 40% of the seizures lasting from 10 to 29 minutes stopped spontaneously without treatment (32), and they had an overall mortality of 2.6% versus 19% for SE (P < 0.001). We define impending status epilepticus as “continuous seizures lasting more than 5 minutes, or intermittent clinical or electrographic seizures lasting over 15 minutes without full recovery of consciousness between seizures.” This recognizes the need to treat those patients intravenously with high-dose anticonvulsants, since their risk of developing frank SE is high, but it also acknowledges that not all of those patients are in frank SE. By adopting a new category of impending SE, these patients will receive proper urgent medical care but will not contaminate morbidity and mortality statistics, outcome measures, or clinical trials with a subpopulation that is not in frank SE. Frank SE continues to use the definition of the EFA’s working group on SE. We also agree with Shorvon (36) and others that different definitions and classifications are needed for different age groups. The current definition should apply to adults and children over 5 years of age. Different criteria should be used for neonates, and yet other criteria for infants and young children. We will not discuss in this chapter the definition of SE in the neonate (for which we refer the reader to Shorvon’s 1994 book [36] and to Wasterlain and Vert’s book, Neonatal Seizures [48]), or the definition of SE in infants and children. In that age group, the high incidence of febrile seizures, which frequently last longer than 5 minutes (22), and their generally benign outcome may change the risk-benefit ratio of status versus treatment, so that most physicians have retained the traditional definition of SE as seizures lasting more than 30 minutes. E B D B S D The traditional argument that SE should be defined as the minimal duration of seizure that produces brain damage has collapsed with the demonstration (7) that even single seizures without a tonic component can produce neuronal loss in experimental animals. We know that generalized convulsive seizures in primates produce neuronal death much more quickly than nonconvulsive seizures (34), and therefore deserve prompt therapeutic attention, but we have no solid data on the minimum seizure duration sufficient to damage the human brain. On the other hand, the demonstration in animal experiments that repeated, brief, seizurelike discharges through excitatory pathways set in motion
: , , ,
self-sustaining seizures (32, 45, 47), which rapidly become resistant to standard anticonvulsants (29), would suggest that treatment should be administered before self-sustaining seizures become established. In the rat, this can take place within 15 minutes (32) or 10 afterdischarges (45). Unfortunately, we have little information on the timing or even the existence of these phenomena in humans. Therefore, experimental data give us a sense of urgency without providing us with a precise time frame for defining or treating SE. I T R O? Intravenous medications undoubtedly entail significant risks: respiratory and even cardiovascular depression can result, some anticonvulsants impair cardiac conduction and can generate arrhythmias, allergic reactions often take the form of anaphylactic shock, idiosyncratic reactions may be more severe than with other forms of administration. Therefore, single generalized seizures that have not been documented to last more than 2 minutes and seizures that are benign or remain focal should not be treated with IV anticonvulsants; oral loading is usually feasible and much safer. A D I SE We propose the following definition, which should be used by clinicians making diagnostic and therapeutic decisions: An acute epileptic condition characterized by continuous generalized convulsive seizures for at least 5 minutes, or by continuous nonconvulsive seizures (clinical or electrographic) or focal seizures for at least 15 minutes, or by two seizures without full recovery of consciousness between them.
A D SE We propose the following definition of SE, which should be used by epidemiologists and other clinical investigators conducting studies of SE: An acute epileptic condition characterized by continuous seizures (partial or generalized, convulsive or nonconvulsive) for at least 30 minutes, or by 30 minutes of intermittent seizures without full recovery of consciousness between seizures.
Classification It is not often recognized that classifications have specific purposes and that several classifications of the same phenomenon can be useful, depending on their goal. Many useful classifications of SE have been published and will not be repeated here. They are based on the symptomatology of the seizures (such as the 1983 classification by Gastaut, given in Table 2.1, or the classifications of Walsh and Delgado-Escueta [46] or Leppik [23]) or on the epileptic syndromes (36), with limited attempts at using pathophysiology (43). We propose two new classifications for specific purposes: first, a therapeutically oriented “clinical” classification of status, which should be helpful in directing treatment, and second, a semiologic classification,
which should be useful for a precise description of seizure phenomenology and for accurate categorization of all the seizure types involved in SE. These attempts are inspired by the systems proposed during the current discussions for new classifications of epileptic seizures. A C C Semiologic classifications, while providing an accurate description that is useful for later comparison or for following the evolution of the illness, do not provide therapeutic guidance for the clinician. The treatment-oriented classification (Table 2.2) outlined below divides SE according to a mix of clinical, EEG, and therapeutic criteria into broad categories that are therapeutically
T 2.2 A clinical classification of status epilepticus Generalized Convulsive Status Epilepticus Tonic-clonic (frank or subtle) or clonic-tonic-clonic: With focal onset (clinical or EEG) With generalized onset (clinical and EEG) Tonic Clonic Myoclonic Multifocal (clinical or EEG) Generalized (clinical and EEG) Treat vigorously with rapid IV infusion of high doses of anticonvulsants. The seizure type determines the choice of anticonvulsant. Exceptions include intolerance to a particular drug. Complex Partial (Limbic) Status Epilepticus Treat as for GCSE with focal onset. Exceptions: same as for GCSE. Absence Status Epilepticus (Spike-Wave Stupor) Treatment is controversial, usually with IV benzodiazepines. Electrographic Status Epilepticus Generalized with impairment of consciousness: Usually a form of “subtle” SE; treat as for GCSE. Generalized without impairment of consciousness: No need for IV treatment. During sleep: No need for IV treatment. Focal: No need for IV treatment. Unilateral Status Epilepticus With spread to hemiconvulsions: Treat as for GCSE. Epilepsia partialis continua: No need for IV treatment. Note: By clinical we mean an operational (treatment-oriented) classification of SE that facilitates the clinician’s therapeutic decisions. This classification does not address neonatal SE or SE in infancy or early childhood, which includes febrile SE. It should be used only for children more than 5 years old and for adults. Abbreviations: SE, status epilepticus; GCSE, generalized convulsive status epilepticus; EEG, electroencephalography; IV, intravenous.
:
13
meaningful, and provides a useful complement to the semiologic, syndrome-oriented, and pathophysiologic classifications described by others (36). For example, from a therapeutic viewpoint, it makes no difference whether generalized convulsive status epilepticus (GCSE) is tonicclonic or clonic-tonic-clonic, or whether it is primary or secondarily generalized, since both will be treated the same way, and thus they have not been separated here, despite the great differences in etiology and seizure mechanisms between them. Therefore, the inclusion of therapeutic criteria differentiates this “clinical” classification from Gastaut’s 1983 (16) classification and from the International League Against Epilepsy’s classification of epileptic seizures (10, 11, 15). Similarly, complex partial and absence seizures are sometimes difficult to differentiate on clinical grounds alone, but because they are therapeutic opposites, one must carefully differentiate between them before treating, and therefore they are placed in completely different categories here (but not in the semiologic classification that follows). A brief list of key therapeutic exceptions is included in the classification. Tonic SE associated with Lennox-Gastaut syndrome, for example, can be aggravated by benzodiazepines (38), which are usually quite beneficial in tonic status symptomatic of frontal lobe lesions in adults. GCSE in the progressive myoclonus epilepsies is often dramatically triggered by fosphenytoin or phenytoin, agents that are most useful in treating other forms of GCSE (1, 24). Finally, the clinical manifestations of frank and “subtle” SE (40, 41) are quite different, yet these conditions are grouped in the same category because they require the same treatment. Semiologic classifications have advantages and drawbacks; they give us a tool to accurately describe the seizures and are useful for the clinical localization of the seizure focus. Since their purpose is simply to accurately describe and classify seizure behavior, our classification excludes pathophysiologic, EEG, or syndromal considerations, which would contaminate the objective description of the seizures (see Table 2.3). For example, partial complex SE and absence SE are very different entities, requiring different treatments, yet both are manifested primarily by a clouding of consciousness, and they may be impossible to distinguish in the absence of additional data, such as past history, EEG, or associated manifestations. A semiologic classification should make no attempt to interpret the clouding of consciousness by bringing in these extraneous considerations, but because it separates description from interpretation and achieves a very precise and objective description of the type of seizures observed, it greatly facilitates both diagnostic and therapeutic decisions. The current classification is inspired by the Cleveland Clinic’s classification of epileptic seizures (27) and uses both a classification of the type of SE and a classification of the type of individual seizure observed during status.
14
D T SE Our description characterizes the pattern of seizure activity rather than the details of each individual seizure. GCSE usually manifests with intermittent generalized motor seizures “strung like red beans on a black thread of unconsciousness” (49). It is important to recognize that both clinical and EEG manifestations are not fixed but evolve during the course of status. For example, the motor manifestations of GCSE may become more limited and less vigorous with time, without losing their significance. This, of course, is the “subtle” form of GCSE (40). Because complex partial and absence seizures cannot always be distinguished clinically, the most accurate term to describe them is “generalized nonconvulsive status epilepticus,” since essentially all generalized nonconvulsive seizures manifest with an impairment of consciousness (the term dialeptic, with interruption, also provides a good description of the phenomenon). It is also important to recognize that most patients experience only a partial impairment of consciousness; the complete loss of contact seen at the onset of partial complex or absence seizures evolves with time into a “cloudy state” in which some consciousness is retained. This evolution may represent the nonconvulsive equivalent of “subtle” GCSE. For each patient, the description should include the type of status, followed by a detailed sequential description of seizure types. D S T Because seizures frequently wax and wane during SE, in a semiologic classification it is most useful to describe them as a sequence. A seizure type needs to be described accurately for each seizure, and successive seizures can be described simply in chronological order (for example, left thumb clonic Æ left corner of mouth clonic Æ left arm clonic Æ left hemiconvulsion Æ generalized). From a semiologic viewpoint, Gastaut’s statement that “there are as many types of status epilepticus as there are types of epileptic seizures” is undoubtedly correct. A few individual seizure types require comment. Complex motor seizures include seizures with manifestations, such as motor automatisms, that are frequently associated with psychic phenomena but are inherently composed of complex motor activity, and other manifestations such as versive or dystonic movements. Complex motor seizures include inhibitory motor seizures, which are sometimes hard to distinguish from postictal manifestation, and include weakness or paralysis, seizures with loss of posture, falls (head drop), negative myoclonus, astatic seizures with ictal falls not necessarily due to a loss of tone, and aphasic seizures in which a patient develops speech arrest or inability to understand spoken language. Sensory seizures can also have positive or negative manifestations and may be simple or complex. They may involve any of the senses and are relatively common. They are classified as sensory if the sensory manifestations are the main
: , , ,
T 2.3 A semiologic classification of status epilepticus Type of Status Epilepticus Generalized convulsive Frank Subtle Nonconvulsive with loss of consciousness (dialeptic) With complete loss of consciousness With partial loss of consciousness Partial Convulsive Nonconvulsive Type of Seizure Motor Simple Tonic Clonic Myoclonic Complex Versive Dystonic Automatisms Other (e.g., salaam, pedaling) Inhibitory Paralytic Atonic Astatic Akinetic Negative myoclonic Aphasic Sensory Somatosensory: simple, complex Auditory: simple, complex Visual: simple, complex Olfactory: simple, complex Gustatory: simple, complex Psychic With cognitive manifestations With psychiatric manifestations Autonomic Dialeptic With complete loss of consciousness With partial loss of consciousness Modifiers: Left, right, bilateral, symmetric, asymmetric, axial, generalized; specific symptom and location (e.g., left arm clonic seizure; dialeptic seizure with orobuccal automatisms) Indicate sequence (e.g., versive-loss of consciousness-tonicclonic) Indicate duration, especially for loss of consciousness. Indicate frequency, pattern of occurrence, precipitants, severity and postictal deficits.
component of the seizure, and as psychic if the complexity of the sensory phenomena makes the psychic component dominant. They include manifestations such as gelastic seizures, visual distortions such as macropsia or micropsia, and complex somatosensory phenomena such as the feeling of a wind passing over one’s body (aura). The duration of isolated seizures is much shorter for absences (seconds) than for complex partial seizures (30 seconds to 2 minutes), but this distinction blurs during the evolution of SE and becomes useless. Some myoclonic states, such as postanoxic multifocal myoclonus following cardiac arrest (8) or the prolonged negative myoclonic seizures seen in benign neonatal convulsions (idiopathic) or in Aicardi’s syndrome or Ohtahara’s syndrome, are not included in this classification. We agree with Shorvon (36) that they should be classified under “status myoclonicus.” This work was supported by the Research Service of VHA (CGW) and by Research Grant NS 13515 from NINDS (CGW), and by a K08 Award from NINDS ( JWYC).
REFERENCES 1. Aminoff, M., and R. Simon. Status epilepticus: Causes, clinical features and consequences in 98 patients. Am. J. Med. 1980;69:657–666. 2. Benbadis, S. R., P. Thomas, and G. Pontone. A prospective comparison between two seizure classifications. Seizure 2001; 10:247–249. 3. Bleck, T. P. Convulsive disorders: Status epilepticus. Clin. Neuropharmacol. 1991;14:191–198. 4. Blume, W. T., S. F. Berkovic, and O. Dulac. Search for a better classification of the epilepsies. In J. Engel, Jr., and T. A. Pedley, eds. Epilepsy: A Comprehensive Textbook. Philadelphia: LippincottRaven, 1998:779–788. 5. Bourneville, D. L’état de mal epileptique. In Recherches cliniques et therapeutiques sur l’epilepsie et l’hysterie. Compte-rendu des observations recueillies a la Salpêtrière. Paris: Delahaye, 1876. 6. Calmeil, L. F. De l’epilepsie, étudies sous le rapport de son siege et de son influence sur la production de l’alienation mentale. Thesis, University of Paris, 1824. 7. Cavazos, J. E., and T. P. Sutula. Progressive neuronal loss induced by kindling: A possible mechanism for mossy fiber synaptic reorganization and hippocampal sclerosis. Brain Res. 1990;527(1):1–6. 8. Celesia, C. G., M. M. Grigg, and E. Ross. Generalized status myoclonicus in acute anoxic and toxic-metabolic encephalopathies. Arch. Neurol. 1988;45:781–784. 9. Clark, L., and T. Prout. Status epilepticus: A clinical and pathological study in epilepsy. Am. J. Insanity 1903–1904;60: 291–306. 10. Commission on Terminology of the International League Against Epilepsy. A proposed international classification of epileptic seizures. Epilepsia 1964;5:297–306. 11. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489–501.
:
15
12. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30:389–399. 13. Delgado-Escueta, A. V., A. A. Ward, Jr., D. M. Woodbury, and R. J. Porter, eds. Basic Mechanisms of the Epilepsies: Molecular and Cellular Approaches. Adv. Neurol. 1986;44 (whole issue). 14. Engel, J., Jr. Classification of the International League Against Epilepsy: Time for reappraisal. Epilepsia 1998;39:1014–1017. 15. Gastaut, H. A propos d’une classification symptomatologique des états de mal epileptiques. In H. Gastaut, J. Roger, and H. Lob, eds. Les états de mal epileptiques. Paris: Masson, 1967:1–8. 16. Gastaut, H. Classification of status epilepticus. Adv. Neurol. 1983;34:15–35. 17. Gastaut, H. Clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1970;11:102–113. 18. Gastaut, H., ed. Dictionary of Epilepsy. Part 1. Definition. Geneva: World Health Organization, 1973. 19. Gastaut, H., and R. Broughton. Epileptic Seizures: Clinical and Electrographic Features, Diagnosis and Treatment. Springfield, Ill.: Charles C Thomas, 1972:25–90. 20. Gastaut, H., and A. Tassinari. Handbook of Electroencephalography and Clinical Neurophysiology. 1975. 21. Kramer, R., and P. Levisohn. The duration of secondarily generalized tonic-clinic seizures (abstract). Epilepsia 1992;33:68. 22. Lennox-Buchthal, M. A. Febrile convulsions. In Handbook of Clinical Neurology. Vol. 15. The Epilepsies (O. Magnus and A. M. Lorentz de Haas, eds.). Amsterdam: North Holland Publishing Co., 1974:246–263. 23. Leppik, L. E. Status epilepticus. Neurol. Clin. 1986;4:633–643. 24. Lowenstein, D., and B. Alldredge. Status epilepticus at an urban public hospital in the 1980s. Neurology 1993;43:483–488. 25. Lowenstein, D. H., and B. K. Alldredge. Current concepts: Status epilepticus. N. Engl. J. Med. 1998;338:970–976. 26. Lowenstein, D. H., T. Bleck, and R. L. Macdonald. It’s time to revise the definition of status epilepticus. Epilepsia 1999;40: 120–122. 27. Luders, H., et al. A new epileptic seizure classification based exclusively on ictal semiology. Acta Neurol. Scand. 1999;99(3): 137–141. 28. Luders, H., et al. Semeiological seizure classification. Epilepsia 1998;39:1006–1013. 29. Mazarati, A. M., R. A. Baldwin, R. Sankar, and C. G. Wasterlain. Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. Brain Res. 1998;814:179–185. 30. Mazarati, A. M., H. Liu, and C. G. Wasterlain. Opioid peptide pharmacology and immunocytochemistry in an animal model of self-sustaining status epilepticus. Neurosci. 1999;89:167–173. 31. Mazarati, A. M., and C. G. Wasterlain. N-methyl--asparate receptor antagonists abolish the maintenance phase of selfsustaining status epilepticus in rat. Neurosci. Lett. 1999;265: 187–190. 32. Mazarati, A. M., C. G, Wasterlain, R. Sankar, and D. Shin. Self-sustaining status epilepticus after brief electrical stimulation of the perforant path. Brain Res. 1998;18:10070–10077. 33. Meldrum, B. S. The revised operational definition of generalized tonic-clonic (TC) status epilepticus in adults (comment). Epilepsia 1999;40:123–124. 34. Meldrum, B. S., and J. B. Brierley. Prolonged epileptic seizures in primates: Ischemic cell change and its relation to ictal physiological events. Arch. Neurol. 1973;28:10–17.
16
35. Roger, J., H. Lob, and C. A. Tassinari. Status epilepticus. In Handbook of Clinical Neurology. Vol. 15. The Epilepsies (O. Magnum and A. M. Lorentz de Haas, eds.). Amsterdam: North Holland Publishing Co. 1974:145–188. 36. Shorvon, S. Status Epilepticus: Its Clinical Features and Treatment in Children and Adults. Cambridge, U.K.: Cambridge University Press, 1994. 37. Status Epilepticus: Mechanisms and Management. An International Symposium. Abstracts of the Second International Conference on Status Epilepticus, Santa Monica, Calif., 1997. 38. Tassinari, C. A., C. Dravet, J. Roger, J. P. Cano, and H. Gastaut. Tonic status epilepticus precipitated by intravenous benzodiazepine in five patients with Lennox-Gastaut syndrome. Epilepsy 1972;13:421–435. 39. Theodore, W., R. Porter, P. Albert, et al. The secondarily generalized tonic-clonic seizure: A videotape analysis. Neurology 1994;44:1403–1407. 40. Treiman, D. Generalized convulsive status epilepticus in the adult. Epilepsia 1993;34(Suppl. 1):S2–S11. 41. Treiman, D., C. DeGiorgio, S. Salisbury, and C. Wickholdt. Subtle generalized convulsive status epilepticus. Epilepsia 1984;25:263. 42. Treiman, D., P. Meyers, N. Walton, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus: Cooperative Study Group. N. Engl. J. Med. 1998;330:792–798. 43. Treiman, D. M., N. Y. Walton, C. Wickboldt, and C. DeGiorgio. Predictable sequence of EEG changes during generalized convulsive status epilepticus in man and three experimental models of status epilepticus in the rat. Neurology 1987;37:244–245. 44. Trousseau, A. Lectures on Clinical Medicine Delivered at the Hotel Dieu, Paris, 1868. Vol. 1. (P. V. Bazire, trans.). London: New Sydenham Society, 1868. [Clinique medicale de L’Hotel-de Paris, tome Ire. Paris: Bailliere et Fils, 1868]. 45. Vicedomini, J. P., and J. V. Nadler. A model of status epilepticus based on electrical stimulation of hippocampal afferent pathways. Exp. Neurol. 1987;96:681–691. 46. Walsh, G. O., and A. V. Delgado-Escueta. Status epilepticus. Neurol. Clin. 1993;11:835–856. 47. Wasterlain, C. G. Mortality and morbidity from serial seizures: An experimental study. Epilepsia 1974;15:155–176. 48. Wasterlain, C. G., and P. Vert. Neonatal Seizures. New York: Raven Press, 1990. 49. Wilson, S. Neurology. Baltimore: Williams & Wilkins, 1940. 50. Wolf, P. International classification of the epilepsies. In J. Engel, Jr., and T. A. Pedley, eds. Epilepsy: A Comprehensive Textbook. Philadelphia: Lippincott-Raven, 1998:773–778. 51. Working Group on Status Epilepticus. Treatment of convulsive status epilepticus: Recommendation of the Epilepsy Foundation of America’s Working Group on Status Epilepticus. JAMA 1993;270:854–859.
: , , ,
3
Incidence and Causes of Status Epilepticus
.
Introduction This chapter reviews the epidemiology and clinical presentation of status epilepticus (SE) in Richmond, Virginia. A database was established at Virginia Commonwealth University to accrue the first population-based information on the natural presentation of SE in a controlled and validated community setting. SE occurred with an absolute incidence of 41 patients per 100,000 population per year in Richmond, Virginia. The frequency of total SE occurrences was 50 patients per 100,000 residents per year, and the overall mortality in this population was 22%. The elderly population had a mortality exceeding 38%. In addition, infants less than one year old were found to have the highest incidence of SE in the overall Richmond population, but the overall elderly population as a major age group had the largest number of cases in comparison to pediatric and young adult cases. The absolute incidence and occurrences of SE in this population proved to be underestimates because of inability (for various reasons) to document all cases of SE. Using validation mechanisms, the underreporting of SE in hospital charts and by physicians was corrected, and estimates for the occurrence of SE were obtained. Extrapolating from the Richmond database, more than 4.5 million cases of SE occur worldwide every year, with almost 1 million deaths per year. The costs associated with SE in the United States may exceed $4.5 billion annually. These figures—prevalence rates and costs—indicate not only the severity and significance of clinical SE, but also the potential costs to society in terms of dollars and chronic health care problems. In Richmond, nonwhite patients had a much higher incidence of and mortality from SE than white patients. Partial SE was the most common form of seizure initiating SE, and generalized tonic-clonic SE was the most common final stage of seizure type in SE. Age, etiology, and seizure duration were found to contribute to mortality. Acute and remote cerebrovascular accidents were the major causes in adults, and infections with fever were the most common cause in children. A significant number of individuals with SE had no previous history of epilepsy. In the elderly population, 70% of the patients had no previous history of epilepsy. The role of the genetic predisposition to
develop SE in contributing to the frequency and presentation of SE in the population is presented. The results of this study provide a summary of the first population-based epidemiological study on SE and provide important clinical features and outcome data on this major medical and neurological condition presenting in both academic and community hospital settings in the Richmond, Virginia, area.
Status epilepticus Status epilepticus is a major neurologic and medical emergency (14, 15). The acute medical management of this condition has been extensively reviewed (2, 4, 5, 11, 13, 15, 21, 31, 34, 38, 41, 44, 54, 57–59). Although there have been several advances in the treatment of this condition over the last three decades, SE is still associated with one of the highest morbidities and mortalities of any neurologic condition (1, 3, 7, 8, 12, 18–20, 22, 24, 25, 27, 32, 33, 36, 39, 42, 46, 47, 53, 56), and therefore the clinical presentation of this condition and the cause of its high mortality need careful investigation. SE is difficult to study because it occurs not only in people with epilepsy but also in individuals with acute systemic and neurologic illnesses (18, 19, 24, 25, 39). Thus, SE is not a simple unified entity, and sophisticated clinical evaluation of large population-based studies is needed before any generalizations about clinical outcome, causes of morbidity and mortality, and treatment can be made. Despite the complexity of the clinical presentation of SE, several studies of SE have provided information concerning some of the important clinical features of this condition (2–5, 13, 20–22, 24, 25, 31, 32, 34, 35, 38, 39, 41, 42, 44, 53–55, 58) and have yielded insights into factors predictive of outcome (25, 28, 32, 39, 50, 53). The initial clinical studies on SE provided many insights into this clinical condition. Epidemiologic data from retrospective analyses (24) and some preliminary prospective data (20) have also allowed an estimate of the natural rate of SE in a population. However, as emphasized by Hauser (24), there is a significant need for prospective, population-based studies of SE to obtain a comprehensive picture of this complex condition. Furthermore, data obtained in hospital-based, tertiary
:
17
care facilities may not be completely relevant to the overall medical community and the total presentation of SE. Thus, to obtain a fuller understanding of SE, it is essential to conduct prospective, population-based studies of SE in a well-characterized community setting. This chapter reviews data obtained by the Virginia Commonwealth University Status Epilepticus Research Study, a validated, populationbased, prospective study of SE in Richmond (12, 18, 19). The data have provided new insights into this important clinical condition.
First population-based epidemiologic study of SE To study the epidemiology of SE, a large population-based, prospectively collected database of cases of SE seen in the Richmond metropolitan area was established at Virginia Commonwealth University (18, 19). The database includes information on patients presenting to all hospitals in the greater Richmond metropolitan area (Figure 3.1). Both academic and community hospitals are represented. Patients residing in the city of Richmond who experienced SE while in a neighboring suburb and who went to a hospital not within the city limits of Richmond were therefore included in the database. SE cases were prospectively identified by the SE research team and evaluated on a daily basis. The case histories and charts of all persons with potential SE were reviewed in order to determine whether each identified case met the International League Against Epilepsy (ILAE) criteria for SE (19). Thus, only individuals with continuous seizures or intermittent seizures without regaining consciousness for 30 minutes or longer were included in the database. The ILAE definition of SE was used so that all identified cases would meet the current standards of inclusion for the definition of SE. The SE research team was on call round-the-clock so as to collect accurate data on the clinical presentation of SE in a prospective, timely manner. Approximately 80% of the potential SE cases reviewed met the ILAE definition of SE. The ILAE definition is rigorous, however, and because not all cases of SE can be completely documented to meet it (because of an unreliable history or unknown duration of SE), the incidence as reported in any study represents an underestimate of the true incidence and presentation of SE in the community. This observation notwithstanding, the Virginia Commonwealth University database is as representative as possible. Clinical research has indicated that a reexamination of the definition of SE is needed (16, 40, 49, 50, 52). Initial data obtained in epilepsy monitoring units indicated that tonic-clonic seizures lasted less than 2 minutes (52), and that more than 90% of routine seizures lasted less than 1 minute. Based on these observations, it has been suggested that the definition of SE be changed to include seizures lasting any-
18
F 3.1 Presentation and intake of patients in the Virginia Commonwealth University SE study. Patients presenting with SE in the greater Richmond metropolitan area (GRMA) enter the database from community hospitals and the MCV Hospital. Community hospital patients are identified by physician referral. Clinical information is entered into the database by form entry and coordinated in the relational database. Patients from the MCV Hospital who are entered into the database are treated for SE and hospitalized in the intensive care unit (ICU) or inpatient services, depending on their clinical condition. Patients admitted to the hospital are handled in the same manner as the community hospital patients and are evaluated with form entry and inclusion in the relational database. Patients admitted to the ICU offer special opportunities for advanced research studies on outcome and physiologic effects on mortality and morbidity. These patients are evaluated both with form entry and with continuous computer monitoring of physiologic parameters such as blood pressure, pulse, intracranial pressure, and other electrophysiologic data, such as EEG and evoked potentials. These data are both entered into the relational database, and also stored and analyzed by the computer monitoring laboratory facility, which provides a unique opportunity to collect data on acute SE. Data on all patients are then analyzed in the relational database and used for outcome studies or for epidemiologic evaluation. This analysis emphasizes the uniformity of form entry and data computation by a highly trained team of researchers. Evaluating each patient with the same rigorous criteria provides the highest assurance of reliable and appropriate data collection.
where from 5 minutes up to 20 minutes or more (40). The need to reevaluate the definition has drawn broad interest among epileptologists (16, 40, 49, 50, 52). Nevertheless, no large series of patients with prolonged seizures (lasting from 10 to 29 minutes) has been evaluated, nor have these patients been compared with patients with SE in a controlled, population-based epidemiologic study. It is essential to acquire data of this type, because efforts to redefine SE currently must rely on a small number of studies and a very select population of seizure patients (16, 40, 49, 50, 52). Despite the importance of understanding and redefining SE, only a few studies have addressed longer durations of seizure activity in the general population (16, 49, 50). Shinnar et al. (49) reported that in children, many seizures
: , , ,
do not terminate in 12–13 minutes, and suggested a possible seizure threshold effect to develop SE. A retrospective analysis of the data in our database indicated that seizures lasting from 10 to 29 minutes are not uncommon in the general population, accounting for more than 30% of the cases of SE overall (16). In this study, data were collected on 81 patients with seizures lasting 10 to 29 minutes for comparison with patients with SE in the same 2-year period. Prolonged seizures that did not meet the current definition of SE had the same distribution of causes as SE and were seen in all age groups (16). Thus, seizures lasting 10 to 29 minutes were not rare in the greater Richmond population and had the same causes as SE. There was, however, a significant difference in mortality between these groups. The overall mortality of the SE patients was 19%, but in the group with seizures lasting 10 to 29 minutes it was 2.6% (P < 0.001). In addition, more than 40% of the seizures lasting 10 to 29 minutes stopped spontaneously without any anticonvulsant treatment (16). This surprising finding indicates that patients in whom seizures will stop spontaneously should be identified so that the effect of these patients can be taken into account in clinical trials for the treatment of SE. These patients would meet the criteria for a definition of SE of seizures lasting 30 minutes or longer. If this type of research is not conducted, clinical trials of SE that include patients with seizure durations lasting 10 minutes or longer may yield very misleading results. These initial studies demonstrated the feasibility of collecting information on a large sample of patients with seizures lasting 10 to 29 minutes, as identified in the Richmond database and at other epilepsy centers. Because the prevalence of SE is much higher when SE is identified prospectively than retrospectively, it is possible that the group with prolonged seizures could account for half or more of the total number of SE cases in our study. This study is expected to provide important data essential for redefining SE, and should also provide epidemiologic data on the frequency of seizures lasting 10 to 29 minutes. However, data are being collected on a wide range of seizure durations. If the definition of SE were changed to include seizures lasting from 5 to 10 minutes, the incidence of SE would increase significantly. Each case was fully reviewed during the patient’s hospitalization or immediately following discharge. This rapid and timely prospective review allowed a more accurate assessment of the data on each patient than could be achieved with a retrospective analysis. A timeline for each SE case was developed so that the duration of SE, electroencephalographic (EEG) characteristics, and other clinical data could be recorded and entered into a computerized database for statistical and epidemiologic analysis (see Figure 3.1). An important part of this study was the validation of the database. A complete review of SE presentations was per-
F 3.2 SE case identification and validation. Shown are two pathways following an occurrence of SE in the greater Richmond metropolitan area. When SE cases are not reported to the SE team, they are recognized by specific mechanisms designed to check for unreported cases: review of hospital computer records, review of EEG evaluation sheets, and review of ER records. (Other mechanisms to identify unreported cases include review of ambulance records and of 911 calls to ER personnel.) By comparing the identified cases not reported to the SE team with the cases that are reported, the team can validate the database (38). With this technique, it is possible to formulate more reliable estimates of the incidence and frequency of SE in the Richmond population (38, 39). However, even this vigorous data collection technique does not uncover all SE cases.
formed to critically evaluate the completeness of case ascertainment (18, 19). This review, conducted on a regular basis, evaluated all hospital ICD-9 codes for seizures (computer records), 911 reports, ER seizures, cases of SE collected on hospital rounds, all EEG laboratory reports, and ICU and ER records (Figure 3.2). Through this review, investigators were able to achive a high degree of accuracy in determining essentially all cases of SE that presented in the greater Richmond metropolitan area (18, 19). The review was conducted at regular intervals during the epidemiologic study, thereby providing an internal mechanism for verifying the accuracy of the database. The definitions of SE, patient age, mortality rates, recurrence rates, history of epilepsy, etiologies, seizure types, ethnicity, and other clinical variables have been discussed in the literature (12, 18, 19). T I P D C We (20) and others (24, 25) have found that it is difficult to study SE from a retrospective review of hospital records because
:
19
of the complex clinical nature of SE. Because hospital records often do not fully document all aspects of SE and the seizure presentation, retrospective data are inconclusive in efforts to understand the natural presentation of SE. For example, a retrospective review conducted at Virginia Commonwealth University found that more than 60% of the SE cases in Richmond community hospitals were not recorded in ICD-9 codes or were not well documented in the hospital chart. Most of the clinical information concerning the duration of seizure activity, seizure type, length of treatment, and follow-up care was incomplete or omitted. Thus, retrospective data analyses resulted in a major bias in patient selection and an incomplete picture of the complex clinical nature of SE. To obtain a more accurate picture of the natural presentation of SE, prospective studies are necessary. These studies have several distinct advantages. First, they allow a more standardized and complete collection of appropriate clinical data. By aggressively identifying and evaluating SE cases when they occur, the Virginia Commonwealth University SE team was able to record the necessary clinical, demographic, laboratory, and other data in each case in a standardized fashion while the patient was still in the hospital. A clinical data form entry system carefully developed for this purpose was used. This type of data collection allowed the SE team to interview family members, nurses, and hospital personnel to acquire the information needed to study SE. Thus, when information such as the duration of SE or the clinical presentation was not appropriately recorded in the chart, the research team had a second chance to acquire the information. Prospective data collection also allows much more accurate data collection. The prospective evaluation of each case in the same time frame in which the data were being collected allowed more accurate record keeping and analysis of the clinical data. Thus, despite an often incomplete hospital record, the SE team can make sure all the necessary information is collected in each case while the patient is still in the hospital. Improved data collection leads to a second major advantage of prospective studies, the accurate analysis of clinical variables associated with SE. This is especially important in evaluating SE seizure types. Our retrospective studies found that normal charting insufficiently documents seizure type during SE. Descriptions of seizure types were omitted or inadequate in more than 65% of routine hospital records for seizure patients. Prospective data collection brings the accuracy of description of seizure types in SE to almost 95%. An accurate description is extremely important for understanding the types of seizures presenting in SE. The identification of nonconvulsive SE by prospective evaluation of EEG records is a third area in which prospective data collection is essential. Nonconvulsive SE is a more
20
subtle presentation of SE. Without prospective data analysis, it is underestimated by more than 80%. A fourth advantage of prospective data analysis is that it allows the evaluation of appropriate control populations to investigate the role of etiology, age, seizure duration, ethnicity, and other variables in determining outcome in SE. There are no well-developed control populations for etiology or other variables in the literature on SE. With prospective data collection, however, control populations can be developed. Prospective analysis also contributes to a more informed picture of morbidity and mortality in SE populations. By prospectively evaluating SE and having a more accurate data evaluation of the true incidence of SE, a more accurate determination of mortality and incidence can be obtained. In sum, prospective evaluation enhances data collection and recording, uncovers a more accurate incidence of associated variables, leads to a truer description of seizure type, and allows comparison with a control population in the community. The research conducted with Virginia Commonwealth University’s prospectively acquired database forms the first prospective population-based, epidemiologic study of SE (18, 19) and has yielded several new insights into the total clinical presentation of this condition.
Incidence of SE From the database, the validated incidence rate of SE in Richmond was 41 per 100,000 individuals per year (Figure 3.3). The incidence rates or pediatric, young adult, and elderly populations were 38, 27, and 86 per 100,000 per year (Figure 3.4). Thus, in our population, the elderly had the highest incidence of SE. Insofar as the elderly population will dramatically increase in the United States over the next 10 to 15 years, SE is expected to become a more common condition in our population (12, 20). Because the rigorous ILAE definition of SE was followed, which does not fully represent some seizure types, and because we identified an underestimate of SE cases seen at community hospitals (through our validation procedures), these incidence rates represent an underestimate of the incidence of SE in the Richmond population. Using estimated correction values for the validation of SE in both community and university hospitals, we obtained an approximate incidence rate of SE in Richmond of 61 per 100,000 population per year (see Figure 3.3). A more detailed distribution of the incidence of SE by age is provided in Figure 3.5. This age distribution of SE is bimodal, with the highest rates seen during the first year of life and again after age 60. In young children up to 12 months old, the incidence as high as 156 per 100,000 individuals per year. This figure indicates the importance of studying SE early in life, as well as in the elderly population. SE in the elderly has been studied (12,
: , , ,
20). The elderly population has several specific etiologic and clinical parameters that differentiate it from the overall population. The frequency of SE was also evaluated taking into account recurrent episodes. Fifty SE episodes per 100,000 population per year occurred in Richmond. Using estimated correction values (based on validation data) pointed to 78 episodes of SE per 100,000 population per year (see Figure 3.3). The total number of episodes of SE per year is an important variable for evaluating the morbidity and mortality associated with SE, since the total number of episodes is proportional to the number of SE events that occur in the population.
F 3.3 Frequency and total number of SE episodes and SE deaths in Richmond, Virginia, and the United States. SE cases are the number of patients presenting with one episode of SE per year. SE episodes are the number of occurrences of SE per year in the population. SE deaths are the number of deaths that occurred in association with SE per year. Shown are the actual and estimated values based on validation by case ascertainment studies in Richmond (38, 39). The estimates projected for the U.S. population assume that the Richmond community is representative of the overall population of the United States.
F 3.4 Incidence of SE for the total, pediatric, adult, and elderly population in Richmond. The data represent the incidence
O SE U S W Our prospective studies of SE in Richmond uncovered an absolute incidence of SE of 41 per 100,000. By using a prospective data collection methodology, it is possible to achieve a much higher ascertainment of individual cases. Several other studies (24–26, 37) have also provided valuable information concerning the incidence and clinical presentation of SE in other areas of the United States (24–26, 61) and in other countries (9, 30, 51). The first estimate of the incidence of SE came from Rochester, Minnesota (24, 25), and was determined using retrospective data analysis. The incidence was approximately 15 per 100,000. More recent studies from this team using the same type of data analysis indicated a slight increase in incidence in the decades from 1965 to 1984 of 18.1 per 100,000 (26). Studies in California (61) utilizing a retrospective evaluation of a statewide hospital discharge database to identify cases of generalized convulsive SE gave a peak incidence of approximately 8.5 per 100,000. When this figure is corrected to account for the underestimation of SE in discharge summaries and for the exclusion of other types of SE, the incidence is comparable with figures reported in other studies. The research group in Hessen, Germany (30), conducted a
of SE per year per 100,000 population in each age group (38, 39).
:
21
F 3.5 Age-specific distribution of the incidence of SE per year per 100,000 in Richmond, Virginia. By incidence is meant the number of patients who experienced a first episode of SE in Richmond per year per 100,000 population in each age group.
These figures do not include patients with recurrent episodes of SE. The population for each age group was obtained from the 1990 U.S. Census Bureau for Richmond, Virginia (38).
prospective population-based study over a 2-year period and estimated the incidence of SE in this city to be 17.1 per 100,000 population. This figure is very close to the Rochester, Minnesota, incidence. A study from the Frenchspeaking part of Switzerland by Coeytaux and colleagues (9) found an incidence of 10.3 per 100,000. Although there are some variations in these studies, a range of 8–41 per 100,000 population has been found. Given the differences in the methods of data collection and nature of the populations in these studies, the incidence figures determined in each study are fairly close to one another. The differences in the incidence figures may reflect different methods of data collection or varying ability to correctly determine cases of SE in medical records. We have found that it is very difficult to identify cases of SE from ICD-9 codes, discharge summaries, and retrospective chart review. The higher incidence figure in the Richmond study may in part reflect the prospective nature of the study. However, environmental differences, genetic differences, ethnic differences, and other variables may contribute to the different incidence determinations for SE reported in these studies. The data reviewed later under Ethnic Origin in SE suggest that the ethnic mix of the population may play an important role in determining the incidence of this condition. Correcting the Richmond data for the higher percentage of African Americans in the population gave an incidence very close to the Rochester and Hessen data. Further studies are needed to more fully evaluate the effects of genetic factors and ethnicity on the incidence of SE. Because the data obtained in the Virginia Commonwealth University study were obtained by prospective case evaluation by a dedicated team of investigators, this study provides a reasonable source of epidemiologic data and can be used as a starting point for estimating the overall impact of SE in
the world population, including mortality. Extrapolating the study figures to the U.S. 1991 census population of 249,924,000 shows that approximately 119,000 to 195,000 SE events occur per year in the United States (see Figure 3.3). These figures do not include cases in neonates or cases in patients not referred to hospitals, such as patients in nursing homes or state facilities. The number of patients with SE who experienced at least one episode of SE per year in the United States was estimated to be 102,000 to 152,000 per year. Extrapolating again to the world’s population, based on the 1997 census, of 5.8 billion, approximately 4.5 million SE events occur per year worldwide. The number of SE cases that develop per year in the world is estimated at 3.5 million. These estimates begin to suggest the immense cost to society of this major neurologic and medical emergency. The data presented in Table 3.1 are conservative estimates of U.S. and world cases and deaths. Both the World Health Organization and the ILAE have recently noted that the vast majority of individuals throughout the world do not receive proper treatment for epilepsy. In many nonindustrial countries, epilepsy either is not treated or is totally inadequately treated, despite the availability of modern anticonvulsant therapies. Thus, the number of SE cases worldwide and the total mortality and morbidity from SE are probably much higher than the figures projected for the United States, and higher than the figures given in Table 3.1. Our group has developed estimates of the cost of treating SE in an urban hospital (56). The cost of care for SE in the United States per year is approximately $3–4 billion. Projecting the population of the United States to the world suggests that SE would cost more than $70–93 billion per year on an international basis. Thus, understanding, treating, and controlling SE represents a major international
22
: , , ,
T 3.1 United States and world SE cases and deaths projected from the Richmond population
SE cases SE episodes SE deaths
United States
World
152,000 195,000 42,000
3,527,920 4,525,950 974,820
Note: Estimates of SE cases, episodes, and deaths are based on projections from the data from the Richmond, Virginia, study (38, 39). The populations used to determine these values for the United States and the world were approximately 250 million and 5.8 billion individuals. The data indicate that worldwide, almost 1 million individuals die each year due to SE.
public health need. Currently, there is no acknowledgment of the increased risk or cost of SE in the diagnostic codes or level-of-care issues. SE is treated no differently than a simple seizure. Studies are needed to more precisely ascertain the health care costs of SE to society and to improve the recognition and understanding of SE by hospital and health agency coding and billing systems. R SE Using the epidemiologic data in the Richmond study, it is possible to determine an age-specific recurrence rate of SE. Recurrence of SE in the Richmond population was much more common during the first year of life (18, 19). In the Richmond population, 13% of patients experienced repeat episodes of SE. Recurrence rates in the pediatric, adult, and elderly populations were 35%, 7%, and 10%. Thus, recurrence of SE was the most common in the pediatric population, very uncommon in the middle years of life, and increased again in the elderly. Despite the higher recurrence rate of SE in the pediatric population, this recurrence rate was not associated with an increased mortality from SE (18, 19).
SE seizure types Prospective data collection allows a much more accurate evaluation of seizure types in SE because the research team can obtain information from witnesses who observed the seizures during the initial presentation in each case. The SE seizure types observed in Richmond, Virginia, are listed in Table 3.2. Partial and secondarily generalized SE in both children and adults were the major seizure types identified. These results point to a new observation concerning the presentation of SE seizure types, namely, the initiation of SE by partial seizures is the most common form of SE. Approximately 69% of adults with SE and 64% of children with SE presented with partial SE as the initial seizure type. This is a new and important finding indicating that generalized
T 3.2 SE seizure types in Richmond, Virginia
Final seizure type Generalized Partial Onset seizure type Generalized Partial Partial SE Simple Complex Partial, secondarily generalized Generalized GTC Absence Myoclonic Electrographic
Pediatric
Adult
Total
71 29
74 26
74 26
36 64
31 69
32 68
29 0 36
22 4 43
23 3 42
36 0 0 0
27 1 3 1
29 1 2 1
Note: Data are expressed as percentage of SE cases with each seizure type (38, 39). The final seizure type represented the major seizure type during SE. Onset seizure type included partial, secondarily generalized, as partial onset.
tonic-clonic SE, although an important form of SE, is not the major initial seizure type. Rather, partial SE is the most common initial seizure type. Because it is impossible to witness all initial SE events, the incidence of partial SE is probably significantly higher than the values given in Table 3.2 for the general population. Table 3.2 also shows the distribution of SE seizure types in adult and pediatric populations (12, 18, 19). When seizures did not secondarily generalize, simple partial SE was more common than partial complex SE in both children and adults. Partial SE with secondary generalization was the most common seizure type in both adults and children, and generalized tonic-clonic SE was the major form of SE as the final seizure type in this study. Generalized absence SE was uncommon in this population in both children and adults. Myoclonic SE was uncommon but was seen in both populations; it was more common in adults than in children. Electrographic SE or nonconvulsive SE was also observed in this study. These results indicate that the majority of SE cases in the general population start with partial seizures. The mechanism that prevents partial seizures from terminating allows these seizures to spread throughout the brain and develop into generalized tonic-clonic seizures in a high percentage of patients. Inability to terminate these seizures eventually leads to the development of SE. Understanding this mechanism and the inability to inhibit or stop generalized seizure activity is important to fully understanding the pathophysiology of SE and warrants further investigation.
:
23
N SE Nonconvulsive SE (NCSE), or electrographic SE, is often very difficult to detect. Patients often do not show any signs of seizure activity. Our prospective data collection methods and coordination of electrophysiology studies on comatose patients in the ICU and hospital settings allowed us to do a large study of the occurrence of NCSE. More than 95% of comatose patients at the Virginia Commonwealth University hospital complex are evaluated by neurology and EEG studies. Using this database, we found that 8% of comatose patients without any overt clinical signs of seizure activity manifested NCSE (54). This figure highlights the potential underestimation of NCSE on a national or international level. Many hospitals do not have round-the-clock or weekend EEG availability, and not all neurologists or other physicians routinely order EEGs for all comatose patients. Thus, many cases of NCSE never come to medical attention. With the large incidence of coma, it is essential that this potentially lethal form of SE be diagnosed. Further studies on the incidence of NCSE are required to more fully understand the clinical presentation of this condition.
Etiology of SE The causes of SE in children and adults are shown in Figures 3.6 and 3.7. In our study, the major cause of SE in children was infection with fever, accounting for more than 52% of all cases. Remote symptomatic causes (39%) and low antiepileptic drug levels (LAED) (21%) also accounted for a significant percentage of cases in children. The other causes in children accounted for less than 10% of the total cases. A much different etiologic picture emerged in the adult population. Although adults had cases that were precipitated by infections with fever, these cases accounted for a much
F 3.6 Etiology of SE in pediatric patients. Some patients had more than one cause identified. The causes included anoxia, hypoxia, cerebrovascular accident (CVA), hemorrhage, tumor, systemic infections with fever, CNS infections, metabolic, low
24
lower percent of the total. In adults, three major causes emerged: LAED (34%), remote symptomatic causes (24%), and cerebrovascular accident (CVA) (22%). Anoxia/ hypoxia, metabolic causes, and alcohol and drug withdrawal each represented between 10% and 20% of all cases of SE. The remote symptomatic group in adults was a category composed primarily of remote CVA and hemorrhage. Combining the CVAs included in the remote symptomatic group and the CVA-alone category, almost 50% of the adult cases of SE were caused by acute or remote cerebrovascular disease in patients with no previous history of epilepsy. In sum, several major etiologic factors contribute to the development of SE in children and adults in the general population. The profile of etiologic risk factors is significantly different in children and adults but is representative of the general disease groups that are most common in these age groups. In children, the most common cause is febrile seizures or infections with fever. In adults, the most common causes of SE are acute or remote cerebrovascular disease and LAED in individuals with epilepsy. The relationship of specific etiology to the presentation and prognosis of SE is an important area for future investigation (18, 19). E O SE The presentation of SE in white and nonwhite patients was evaluated. As shown in Figure 3.8, nonwhite individuals had a higher incidence of SE across all age ranges than white patients. The increased incidence in nonwhite patients was especially significant in the older and younger age groups. The frequency of SE in nonwhite individuals less than 1 year old was above 300 per 100,000, and the frequency in nonwhite elderly patients exceeded 200 per 100,000 individuals. These results provide striking evidence that ethnicity may be an important risk factor for SE. Further studies are needed to determine how much of the
antiepileptic drug levels (LAED), drug overdose, trauma, remote causes, and idiopathic. Data are expressed as the percent of cases with each cause.
: , , ,
F 3.7 Etiology of SE in adult patients. Some patients had more than one cause identified. Causes included anoxia, hypoxia, cerebrovascular accident (CVA), hemorrhage, tumor, systemic infections with fever, CNS infection, metabolic, low antiepileptic
drug levels (LAED), drug overdose, EtOH (alcohol-related), trauma, remote, and idiopathic. Data are expressed as the percent of cases with each cause.
F 3.8 Age-specific distribution of the incidence of SE for white (white bars) and nonwhite (black bars) patients. Data are expressed as the number of patients with a first episode of SE per
year per 100,000 in Richmond, Virginia, for each age group. Populations of white and nonwhite individuals in each age group were determined from 1990 U.S. Census Bureau data (38).
difference in incidence can be attributed to socioeconomic or cultural differences. As noted earlier, our prospective population-based studies of SE in Richmond disclosed an absolute incidence of SE of 41 per 100,000. This incidence was about two times that of SE in the predominantly white (Caucasian) Hessen, Germany (30), and Rochester, Minnesota (24–26), studies. The incidence in the white population alone in Richmond was approximately 19 per 100,000, which compares well with the incidence figures for the two other predominantly white populations (24–26, 30). However, the nonwhite, African-American population in Richmond had a much higher incidence of SE, 57 per 100,000. Because Richmond is over 50% African American, the higher incidence in this group can partially account for the higher incidence in the overall Richmond population.
It is essential to further evaluate these ethnic disparities in the incidence and mortality of SE. Our study is uniquely qualified to evaluate these differences in comparing the incidence in the African-American and Caucasian populations, since we have an almost equal proportion of white and African Americans in Richmond and both populations have a broad spectrum of financial, educational, and cultural diversity. Our studies are directed at determining if the higher incidence of SE in the African-American population is associated with differences in etiologic presentations, socioeconomic factors, employment factors, genetic factors, or some other variables. However, further studies are also needed to evaluate the incidence of SE in the Hispanic and Asian populations and other geographicethnic groups.
:
25
F 3.9 Epilepsy history of SE patients for the total population, children, adult, young adult, and elderly patients. The data are expressed as the percentage of patients in each age category
with a history of epilepsy. Each age category was defined as described previously (38, 39).
P H E In studies of SE based primarily on neurologic practice settings, the most common cause of SE was lowered antiepileptic drug levels in patients with epilepsy who stopped taking their anticonvulsant medications. However, a population-based analysis of SE shows that SE can be caused by or associated with numerous other medical, surgical, and physical conditions in the absence of a previous history of epilepsy. Unless SE is evaluated in a population setting, an incomplete distribution of etiologic presentations is obtained. The percentage of SE patients with a previous history of epilepsy is shown in Figure 3.9. Rates are shown for the total, pediatric, adult, young adult, and elderly populations. In the elderly population, 70% of patients who developed SE had no previous history of epilepsy. In pediatric patients and in young adults, a previous history of epilepsy was noted in 38% and 54%, respectively. Although SE occurred in patients with epilepsy, the lack of a seizure history, especially in the elderly, does not protect against the development of SE. These results indicate that SE in the elderly is primarily caused by non-epilepsy-related factors. It is essential to educate internists, surgeons, and other physicians who care for these populations as to the importance of evaluating for and diagnosing SE, since many of these cases will show up in nonneurological settings in association with postsurgical problems, medical complications, and other disease states. This represents an important challenge for the epileptologist in the years ahead.
that the mortality from SE varies from 11% to 34% (24, 25). This significant difference in mortality rates across clinical studies is accounted for primarily by the different distributions of causes and difference in patient ages in the various studies. Determining the mortality from SE in a prospective, population-based study would go far toward understanding the risk factors for death from this condition. The mortality from SE for pediatric, adult, and elderly populations was evaluated for the Richmond population (12, 18, 19, 53). The overall mortality in the entire Richmond population, including adults and children, was 22%. For children alone it was 3%. This lower mortality in the pediatric population is consistent with observations of Maytal and colleagues (42) and Dunn (22) indicating that children have a lower mortality from SE than adults. Adults below the age of 60 have a mortality of approximately 14%, and the elderly have a mortality of 38%. The age distribution of mortality for the Richmond population (Figure 3.10) emphasizes the dramatic increase in mortality with age. Although the mortality in the elderly is highest, the mortality from SE in younger adults is considerable when compared with death rates from other neurological diseases. Understanding the causes of this significant mortality and finding possible ways of preventing complications associated with SE are a major challenge for the neurologist. Employing the mortality rate for the Richmond community, it is possible to estimate the number of deaths expected from SE per year in the U.S. population, as well as in the world population (see Table 3.1). The estimated number of deaths from SE per year in the United States is approximately 22,000–42,000. Extrapolating this figure to the world population, approximately 975,000 individuals per year die from SE. These estimates underscore the importance of understanding the clinical presentation and cause of death from this major neurologic emergency.
Mortality from SE Several large case studies of SE have described determinants of mortality from SE (1, 3, 7, 8, 12, 18–20, 22, 24, 25, 27, 30, 33, 36, 42, 43, 46, 47, 53, 56). These reports indicate
26
: , , ,
F 3.10 Age-specific distribution of mortality from SE in Richmond, Virginia. The data are expressed as the number of deaths per 100,000 population per year. The population for each
age group was obtained from the 1990 U.S. Census Bureau for Richmond, Virginia (38).
Outcome of SE
using novel treatment approaches, given that there are several acceptable therapies for SE, will require the ability to predict with significant accuracy outcomes with survival rates poorer than 50%–60%. Thus, validated outcome scales will be essential to develop new treatments for SE. Etiology has been shown to be useful in predicting outcome in SE (8, 24, 25, 53). Leppik initially described the important role that etiology plays in predicting outcome (32, 34, 35). The mortality for each cause of adult cases of SE are presented in Figure 3.11. Anoxia and hypoxia were associated with the highest mortality in both children and adults. Other causes, such as alcohol withdrawal or LAED, were associated with a significantly lower mortality. The pediatric population essentially has no mortality associated with SE, and only a small number of deaths in patients with significant neurologic complications were seen in children. These studies demonstrate the importance of etiology in determining outcome. Waterhouse et al. (60) have shown that cerebrovascular injury and SE have a synergistic effect. Using appropriate control-matched populations, these investigators found that the type of etiology may play a role in increasing the mortality and morbidity associated with SE. The combination of an underlying neurological injury of a specific etiology and the excitotoxicity associated with SE produces a synergistic injury with higher mortality than that associated with either the etiology or the SE alone (60). These results provide an exciting opportunity to consider therapeutic interventions during the acute process of the underlying etiology and its association with SE in attempting to decrease morbidity and mortality. Another variable that plays a major role in outcome and refractoriness in SE is seizure duration (20, 39, 53). For this reason, evaluating the causes of refractory SE and developing new treatments for it is an important area for future
Using prospective data analysis, it is possible to evaluate predictive indicators of outcome in SE (17–20). Being able to predict outcome has several important advantages that are useful to clinicians. Thus, a major goal of the Medical College of Virginia’s Epilepsy Institute is to develop a practical outcome scale that can be used to predict mortality in SE. At the present time we are working on the Richmond Outcome Scale, which will be able to predict mortality with a 90% or greater accuracy in patients with SE. This scale requires the collection of approximately six to ten variables relating to the presentation of SE, with data collection initiated within 24 hours of the onset of SE. A simpler and more condensed clinical scale is being developed to predict outcome with a greater than 80% accuracy within the first hour of a patient’s presentation with SE. Recent results (17) indicate that applying logistic regression analysis to important clinical predictors of outcome will allow us to develop predictive scales for use by clinicians in predicting outcomes in SE. In addition, the use of clinical outcome scales should have a positive impact on physicians’ ability to treat patients with SE. These scales will allow clinicians to evaluate the severity of SE cases, and to initiate appropriate ICU treatment of patients with the more severe cases. In addition, the scales will help the clinician provide information to families about the likelihood of specific outcomes in each case. In light of the significant mortality associated with SE, these outcome scales will help clinicians recognize and express to families that patients die not because of poor medical care but because of the underlying pathophysiology of the disease. Another major use of outcome scales is to allow research programs to initiate new treatment protocols for SE. To be able to obtain human investigation committee approval for
:
27
F 3.11 Mortality from SE in adults, by etiology. The data are expressed as the percent mortality for each cause of SE. The causes are as presented in Figure 3.7.
investigation. Age also has been shown to be an important variable in outcome in SE (53). The elderly population is much more at risk for mortality and morbidity than the younger population. Boggs and colleagues (6) have shown that underlying cardiovascular disease is a risk factor that may increase the mortality from SE in the elderly. The elderly are also much more susceptible to brain injury because they lack the plasticity and the recuperative powers of the younger brain (10, 29). Response to treatment is another important variable that contributes to outcome in SE. Identifying the major variables that predict outcome in SE forms the initial basis for developing an accurate outcome scale. It is important to have a population-based database with a large enough population size so that several analyses can be done using sophisticated multiregression, nonlinear analyses to determine whether each variable influencing outcome does so independently of other variables or synergistically. So far it has been possible to show that specific causes of SE, age, and seizure duration play independent roles in determining outcome (17, 53).
New advances through epidemiological studies Population-based epidemiologic studies of SE have provided important information concerning the incidence and overall mortality of this major neurologic condition (18, 19). In addition, these results indicate that almost a quarter of a million episodes of SE occur per year in the United States and as many as 4.5 million cases may occur in the world each year (see Table 3.1). The number of deaths per year in the world estimated from SE (Table 3.1) approaches 1 million. These numbers are more meaningful when it is considered that they are based on conservative evaluations. Only cases that could be 100% documented by rigid definitional requirements were included in our study. The large number of cases that
28
were not witnessed at onset or in which seizure duration could not be determined accurately had to be excluded from these studies. The cost estimates of $4 billion per year in the United States (45) and more than $90 billion in the world economy, if SE was treated properly, represent a major public health issue for the United States and for the world. Another important finding that has developed from epidemiologic studies of SE is that generalized tonic-clonic SE is not the most common seizure type of SE. Because SE is associated with numerous etiologic conditions and with several focal pathologies in the brain, it is not surprising that partial seizures are the initial precipitating event in the majority of SE cases. However, it is clear that the majority of partial SE cases will eventually secondarily generalize. The most common final seizure type in SE is generalized tonic-clonic SE. A large portion of the population is at risk to develop SE even though the individuals have no seizure history. In the adult population, CVA represents a major cause of SE (12, 18, 19). Both acute and subacute cerebrovascular injury to the brain are associated with SE (12). The relationship between brain injury and the development of continuous seizure discharge has not been carefully evaluated. The high frequency of SE in relationship to CVA indicates that further human and animal investigations should be initiated to evaluate the causal relationship between brain injury and the development of continuous seizure discharge. The basic mechanisms that regulate the generalization of seizure activity and the inability to shut off seizure discharge following a CVA are an important area for further research. The finding that the combination of a CVA and SE produces a synergistic increase in mortality (60) raises the important possibility that this condition is similar to the combination of injuries seen with head injury (29, 48). The combination of multiple small injuries in succession has
: , , ,
a much greater synergistic effect on mortality and morbidity than of the injuries combined (29, 48). This important finding in association with the relationship between SE and etiology is an exciting area for future investigation. This result also raises the importance of having controlled etiology populations to compare to SE. It is essential to develop population-based, controlled etiologies in combination with the etiologies plus SE in comparing outcomes both for morbidity and mortality. A G P M C I SE SE is precipitated by numerous medical and neurologic conditions (18, 19, 24, 25). In evaluating the specific causes of SE and control populations in the Richmond database, it became apparent that only a small fraction of the precipitating causes ever resulted in SE. The susceptibility of some individuals to develop SE in association with conditions such as LAED, cerebrovascular disease, metabolic disease, anoxia, or other conditions raises the possibility that there may be underlying susceptibilities in individuals to precipitate SE. However, the other possibility is that the severity of the underlying etiology may be contributing to the development of SE. To evaluate this possibility studies were conducted on the role of CVA in precipitating SE. This research (55) demonstrated that the size or severity of the CVA in both control and SE patients was similar. Thus, it could not be postulated that larger or more severe CVAs resulted in SE. There had to be some type of underlying susceptibility in the individual patient for SE to develop. In an attempt to evaluate potential susceptibility to develop SE, we utilized the human twin registry at the Medical College of Virginia of Virginia Commonwealth University to study the genetic predisposition to develop SE. Using the twin database, it was established that there is a genetic predisposition to develop SE (10). These results provide the first evidence that genetic background may contribute to the susceptibility to develop SE given certain insults to the central nervous system. Studying the genetics of SE is particularly difficult, since this tendency may only be evident when a precipitating cause of SE is encountered, such as an initial seizure, CVA, head injury, or other cause. However, this is an important and challenging aspect of research in SE, since it may provide an insight into predicting which patients are at high risk for developing this condition. Being able to predict these patients may play an important role in therapeutic intervention and preventative strategies to significantly reduce the morbidity and mortality associated with SE. Although data have been provided that SE has a genetic predisposition, it is also possible that a specific type of brain injury may also precipitate SE in a nongenetically susceptible individual. The potential role of genetic predisposition
and the actual pathophysiology of SE offers an exciting and challenging area for future research to predict and understand patients at risk for developing SE. The incidence and clinical presentation of SE in a population may be significantly influenced by genetic factors as well as environmental risks. Understanding these variables offers exciting challenges in treating this condition in the future. The work reported in this chapter represents an ongoing collaboration with the status epilepticus research team at the Medical College of Virginia of Virginia Commonwealth University. The assistance and efforts of my research colleagues are greatly appreciated. This work was supported by National Institutes of Health Program Project Grant P50 NS25630, research grant R01 NS23350, the Sophie and Nathan Gumenick Research Fund, and the Milton L. Markel Neuroscience and Alzheimer’s Research Fund (R.J.D.).
REFERENCES 1. Aicardi, J., and J. J. Chevrie. Convulsive status epilepticus in infants and children: A study of 239 cases. Epilepsia 1970; 11:187–197. 2. Alldredge, B. K., A. M. Gelb, S. M. Isaacs, M. D. Corry, F. Allen, S. Ulrich, M. D. Gottwald, N. O’Neil, J. M. Neuhaus, and D. H. Lowenstein. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N. Engl. J. Med. 2001;354(9):631–637. 3. Aminoff, N. J., and R. P. Simon. Status epilepticus: Causes, clinical features and consequences in 98 patients. Am. J. Med. 1980;69:657–666. 4. Bassin, S., T. L. Smith, and T. P. Bleck. Clinical review: Status epilepticus. Crit. Care 2002;6(2):137–142. 5. Bleck, T. Convulsive disorders: Status epilepticus. Clin. Neuropharmacol. 1991;14:191–198. 6. Boggs, J. G., A. Marmarou, J. P. Agnew, L. I. D. Morton, A. R. Towne, E. J. Waterhouse, J. M. Pellock, and R. J. DeLorenzo. Hemodynamic monitoring prior to and at the time of death in status epilepticus. Epilepsy Res. 1998;31: 199–209. 7. Celesia, G. G. Prognosis in convulsive status epilepticus. In A. Delgado-Escueta, C. Wasterlain, D. Treiman, and R. Porter, eds. Status Epilepticus: Mechanisms of Brain Damage and Treatment. New York: Raven Press, 1983:55–59. 8. Claassen, J., J. K. Lokin, B. F. Fitzsimmons, F. A. Mendelsohn, and S. A. Mayer. Predictors of functional disability and mortality after status epilepticus. Neurology 2002;58(1):139–142. 9. Coeytaux, A., P. Jallon, B. Galobardes, and A. Morabia. Incidence of status epilepticus in French-speaking Switzerland: (EPISTAR). Neurology 2000;55(5):693–697. 10. Corey, L. A., J. M. Pellock, J. G. Boggs, L. L. Miller, and R. J. DeLorenzo. Evidence for a genetic predisposition for status epilepticus. Neurology 1998;50(2):558–560. 11. Delgado-Escueta, A., C. G. Wasterlain, D. M. Treiman, and R. J. Porter. Management of status epilepticus. N. Engl. J. Med. 1982;36:1337–1340. 12. DeLorenzo, R. J. Clinical and epidemiological study of status epilepticus in the elderly. In A. J. Rowan and R. E. Ramsey, eds. Seizures and Epilepsy in the Elderly. Newton, Mass.: Butterworth-Heinemann, 1997:191–205.
:
29
13. DeLorenzo, R. J. Management of status epilepticus. Virginia Med. Q. 1996;123:103–111. 14. DeLorenzo, R. J. Status epilepticus. In R. T. Johnson, ed. Current Therapy in Neurologic Disease. Vol. 3. Philadelphia: B.C. Decker, 1990:47–53. 15. DeLorenzo, R. J. Status epilepticus: Concepts in diagnosis and treatment. Semin. Neurol. 1990;2:396–405. 16. DeLorenzo, R. J., L. K. Garnett, A. R. Towne, E. J. Waterhouse, J. G. Boggs, L. Morton, M. A. Choudhry, T. Barnes, and D. Ko. Comparison of status epilepticus with prolonged seizure episodes lasting from 10 to 29 minutes. Epilepsia 1999;40(2):164–169. 17. DeLorenzo, R. J., D. Ko, A. Towne, L. K. Garnett, J. G. Boggs, E. J. Waterhouse, and L. I. D. Morton. Prediction of outcome in status epilepticus. Epilepsia 1997;38(8):210. 18. DeLorenzo, R. J., J. M. Pellock, A. R. Towne, and J. G. Boggs. Epidemiology of status epilepticus. J. Clin. Neurophysiol. 1995; 12(4):316–325. 19. DeLorenzo, R. J., A. R. Towne, D. Ko, et al. Prospective population-based epidemiological study of status epilepticus in Richmond, VA. Neurology 1996;46:1029–1032. 20. DeLorenzo, R. J., A. R. Towne, J. M. Pellock, and D. Ko. Status epilepticus in children, adults and the elderly. Epilepsia 1992;33(Suppl. 4):515–525. 21. Dodson, W. E., R. J. DeLorenzo, T. A. Pedley, S. Shinnar, D. M. Treiman, and B. B. Wannamaker. The treatment of convulsive status epilepticus: Recommendations of the Epilepsy Foundation of America’s working Group on Status Epilepticus. JAMA 1993;270(7):854–859. 22. Dunn, D. W. Status epilepticus in children: Etiology, clinical features, and outcome. J. Child Neurol. 1988;3:167–173. 23. Gastaut, H. Classification of status epilepticus. In A. V. Delgado-Escueta, C. G. Wasterlain, D. M. Treiman, and R. R. Porter, eds. Status Epilepticus: Mechanisms of Brain Damage and Treatment. Adv. Neurol. 1983;34:15–35. 24. Hauser, W. A. Status epilepticus: Epidemiology considerations. Neurology 1990;40(Suppl. 2):9–12. 25. Hauser, W. A. Status epilepticus: Frequency, etiology, and neurological sequelae. In A. V. Delgado-Escueta, C. G. Wasterlain, D. M. Treiman, and R. J. Porter, eds. Status Epilepticus: Mechanisms of Brain Damage and Treatment. Adv. Neurol. 1983;34:3–14. 26. Hesdorffer, D. C., G. Logroscino, G. Cascino, J. F. Annegers, and W. A. Hauser. Incidence of status epilepticus in Rochester, Minnesota, 1965–1984. Neurology 1998;50(3):735–741. 27. Hunter, R. A. Status epilepticus: History, incidence and problems. Epilepsia 1959;60(1):162–188. 28. Jaitly, R. K., J. A. Sgro, A. R. Towne, et al. Prognostic value of EEG monitoring after status epilepticus: A prospective adult study. J. Clin. Neurophysiol. 1997;14(4):326–334. 29. Kelly, J. P., J. S. Nichols, C. M. Filley, K. O. Lillehei, D. Rubinstein, and B. K. Kleinschmidt-DeMasters. Concussion in sports: Guidelines for the prevention of catastrophic outcome. JAMA 1991;266:2867–2869. 30. Knake, S., F. Rosenow, M. Vescovi, W. H. Oertel, H. H. Mueller, A. Wirbatz, N. Katsarou, and H. M. Hamer. Incidence of status epilepticus in adults in Germany: A prospective, population-based study. Epilepsia 2001;42:714–718. 31. Leppik, I. E. Diagnosis and treatment of status epilepticus. Merritt Putnam Q. 1987;4(2):3–13. 32. Leppik, I. E. Status epilepticus. Clin. Ther. 1985;7:272–278. 33. Leppik, I. E. Status epilepticus. Neurol. Clin. 1986;4:633–643. 34. Leppik, I. E. Status epilepticus: The next decade. Neurology 1990;40(Suppl. 2):4–9.
30
35. Leppik, I. E. Status epilepticus. In E. Wyllie, ed. The Treatment of Epilepsy: Principles and Practice. Philadelphia: Lea & Febiger, 1993:678–683. 36. Logroscino, G., D. C. Hesdorffer, G. Cascino, J. F. Annegers, E. Bagiella, and W. A. Hauser. Long-term mortality after a first episode of status epilepticus. Neurology 2002;58(4): 537–541. 37. Logroscino, G., D. C. Hesdorffer, G. Cascino, J. F. Annegers, and W. A. Hauser. Time trends in incidence, mortality, and case-fatality after first episode of status epilepticus. Epilepsia 2001;42(8):1031–1035. 38. Lowenstein, D. H., and B. K. Alldredge. Status epilepticus. N. Engl. J. Med. 1998;338:970–976. 39. Lowenstein, D. H., and B. K. Alldredge. Status epilepticus at an urban public hospital in the 1980s. Neurology 1992;43: 483–488. 40. Lowenstein D. H., T. Bleck, and R. Macdonald. It’s time to revise the definition of status epilepticus. Epilepsia 1999; 40:120–122. 41. Mayer, S. A., J. Claassen, J. Lokin, F. Mendelsohn, L. J. Dennis, and B. F. Fitzsimmons. Refractory status epilepticus: Frequency, risk factors, and impact on outcome. Arch. Neurol. 2002; 59(2):205–210. 42. Maytal, J., S. Shinnar, S. L. Moshe, and L. A. Alvarez. Low morbidity and mortality of status epilepticus in children. Pediatrics 1989;83:323–331. 43. Oxbury, J. M., and C. W. M. Whitty. Causes and consequences of status epilepticus in adults: A study of 86 cases. Brain 1971; 94:733–744. 44. Payne, T. A., and T. P. Bleck. Status epilepticus. Crit. Care Clin. 1997;13(1):17–38. 45. Penburthy, L., A. Towne, L. K. Garnet, and R. J. DeLorenzo. Costs of status epilepticus. Epilepsia 1997;38(8):225. 46. Roger, J., H. Lob, and C. A. Tassinari. Status epilepticus. In P. J. Vinken and G. W. Bruyn, eds. Handbook of Clinical Neurology. Vol. 15. New York: Elsevier, 1974:169–178. 47. Rowan, A. J., and D. F. Scott. Major status epilepticus: A series of 42 patients. Acta Neurol. Scand. 1970;46:573–584. 48. Saunders, R. L., and R. D. Harbaugh. The second impact in catastrophic contact sports head trauma. JAMA 1984;252: 538–539. 49. Shinnar, S., A. T. Berg, S. L. Moshe, and R. Shinnar. How long do new-onset seizures in children last? Ann. Neurol. 2001;49(5): 659–664. 50. Shinnar, S., J. M. Pellock, A. T. Berg, C. O’Dell, S. M. Driscoll, J. Maytal, S. L. Moshe, and R. J. DeLorenzo. Short-term outcomes of children with febrile status epilepticus. Epilepsia 2001; 42(1):47–53. 51. Sillanpää, M., and S. Shinnar. Status epilepticus in a population-based cohort with childhood-onset epilepsy in Finland. Ann. Neurol. 2002;52(3):303–310. 52. Theodore, W., R. Porter, P. Albert, et al. The secondarily generalized tonic-clonic seizure: A videotape analysis. Neurology 1994;41:1403–1407. 53. Towne, A. R., J. M. Pellock, D. Ko, and R. J. DeLorenzo. Determinants of mortality in status epilepticus. Epilepsia 1994;5(1):27–36. 54. Towne, A. R., E. J. Waterhouse, J. G. Boggs, L. K. Garnett, A. J. Brown, J. R. Smith, and R. J. DeLorenzo. Prevalence of nonconvulsive status epilepticus in comatose patients. Neurology 2000;54(2):340–345. 55. Treiman, D. M. Convulsive status epilepticus. Curr. Treat. Options Neurol. 1999;1(4):359–369.
: , , ,
56. Treiman, D. M. Generalized convulsive status epilepticus in the adult. Epilepsia 1993;34:S2–S11. 57. Treiman, D. M. Status epilepticus. In R. T. Johnson, ed. Current Therapy of Neurologic Disease. Vol. 2. Philadelphia: B.C. Decker, 1987:38–42. 58. Treiman, D. M., P. D. Meyers, N. Y. Walton, J. F. Collins, C. Colling, A. J. Rowan, A. Hanforth, E. Faught, V. P. Calabrese, B. M. Uthman, R. E. Ramsy, and M. B. Mamdani. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N. Engl. J. Med. 1998;399(12):792–798. 59. Waterhouse, E. J., L. K. Garnett, A. R. Towne, L. D. Morton, T. Barnes, D. Ko, and R. J. DeLorenzo. Prospective population-based study of intermittent and continuous convulsive status epilepticus in Richmond, Virginia. Epilepsia 1999;40(6): 752–758. 60. Waterhouse, E. J., J. K. Vaughan, T. Y. Barnes, J. G. Boggs, A. R. Towne, L. Garnett, and R. J. DeLorenzo. Synergistic effect of status epilepticus and ischemic brain injury on mortality. Epilepsy Res. 1998;31:199–209. 61. Wu, Y. W., D. W. Shek, P. A. Garcia, S. Ahao, and S. C. Johnston. Incidence and mortality of generalized convulsive status epilepticus in California. Neurology 2002;58(7):1070– 1076.
:
31
4
Prognosis after a First Episode of Status Epilepticus
, . , .
Introduction There is wide variation in the reported prognosis among people with status epilepticus (SE). This variation relates to differences in the definition of SE, the etiologic classification of SE, the definition of outcomes, and the study of outcomes in heterogeneous populations. The most important cause of variation is the source of cases, which is an indirect measure of disease severity and etiology. A study from the Netherlands found a sixfold variation in mortality associated with SE across medical care facilities (26). Mortality was lowest in an epilepsy center (1.9%), intermediate in community hospitals (6.7%), and highest in large hospitals and university clinics (11.9%). This variation was related to differences in the mix of etiology of SE in patients seen at these centers. Another example of heterogeneity may be seen in studies reported in this book. The case-fatality ratio was 21% in the population-based studies in Rochester, Minnesota, and Richmond, Virginia (8, 9, 20), but 55% in the Veterans Administration clinical trial of SE treatments (see Treiman, Chapter 6, this volume). The use of population-based data can provide insights into the frequency of adverse outcomes following SE. In addition, population-based data can allow comparison of outcomes in individuals with seizures or epilepsy but without SE to determine the contribution of SE. It also allows comparison with the frequency of events and outcomes in the general population. This chapter examines the prognosis for SE from a population-based study of people with convulsive disorders and epilepsy (9, 11, 13).
The Rochester, Minnesota, study: Source of patients and definitions D For the studies conducted in Rochester, Minnesota, we defined SE as a convulsion of any type lasting 30 minutes or more, or multiple seizures occurring for a similar duration without an intervening period of lucidness. We have excluded individuals with electrical SE (identified on electroencephalography [EEG] alone) without clear clinical manifestations, individuals with seizures of less than 30 minutes’ duration that stopped after the use of intravenous
medication, and individuals with multiple seizures with intervening intervals of lucidity and normal function. This 30-minute definition was selected when abstraction for these studies started in 1980 and was based on reports suggesting that seizures in baboons lasting 30 minutes or longer were associated with neuronal damage (23, 24). S P We used the population-based convulsive disorder data set from Rochester, Minnesota, to address questions regarding outcome following SE. SE is seldom recorded as a final diagnosis by clinicians. Hence, we reviewed all medical records of the 2,654 incidence cases of convulsive disorders that came to medical attention between 1935 and 1984 to identify individuals who had experienced one or more episodes of SE (10). There was virtually never a statement in the medical record about the actual duration of SE, and SE was seldom included among the discharge diagnoses. Cases were identified by screening all incidence cases of convulsive disorders by one of us (W.A.H.) (13). The duration of SE was estimated through review of records written by outcall physicians, ambulance personnel, emergency room personnel, and inpatient personnel, including nurses, house staff, and attending physicians. Few individuals in this cohort underwent EEG monitoring either during or after their episode(s) of SE, so the total duration of SE may be underestimated when compared with criteria used in the Veterans Administration clinical trial. C C We classified SE based upon the classification of convulsive disorders used in previous epidemiologic studies in the community (11), taking into account modifications recommended by the Commission on Epidemiology and Prognosis of the International League Against Epilepsy (7) and the adaptations of Maytal et al. (22). This same classification was described and used in a recent hospital-based series (3). Essentially, the classification requires two independent axes of classification: the first related to the clinical manifestations of the seizures, based on the International League Against Epilepsy’s seizure type (6), the second based on an etiologic classification that takes into account temporal relationships between SE and neurologic and systemic insults (7, 13).
, , :
33
Incidence of SE For short-term mortality to be compared across studies the incidence must first be known, because mortality depends on incidence and the case-fatality ratio. The lowest reported incidence of SE per 100,000 population was from Switzerland (9.9/100,000) (5). This study did not include myoclonic SE. SE incidence was higher in males (12.1; 95% confidence interval [CI]: 9.8–14.5) than in females (7.8; 95% CI: 6–9.7), with a male-female sex ratio of 1.5. The incidence was higher in Rochester, Minnesota (18.1/100,000; CI: 15.9–21.1), where the incidence was almost twofold greater in males than in females (14). In Richmond, Virginia, the incidence was even higher (41/100,000) (8; see also DeLorenzo, Chapter 3, this volume). When the incidence in Richmond was stratified by ethnic group, however, the incidence in whites was lower (20/100,000) than in other ethnic groups, mainly African American (57/100,000). The incidence in whites alone in Richmond was similar to that found in the Rochester study (8, 14). The incidence was similar in a population-based study conducted in the metropolitan area of Marburg, Germany (15.8/100,000; 95% CI: 11.2–21.6) (17). A study conducted in California using a hospital discharge database estimated the incidence of generalized convulsive SE to be 6.2/100,000 with a trend for decreasing incidence over time from 1991 to 1998 (29). This lower incidence when compared with community-based studies suggests that reliance on diagnostic rubrics will miss a considerable number of cases. The incidence of generalized SE in Rochester was 4.7 per 100,000, but it was 7.5 per 100,000 if those with secondary generalized SE were included. Trends in age-specific incidence are consistent across the community-based studies: high in the very young and high in the elderly (Figure 4.1).
Mortality We determined short- and long-term mortality among the 201 residents of Rochester, Minnesota, who experienced a first episode of SE between January 1, 1965, and December 31, 1984 (19, 20). The index episode of SE was the first seizure for the majority of individuals. More than half of all cases of SE occurred in situations other than epilepsy or unprovoked seizures. No deaths occurred among the 17 children with SE associated with a childhood febrile illness, and these cases were excluded from further analysis of mortality. S-T M (30-) Case-fatality ratio We defined short-term mortality as death occurring within the first 30 days following SE (20). This definition follows analytic strategies used in patients with
34
F 4.1 Incidence of status epilepticus. The crude incidence rate was 17 per 100,000 population. The incidence rate adjusted to the 1990 U.S. population was 16.2 per 100,000 population. The age-specific incidence curve is U-shaped. The highest incidence occurred in young children (<1 year old) and the elderly (>85 years, 111/100,000). The incidence was less than 10 per 100,000 population between ages 10 and 60 years.
cerebrovascular and cardiovascular disease and has been the definition of mortality used in the only other populationbased study of SE mortality (7). The case fatality in the first month after SE was 21%. Although similar to the case fatality of 22% reported from the community-based study of SE in Richmond, Virginia, differences in classification of SE and ethnic heterogeneity of the populations make further comparisons difficult (8; see also DeLorenzo, Chapter 3, this volume). The case fatality was much lower in Switzerland (7.6%) (5). Of the deaths, 30.8% occurred in children (<15 years old), 15.4% occurred in adults (ages 15–59 years), and 53.9% occurred in patients more than 60 years old. Deaths were directly related to the cause of SE in seven cases, to complications of SE in two cases, and to other causes in four cases. The low case fatality in Switzerland could be explained in part by the quality of medical care in the area. A more likely reason for the low case fatality in Switzerland is the exclusion of patients with anoxic encephalopathy, a condition known to be associated with a high mortality. S-T M R F Etiology We found heterogeneity across etiologic subgroups in the Rochester study (Figure 4.2). Almost all early deaths (90%) occurred among those with acute symptomatic SE. There was one death (5%) among people with remote symptomatic SE and one death (5%) among people with progressive symptomatic SE. No deaths occurred in the first 30 days in those with idiopathic/cryptogenic SE. Concurrent illness is therefore the most important determinant of early mortality. Among the acute symptomatic cases, cerebrovascular disease and anoxia secondary to cardiac arrest were the two most frequent causes of SE for those dying in the first 30 days. Both of these conditions are characterized by
: , , ,
trolling for other factors. This is at variance from the finding in the population-based study in Richmond and may relate to differences in case classification, analytic methods, or ethnic heterogeneity (8).
F 4.2 Thirty-day mortality in people with status epilepticus according to cause. Charted are survival figures.
high mortality independent of the occurrence of SE or seizures, making it impossible to evaluate the independent contribution of SE to mortality in these conditions. Similarly, in the Richmond study, anoxia and hypoxia were associated with a very high mortality. Age In Rochester, almost 75% of deaths occurred in those over 65. Age was the single most important predictor of death following SE. Short-term mortality was increased nearly 20-fold in those older than 65 when compared with the reference group of persons ages 1–19. The Richmond study also noted a high mortality among the elderly (38%). Mortality was low in children in both Richmond and Rochester. Sex The risk of death for males in the first 30 days was twice that for females. This was true even after restriction of the analysis to cerebrovascular and anoxic encephalopathic SE in the elderly to account for possible confounding by age or etiology of SE. A difference in the short-term prognosis of SE associated with sex has not been previously described. Males may have a higher frequency of other comorbid conditions, such as cardiopathies, that are more likely to be fatal if associated with SE (1). There may also be a biological explanation. The GABA-sensitive region of substantia nigra associated with regulation of seizure threshold is under steroid hormone control. Female rats have a higher seizure threshold than male rats, and after castration, neonatal male rats experience upregulation of their seizure threshold (25). The incidence of SE in males is twice that in females (14). The mortality in males with epilepsy is also increased over that expected in the general population (9). All of these observations suggest that mechanisms controlling seizure suppression or termination or mechanisms protecting against neuronal damage induced by prolonged seizures may be under hormonal control. Duration In the Rochester studies, we did not find duration of SE to be a predictor of short-term mortality after con-
L-T M The majority of studies of mortality following SE have focused on short-term outcome. Our historical cohort study of the Rochester population allows evaluation of mortality at specific intervals following SE. We can also make external comparisons with other seizure disorders and with the general population, in addition to internal comparisons. Information regarding vital status (living or dead) was complete through 1996 (19). Case-fatality ratio More than 40% of those with SE who survived the first 30 days died in the next 10 years. The risk of death was increased threefold compared with the general population. As in short-term mortality, three out of four deaths occurred among the elderly. In contrast to short-term mortality, where deaths occurred almost exclusively in those with acute symptomatic SE, the case fatality was greatest in those with SE in association with progressive symptomatic SE (75%). The mortality was similar for those with acute symptomatic SE (41%) and with remote symptomatic SE (43%). This finding is not surprising, since causes of acute symptomatic SE are for the most part the same factors associated with remote symptomatic SE. As expected, the case fatality was lowest among those with idiopathic/cryptogenic SE (29%) when compared with the other etiologic subgroups. This case fatality was higher than that expected in the general population but is not clearly elevated when compared with mortality in people with idiopathic/cryptogenic epilepsy who never had an episode of SE. L-T M R F Predictors of longterm mortality differ from predictors of mortality in the first 30 days. Age Mortality among those over age 65 at the time of SE was increased more than 50-fold when compared with those ages 1–19 years. It is not surprising that older individuals are at increased risk for death. The magnitude is related to the inclusion of most of the progressive symptomatic cases in this age group. The elderly had a twofold increase in the risk of death compared with elderly in the general population. In contrast, subjects less than 65 years of age had a mortality rate fivefold greater than the rate in the general population. The excess risk was greater among the young because of the low mortality of the reference group. Sex Sex was not a predictor of long-term mortality. Etiology Using mortality in the idiopathic/cryptogenic cases as a referent, the mortality among those with remote
, , :
35
symptomatic SE was increased 1.5-fold and was doubled in those with progressive and acute symptomatic SE. None of these differences was significant. Seizure type We confirm the malignancy of myoclonic SE observed in previous studies (relative risk = 3.1 with generalized SE as a referent); the poor prognosis is largely attributable to the fact that the underlying cause of SE in all cases was anoxic encephalopathy following myocardial arrest. Future studies evaluating prognostic factors should segregate patients with myoclonic causes from patients with other causes of SE. Duration The duration of SE was a predictor of long-term mortality. After controlling for other factors, those with SE of more than 24 hours’ duration were more than twice as likely to die than those with SE of less than 2 hours’ duration. There was an interaction between duration and etiology. The effect was accounted for primarily through increased mortality in 30-day survivors of acute symptomatic SE. Duration may be an indicator of severity of the associated insult rather than an independent predictor of prognosis. T T M SE Although no studies have specifically examined the question, there is a general perception that mortality after SE has decreased in recent years. This decrease has been attributed to better recognition and thus more rapid treatment of SE, and to better management of those with SE (22). Our studies in Rochester failed to support this perception, and in fact, time trends were in the opposite direction: the mortality following SE increased over the 50-year study period (1935–1984) (21). The increase was caused by an increase in incidence and an unchanged summary case fatality. The increased incidence and increased mortality are due to the occurrence of myoclonic SE after cardiac arrest in the last decade of our study. The mortality in the elderly was twice that of the youngest group across the entire study period. Mortality decreased in children over time, particularly in those less than 1 year old. If myoclonic SE is excluded, survivorship in the last decade of the study shows an improvement. Changes in causes of SE over time, particularly the high frequency of SE associated with anoxic encephalopathy following cardiac arrest in recent years, suggest that overall mortality and case fatality can be expected to increase further in the future (18).
Morbidity There have been anecdotal reports that SE is associated with an increase in morbidity, including a risk for continuing epilepsy and for cognitive and neurologic dysfunction. Few
36
systematic studies of these issues have been conducted in humans, however. In our population-based study from Rochester, new neurologic findings after SE not obviously attributed to the precipitating insult included hemiparesis, encephalopathy, mental retardation, and aphasia. Such findings occurred in five of 146 patients who survived the first 30 days (3.4%) (4). These outcomes occurred predominantly in patients with acute or remote symptomatique SE and the association between the convulsive episode and these outcomes remains uncertain. Unprovoked seizures after a first episode of unprovoked SE Studies that address the relationship between SE and seizure recurrence following a first unprovoked seizure are somewhat conflicting. In adults, SE as a first unprovoked convulsive episode is associated with an increased risk for seizure recurrence, although on multivariable analysis, this observation is limited to those with a first unprovoked seizure associated with a prior neurologic insult (13). In children, this seems not to be the case (27). Unprovoked seizures after acute symptomatic SE We compared the risk for unprovoked seizures after a brief acute symptomatic seizure with the risk following acute symptomatic SE (15). By 10 years of follow-up, the risk of unprovoked seizure following an episode of acute symptomatic SE was 41%. By contrast, the risk of unprovoked seizures was 13% for those with brief acute symptomatic seizure. Controlling for age, sex, and cause, SE increased the risk for subsequent unprovoked seizure 3.3-fold (95% CI: 1.8–6.1) when compared with brief acute symptomatic seizures. Among patients with acute symptomatic SE, the risk of unprovoked seizure was increased 18.8-fold in patients with anoxic encephalopathy, 7.1-fold in patients with a structural brain lesion associated with the acute illness, and 3.6-fold in patients with a metabolic cause of the acute illness. The increased risk for unprovoked seizure after acute symptomatic SE when compared with shorter seizures may reflect a more severe injury or more extensive damage in those with SE. Other possible explanations include damage caused by SE, or the biological substrate associated with the tendency to experience SE. SE may also be associated with the development of intractable epilepsy in those with recurrent unprovoked seizures (2).
SE Recurrence Individuals who have experienced one episode of SE are at substantially increased risk for subsequent episodes of SE when compared with those with seizures who have never experienced SE (16). It seems this is more likely a result of the underlying substrate than a result of the SE. In the Rochester study, SE recurrence was highest (about 80%) in
: , , ,
those with progressive symptomatic SE. This observation is similar to the findings of Shinnar et al. (27, 28). Recurrence risk is lower in other etiologic subgroups.
Summary The short-term mortality following SE is substantial but occurs primarily in those with acute symptomatic SE associated with illnesses that are also associated with a high mortality. As yet, the contribution of SE to mortality has not yet been properly evaluated with a comparison group with similar insults but without SE, and it is inappropriate to attribute this mortality to SE without further study. Clearly, SE is associated with an increased long-term mortality, and this observation seems independent of etiologic considerations. SE is also associated with an increased morbidity in terms of recurrence of SE. In adults, there seems an increased risk for subsequent epilepsy in those with a first remote symptomatic episode of SE, although children may not be at the same risk. Acute symptomatic SE is associated with an increased risk for subsequent epilepsy when compared with those with brief acute symptomatic seizures. SE may also be associated with progression to intractable epilepsy, and with permanent neurologic deficits independent of the associated insult. The causal associations for these observations are as yet unclear. Based on recent studies, the prognosis for people with SE is mainly conditional on the nature of the underlying condition. Clinical trials of SE should separately evaluate patients with a clearly poor prognosis, such as those with myoclonic SE following cardiac arrest and an anoxic encephalopathy (21). REFERENCES 1. Anderson, K., P. Wilson, P. Odell, and W. Kannel. An updated coronary risk profile: A statement for health professionals. Circulation 1991;83:356–362. 2. Barry, E., and W. A. Hauser. Status epilepticus: The interaction of epilepsy and acute brain disease. Neurology 1993;43: 1473–1478. 3. Berg, A. T., S. R. Levy, E. J., Novotny, and S. Shinnar. Predictors of intractable epilepsy in childhood: A case-control study. Epilepsia 1996;37:24–30. 4. Cascino, G. D., D. Hesdorffer, G. Logroscino, and W. A. Hauser. Morbidity of non-febrile status epileptius in Rochester, Minnesota. Epilepsia 1998;39:829–832. 5. Coeytaux, A., P. Jallon, B. Galobardes, and A. Morabia. Incidence of status epilepticus in French-speaking Switzerland: (EPISTAR). Neurology 2000;55:693–697. 6. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489–501.
7. Commission on Epidemiology and Prognosis, International League Against Epilepsy. Guidelines for epidemiologic studies on epilepsy. Epilepsia 1993;34(4):592–596. 8. DeLorenzo, R. J., W. A. Hauser, A. R. Towne, J. G. Boggs, J. M. Pellock, L. Penberthy, L. Garnett, C. A. Fortner, and D. Ko. A prospective population-based epidemiological study of status epilepticus in Richmond, Virginia. Neurology 1996;46: 1029–1035. 9. Hauser, W. A., J. F. Annegers, and L. R. Elveback. Mortality in patients with epilepsy. Epilepsia 1980;21:399–412. 10. Hauser, W. A., J. F. Annegers, and L. T. Kurland. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia 1993;34(3):453–468. 11. Hauser, W. A., J. F. Annegers, and L. T. Kurland. Prevalence of epilepsy in Rochester, Minnesota: 1940–1980. Epilepsia 1991;32:429–445. 12. Hauser, W. A., J. F. Annegers, and W. Rocca. Descriptive epidemiology of epilepsy: Contributions of population-based studies from Rochester, Minnesota. Mayo Clin. Proc. 1996; 71(6):576–586. 13. Hauser, W. A., S. S. Rich, J. F. Annegers, and V. E. Anderson. Seizure recurrence following a first unprovoked seizure: An extended follow-up. Neurology 1990;40:1163–1170. 14. Hesdorffer, D. C., G. Logroscino, G. Cascino, J. F. Annegers, and W. A. Hauser. Incidence of status epilepticus in Rochester, Minnesota, 1965–1984. Neurology 1998;50:735–741. 15. Hesdorffer, D. C., G. Logroscino, G. Cascino, J. F. Annegers, and W. A. Hauser. Risk of unprovoked seizure after acute symptomatic seizure: Effect of status epilepticus. Ann. Neurol. 1998;44(6):908–912. 16. Hesdorffer, D. C., G. Logroscino, W. A. Hauser, and G. D. Cascino. Risk of and predictors for recurrence in status epilepticus. Epilepsia 1995;36(Suppl. 4):149. 17. Knake, S., F. Rosenow, M. Vescovi, W. H. Oertel, H. H. Mueller, A. Wirbatz, N. Katsarou, H. M. Hamer, and the Status Epilepticus Study Group Hessen (SESGH). Incidence of status epilepticus in adults in Germany: A prospective, population-based study. Epilepsia 2001;42:714–718. 18. Krumholz, A., and A. T. Berg. Further evidence that for status epilepticus “one size fits all” doesn’t fit. Neurology 2002; 58(4):515–516. 19. Logroscino, G., D. C. Hesdorffer, G. D. Cascino, J. F. Annegers, E. Bagiella, and W. A. Hauser. Long-term mortality after a first episode of status epilepticus. Neurology 2002;58:537–541. 20. Logroscino, G., D. Hesdorffer, G. Cascino, J. F. Annegers, and W. A. Hauser. Short-term mortality after a first episode of status epilepticus. Epilepsia 1997;38:1344–1349. 21. Logroscino, G., D. Hesdorffer, G. Cascino, J. F. Annegers, and W. A. Hauser. Time trends in incidence, mortality, and casefatality after first episode of status epilepticus. Epilepsia 2001;42:1031–1035. 22. Maytal, J., S. Shinnar, S. L. Moshe, and L. A. Alvarez. Low morbidity and mortality of status epilepticus in children. Pediatrics 1989;83:323–331. 23. Meldrum, B. S., and J. B. Brierley. Prolonged epileptic seizures in primates: Ischemic cell change and its relation to ictal, physiological events. Arch. Neurol. 1973;28:10–17. 24. Meldrum, B. S., and R. W. Horton. Physiology of status epilepticus in primates. Arch. Neurol. 1973;28:1–9. 25. Moshe, S. L., S. D. Garnt, E. Sperber, J. Veliskova, H. Kubova, and L. Brown. Ontogeny and topography of seizure regulation by the substantia nigra. Brain Dev. 1995:17(Suppl.): 61–72.
, , :
37
26. Scholtes, F. B., W. O. Renier, and H. Meinardi. Generalized convulsive status epilepticus: Causes, therapy and outcome in 346 patients. Epilepsia 1994;35:1104–1112. 27. Shinnar, S., A. T. Berg, S. L. Moshe, C. O’Dell, M. Alemany, D. Newstein, H. Kang, E. S. Goldensohn, and W. A. Hauser. The risk of seizure recurrence after a first unprovoked afebrile seizure in childhood: An extended follow-up. Pediatrics 1996;98:216–225. 28. Shinnar, S., J. Maytal, L. Krasnoff, and S. L. Moshe. Recurrent status epilepticus in children Ann. Neurol. 1992;31:598– 604. 29. Wu, Y. W., D. W. Shek, P. A. Garcia, S. Zhao, and S. C. Johnston. Incidence and mortality of generalized convulsive status epilepticus in California. Neurology 2002;58(7):1070– 1076.
38
: , , ,
5
Epidemiology of Childhood Status Epilepticus
Introduction Status epilepticus (SE) is a common neurologic emergency that is associated with significant morbidity and mortality (36–38, 41, 61–63, 126). It occurs most commonly in children and can occur either as part of an established seizure disorder or in the context of an acute illness (22, 36–38, 41, 61–63). In more than 50% of cases there is no prior history of seizures (41, 62, 118). The incidence and etiology are highly age dependent (36–38, 87, 118). In the last 30 years there has been a dramatic decline in the morbidity and mortality from childhood SE. This chapter reviews the available epidemiologic data on childhood SE. The discussion includes the incidence of childhood SE, the causes and their age-dependent distributions, the specific populations at risk for an episode of SE, the morbidity and mortality from SE, and long-term sequelae of childhood SE. The long-term sequelae considered in the chapter include cognitive deficits in children who have an episode of SE. Finally, the chapter reviews what is known of the prognosis following SE as a first unprovoked seizure, febrile SE, and its association with subsequent epilepsy and recurrent SE.
of SE in the intensive care unit (ICU) in a critically ill child with a variety of acute complications may also go unreported. SE is most common in the very young and very old (36, 37, 62). The distribution of SE by age parallels that of all seizure disorders (13, 62, 65–67). Young children appear to be particularly susceptible. In the overall population, infants less than 1 year old have the highest incidence, but the elderly population has the highest number of cases (37). In an analysis of the two largest pediatric series, reported from Bronx, New York, and Richmond, Virginia (118), we found that 26% of cases occurred in the first year of life, 43% in the first 2 years of life, and 67% in the first 5 years of life. The distribution of cases from that study is shown in Figure 5.1. Figures reported in other series are comparable (5, 47, 132, 135). SE may occur in the setting of an acute insult, in patients with established epilepsy, or as a first unprovoked seizure in a patient without an acute insult or a prior history of seizures. The different causes and their relative frequency as a function of age in children are discussed below.
Etiology
Incidence SE is a not uncommon occurrence. Based on earlier studies, it was estimated that 50,000–60,000 cases of SE occur in the United States each year (62). More recent data from the prospective population-based study of SE in Richmond, Virginia, indicate an annual incidence of SE of 41 patients per 100,000 population per year and a total of 50 episodes of SE per 100,000 population per year (36–38). The higher number of episodes is due to the substantial proportion of cases with recurrent status. These numbers would correspond to 126,000–195,000 episodes of SE annually in the United States (37). The true incidence of SE is probably even higher, as not all cases are reported (36, 37, 62). Although convulsive SE usually presents to medical attention, it is not always recognized as such. In both children and adults, cases with two seizures without full recovery between seizures may be diagnosed as two seizures rather than as SE. The occurrence
The currently accepted etiologic classification of SE recognizes five etiologic categories of SE in childhood, as follows (34, 37, 41, 87): 1. Cryptogenic/idiopathic: SE occurring in the absence of an acute precipitating central nervous system (CNS) insult or systemic metabolic dysfunction. Included in this group are otherwise neurologically normal individuals with an established seizure disorder, as well as children who present with a first unprovoked seizure. The term idiopathic, which was previously used to classify all of these cases, is, under the new guidelines for epidemiologic research in epilepsy developed by the International League Against Epilepsy (ILAE), now reserved for children with genetically determined, agedependent epilepsy syndromes such as benign rolandic epilepsy and the primary generalized epilepsies (34). Using this definition, idiopathic SE is quite rare. Most of the cases referred to as idiopathic in the literature using the previous classification are in fact cryptogenic.
:
39
F 5.1 Age distribution of 394 children with status epilepticus in Bronx, New York, and Richmond, Virginia (n = 394). (Adapted from Shinnar et al. [121].)
2. Remote symptomatic: A seizure occurring without acute provocation in a patient with a prior history of CNS insult or abnormality known to be associated with an increased risk of convulsions. This category includes children with mental retardation or cerebral palsy of various causes, as well as children who have sustained a prior neurologic insult such as meningitis, head trauma, or intracerebral hemorrhage (34, 67). 3. Febrile: A febrile seizure is a seizure in association with a febrile illness in the absence of a CNS infection or acute electrolyte imbalance in children without prior afebrile seizures. The febrile illness must include a temperature greater than 38.4°C, although the temperature may not be evident until after the seizure (91). The child may be neurologically normal or abnormal. In the new guidelines for epidemiologic research, febrile seizures, and by extension febrile SE, are further divided into those without prior neonatal seizures and those with prior neonatal seizures (34). However, for purposes of this discussion, the two groups can be combined. Febrile SE, which represents the extreme end of complex febrile seizures (8, 15, 41, 49, 85), is really a form of acute symptomatic seizures. However, it is classified separately in children because it accounts for almost 25% of childhood SE and because it has a very different prognosis than other acute symptomatic seizures (49, 85, 118). 4. Acute symptomatic: SE occurring during an acute illness in which there was a known neurologic insult or systemic metabolic dysfunction. Insults include meningitis, hypoxia, and acute head trauma. Also included in this category are episodes of SE occurring within 1 week after the abrupt discontinuation of antiepileptic drugs (AEDs). However, a
40
clear history of abrupt discontinuation of AEDs rather than simply a measured subtherapeutic level, which may be longstanding, is required (42, 62, 87). 5. Progressive encephalopathy: SE occurring in association with a progressive neurologic disorder. Included in this category are patients with neurodegenerative diseases, malignancies not in remission, and neurocutaneous syndromes (41, 87). In many studies this group is included in the remote symptomatic group (5, 47). More recent studies have separated them (41, 89, 118) in recognition of the uniformly poor prognosis in this group, which reflects the prognosis of the underlying disease. Although this group represents less than 10% of children with SE, SE associated with a progressive neurologic disorder accounts for a significant proportion of the morbidity and mortality associated with childhood SE (87). The distribution of causes is different in children than in adults, with a higher proportion of acute symptomatic cases, particularly ones related to cerebrovascular disease (38). Febrile SE is seen only in childhood. Even in childhood, the distribution of causes is highly age dependent (118). The results from a study that analyzed the two largest pediatric series are summarized in Figure 5.2. In the first year of life, acute symptomatic seizures accounted for over 50% of the cases of SE. Febrile SE accounted for more than two-thirds of cases in the second year of life. In contrast, more than 60% of cases in children over age 4 were of cryptogenic and remote symptomatic etiology (118). The most common causes of acute symptomatic SE in childhood in the Bronx and Richmond cohorts were CNS infection, including both meningitis and encephalitis (29%); metabolic causes (25%);
: , , ,
F 5.2 Etiology of status epilepticus and age in 394 children with SE from Bronx, New York, and Richmond, Virginia. (Reprinted with permission from Shinnar et al. [118].)
trauma (17%); and anoxia (12%) (118). These different causes of acute symptomatic status were also age dependent. Other pediatric series show a similar distribution of causes (5, 41, 46, 47, 95, 132, 135).
Type of seizure The revised international classification of seizures separates seizures into those with generalized onset, including tonicclonic, tonic, absence, atonic, and myoclonic, and those with partial onset, including simple partial, complex partial, and partial with secondary generalization (33). In theory, all of these, with the exception of atonic, can occur as SE. SE can also be divided into convulsive and nonconvulsive types (41, 62, 87). Most cases of childhood SE are of the convulsive type. In a series of 193 children, only 13 (6.7%) had nonconvulsive SE (87). Other reports give similar results (47). In these series, convulsive SE included both generalized tonic-clonic and partial seizures with secondary generalization (38, 47, 87). Prior series reported that most cases of childhood SE were of generalized onset (5, 47, 87, 135). Thus, in the series of Maytal et al. (87), 133 of 193 cases (71%) were generalized, of which 130 were tonic-clonic and three were absence. Other prior series reported a rate of 50%–60% generalized cases (5, 47). These series were all based on clinical observation only, as electroencephalographic (EEG) data were not routinely available. Therefore, the true proportion of partial onset seizures was undoubtedly underestimated. The more recent greater Richmond SE study found that 71% of pediatric SE and 74% of adult SE episodes ended up as generalized seizures. However, with more intensive monitoring of
EEG data, it was felt that 64% of pediatric cases and 69% of adult cases were of partial onset (38). Generalized onset SE was most common in the first year of life, which is the age group in which SE is most likely to occur (38, 118). Although the precise frequency of partial onset SE in children remains unclear, it seems probable that for SE, the differences between pediatric and adult cases are less than was previously thought. In prior reports of pediatric SE, the vast majority were of partial onset status, secondarily generalized (5, 87, 135). Thus, in the series of Maytal and colleagues (87), the 56 cases with partial onset included 3 (5%) simple partial, 7 (13%) complex partial, and 46 (82%) partial with secondary generalization. The recent Richmond series reported a somewhat higher proportion of simple partial cases (38). Although nonconvulsive SE in childhood is uncommon, it certainly does occur. There have been reports limited to solely nonconvulsive SE in children (42, 57, 89, 99). Cases of nonconvulsive SE were also included in the larger series of SE (5, 38, 46, 47, 87). In a comparison with adult SE, DeLorenzo et al. reported that myoclonic SE and electrographic SE without clinical correlate, both of which are subtle forms of SE, were uncommon in childhood (38). Absence status was uncommon in all age groups. Seizure type is correlated with etiology. Febrile SE is more likely to be generalized, whereas remote symptomatic cases and acute symptomatic cases are more likely to be of partial onset (87). A breakdown of seizure type by etiology is not given in the other studies. It is hardly surprising that seizures associated with acute or remote brain injuries, many of which are focal, are more likely to be partial in origin.
:
41
Who gets SE?
P N A Both epilepsy in general and SE in particular are more common in neurologically abnormal children. Most series report that 14%–40% of children with SE have preexisting neurologic abnormalities (5, 21, 47, 84, 87, 95, 118, 122, 135). These numbers may underestimate the true incidence of neurologic abnormalities in this population. Moreover, many authors do not record the percentage of children with acute symptomatic or febrile seizures who have prior neurologic abnormalities. Also, in some studies, any child with SE and a low serum AED level was considered to have had acute symptomatic SE triggered by AED withdrawal or noncompliance (46), regardless of the child’s neurologic condition. In reports that do describe the rate of prior neurologic abnormalities in children who are not included in the remote symptomatic group (5, 84, 87, 118), the rates of prior abnormalities are high in both the febrile and acute symptomatic group (5, 86, 113). Recent data indicate that the proportion of children who are neurologically abnormal is age dependent. In an analysis of the data from Bronx, New York, and Richmond, Virginia (118), we found that 158 (40%) of 394 children with SE were known to be previously neurologically abnormal, including 35 (21%) of 169 under age 2 years and 123 (55%) of 225 older than 2 years (P < 0.001). Although it is possible that some of the children with SE at a young age who are subsequently found to have neurologic impairment had prior undiagnosed neurologic abnormalities, this does not appear to be the whole story.
order occurs primarily in the cryptogenic group. In a study of SE in children, more than 50% of subjects with cryptogenic SE had no prior history of seizures (87). In contrast, more than 80% of the subjects with remote symptomatic SE had had prior seizures. SE in children with no prior history of seizures occurs primarily in the young. In the analysis of the Bronx, New York, and Richmond, Virginia, data (118), 177 (45%) of 394 children had a history of prior seizures, including 142 (41%) of the 349 children with a first episode of status. A history of prior seizures was present in 34 (20%) of those under age 2 years, compared with 143 (64%) of those older than 2 years (P < 0.001). The effect of age remained significant even when the analysis was limited to those with SE of cryptogenic or remote symptomatic etiology. However, the older children were more likely to also be neurologically abnormal. Thus it appears that SE in young children occurs primarily in children who are neurologically normal and have no prior history of unprovoked seizure. In older children, SE occurs primarily in those who are known to have had prior unprovoked seizures and who are often also neurologically abnormal. SE also occurs as part of established seizure disorders. Between 10% and 27% of patients with epilepsy will experience at least one episode of SE (22, 41, 61–63, 70, 122). SE is particularly common in patients with remote symptomatic epilepsy. These patients account for 30% of cases of epilepsy but for 50% of cases of unprovoked status (5, 87, 99). Neurologically abnormal children with epilepsy are more likely to develop SE despite “therapeutic” AED levels (84, 115). They are also at high risk for recurrence of SE, which occurs in as many as 50% of the children (36, 37, 43, 115). SE is also very common in children with onset of seizures before 1 year of age (22, 26, 46, 56, 70, 83, 86, 122), a group that includes many children with static and progressive encephalopathies. Data from patients with intractable partial seizures suggest that the patients at risk for SE are the same patients who get seizure clusters. A recent community-based study of children with newly diagnosed epilepsy found a particularly high risk of SE in children who had undergone a craniotomy in the past (22). In adults, SE occurs more commonly in patients with partial seizure disorders, particularly those with frontal lobe epilepsy (41, 62).
P S SE is a common occurrence in both children and adults with seizure disorders. In studies of children and adults (64, 68, 111, 112) who presented with a first unprovoked seizure, approximately 8%–12% presented with SE. Similar numbers are expected in patients with epilepsy who first come to medical attention (22, 62, 122). These groups account for approximately one-third of the cases of SE (41, 62). SE as the initial presentation of a seizure dis-
R In the recent epidemiologic study of the incidence of SE in Richmond, Virginia (37, 38), an increased incidence was found in nonwhite population. In this geographic locale, this would reflect primarily an African-American population. The estimated incidence of SE in nonwhites was 57 per 100,000, compared with 20 per 100,000 in whites. Other studies of SE either do not contain incidence data by race or were done in racially homogeneous populations.
The majority of cases of SE occur in children who are neurologically normal and have no prior history of seizures (38, 41, 62, 87, 118). However, certain populations, such as the very young, those with prior neurologic abnormalities, and those with preexisting seizure disorders, are known to be at increased risk. The incidence by age was reviewed earlier. In addition, it seems that there is a subgroup of children with seizures with an inherent predisposition to prolonged seizures (15, 21, 35, 113, 114, 122); this situation is discussed later in the chapter (see Recurrent SE). This section reviews the other risk factors for experiencing an episode of SE.
42
: , , ,
There are data that indicate an increased incidence of seizure disorders in inner-city, predominantly nonwhite populations, though it is unclear whether this difference is based on ethnic or socioeconomic factors (62). As the incidence of SE tends to mirror the incidence of epilepsy, these data would be consistent with an increased rate of SE in innercity populations (13, 66).
Morbidity and mortality The morbidity and mortality of SE have decreased significantly over the past 30 years. Mortality from pediatric SE in two recent large series was 3% and was essentially limited to cases where the etiology was acute symptomatic or progressive encephalopathy (36, 87). This compares favorably with mortality in adults from the same Richmond series of 26% (36, 126). The decreased mortality in children is due both to a different distribution of causes, with fewer acute symptomatic cases and more cryptogenic and febrile cases, and to an apparent decreased morbidity and mortality in children compared with adults with similar insults (36, 61, 87). Other recent pediatric series report similar findings (46, 47, 88, 95, 132, 135). Older studies of SE in children reported a mortality of 11% (5). Approximately half of the deaths were associated with the acute event, and the remainder were the result of the disorders causing the episode of SE. Neurologic abnormalities were found in 45%–51% of the survivors. Even children with SE of cryptogenic or idiopathic etiology had a high rate (44%) of subsequent neurologic disabilities (4, 5, 56). Recent series paint a much more favorable picture. New cognitive or motor deficits are reported in 9%–28% of survivors (36, 46, 47, 62, 86–88, 95, 132, 135), with the great majority occurring in those with acute symptomatic or progressive encephalopathy etiology. In the series of Maytal et al. (87), 9% of the surviving children had neurologic deficit, but only 1.5% of the 137 children with cryptogenic, remote symptomatic, or febrile SE developed a new neurologic deficit. None of the 67 prospectively identified children with cryptogenic, remote symptomatic, or febrile SE developed a new neurologic deficit (87). Even Yager et al. (135), who reported a 28% incidence of sequelae in survivors, found only one child with cryptogenic SE who had neurologic sequelae. Their higher rate of sequelae can be attributed to the high proportion of acute symptomatic cases in their population. Similar results were reported by Dulac et al. (46). In a recent report of 172 prospectively identified children with febrile SE, none of the children had new cognitive or motor deficits following the episode of febrile status (94). Interestingly, the syndrome of hemiconvulsionshemiparesis-epilepsy, which was a commonly reported sequela of status in the older literature (3, 5, 56, 59), has
essentially disappeared and has not been reported in the more recent series. Earlier reports had emphasized the higher morbidity and mortality of SE occurring in the first year of life. Several studies have now reported that death and all types of sequelae are more common in younger children (5, 47, 87). As previously discussed, the incidence of SE is highest in the first year of life (36, 41, 62). However, the distribution of causes is also highly age dependent. While in general, the causes in children are more benign than in adults (36, 41), this is not true in the first year of life. In the Bronx, New York, and Richmond, Virginia, data (118), more than 50% of cases of SE in the first year of life were due to acute symptomatic causes, including CNS infection, metabolic causes, hypoxia, and trauma, all of which can be expected to have a high rate of sequelae (Figure 5.2). Thus the higher mortality and morbidity of status in this age group can be attributed to the higher proportion of acute symptomatic causes rather than to a particular vulnerability of the immature CNS to damage. This is confirmed by the data of Dulac et al. (46), who studied 79 children between 1 month and 2 years of age with SE and found only two children in whom the neurologic deficit could be attributed to sequelae of the seizure itself. We also note that cases of febrile SE occurring in the first year of life are not associated with an increased morbidity and mortality (85, 118). The precise reasons for the dramatic decline in the morbidity and mortality of convulsive SE in recent years, particularly in cryptogenic cases, are not fully understood. Although treatment has substantially improved, not just in terms of the availability of effective AED therapy but also in terms of supportive care for airway and circulation, the decline in pediatric morbidity and mortality has not been paralleled by a similar decline in morbidity and mortality in adult series (76). Perhaps the most dramatic impact of treatment was to drastically reduce morbidity and mortality in cases without an acute or progressive underlying neurologic insult. The more recent series, which report favorable outcomes of SE in children, are all based on children who were treated in modern emergency departments. It seems reasonable to speculate that the major reduction in morbidity and mortality has resulted from the availability of improved care. The disappearance of the hemiconvulsionshemiparesis-epilepsy syndrome (5, 56, 59) over this time period is most likely not a coincidence but a reflection of available effective treatment for these cases. Thus, while SE remains a neurological emergency, in properly treated cases in which effective treatment and supportive care are applied, the morbidity and mortality appear to be primarily a function of etiology. It should be noted that in the older series, a definition of SE of 60 minutes or longer was used (5, 56). The more recent series, which used the current definition of ≥30
:
43
minutes, include enough cases of status lasting ≥60 minutes to indicate that the decreased morbidity is not simply due to a less severe case mix (38, 46, 47, 87, 135). However, in the more recent series, in which children received appropriate treatment, the majority of episodes lasting more than an hour were associated with an acute or progressive underlying neurologic insult. In the series of Maytal et al. (87), acute symptomatic cases accounted for 23% of all cases but for 46% of episodes lasting longer than 1 hour. Most episodes of cryptogenic, febrile, or remote symptomatic SE are readily controlled with AED therapy. Only 18% of these episodes lasted longer than 60 minutes. Some of the differences in reported outcomes may be due to identification bias. The older series (5, 56) were primarily retrospective. Many of the affected patients were seen initially at smaller community hospitals and were not seen by the investigators until many years after the episodes of SE. This retrospective review would skew the results toward cases with a bad outcome, because patients with a favorable outcome would not require a referral to a specialist years later. This type of referral bias is particularly evident in the evaluation of subsequent seizures. When Fujiwara et al. (56) retrospectively identified the children at an epilepsy center who had previously had an episode of SE, they found that all had epilepsy. However, even in prospectively identified children from that era (2, 5), the morbidity and mortality were substantially higher than that reported today.
Long-term sequelae of SE in childhood C S In any entity associated with a significant morbidity and mortality, it is not surprising that cognitive impairment may occur as a sequela. Indeed, isolated case reports of cognitive impairment following SE abound (5, 42, 103, 107). However, much of the morbidity and mortality of SE is associated with the precipitating acute neurologic insult (5, 38, 40, 41, 46, 47, 61, 63, 87, 94, 132, 135). Also, the high rates of adverse sequelae reported in the older series are probably not representative of the current reality, as there has been a decline in the rate of all reported sequelae (38, 40, 41, 61, 62, 126). To address the issue of whether an episode of SE in childhood per se is associated with subsequent cognitive impairment, one must study the appropriate subjects. This is not a simple task, as SE often occurs in the context of an acute brain insult, in which setting it is difficult to separate the adverse effects of status from those of the acute insult (5, 40, 41, 87). In the cases of SE occurring as part of a chronic intractable seizure disorder, it is difficult to distinguish the effects of the isolated prolonged seizure from that of the repeated briefer seizures. In children, there is the additional difficulty that SE most often occurs in very young children, less than 2 years old (38, 41, 62, 118), an age where it is very
44
difficult to get an accurate estimate of premorbid intellectual function except in the setting of severe impairment. Children who present with SE as a first unprovoked seizure would seem to be an ideal population in which to study this issue. Although this is a not uncommon occurrence (9, 17, 62, 65, 66, 68, 85, 107, 108), very few such children have had prior neuropsychological testing and it is thus difficult to separate sequelae from premorbid deficits when one finds a subtle deficit. The data regarding cognitive impairment following SE were reviewed by Dodrill and Wilensky (39). Of the 14 studies reviewed (5, 6, 31, 39, 42, 46–49, 56, 63, 74, 87, 94, 99), the more recent and prospective ones were the ones that reported the lowest morbidity, including cognitive outcomes. However, few of the studies utilized any formal psychological testing. These same authors also performed a study on adults with refractory epilepsy in which serial neuropsychological testing was performed. They found that while SE tended to occur in more impaired individuals, there was little evidence of cognitive decline following an episode of SE in this population (40). The pediatric data also indicate that SE per se is rarely associated with long-term cognitive deficits. Ellenberg and Nelson examined 27 children from the National Collaborative Perinatal Project with febrile SE and found no differences in cognitive function at 7 years of age between them and their siblings (49). The British National Cohort Study also found no differences in intelligence, behavior, and academic achievement at age 10 between children with febrile seizures (including prolonged ones) and control subjects who were born in the same week and never had seizures (130). In children with epilepsy, the results are similar. Analysis of the data from the National Collaborative Perinatal Project also found no evidence of decline in cognitive function in children who had cognitive testing at 4 and 7 years of age as part of that study and who had onset of epilepsy between ages 4 and 7, including eight children who had experienced at least one episode of SE during that time (48). Dunn (47) and Maytal et al. (87) also found no long-term sequelae following SE in children, unless the episode of status was associated with an acute or progressive CNS insult, but those studies did not include formal psychological testing of the subjects. The available data indicate that the occurrence of cognitive deficits following an episode of SE not associated with an acute or progressive CNS insult is a rare event (107). SE F E The textbook definition of SE as “a seizure of such duration as to create a fixed epileptic condition” (58, 95) might lead one to assume that all cases of SE are inevitably associated with a subsequent chronic seizure disorder, but there is little evidence that this is the case. In this section we review the epidemiologic data on the risk of future seizures following an episode of SE in child-
: , , ,
hood in the setting of a first unprovoked seizure, febrile SE, and acute symptomatic status. SE as a first unprovoked seizure Approximately 10% of children and adults who come to medical attention with a first unprovoked seizure present with SE (9, 17, 41, 62, 64, 66, 68, 88, 111, 112, 122). In children, the risk of seizure recurrence following a cryptogenic or idiopathic first unprovoked seizure is not influenced by the duration of the initial seizure (9, 17, 56, 68, 109, 111–113). This is true whether one examines seizure duration as a continuous variable or compares those with SE as their first unprovoked seizure with those who presented with a brief first seizure. However, as discussed later (see the section, Recurrent SE), if a child with a prolonged first seizure does experience a seizure recurrence, the recurrent seizure is likely to be prolonged (112, 113). These studies, which include follow-up periods of over 10 years, provide the best evidence that SE per se does not create a permanent seizure disorder (68, 109, 111–113). When children present with SE as a first unprovoked seizure of remote symptomatic etiology, the risk of recurrence is increased (9, 17, 64, 68, 111, 112). These patients are at increased risk not just for recurrent seizures but also for recurrent SE (17, 43, 115). However, SE as the initial seizure is relatively uncommon in this group. In one study of childhood SE, 29 (63%) of 46 children with cryptogenic SE had no prior history of seizures, whereas 34 (75%) of 45 children with remote symptomatic status had a prior history of seizures (87). The fact that SE is a risk factor for subsequent seizures in remote symptomatic cases but not in cryptogenic ones suggests either that it is a marker for epilepsy in those cases or that the already compromised brain is more susceptible to injury as a result of SE (60, 106). The epidemiologic data in children also do not demonstrate an adverse impact of an isolated episode of SE on long-term outcome. The occurrence of SE does not influence long-term remission rates in children who present with SE as their first unprovoked cryptogenic seizure (109, 110). In a case-control study of predictors of intractability in children with newly diagnosed epilepsy, the occurrence of SE was found to be a marker for future intractability (14). The best predictor, however, was the presence of an underlying neurologic abnormality. Furthermore, of the four children thought to have cryptogenic epilepsy and whose presentation included an episode of SE, one was later diagnosed as having a brain tumor, one was later diagnosed as mentally retarded, and one was found to have a progressive neurologic disorder. Thus, the occurrence of SE in this population seems to be a marker for an abnormal brain, which is known to be a predictor of future intractability (14). In the prospective Connecticut study of newly diagnosed childhood-onset epilepsy, the occurrence of either febrile or unprovoked SE was not associated with the development of
intractable epilepsy (23). Similar results were reported in a population-based study of long-term outcomes of childhood-onset epilepsy from Finland (119–122). While the occurrence of SE was a predictor of future intractability on univariate analysis, it appeared to be a marker for the symptomatic cases, and in the multivariable analysis of outcome it had only a modest effect on remission rates and no effect on mortality or psychosocial outcomes (119–122). A recent imaging study found that SE, along with age at onset, etiology, and several other factors, was associated with decreased brain volume. The significance of these findings remains unclear, as status was but one of many factors associated with a decreased brain volume in this population of children with epilepsy. Febrile status epilepticus The morbidity and mortality of febrile SE in recent studies are low (7, 8, 37, 38, 41, 46, 47, 48, 62, 71, 85, 87, 93, 117, 127, 129–132, 135). In a group of 172 children with febrile SE prospectively identified between 1984 and 1994 in Bronx, New York, and Richmond, Virginia, only one child died due to malignant cerebral edema in association with presumed Shigella encephalopathy. There were no new motor or cognitive deficits in the 171 survivors (117). The risk of a subsequent febrile seizure is no different following a prolonged febrile seizure than following a brief one (15, 19, 93). However, if another febrile seizure does occur, it too is likely to be prolonged (15). This is very similar to the data in children with a first unprovoked seizure. The risk of subsequent epilepsy is increased following any complex febrile seizure, including febrile SE (7, 8, 15, 18, 41, 49, 71, 85, 91, 93, 129, 131). Risk factors for the development of epilepsy in the first few years following the febrile seizures include neurodevelopmental abnormality, complex febrile seizures, a family history of epilepsy, and the duration of fever prior to the febrile seizure (8, 18, 91, 93, 129, 131). Age at the time of febrile seizure and the height of the fever are not associated with a differential risk of subsequent epilepsy (18). The majority of children who develop epilepsy within a few years of their febrile seizure do not appear to have mesial temporal epilepsy. With long-term follow-up, the highest risk of subsequent epilepsy occurs in those whose febrile seizures were both prolonged and focal (8). In the Rochester, Minnesota, data, the cumulative risk for developing epilepsy in this small subgroup was 40%–50% (8). It is difficult to separate the effect of a prolonged febrile seizure from that of a focal one, as prolonged febrile seizures also tend to be focal (5, 8, 85, 117). One of the most controversial topics in epileptology is the issue of whether prolonged febrile seizures cause mesial temporal sclerosis. Retrospective studies from tertiary epilepsy centers report that many adults with intractable temporal
:
45
lobe epilepsy had a history of prolonged or atypical febrile seizures in childhood (1, 24, 27, 28, 29, 50–53, 55, 77–82, 99). However, population-based studies have failed to find this association, as have prospective studies of febrile seizures (7, 8, 16, 49, 71, 85, 93, 104, 105, 129, 131). In the Rochester, Minnesota, study, those with generalized febrile seizures were at increased risk for generalized epilepsies, particularly idiopathic epilepsies associated with generalized spike-and-wave abnormalities on EEG, whereas those who had focal seizures were at increased risk for partial epilepsy (8). This is precisely what one would expect if febrile seizures were an age-specific marker for future seizure susceptibility (119). Febrile SE is much more common in children who are already neurologically abnormal and are most likely to be focal suggesting prior focal pathology (8, 32, 49, 93, 106, 117, 118, 129, 131). Recent population- and community-based studies of children with new-onset seizures have not found an association between prior febrile seizures and temporal lobe epilepsy (21, 25). In addition, studies that have focused on treating febrile seizures have reduced the incidence of febrile seizures but have had no effect on the rate of subsequent epilepsy (16, 71–73, 97, 98, 104, 107, 133, 134). The epidemiological data do not support a causal relationship between prolonged febrile seizures and subsequent mesial temporal epilepsy. A fuller discussion of this issue can be found in several reviews focusing on this specific topic (16, 71, 104–108, 116). Very recently an association between very prolonged and focal febrile seizures and mesial temporal sclerosis has been demonstrated using MRI (52, 101, 102, 132). Van Landingham et al. (128) reported acute MRI changes in a few children with very prolonged (mean duration >90 minutes) and focal febrile seizures that in two cases progressed to mesial temporal sclerosis. The changes were not seen in children with prolonged febrile seizures that were generalized. In addition, the children had evidence of preexisting focal pathology, such as a temporal lobe arachnoid cyst. Similar findings in a study that examined children both acutely and long term were reported by Scott et al. (101, 102). Another recent MRI study (52) found evidence of subtle preexisting hippocampal abnormalities that were associated with familial febrile seizures. When very prolonged, these were associated with mesial temporal sclerosis. The finding of mesial temporal sclerosis in this report was retrospective. Whereas these recent studies demonstrate that mesial temporal sclerosis can occur as a consequence of very prolonged febrile seizures, they also suggest that the event is uncommon and may require a preexisting temporal lobe abnormality to occur. Thus, this association is unlikely to account for most cases of mesial temporal lobe epilepsy (71, 106). Interestingly, these recent clinical reports are consistent with very recent pathologic and animal data. Mathern and colleagues have described a high incidence of small areas of
46
heterotopias and subtle migration defects in the temporal lobes of patients undergoing temporal lobectomy for medically refractory mesial temporal lobe epilepsy, some of whom have a history of prior febrile convulsions (81, 82). Germano et al. (60) have recently reported that, in a rat hyperthermia model of febrile seizures, immature rats with experimentally induced neuronal migration defects have a lower threshold to hyperthermia-induced seizures and are more susceptible to irreversible hippocampal neuronal damage than control immature rats without migration defects. The evolving concept is that preexisting pathology was responsible for the febrile seizure being both focal and prolonged and caused the brain to be more susceptible to seizure-induced damage (106). The event is sufficiently uncommon that the association is not seen in epidemiologic studies. Recently, a large cohort of children with febrile SE has been assembled that will hopefully allow more detailed study of the association between these seizures and mesial temporal sclerosis (117). The development of experimental models of febrile seizures will soon shed further light on this issue. The results of Germano et al. (60) have already been discussed. Baram and colleagues recently developed an immature rat model of febrile seizures (11). Interestingly, the findings in this immature rat model of prolonged febrile seizures show that these seizures do not result in loss of hippocampal and amygdala neurons but cause significant, yet transient, structural alterations (11, 125). In addition, these seizures lead to longlasting functional changes in the hippocampal circuit, consisting of increased presynaptic GABA release, (30), yet enhanced susceptibility to further seizures (44). Some of these longlasting changes are due to changes in the distribution of subunits of the hyperpolarization-activated, mixed-cation channels (h-channels), which leads to increased seizure susceptibility (30, 44, 45, 124). The animal data are extensively reviewed in a recent monograph on febrile seizures (11). Further animal studies of this model may lead us to a better understanding of what is occurring in children with prolonged febrile seizures (10). Acute symptomatic SE Approximately 15%–30% of children who experience seizures in association with an acute insult will subsequently develop epilepsy (62,107). However, while acute symptomatic seizures, including SE, are associated with an increased risk of subsequent epilepsy in patients with acute CNS injury, it is unclear whether children with acute symptomatic SE are at higher risk for subsequent epilepsy than children with briefer acute symptomatic seizures (61–65). The use of AEDs reduces the incidence of acute symptomatic seizures but does not alter the proportion who subsequently develop epilepsy, suggesting that these seizures usually are more a marker of damage than the cause of the damage (54, 90, 108, 123).
: , , ,
Recurrent SE We have already reviewed the issue of which children are at risk for developing SE. Also of interest is the question of who is at risk for developing recurrent episodes of SE. While the question is of interest in both adults and children, most of the available data are in children. Studies of SE in children report that 11%–25% of children with SE will experience at least two episodes (5, 22, 36, 43, 47, 87, 115, 122). These studies included both prospectively and retrospectively identified cases. In a prospective study (115), we followed 95 children from the time of their first episode of SE. Sixteen children (17%) experienced recurrent status, including five with three or more episodes. Fourteen (88%) had prior neurologic abnormalities. The risk of recurrent SE in the remote symptomatic and progressive encephalopathy group was almost 50%, compared with only 3% in children who were otherwise neurologically normal. The neurologically abnormal group constituted 32 (34%) of the 95 children, but they accounted for 14 (88%) of 16 children with recurrent SE and all five children with three or more episodes of SE. Driscoll et al. (43) reported similar findings in a retrospective review of the Richmond, Virginia, SE data set. Thus, it would appear that the risk of recurrent SE is primarily in children with preexisting neurologic abnormalities. This is also the population that is at higher risk for developing seizures (15, 77, 79, 112) and SE in the first place (5, 38, 41, 46, 47, 62, 86, 87, 132, 135). Data from the prospective greater Richmond population-based study of SE also report a much higher risk of recurrent SE in children than in adults (37). As previously discussed, studies of children who present with a first unprovoked seizure (112, 113) or with febrile seizures (15) indicate that while a prolonged initial seizure does not alter recurrence risk, if the child does experience recurrent seizures, the recurrence is likely to be prolonged. Recent data from large cohorts of patients with childhoodonset epilepsy provide additional support for the concept that there is a group of children with an increased susceptibility to having prolonged seizures. A population-based study of childhood-onset epilepsy from Finland reported that 27% of patients with childhood-onset epilepsy experienced at least one episode of SE. The majority of initial cases of SE occurred at or prior to the diagnosis of epilepsy. Of those that had one episode, approximately half experienced two or more episodes of SE (122). Conversely, if the child did not have an episode of status within 2 years of the onset of the seizure disorder, the likelihood of status occurring later in life was very low. Similar data, though with a shorter duration of follow-up, were reported from the community-based study of newly diagnosed childhood-onset epilepsy in Connecticut (22). A recent review of SE occurring in the context of drug trials also found that the patients most likely to expe-
rience SE during a trial of a new AED were those with prior episodes of status (109). Further support for this position comes from studies of twins that show that if one twin experiences an episode of SE, the other twin is at high risk not just for seizures but for an episode of SE (35). The combined available data suggest that the occurrence of SE is a marker of a predisposition to prolonged seizures rather than a cause of subsequent seizures. It can be a marker either of a damaged brain or of a genetic predisposition to prolonged seizures. There is clearly a subgroup of children with a predisposition to prolonged seizures. If one views SE as the failure of inhibitory processes that terminate a seizure, then this should not be surprising. The mechanisms that underlie seizure susceptibility may be different than the mechanisms by which seizures are turned off. Patients with refractory epilepsy in monitoring units have frequent seizures, almost all of which are very brief. In contrast, there is a subgroup of children who tend to have longer seizures, and these signal a predisposition to prolonged seizures rather than necessarily to frequent seizures (114).
Summary SE is a common event in childhood, with children under age 2 at highest risk. In young children, SE occurs primarily in children who are neurologically normal and with no prior history of unprovoked seizure. In older children, it occurs primarily in those who are known to have prior unprovoked seizures and who are often also neurologically abnormal. The morbidity and mortality of SE are low and are primarily a function of the underlying etiology. The epidemiologic data suggest that, in the absence of an underlying neurologic abnormality or insult, childhood SE, though often a marker for preexisting CNS pathology, is not associated with detectable long-term sequelae. More studies are needed on the consequences of very prolonged febrile seizures, which appear to have different pathophysiologic consequences than other types of seizures in children. This work was supported in part by NIH grants R01 NS26151 and R01 NS043209 from the National Institute of Neurological Disorders and Stroke.
REFERENCES 1. Abou-Khalil, B., E. Andermann, F. Andermann, A. Olivier, and L. F. Quesney. Temporal lobe epilepsy after prolonged febrile convulsions: Excellent outcome after surgical treatment. Epilepsia 34:878–883. 2. Aicardi, J. Consequences and prognosis of convulsive status epilepticus in infants and children. Jpn. J. Psychiatr. Neurol. 1986;40:283–290.
:
47
3. Aicardi, J., J. Amsili, and J. J. Chevrie. Acute hemiplegia in infancy and childhood. Dev. Med. Child Neurol. 1969;11: 162–173. 4. Aicardi, J., and J. J. Chevrie. Consequences of status epilepticus in infants and children. In A. V. Delgado-Escueta, C. G. Wasterlain, D. M. Treiman, and R. J. Porter, eds. Status Epilepticus. New York: Raven Press, 1983:115–125. 5. Aicardi, J., and J. J. Chevrie. Convulsive status epilepticus in infants and in children: A study of 239 cases. Epilepsia 1970;11:187–197. 6. Aminoff, M. J., and R. P. Simon. Status epilepticus: Causes, clinical features and consequences in 98 patients. Am. J. Med. 1980;69:657–666. 7. Annegers, J. F., W. A. Hauser, L. R. Elveback, and L. T. Kurland. The risk of epilepsy following febrile convulsions. Neurology 1979;29:297–303. 8. Annegers, J. F., W. A. Hauser, and S. B. Shirts, et al. Factors prognostic of unprovoked seizures after febrile convulsions. N. Engl. J. Med. 1987;316:493–498. 9. Annegers, J. F., S. B. Shirts, W. A. Hauser, and L. T. Kurland. Risk of recurrence after an initial unprovoked seizure. Epilepsia 1986;27:43–50. 10. Baram, T. Z., M. Eghbal-Ahmadi, and R. A. Bender. Is neuronal death required for seizure-induced epileptogenesis in the immature brain. Prog. Brain Res. 2002;135:365–375. 11. Baram, T. Z., A. Gerth, and L. Schultz. Febrile seizures: An age appropriate model. Dev. Brain Res. 1997;246:134–143. 12. Baram, T. Z., and S. Shinnar, eds. Febrile Seizures. San Diego, Calif.: Academic Press, 2002. 13. Berg, A. T. The epidemiology of seizures and epilepsy in children. In S. Shinnar, N. Amir, and D. Branski, eds. Childhood Seizures. Basel, Switzerland: S. Karger, 1995:1–10. 14. Berg, A. T., S. R. Levy, E. J. Novotny, and S. Shinnar. Predictors of intractable epilepsy in childhood: A case control study. Epilepsia 1996;37:24–30. 15. Berg, A. T., and S. Shinnar. Complex febrile seizures. Epilepsia 1996;37:126–133. 16. Berg, A. T., and S. Shinnar. Do seizures beget seizures? An assessment of the clinical evidence in humans. J. Clin. Neurophysiol. 1997;14:102–110. 17. Berg, A. T., and S. Shinnar. The risk of seizure recurrence following a first unprovoked seizure: A quantitative review. Neurology 1991;41:965–972. 18. Berg, A. T., and S. Shinnar. Unprovoked seizures in children with febrile seizures: Short term outcome. Neurology 1996;47: 562–568. 19. Berg, A. T., S. Shinnar, W. A. Hauser, and J. M. Leventhal. Predictors of recurrent febrile seizures: A metaanalytic review. J. Pediatr. 1990;116:329–337. 20. Berg, A. T., S. Shinnar, W. A. Hauser, et al. Predictors of recurrent febrile seizures: A prospective study of the circumstances surrounding the initial febrile seizure. N. Engl. J. Med. 1992;327:1122–1127. 21. Berg, A. T., S. Shinnar, S. R. Levy, and F. M. Testa. Childhood-onset epilepsy with and without preceding febrile seizures. Neurology 1999;53:1742–1748. 22. Berg, A. T., S. Shinnar, S. R. Levy, and F. M. Testa. Status epilepticus in children with newly diagnosed epilepsy. Ann. Neurol. 1999;45:618–623. 23. Berg, A. T., S. Shinnar, S. R. Levy, F. M. Testa, S. SmithRapaport, and B. Beckerman. Early development of intractable epilepsy in children: A prospective study. Neurology 2001;56:1445–1452.
48
24. Bruton, C. J. The Neuropathology of Temporal Lobe Epilepsy. New York: Oxford University Press, 1988:1–158. 25. Camfield, P., C. Camfield, K. Gordon, and J. Dooley. What types of epilepsy are preceded by febrile seizures? A population based study of children. Dev. Med. Child Neurol. 1994;36:887–892. 26. Cavazzuti, G. B., P. Ferrari, and M. Lalla. Follow-up study of 482 cases with convulsive disorders in the first year of life. Dev. Med. Child Neurol. 1984;26:425–437. 27. Cendes, F., and F. Andermann. Do febrile seizures promote temporal lobe epilepsy? Retrospective studies. In T. Z. Baram and S. Shinnar, eds. Febrile Seizures. San Diego, Calif.: Academic Press, 2002:63–76. 28. Cendes, F., F. Andermann, and F. Dubeau, et al. Early childhood prolonged febrile convulsions, atrophy and sclerosis of mesial structures, and temporal lobe epilepsy: An MRI volumetric study. Neurology 1993;43:1083–1087. 29. Cendes, F., F. Andermann, and P. Gloor, et al. Atrophy of mesial structures in patients with temporal lobe epilepsy: Cause or consequence of repeated seizures. Ann. Neurol. 1993;34:795–801. 30. Chen, K., T. Z. Baram, and I. Soltesz. Febrile seizures in the immature brain result in persistent modification of neuronal excitability in limbic circuits. Nat. Med. 1999;5:888–894. 31. Chevrie, J. J., and J. Aicardi. Convulsive disorders in the first year of life: Neurological and mental outcome and mortality. Epilepsia 1978;19:67–74. 32. Chevrie, J. J., and J. Aicardi. Duration and lateralization of febrile convulsions: Etiological factors. Epilepsia 1975;16: 781–789. 33. Commission on Classification and Terminology of the International League Against Epilepsy: Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489–501. 34. Commission on Epidemiology and Prognosis, International League Against Epilepsy. Guidelines for epidemiologic studies on epilepsy. Epilepsia 1993;34:592–596. 35. Corey, L. A., J. M. Pellock, J. G. Boggs, L. L. Miller, and R. J. DeLorenzo. Evidence for a genetic predisposition for status epilepticus. Neurology 1998;50:558–560. 36. DeLorenzo, R. J., W. A. Hauser, A. R. Towne, J. G. Boggs, J. M. Pellock, L. Penberthy, L. Garnett, C. A. Fortner, and D. Ko. A prospective population-based epidemiological study of status epilepticus in Richmond, Virginia. Neurology 1996; 46:1029–1035. 37. DeLorenzo, R. J., J. M. Pellock, A. R. Towne, and J. G. Boggs. Epidemiology of status epilepticus. J. Clin. Neurophysiol. 1995; 12:316–325. 38. DeLorenzo, R. J., A. R. Towne, and J. M. Pellock, et al: Status epilepticus in children, adults and the elderly. Epilepsia 1992;33(Suppl. 4):S15–S25. 39. Dodrill, C. B. Correlates of generalized tonic-clonic seizures with intellectual, neuropsychological, emotional and social function in patients with epilepsy. Epilepsia 1986; 27:399–411. 40. Dodrill, C. B., and A. J. Wilensky. Intellectual impairment as an outcome of status epilepticus. Neurology 1990;40(Suppl. 2):23–27. 41. Dodson, W. E., R. J. DeLorenzo, T. A. Pedley, S. Shinnar, D. M. Treiman, and B. B. Wannamaker. The treatment of convulsive status epilepticus: Recommendations of the Epilepsy Foundation of America’s Working Group on Status Epilepticus. JAMA 1993;270:854–859.
: , , ,
42. Doose, H., and E. Volzke. Petit mal status in early childhood and dementia. Neuropaediatrie 1979;10:10–14. 43. Driscoll, S. M., A. R. Towne, J. M. Pellock, and R. J. DeLorenzo. Recurrent status epilepticus in children (abstract). Neurology 1990;40(Suppl. 1):297. 44. Dube, C. Do prolonged febrile seizures in an immature rat model cause epilepsy? In T. Z. Baram and S. Shinnar, eds. Febrile Seizures. San Diego, Calif.: Academic Press, 2002: 216–229. 45. Dube, C., K. Chen, M. Eghbal-Ahmadi, K. Brunson, I. Soltesz, and T. Z. Baram. Prolonged febrile seizures in the immature rat model enhance hippocampal excitability longterm. Ann. Neurol. 2000;47:336–344. 46. Dulac, O., P. Aubourg, and A. Chercoury, et al: Infantile status epilepticus: Clinical, etiological and prognostic aspects. Rev. Electroencephalogr. Neurophysiol. 1985;14:255–262. 47. Dunn, W. D. Status epilepticus in children: Etiology, clinical features and outcome. J. Child Neurol. 1988;3:167–173. 48. Ellenberg, J. H., D. G. Hirtz, and K. B. Nelson. Do seizures in children cause intellectual deterioration? N. Engl. J. Med. 1986;314:1085–1088. 49. Ellenberg, J. H., and K. B. Nelson. Febrile seizures and later intellectual performance. Arch. Neurol. 1978;35:17–21. 50. Falconer, M. Genetic and related etiological factors in temporal lobe epilepsy: A review. Epilepsia 1971;12:13–31. 51. Falconer, M. A., E. A. Serafetinides, and J. A. N. Corsellis. Etiology and pathogenesis of temporal lobe epilepsy. Arch. Neurol. 1964;10:233–248. 52. Fernandez, G., O. Effenberger, and B. Vinz, et al. Hippocampal malformation as a cause of familial febrile convulsions and subsequent hippocampal sclerosis. Neurology 1998; 50:909–917. 53. Fowler, M. Brain damage after febrile convulsions. Arch. Dis. Child. 1957;32:67–76. 54. Foy, P. M., D. W. Chadwick, and N. Rajgopalan, et al. Do prophylactic anticonvulsant drugs alter the pattern of seizures after craniotomy? J. Neurol. Neurosurg. Psychiatry 1992;55: 753–757. 55. French, J. A., P. D. Williamson, and M. Thadani, et al. Characteristics of medial temporal lobe epilepsy. I. Results of history and physical examination. Ann. Neurol. 1993;34: 774–780. 56. Fujiwara, T., S. Ishida, and M. Mlyakoshi. Status epilepticus in childhood: A retrospective study of initial convulsive status and subsequent epilepsies. Folia Psychiatr. Neurol. Jpn. 1979; 33:337–344. 57. Fujiwara, T., M. Watanabe, H. Nakamura, T. Kudo, K. Yagi, and M. Seino. A comparative study of absence status epilepticus between children and adults. Jpn. J. Psychiatr. Neurol. 1988;42:497–508. 58. Gastaut, H. Dictionary of Epilepsy. Part I. Definitions. Geneva: World Health Organization, 1973. 59. Gastaut, H., F. Poirer, G. Pagan, G. Salomon, M. Toga, and M. Vigoroux. HHE syndrome: Hemiconvulsions, hemiplegia, epilepsy. Epilepsia 1960;1:418–447. 60. Germano, I. M., Y. F. Zhang, E. F. Sperber, and S. L. Moshe. Neuronal migration disorders increase susceptibility to hyperthermia-induced seizures in developing rats. Epilepsia 1996;37:902–910. 61. Gross-Tsur, V., and S. Shinnar. Convulsive status epilepticus in children. Epilepsia 1993;34(Suppl. 1):S12–S20. 62. Hauser, W. A. Status epilepticus: Epidemiologic considerations. Neurology 1990;40(Suppl. 2):9–13.
63. Hauser, W. A. Status epilepticus: Frequency, etiology and neurological sequellae. In A. V. Delgado-Escueta, C. G. Wasterlain, and D. M. Treiman, et al., eds. Status Epilepticus Adv. Neurol. 1983;34:3–14. 64. Hauser, W. A., V. E. Anderson, and R. B. Loewenson. Seizure recurrence after a first unprovoked seizure. N. Engl. J. Med. 1982;307:522–528. 65. Hauser, W. A., J. F. Annegers, and L. T. Kurland. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia 1993;34:453–468. 66. Hauser, W. A., and D. C. Hesdorffer. Epilepsy: Frequency, Causes and Consequences. New York: Demos, 1990. 67. Hauser, W. A., and L. T. Kurland. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia 1975;16:1–66. 68. Hauser, W. A., S. S. Rich, J. F. Annegers, and V. E. Anderson. Seizure recurrence following a first unprovoked seizure: An extended follow-up. Neurology 1990;40:1163–1170. 69. Haut, S. R., S. Shinnar, S. L. Moshe, C. O’Dell, and A. D. Legatt. The association between seizure clustering and convulsive status epilepticus in patients with intractable complex partial seizures. Epilepsia 1999;1832–1834. 70. Hesdorffer, D. C., G. Logroscino, G. Cascino, J. F. Annegers, and W. A. Hauser. Incidence of status epilepticus in Rochester, Minnesota, 1965–1984. Neurology 1998;50:735– 741. 71. Knudsen, F. U. Febrile seizures: Treatment and prognosis. Epilepsia 2000;41:2–9. 72. Knudsen, F. U. Recurrence risk after first febrile seizure and effect of short-term diazepam prophylaxis. Arch. Dis. Child. 1985;60:1045–1049. 73. Knudsen, F. U., A. Paerregaard, R. Andersen, and J. Andresen. Long term outcome of prophylaxis for febrile convulsions. Arch. Dis. Child. 1996;74:13–18. 74. Lawson, J. A., S. Vogrin, A. F. Bleasel, M. J. Cook, L. Burns, L. McAnally, J. Pereira, and A. M. Bye. Predictors of hippocampal, cerebral, and cerebellar volume reduction in childhood epilepsy. Epilepsia 2000;41:1540–1545. 75. Lindsay, J., C. Ounsted, and P. Richards. Long-term outcome in children with temporal lobe seizures. Dev. Med. Child Neurol. 1979;21:285–298. 76. Logroscino, G. Mortality after incident status epilepticus: A retrospective cohort study. Doctoral thesis. Columbia University, 1997. 77. Margerison, J. H., and J. A. N. Corsellis. Epilepsy and the temporal lobes. Brain 1966;89:499–530. 78. Maher, J., and R. S. McLachlan. Febrile convulsions: Is seizure duration the most important predictor of temporal lobe epilepsy? Brain 1995;118:1521–1528. 79. Mathern, G. W., T. L. Babb, P. S. Mischel, H. V. Vinters, J. K. Pretorius, J. P. Leite, and W. J. Peacock. Childhood generalized and mesial temporal epilepsies demonstrate different amounts and patterns of hippocampal neuron loss and mossy fiber synaptic reorganization. Brain 1996;119:965–987. 80. Mathern, G. W., T. L. Babb, J. K. Pretorius, M. Melendez, and M. F. Levesque. The pathophysiologic relationships between lesion pathology, intracranial ictal EEG onsets, and hippocampal neuron losses in temporal lobe epilepsy. Epilepsy Res. 1995;21:133–147. 81. Mathern, G. W., T. L. Babb, B. G. Vickrey, M. Melendez, and J. K. Pretorius. The clinical-pathologic mechanisms of hippocampal neuronal loss and surgical outcomes in temporal lobe epilepsy. Brain 1995;118:105–118.
:
49
82. Mathern, G. W., J. K. Pretorius, and T. L. Babb. Influence of the type of initial precipitating injury and at what age it occurs on course and outcome in patients with temporal lobe seizures. J. Neurosurg. 1995;82:220–227. 83. Matsumoto, A., K. Watanabe, M. Sugiura, T. Negoro, E. Takaesu, and K. Iwase. Long term prognosis of convulsive disorder in the 1st year of life. Epilepsia 1983;24:321–329. 84. Maytal, J., G. Novak, C. Ascher, and R. Bienkowski. Status epilepticus in children with epilepsy: The role of antiepileptic drug levels in prevention. Pediatrics 1996;98:1119–1121. 85. Maytal, J., and S. Shinnar. Febrile status epilepticus. Pediatrics 1990;86:611–616. 86. Maytal, J., and S. Shinnar. Status epilepticus in children. In S. Shinnar, N. Amir, and D. Branski, eds. Childhood Seizures. Basel: S. Karger, 1995:111–122. 87. Maytal, J., S. Shinnar, S. L. Moshe, and L. A. Alvarez. Low morbidity and mortality of status epilepticus in children. Pediatrics 1989;83:323–331. 88. Metsaranta, P., M. Koivikko, J. Peltola, and K. Eriksson. Outcome after prolonged convulsive seizures in 186 children: Low morbidity, no mortality. Dev. Med. Child Neurol. 2004;46: 4–8. 89. Mikati, M. A., W. L. Lee, and G. R. DeLong. Protracted epileptiform encephalopathy: An unusual form of partial complex status epilepticus. Epilepsia 1985;26:563–571. 90. Moshe, S. L., and S. Shinnar. Early Intervention. In J. Engel, Jr., ed. Surgical Treatment of the Epilepsies. 2nd ed. New York: Raven Press, 1993:123–132. 91. National Institutes of Health. Febrile Seizures: Consensus Development Conference Summary. Vol. 3, No. 2. Bethesda, Md.: National Institutes of Health, 1980. 92. Nelson, K. B., and J. H. Ellenberg. Antecedents of seizure disorders in early childhood. Am. J. Dis. Child. 1986;140: 1053–1061. 93. Nelson, K. B., and J. H. Ellenberg. Prognosis in children with febrile seizures. Pediatrics 1978;61:720–727. 94. Oxbury, J. M., and C. W. Whitty. Causes and consequences of status epilepticus in adults: A study of 86 cases. Brain 1971;94:733–744. 95. Phillips, S. A., and R. J. Shanahan. Etiology and mortality of status epilepticus in children: A recent update. Arch. Neurol. 1989;46:74–76. 96. Roger, J., H. Lob, and C. A. Tassinari. Status epilepticus. In P. L. Vinken and C. W. Bruyn, eds. Handbook of Clinical Neurology. The Epilepsies. Amsterdam: Elsevier, 1974;15:145–188. 97. Rosman, N. P., T. Colton, and J. Labazzo, et al. A controlled trial of diazepam administered during febrile illnesses to prevent recurrence of febrile seizures. N. Engl. J. Med. 1993;329:79–84. 98. Rosman, N. P., J. L. Labazzo, and T. Colton. Factors predisposing to afebrile seizures after febrile convulsions and preventive treatment. Ann. Neurol. 1993;34:452. 99. Rowan, A. J., and D. F. Scott. Major status epilepticus. Acta Neurol. Scand. 1970;46:573–584. 100. Sagar, H. J., and J. M. Oxbury. Hippocampal neuron loss in temporal lobe epilepsy: Correlation with early childhood convulsions. Ann. Neurol. 1987;22:334–340. 101. Scott, R. C., D. G. Gadian, M. D. King, W. K. Chong, T. C. Cox, B. G. Neville, and A. Connely. Magnetic resonance imaging findings within 5 days of status epilepticus in childhood. Brain 2002;125(Pt. 9):1951–1959. 102. Scott, R. C., M. D. King, D. G. Gadian, B. G. Neville, and A. Connely. Hippocampal abnormalities after prolonged
50
103. 104.
105.
106. 107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
febrile convulsion: Longitudinal MRI study. Brain 2003; 126(Pt. 11):2551–2557. Shalev, R. S., and N. Amir. Complex partial status epilepticus. Arch. Neurol. 1983;40:90–92. Shinnar, S. Do febrile seizures lead to temporal lobe epilepsy? Prospective and epidemiological studies. In T. Z. Baram, and S. Shinnar, eds. Febrile Seizures. San Diego, Calif.: Academic Press, 2002:87–101. Shinnar, S. Febrile seizures. In K. E. Swaiman, and S. Ashwal, eds. Pediatric Neurology: Principles and Practice. 3rd. ed. St Louis, Mo.: Mosby, 1999:676–682. Shinnar, S. Prolonged febrile seizures and mesial temporal sclerosis. Ann. Neurol. 1998;43:411–412. Shinnar, S., and T. L. Babb. Long term sequellae of status epilepticus. In J. Engel, Jr., and T. A. Pedley, eds. Epilepsy: A Comprehensive Text. Philadelphia: Lippincot-Raven, 1997: 755–763. Shinnar, S., and A. T. Berg. Does antiepileptic drug therapy prevent the development of “chronic” epilepsy? Epilepsia 1996;37:701–708. Shinnar, S., A. T. Berg, and S. L. Moshe. The effect of status epilepticus on the long term outcomes of a cohort of children prospectively followed from the time of their first idiopathic unprovoked seizure. Presented at the European Child Neurology Society meetings, March 1995, Eilat, Israel. Shinnar, S., A. T. Berg, and S. L. Moshe, et al. Long term outcomes of children with epilepsy after withdrawal of antiepileptic drugs. Epilepsia 1994;35(Suppl. 8):34. Shinnar, S., A. T. Berg, and S. L. Moshe, et al. Risk of seizure recurrence following a first unprovoked seizure in childhood: A prospective study. Pediatrics 1990;85:1076–1085. Shinnar, S., A. T. Berg, and S. L. Moshe, et al. The risk of seizure recurrence following a first unprovoked afebrile seizure in childhood: An extended follow-up. Pediatrics 1996;98:216–225. Shinnar, S., A. T. Berg, S. L. Moshe, and R. Shinnar. How long do new-onset seizures in children last? Ann. Neurol. 2001;49:659–664. Shinnar, S., A. T. Berg, D. M. Treiman, W. A. Hauser, D. C. Hesdorffer, J. C. Sackellares, I. Leppik, M. Sillanpää, and K. W. Sommerville. Status epilepticus and tiagabine therapy: Review of safety data and epidemiologic comparisons. Epilepsia 2001;42:372–379. Shinnar, S., J. Maytal, L. Krasnoff, and S. L. Moshe. Recurrent status epilepticus in children. Ann. Neurol. 1992;31: 598–604. Shinnar, S., and S. L. Moshe. Age specificity of seizure expression in genetic epilepsies. In V. E. Anderson, W. A. Hauser, I. E. Leppik, J. L. Noebels, and S. S. Rich, eds. Genetic Strategies in Epilepsy Research. New York: Raven Press, 1991:69–85. Shinnar, S., J. M. Pellock, A. T. Berg, C. O’Dell, S. M. Driscoll, J. Maytal, S. L. Moshe, and R. J. DeLorenzo. Shortterm outcomes of children with febrile status epilepticus. Epilepsia 2001;42:47–53. Shinnar, S., J. M. Pellock, and S. L. Moshe, et al. In whom does status epilepticus occur: Age related differences in children. Epilepsia 1997;38:907–914. Silanpää, M. Remission of seizures and prediction of intractability in long-term followup. Epilepsia 1993;34: 930–936. Silanpää, M. Social functioning and seizure status of young adults with onset of epilepsy in childhood: An epidemiologi-
: , , ,
121.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
cal 20-year follow-up study. Acta Neurol. Scand. 1983;68(Suppl. 96):7–77. Sillanpää, M., M. Jalava, O. Kaleva, and S. Shinnar. Longterm prognosis of seizures with onset in childhood. N. Engl. J. Med. 1998;338:1715–1722. Sillanpää, M., and S. Shinnar. Status epilepticus in a population-based cohort with childhood-onset epilepsy in Finland. Ann. Neurol. 2002;52:303–310. Temkin, N. R., S. S. Dikmen, A. J. Wilensky, J. Keihm, S. Chabal, and H. R. Winn. A randomized double-blind study of phenytoin for the prevention of post-traumatic seizures. N. Engl. J. Med. 1990;323:497–502. Thon, N., K. Chen, I. Aradi, and I. Soltesz. Physiology of limbic hyperexcitability after experimental complex febrile seizures: Interactions of seizure induced alterations at multiple levels of neuronal organization. In T. Z. Baram and S. Shinnar, eds. Febrile Seizures. San Diego, Calif.: Academic Press, 2002:203–213. Toth, Z., X. X. Yan, S. Haftoglou, C. E. Ribak, and T. Z. Baram. Seizure-induced neuronal injury: Vulnerability to febrile seizures in immature rat model. J. Neurosci. 1998; 18:4285–4294. Towne, A. R., J. M. Pellock, D. Ko, and R. J. DeLorenzo. Determinants of mortality in status epilepticus. Epilepsia 1994;35:27–34. van Esch, A., I. R. Ramlal, H. A. Steensel-Moll, E. W. Steyerberg, and G. Derksen-Lubsen. Outcome after febrile status epilepticus. Dev. Med. Child Neurol. 1996;38:19–24. VanLandingham, K. E., E. R. Heinz, J. E. Cavazos, and D. V. Lewis. MRI evidence if hippocampal injury following prolonged, focal febrile convulsions. Ann. Neurol. 1998;43: 413–426. Verity, C. M., and J. Golding. Risk of epilepsy after febrile convulsions: A national cohort study. B. M. J. 1991;303: 1373–1376. Verity, C. M., R. Greenwood, and J. Golding. Long-term intellectual and behavioral outcomes of children with febrile convulsions. N. Engl. J. Med. 1998;338:1723–1728. Verity, C. M., E. M. Ross, and J. Golding. Outcome of childhood status epilepticus and lengthy febrile convulsions: Findings of national cohort study. B. M. J. 1993;307:225–228. Vigevano, F., and S. Gregory. Status epilepticus in the pediatric age. In C. Dirocco and F. Vigevano, eds. Neurologic Emergencies in Infancy and Childhood. Rome: Ricerca Scientifica Editrice, 1987:69–80. Wolf, S. M., A. Carr, and D. C. Davis, et al. The value of phenobarbital in the child who has had a single febrile seizure: A controlled prospective study. Pediatrics 1977;59: 378–385. Wolf, S. M., and A. Forsythe. Epilepsy and mental retardation following febrile seizures in childhood. Acta Paediatr. Scand. 1989;78:291–295. Yager, J. Y., M. Cheang, and S. S. Seshia. Status epilepticus in children. Can. J. Neurol. Sci. 1988;15:402–405.
:
51
II STATUS EPILEPTICUS: CLINICAL PHENOMENOLOGY
6
Generalized Convulsive Status Epilepticus
. If an epilepsy demon falls again and again upon him, his eyes are suffused with blood and he blinks his eyes; —if his lower cheek area twitch and his hands and feet are extended; if when the exorcist comes to see him hope is perishing that he will ever regain consciousness, he will die. —All Diseases, ca. 718–612 ..
The first description of the entity known today as status epilepticus (SE) appeared on a cuneiform tablet of the Babylonian medical diagnostic text Sakikku (All Diseases), written more than 2,500 years ago (172). The text describes a series of convulsions—recognizable today as overt generalized convulsive status epilepticus—and notes the evolution from repeated overt convulsions to more subtle symptoms, such as eye blinks and muscle twitches during coma, as described in the passage at the head of this chapter. Subsequent references to SE in medical writings over the next two millennia are sparse. Neither Hippocrates nor Galen described status in their extensive writings on epilepsy. It was not until the nineteenth century that SE was again systematically reviewed and the terms état de mal (17) and status epilepticus (163) were introduced. Most early discussions of SE referred to grand mal status, now called generalized convulsive status epilepticus (GCSE). Although other forms of SE are mentioned in the late nineteenth- and early twentieth-century literature, none was studied in detail until 1964, when the first major conference on SE was held in Marseilles (44).
Definition SE is now defined in one of two ways: (1) as recurrent epileptic seizures without full recovery of neurologic function between the seizures, or (2) as continuous seizure activity lasting 30 minutes or more. If the first definition is used, then GCSE can be defined as recurrent generalized convulsions without complete recovery of neurologic function (usually assessed by level of consciousness) between seizures. However, if GCSE is allowed to continue untreated or is inadequately treated, so that seizure activity persists, there is an evolution from overt to subtle motor manifestations. This evolution has been described in both clinical (148, 155) and experimental (48, 89) GCSE. Overt GCSE is easily
recognized as recurrent generalized convulsions without full recovery of neurologic function between seizures. In 1984 Treiman and colleagues (160) proposed that the term subtle generalized convulsive status epilepticus be used whenever a patient in GCSE exhibits profound coma and ictal discharges on the electroencephalogram (EEG), but only subtle rhythmic motor activity, such as focal twitches of the eyelid, face, jaw, trunk, or extremities, or nystagmoid jerks of the eyes. This concept of GCSE as a dynamic state, with evolution through progressive clinical stages from overt to subtle motor manifestations over time, was a rediscovery of a phenomenon first recognized by Bourneville in 1876 (12) in the first full clinical description of SE, and further elaborated by Clark and Prout in their extensive and detailed study of SE, published in 1903 and 1904 (22–24). Although overt GCSE may evolve into subtle GCSE if inadequately treated, a history of overt GCSE is not essential to make the diagnosis of subtle GCSE. Sometimes subtle GCSE may appear de novo after a severe insult to the brain. Full motor expression of seizure activity appears to depend on a relatively healthy brain. The greater the degree of encephalopathy present, the more subtle is the convulsive activity. Thus, overt GCSE may evolve into subtle GCSE because inadequately treated seizure activity is itself encephalopathogenic, or GCSE may start with only subtle motor manifestations, if the episode of status is the result of some other encephalopathic insult. Patients who develop SE as a consequence of a severe insult to the brain (hypoxia, profound ischemia, severe CNS infection) may present with subtle or electrical GCSE. Privitera and colleagues (123) studied 29 patients with subtle GCSE; only 30% had a witnessed generalized tonic-clonic seizure prior to the onset of coma. Drislane and Schomer (32) identified 48 patients with “generalized electrographic status epilepticus” (ESE), which they considered similar to subtle GCSE; fewer than half of the patients had discrete convulsions preceding EEG identification of ESE. In the case of severe encephalopathy, there may be no motor activity observed. Some investigators have used the term nonconvulsive status epilepticus for this situation (29, 31, 32, 60, 82). However, Treiman suggested that this entity be labeled electrical GCSE (148, 149, 151, 155) or GCSE with electrographic seizures only (153), because such
:
55
a presentation is the end-stage of the spectrum of clinical features that occur in GCSE during its evolution. Furthermore, the term nonconvulsive SE is used for SE with associated nonconvulsive seizures, such as complex partial SE and absence SE, in which the clinical presentation is of an epileptic twilight state and not the profound coma of endstage GCSE (31, 61, 62, 77). Thus, there is danger of combining very different types of SE if patients with subtle GCSE are included. The term myoclonic SE has also been applied to some instances of subtle GCSE, which also creates the problem of combining dissimilar entities: (1) SE that is a complication of generalized myoclonic epilepsy (where consciousness is generally preserved) and (2) encephalopathy with epileptic myoclonus (where the patient is in profound coma). Therefore, Treiman (148) argued that the term myoclonic SE should be reserved for SE in myoclonic epilepsy. Not all patients with SE as a complication of an encephalopathic insult have epileptic myoclonus, but some do, and they probably have a different prognosis than other patients with subtle GCSE.
Epidemiology GCSE is the most common type of status, and many case series in the past included only GCSE. Two large population-based studies of the epidemiology of SE have been published. DeLorenzo and colleagues (28) attempted to identify all cases of SE in the greater Richmond, Virginia, area. From their data they calculated an annual incidence of SE of 41 per 100,000 population, with about 70% presenting with GCSE. Richmond has a large African-American population. The Richmond population is 43% white and 57% nonwhite. Among white patients with SE, the annual incidence is 20 per 100,000. This incidence is similar to the 18.3 per 100,000 found in the mostly (96%) white Rochester, Minnesota, population (54), in good agreement with Shorvon’s (137) estimate of 18–28 per 100,000 population annual cases of convulsive status in the United States and United Kingdom, and slightly higher than the 15 per 100,000 population reported for the canton of Geneva in Switzerland (61). The incidence of SE in developing countries is likely to be much higher, but population-based data are not yet available (44, 57). Overall, the available data suggest there are between 60,000 and 150,000 cases of SE in the United States each year and perhaps as many as 3.5 million cases worldwide, most of which are cases of GCSE. In children, more than 90% of status is GCSE (35, 87).
Etiology There are many causes of SE, and most series have not differentiated among different types of status, although GCSE accounts for the large majority. Hauser (51) suggested that
56
:
about one-third of cases are the first presentation of newonset epilepsy, one-third occur in patients with established epilepsy or febrile convulsions, and one-third occur as the result of acute insult to the brain. The cause of status as an initial presentation of new-onset epilepsy is age dependent and is similar to the cause of new-onset epilepsy that does not present as SE. In most series, head trauma, tumor, cerebrovascular insults, and CNS infection account for the bulk of the cases. Medication change or antiepileptic drug (AED) noncompliance is a common cause of SE in patients with established epilepsy. In children, chronic epilepsy, febrile seizures, CNS infection, and metabolic disease are the most common causes of GCSE (78); recurrent episodes occur most often in neurologically abnormal children (130). The causes of overt and subtle presentations of GCSE differ. Table 6.1 presents the etiology of overt and subtle GCSE in patients who participated in the Veterans Affairs cooperative comparative treatment study (159). There was a much higher incidence of anoxic encephalopathy and other life-threatening disorders in the group of patients with subtle GCSE, laboratory abnormalities were more common in this group (162), and most of the patients were seen in the intensive care units of participating hospitals.
Pathophysiology SE occurs when there is a failure of the mechanisms that terminate a single seizure and normally produce a refractory period before another seizure can occur. This may occur as the result of excessive excitation, impaired neuronal inhibition, or a combination of both factors. A number of mechanisms may be responsible for termination of seizures, including activation of Na+-K+ adenosine triphosphatase (42, 52, 80), acidification of the extracellular environment that stabilizes neuronal membranes (19), blockade of Nmethyl--aspartate channels by Mg2+, and activation of K+ conductances and thus repolarization of neurons (6, 141). Endogenous opioids may also contribute to seizure termination and to the postictal refractory period (123). A role for neuropeptide Y has also been proposed (2, 71, 119, 139). Failure of these seizure-stopping mechanisms, or the occurrence of a strong excitatory stimulus, may result in repeated or prolonged seizures. Coulter and DeLorenzo (26) reported that SE is difficult to produce in vitro in normal extracellular medium, and thus suggested that seizure-terminating mechanisms must be quite robust. They found it necessary to include reciprocally connected entorhinal cortex in their hippocampal slice preparation, thus closing the normal excitatory limbic loop. This allowed generation of epileptic discharges of long duration, which progress through a sequence of morphologic changes (120) remarkably similar to the sequence described by Treiman et al. (161) in GCSE in humans.
T 6.1 Characteristics of overt and subtle generalized convulsive status epilepticus (GCSE) Parameter Evaluated Number of patients Age (yr), mean ± SD Veterans (%) Male (%) Not pretreated acutely (%) Previous history of acute seizures (%) Previous history of epilepsy (%) Previous history of status epilepticus (%) Median duration of status prior to enrollment (hr) Etiologic factors present*: Remote neurologic (%) Acute neurologic (%) Life-threatening medical condition (%) Cardiopulmonary arrest (%) Therapeutic or recreational drug toxicity (%) Alcohol withdrawal (%)
Overt GCSE
Subtle GCSE
384 58.6 ± 15.6 70.1 82.3 51.3 54.2 42.4 12.8 2.8
134 62.0 ± 15.1 80.6 85.1 51.5 25.4 12.7 4.5 5.8
69.5 27.3 32.0 6.3 6.3 6.5
34.3 37.3 56.7 38.1 5.2 0.7
* Some patients had more than one etiologic factor present. Table from Treiman et al. (165).
Clearly, some alteration of neuronal function, either acute or chronic, must be necessary to allow failure of seizureterminating mechanisms. Dube et al. (33) observed that prolonged hyperthermia-induced convulsions in rat pups markedly lowered the threshold for status induction in adults by low-dose kainic acid in vivo or by Schaeffer collateral stimulation in hippocampal-entorhinal cortex slices. A variety of acute neurologic insults either lower seizure threshold or result in excessive excitation or inhibitory failure. Penicillin (presumably the result of GABA antagonism via an allosteric modulation of the GABA receptor) has been reported to cause GCSE experimentally (97, 113) and clinically (68, 86). The neurotoxin domoic acid, a structural analogue of glutamate and kainite, caused GCSE when contaminated mussels were ingested accidently (33, 112). A number of organophosphorus cholinesterase inhibitor nerve agents produce SE in experimental animals by inhibiting acetylcholine esterase and thus allowing excessive synaptic concentrations of the excitatory neurotransmitter, acetylcholine (129). Atropine and other anticholinergic compounds block development of organophosphorus compound–induced seizures but are far less effective once SE has developed (89, 90, 129). Once status does occur, regardless of the precipitating cause, several mechanisms may contribute to continuing seizure activity, including alterations in calcium- and calmodulin-dependent kinase II activity (72), increases in substance P (83), and impairment of GABA-mediated inhibition (63, 64, 67). An experimental study suggests that such a loss
of inhibition may be due to altered GABAA receptor function. Kapur and Macdonald (68) found a marked reduction in whole-cell GABA receptor currents in hippocampal dentate granule cells isolated acutely from rats undergoing lithium/pilocarpine-induced SE compared with cells from naive controls. GABA receptor currents from SE rats were less sensitive to diazepam and zinc, but retained their sensitivity to GABA and pentobarbital. These investigators concluded that prolonged seizure activity in this model rapidly alters the functional properties of hippocampal dentate granule cell GABA receptors. They proposed structural rearrangement in the subunit composition of the GABAA receptor as one possible mechanism for such an alteration. Brooks-Kayal et al. (14) provided support for this hypothesis. Single-cell messenger RNA amplification was used to show selective changes in dentate granule cell GABAA receptor subunit composition after experimental SE induction. Walton and Treiman (166) reported that the NMDA receptor channel blocker, dizoclipine, reversed seizure-induced refractoriness to benzodiazepines in prolonged experimental SE. These studies of attenuation of GABA-mediated inhibition during SE help explain the observation that the order of drug administration may influence its efficacy in experimental SE (167). Phenytoin followed 10 minutes later by diazepam is more effective in controlling seizure activity in the cobalt-homocysteine model of secondarily generalized convulsive SE in the rat than identical doses of diazepam followed 10 minutes later by phenytoin. It may be that phenytoin sufficiently reduces excitation that there is recovery of
:
57
GABAA receptor sensitivity to diazepam and thus reestablishment of the capacity for GABA-mediated inhibition. Previous studies have shown that NMDA receptors become activated during hippocampal stimulation (8) and that NMDA antagonists block the deterioration of GABA-mediated inhibition (65). Furthermore, NMDA receptor antagonists abolish the maintenance phase of self-sustaining SE in the perforant path stimulation model (90), and a role for NMDA receptors in the late stages of cholinesterase inhibitor-induced SE has been proposed (89, 128).
Clinical features Treiman (147) characterized GCSE as paroxymal or continuous tonic and/or clonic convulsive motor activity that may be symmetric or asymmetric, overt or subtle, and is associated with marked impairment of consciousness and with bilateral (although frequently asymmetric) ictal discharges on the EEG. This broad description of GCSE emphasizes its dynamic character. Over the last 15 years it has been recognized that not only is there a progression from overt to increasingly subtle motor activity (48, 148, 153), but there is also a predictable progression of EEG changes (161), refractoriness to treatment (157, 160), degree of histologic damage (40), and physiologic changes (38, 93, 134, 164) if GCSE is allowed to continue untreated or inadequately treated. Overt GCSE is characterized by recurrent primarily or secondarily generalized tonic-clonic convulsions, each of which evolves in the same manner as a single generalized tonic-clonic seizure. Each discrete convulsion begins with tonic stiffening, either focal or generalized, which is then replaced by clonic jerking, which increases in amplitude and decreases in frequency until abrupt cessation of the clonic jerks. The average duration of the tonic and clonic phases initially is about 90 seconds but tends to shorten as GCSE progresses (124). Roger et al. (124) reported a frequency of four to five convulsions per hour, but 20 or more attacks per hour were frequently described in the era before effective drug therapy became available (17, 22–24) and may be seen even today (131). Postictal coma is gradually replaced by increasing consciousness, but if another convulsion occurs before complete recovery to full alertness and normal mental function, the patient is considered to be in GCSE. If overt GCSE continues without complete suppression of ictal discharges on the EEG, the ongoing seizure activity is itself encephalopathogenic, and there is a gradual evolution of behavioral manifestations to more subtle motor convulsions and eventually complete cessation of all visible seizure activity (48). However, the rapidity of the change from overt to subtle motor activity is highly variable and appears to be largely determined by the precipitating cause of GCSE.
58
:
Evolution from overt to subtle motor manifestations of GCSE has not been reported in primarily generalized tonicclonic SE, but Roger et al. (124) described attenuation of initial generalized tonic-clonic activity to tonic activity only. Just as there is a progression from overt to subtle convulsive activity, there also is a progression of predictable changes in the ictal discharges on the EEG if GCSE is allowed to progress without effective treatment (161) (Figures 6.1 to 6.5). Initially, discrete electrographic seizures—identical in morphology to individual generalized convulsions like those recorded on epilepsy monitoring units—are recorded during generalized convulsions. However, as GCSE progresses and motor activity becomes increasingly attenuated, the discrete seizures begin to merge to produce waxing and waning of amplitude, frequency, and distribution of the ictal discharges. This transitional period is followed by a prolonged period of continuous ictal activity, with little variation in the morphology of the EEG rhythms. Eventually another transitional pattern occurs, as continuous ictal discharges are punctuated by low-voltage, relatively flat periods. These flat periods become longer as ictal discharges shorten, until finally periodic epileptiform discharges (PEDs) on a low-voltage background are seen. This sequence of progressive EEG changes was initially postulated after review of 109 EEGs recorded during GCSE, 60 of which exhibited one or more ictal patterns in the sequence just described (161), and has been confirmed by the observation of the same sequence in at least eight different models of experimental SE in the rat (48, 70, 73, 85, 96, 161). Just as there is considerable variation in the rate of evolution from overt to subtle convulsive activity in GCSE, there is also considerable variation in the rate of progression through these EEG patterns in both humans and rats, most likely determined by the etiology of GCSE or the experimental technique used to induce SE in the experimental models. Progression through at least part of the sequence has also been reported in complex partial SE (105). However, Nei et al. (103) reported they were unable to detect a predictable sequence of EEG changes in their restrospective review of 36 SE ictal records, but only 23 of their 50 cases of SE were classified as convulsive, and their recordings may not have been long enough to detect sequential changes. Not all patients with subtle GCSE or late EEG patterns start out with discrete electrographic seizures on their EEG. Just as the initial clinical expression of GCSE may be subtle or even without any motor activity, if the precipitating encephalopathic insult is sufficiently severe, the initial EEG pattern may be one of continuous ictal discharges with or without flat periods or PEDs. There has been considerable controversy over the ictal nature of PEDs, with some investigators (43, 138, 142, 169) viewing PEDs as an injury pattern that reflects cerebral
F 6.1 Discrete generalized tonic-clonic seizures with interictal slowing, recorded prior to treatment in a 39-year-old man. The example shows the end of the clonic phase of the seizure and
the appearance of postictal slowing. (Reprinted with permission from Treiman et al. [161].)
F 6.2 Merging of discrete seizures, recorded prior to treatment in a 64-year-old man. Ictal discharges are continuous, but with waxing and waning of frequency and amplitude. An increase
in frequency and amplitude can be seen beginning on the right side of the recording. (Reprinted with permission from Treiman et al. [161].)
F 6.3 Continuous ictal discharges recorded prior to treatment in a 68-year-old man. Examples were recorded 16 minutes apart. Continuous ictal activity persisted for 101 minutes, stopping
only after phenytoin infusion was completed and 4 minutes after the end of lorazepam infusion. (Reprinted with permission from Treiman et al. [161].)
F 6.4 Continuous ictal discharges with flat periods recorded prior to treatment in a 68-year-old man. The seizure focus is clearly in the left hemisphere, but the spread of ictal activity to the right
hemisphere can be seen as well. (Reprinted with permission from Treiman et al. [161].)
60
:
F 6.5 Periodic epileptiform discharges on a flat background recorded prior to treatment in a 64-year-old man. (Reprinted with permission from Treiman et al. [161].)
dysfunction rather than ongoing seizure activity. Others have suggested that PEDs are a fragment of GCSE (20) and common in end-stage GCSE (136). Treiman (148, 150, 152, 154) has argued that to exclude PEDs from the other ictal sequences observed in experimental models of SE, where the entire EEG sequence can be observed without administering antiepileptic drugs, is arbitrary, especially because there is a gradual evolution from the continuous ictal discharge pattern to PEDs. Furthermore, Handforth and colleagues, using 2-deoxyglucose studies in experimental SE in the rat (49) and positron emission tomography studies in a human patient (48), observed hypermetabolism in specific areas of the brain when PEDs were observed on the EEG. Finally, although PEDs are seen in the late, treatmentresistant stages of GCSE, anticonvulsants abolish PEDs in at least some cases. Response to treatment is influenced by a number of factors. Treiman and colleagues demonstrated that the later the EEG stage, the more resistant to treatment the episode of SE will be in both human GCSE (157) and experimental SE in the rat (165). The longer the duration of GCSE (160) and the more subtle the motor manifestations (159), the more difficult GCSE is to stop and the more likely neuronal damage will occur (40, 101). A number of physiologic changes occur during inadequately treated clinical (164) and untreated experimental (91, 134) GCSE, and progress during prolonged SE (15, 16,
91, 164). The initial event is a massive release of catecholamines into the circulation (7, 45, 51, 133), which results in increased systemic, pulmonary, and left atrial pressure, heart rate, and plasma glucose concentration (7, 9–11, 21, 45, 54, 57, 74–76, 93, 94, 98, 115–117, 137, 168), and the potential for cardiac arrhythmias (18, 79, 93, 94, 126, 168). Respiratory function is frequently impaired early in SE (5, 69, 111), and pulmonary edema is common in experimental SE (69, 135) and may occur in human GCSE (108). Acidosis, due to a combination of respiratory failure and systemic lactate release, has been observed frequently in clinical GCSE (1, 13, 171, 174) and also in experimental SE (9, 10, 34, 37, 54, 57, 58, 93, 168). Hyperpyrexia has been known since the nineteenth century to occur during early SE (12, 22–24) and is the most important physiologic cause of poor outcome following an episode of SE (1). SE-induced cerebellar damage has been reported following sustained hyperpyrexia in baboons (92, 95) and in human GCSE (134). When the white blood cell (WBC) count is also elevated during an episode of GCSE in which hyperpyrexia is seen, an infectious etiology may be assumed by the clinician. However, peripheral WBC counts are frequently elevated during GCSE (1), and a low-grade pleocytosis in the cerebral spinal fluid (CSF) may also occur. Barry and Hauser (3) found, however, that the CSF WBC count was never above 30/mm3 in the absence of another cause for CSF pleocytosis.
:
61
Diagnosis The diagnosis of GCSE is not difficult when a patient presents with a series of primarily or secondarily generalized convulsions and remains comatose between the seizures. Typically, there is some degree of recovery between seizures, perhaps even to the point of capacity for verbal communication. However, unless there is complete recovery before the next seizure, with no clinical, EEG, or laboratory evidence of residual effects of the preceding seizure, the patient meets the definition of GCSE and should be treated accordingly. EEG monitoring during GCSE is extremely useful but is not essential if the effect of treatment and the patient’s progress can be ascertained by clinical observation. Clearly, if there is progressive recovery of consciousness toward return to a normal mental state following treatment of GCSE, it is not necessary to verify success by EEG recording. However, if there is no recovery and the patient remains in a coma, verification of cessation of all epileptiform discharges on the EEG is essential, because continuing electrical seizure activity may cause profound neuronal damage, even in the absence of any motor convulsions. In addition to the five ictal EEG patterns described earlier, other ictal discharges may include paroxysmal or continuous slow waves, spike-wave discharges, and certain burst-suppression patterns (150). Once the episode of GCSE is stopped, a search for the underlying etiology must be undertaken and, if different, the precipitating cause of the episode must be sought. This evaluation should include a careful review of the patient’s medical, neurologic, and medication history, a search for systemic illness by blood cell count and serum chemistry determinations, cerebral imaging studies, and a consideration of the possibility of CNS infection, with a lumbar puncture to obtain CSF for analysis if indicated. Although relatively uncommon except in epilepsy centers, the possibility of pseudo-GCSE must be entertained under some circumstances. Clues that should alert the clinician to the possibility of pseudostatus include variability of clinical appearance from seizure to seizure, the inability to sustain continuous motor activity without brief pauses, the appearance of alpha activity on the EEG during such pauses when the record is not obscured by muscle artifact, retained pupillary response, eye closure during convulsive activity, and resistance to eye opening. Pseudo-GCSE has been discussed by a number of investigators (4, 46, 55, 102, 109, 110, 121, 122, 132, 144, 169, 172).
Pathology and mortality Animal data make it abundantly clear that GCSE, if sufficiently prolonged, may cause neuronal damage and even
62
:
death. Although systemic complications such as hypoxia, hypoglycemia, lactic acidosis, and especially hyperpyrexia may exacerbate neuronal damage caused by sustained seizure activity (9, 95, 134, 137), observation of neuronal damage in normoglycemic, well-ventilated animals supports the concept that electrical seizure activity itself contributes substantially to SE-induced neuronal damage (58, 81, 100, 106, 145). SE-induced neuronal damage has been demonstrated in a number of animal models (36, 41, 56, 107, 127, 140). Continuous seizure activity for as little as 20 minutes has been associated with detectable hippocampal neuronal loss in pilocarpine-induced experimental SE (40). The pathologic consequences of GCSE are more difficult to ascertain in human subjects, because pathologic changes associated with the cause of SE and those that are the consequence of SE cannot easily be differentiated. However, neuronal damage in neocortex, hippocampus, thalamus, and cerebellum has been reported in children and adults dying shortly after an episode of GCSE (25, 39, 104, 114, 125). DeGiorgio and colleagues (27), in a case-matched control study of neuronal loss after GCSE in five hippocampal regions, found the greatest loss in SE cases and less cell loss in case-matched controls, compared with age-matched controls without CNS insult, thus suggesting a direct role of GCSE in neuronal cell loss in humans. Progressive hippocampal sclerosis and atrophy (103, 143, 170) and other focal lesions (men, morimoto, Nixon) have also been demonstrated by magnetic resonance imaging following GCSE. Mortality rates of 5%–50% following GCSE have been reported since the introduction of bromides (50, 156), although most deaths do not occur during the episode of GCSE and have been attributed to the underlying cause of the status episode. Mortality rates in three large SE series have been reported. Towne et al. (151) studied the Richmond database. They reported a 20.7% mortality within 30 days of an episode of “generalized SE,” in which they included primarily and secondarily generalized tonic-clonic, absence, and myoclonic seizures. Most were cases of GCSE. Duration longer than 1 hour and age older than 60 both predicted a substantially higher 30-day mortality. Logroscino et al. (86) found a 17.9% 30-day mortality after the first episode of SE in 84 patients in the Rochester series with primarily or secondarily generalized SE. The 30-day mortality in 19 patients with myoclonic SE, which they considered equivalent to subtle GCSE, was 68%. Treiman et al. (159), in the VA treatment study of GCSE, reported a 30-day mortality of 27.0% in patients with overt GCSE and 64.7% in patients with the subtle form. Thirty-day mortality was substantially higher in patients older than 65 in both overt and subtle groups (158). Mean ages in the two groups in the VA study were 58.6 years and 62.0 years, respectively (159). A recent
population-based study in Bologna, Italy (170), reported a similarly high mortality of 39% (33% if postanoxic cases are excluded).
Summary GCSE was first described in a Babylonian medical text more than 2,500 years ago, but it received little attention until the nineteenth century. GCSE is the most common type of SE, accounting for at least 70% of all SE cases and more than 90% of cases in children. It is now recognized to be a dynamic entity, with progression from overt to subtle clinical presentations and through a predictable sequence of EEG changes if untreated or inadequately treated. The longer the duration the more difficult it is to stop and the more neuronal damage is done. Most GCSE occurs in the very young and very old. There are at least 40,000 and perhaps more than 100,000 cases of GCSE in the United States each year, and at least 3 million cases annually worldwide. Head trauma, brain tumor, cerebral infarction, CNS infection, hypoxia, and preexisting epilepsy are the most common causes of GCSE in adults; in children, chronic epilepsy, febrile seizures, CNS infection, and metabolic disease are the most common causes. With the advent of effective drugs for the management of GCSE, death directly caused by GCSE is rare, but 30-day mortality, which largely reflects the underlying cause of the episode of GCSE, is high, especially in cases of subtle GCSE. The diagnosis is made by clinical observation of repeated convulsions without full recovery between the seizures, or by observation of ictal discharges on the EEG when the clinical manifestations are subtle. EEG monitoring is essential to verify successful treatment if this cannot be ascertained on clinical grounds. Mechanisms underlying the progression of GCSE and SE-induced neuronal damage are beginning to be elucidated, but much work remains to be done to achieve sufficient understanding to develop consistently effective treatment. REFERENCES 1. Aminoff, M. J., and R. P. Simon. Status epilepticus: Causes, clinical features and consequences in 98 patients. Am. J. Med. 1980;69:657–666. 2. Baraban, S. C., G. Hollopeter, J. C. Erickson, P. A. Schwartzkroin, and R. D. Palmiter. Knock-out mice reveal a critical antiepileptic role for neuropeptide Y. J. Neurosci. 1997;17:8927–8936. 3. Barry, E., and W. A. Hauser. Pleocytosis after status epilepticus. Arch. Neurol. 1994;51:190–193. 4. Bateman, D. E. Pseudostatus epilepticus. Lancet 1989;2: 1278–1279. 5. Bean, J. W., D. Zee, and B. Thom. Pulmonary changes with convulsions induced by drugs and oxygen at high pressure. J. Appl. Physiol. 1966;21:865–872.
6. Bennett, M. R., R. Kerr, and K. Nichol. Adenosine modulation of potassium currents in postganglionic neurones of cultured avian ciliary ganglia. Br. J. Pharmacol. 1991;104: 459–465. 7. Benowitz, N. L., R. P. Simon, and J. R. Copeland. Status epilepticus: Divergence of sympathetic activity and cardiovascular response. Ann. Neurol. 1986;19:197–199. 8. Bertram, E. H., and E. W. Lothman, NMDA receptor antagonists and limbic status epilepticus: A comparison with standard anticonvulsants. Epilepsy Res. 1990;5:177–184. 9. Blennow, G., J. B. Brierley, B. S. Meldrum, and B. K. Siesjö. Epileptic brain damage: The role of systemic factors that modify cerebral energy metabolism. Brain 1978;101:687–700. 10. Blennow, G., J. Folbergrová, B. Nilsson, and B. K. Siesjö. Cerebral metabolic and circulatory changes in the rat during sustained seizures induced by DL-homocysteine. Brain Res. 1979;179:129–146. 11. Blennow, G., J. Folbergrová, B. Nilsson, and B. K. Siesjö. Effects of bicuculline-induced seizures on cerebral metabolism and circulation of rats rendered hypoglycemic by starvation. Ann. Neurol. 1979;5:139–151. 12. Bourneville, D. M. L’état de mal epileptique: Recherches cliniques et therapeutiques sur l’epilepsie et l’hysterie. Compte-rendu des observations recueilles a la Salpêtrière. Paris: Delahaye, 1876. 13. Brivet, F., M. Bernardin, P. Cherin, J. Chalas, P. Galanaud, and J. Dormont. Hyperchloremic acidosis during grand mal seizure lactic acidosis. Intensive Care Med. 1994;20:27–31. 14. Brooks-Kayal, A. R., M. D. Shumate, H. Jin, T. Y. Rikhter, and D. A. Coulter. Selective changes in single cell GABA(A) receptor subunit expression and function in temporal lobe epilepsy. Nat. Med. 1998;4:1166–1172. 15. Brown, J. K., and I. H. M. I. Hussain. Status epilepticus. I. Pathogenesis. Dev. Med. Child Neurol. 1991;33:3–17. 16. Brown, J. K., and I. H. M. I. Hussain. Status epilepticus. II. Treatment. Dev. Med. Child Neurol. 1991;33:97–109. 17. Calmeil, J. De l’épilepsie, étudiée sous le rapport de son siège et de son influence sur la production de l’aliénation mentale. Thesis, University of Paris, 1824. 18. Carnel, S. B., P. L. Schraeder, and C. M. Lathers. Effect of phenobarbital pretreatment on cardiac neural discharge and pentylenetetrazol-induced epileptogenic activity in the cat. Pharmacology 1985;30:225–240. 19. Caspers, H., E. J. Speckmann, and A. Lehmenkuhler. DC potentials of the cerebral cortex: Seizure activity and changes in gas pressures. Rev. Physiol. Biochem. Pharmacol. 1987;106: 127–178. 20. Celesia, G. G., M. M. Grigg, and E. Ross. Generalized status myoclonicus in acute anoxic and toxic-metabolic encephalopathies. Arch. Neurol. 1988;45:781–784. 21. Chapman, A. G., B. S. Meldrum, and B. K. Siesjö. Cerebral metabolic changes during prolonged epileptic seizures in rats. J. Neurochem. 1977;28:1025–1035. 22. Clark, L. P., and T. P. Prout. Status epilepticus: A clinical and pathological study in epilepsy. [Part 1.] Am. J. Insanity 1903; 60:291–306. 23. Clark, L. P., and T. P. Prout. Status epilepticus: A clinical and pathological study in epilepsy. [Part 2.] Am. J. Insanity 1903; 60:645–699. 24. Clark, L. P., and T. P. Prout. Status epilepticus: A clinical and pathological study in epilepsy. [Part 3.] Am. J. Insanity 1904;61:81–108. 25. Corsellis, J. A. N., and C. J. Bruton. Neuropathology of status epilepticus in humans. In A. V. Delgado-Escueta, C. C.
:
63
26.
27.
28.
29.
30.
31. 32.
33.
34.
35. 36.
37.
38. 39. 40.
41.
42.
43. 44.
45.
64
Wasterlain, D. M. Treiman, and R. J. Porter, eds. Status Epilepticus: Mechanisms of Brain Damage and Treatment. Adv. Neurol. 1983;34:129–139. Coulter, D. A., and R. J. DeLorenzo. Basic mechanisms of status epilepticus. In A. V. Delgado-Escueta, W. A. Wilson, R. W. Olsen, and R. J. Porter, eds. Jasper’s Basic Mechanisms of the Epilepsies. Adv. Neurol. 1999;79:725–733. DeGiorgio, C. M., U. Tomiyasu, P. S. Gott, and D. M. Treiman. Hippocampal pyramidal cell loss in human status epilepticus. Epilepsia 1992;33:23–27. DeLorenzo, R. J., W. A. Hauser, A. R. Towne, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996;46: 1029–1035. DeLorenzo, R. J., E. J. Waterhouse, A. R. Towne, et al. Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia 1998;39:833–840. Drislane, F. W. Evidence against permanent neurologic damage from nonconvulsive status epilepticus. J. Clin. Neurophysiol. 1999;16:323–331. Drislane, F. W. Nonconvulsive status epilepticus in patients with cancer. Clin. Neurol. Neurosurg. 1994;96:314–318. Drislane, F. W., and D. L. Schomer. Clinical implications of generalized electrographic status epilepticus. Epilepsy Res. 1994;19:111–121. Dube, C., K. Chen, M. Eghbal-Ahmadi, K. Brunson, I. Soltesz, and T. Z. Baram. Prolonged febrile seizures in the immature rat model enhance hippocampal excitability long term. Ann. Neurol. 2000;47:336–344. Duffy, T. E., D. C. Howse, and F. Plum. Cerebral energy metabolism during experimental status epilepticus. J. Neurochem. 1975;24:925–934. Dunn, D. W. Status epilepticus in children: Etiology, clinical features, and outcome. J. Child Neurol. 1988;3:167–173. Evans, M., T. Griffiths, and B. Meldrum. Early changes in the rat hippocampus following seizures induced by bicuculline or -allylglycine: A light and electron microscope study. Neuropathol. Appl. Neurobiol. 1983;9:39–52. Folbergrová, J., M. Ingvar, and B. K. Siesjö. Metabolic changes in cerebral cortex, hippocampus, and cerebellum during sustained bicuculline-induced seizures. J. Neurochem. 1981;37:1228–1238. Fountain, N. B., and E. W. Lothman. Pathophysiology of status epilepticus. J. Clin. Neurophysiol. 1995;12:326–342. Fowler, M. Brain damage after febrile convulsions. Arch. Dis. Child 1957;32:67–76. Fujikawa, D. G. The temporal evolution of neuronal damage from pilocarpine-induced status epilepticus. Brain Res. 1996; 725:11–22. Fujikawa, D. G., S. S. Shinmei, and B. Y. Cai. Lithiumpilocarpine-induced status epilepticus produces necrotic neurons with internucleosomal DNA fragmentation in adult rats. Eur. J. Neurosci. 1999;11:1605–1614. Fukuda, A., and D. A. Prince. Excessive intracellular Ca2+ inhibits glutamate-induced Na(+)-K+ pump activation in rat hippocampal neurons. J. Neurophysiol. 1992;68:28–35. Gaches, J. Activites periodiques en EEG. Rev. Electroencephalogr. Neurophysiol. Clin. 1971;1:9–33. Garzon, E., R. M. Fernandes, and A. C. Sakamoto. Analysis of clinical characteristics and risk factors for mortality in human status epilepticus. Seizure 2003;12(6):337–345. Gastaut, H., J. Roger, and H. Lob, eds. Les états de mal épileptiques. Paris: Masson, 1967.
:
46. Gravenstein, J. S., A. H. Anton, S. M. Wiener, and A. G. Tetlow. Catecholamine and cardiovascular response to electroconvulsive therapy in man. Br. J. Anaesth. 1965;37:833–839. 47. Gunatilake, S. B., H. J. De Silva, and G. Ranasinghe. Twentyseven venous cutdowns to treat pseudostatus epilepticus. Seizure 1997;6:71–72. 48. Handforth, A., J. T. Cheng, M. A. Mandelkern, and D. M. Treiman. Markedly increased mesiotemporal lobe metabolism in a case with PLEDs: Further evidence that PLEDs are a manifestation of partial status epilepticus. Epilepsia 1994; 35:876–881. 49. Handforth, A., and D. M. Treiman. Functional mapping of the late stages of status epilepticus in the lithium-pilocarpine model in rat: A 14C-2-deoxyglucose study. Neuroscience 1995;64:1075–1089. 50. Handforth, A., and D. M. Treiman. A new, nonpharmacologic model of convulsive status epilepticus induced by electrical stimulation: Behavioral/electroencephalographic observations and response to phenytoin and phenobarbital. Epilepsy Res. 1994;19:15–25. 51. Hauser, W. A. Status epilepticus: Epidemiologic considerations. Neurology 1990;40(Suppl. 2):9–13. 52. Havens, L. L., M. S. Zileli, A. DiMascio, L. Boling, and A. Goldfien. Changes in catecholamine response to successive electric convulsive treatments. J. Ment. Sci. 1959;105:821–829. 53. Heinemann, U., and H. D. Lux. Undershoots following stimulus-induced rises of extracellular potassium concentration in cerebral cortex of cat. Brain Res. 1975;93:63–76. 54. Hesdorffer, D. C., G. Logroscino, G. Cascino, J. F. Annegers, and W. A. Hauser. Incidence of status epilepticus in Rochester, Minnesota, 1965–1984. Neurology 1998;50: 735–741. 55. Horton, R. W., B. S. Meldrum, T. A. Pedley, and J. R. McWilliam. Regional cerebral blood flow in the rat during prolonged seizure activity. Brain Res. 1980;192:399–412. 56. Howell, S. J., L. Owen, and D. W. Chadwick. Pseudostatus epilepticus. Q. J. Med. 1989;71:507–519. 57. Hui, A. C., G. M. Joynt, H. Li, and K. S. Wong. Status epilepticus in Hong Kong Chinese: Aetiology, outcome and predictors of death and morbidity. Seizure 2003;12(7):478– 482. 58. Ingvar, M., P. F. Morgan, and R. N. Auer. The nature and timing of excitotoxic neuronal necrosis in the cerebral cortex, hippocampus and thalamus due to flurothyl-induced status epilepticus. Acta Neuropathol. 1988;75:362–369. 59. Ingvar, M., and B. K. Siesjö. Local blood flow and glucose consumption in the rat brain during sustained bicuculline induced seizures. Acta Neurol. Scand. 1983;69:129–144. 60. Ingvar, M., B. Söderfeldt, J. Folbergrová, H. Kalima, Y. Olsson, and B. K. Siesjö. Metabolic, circulatory, and structural alterations in the rat brain induced by sustained pentylenetetrazole seizures. Epilepsia 1984;25:191–204. 61. Jallon, P., A. Coeytaux, B. Galobardes, and A. Morabia. Incidence and case-fatality rate of status epilepticus in the Canton of Geneva. Lancet 1999;353:1496. 62. Jordan, K. G. Nonconvulsive status epilepticus in acute brain injury. J. Clin. Neurophysiol. 1999;16:332–340. 63. Kaplan, P. W. Assessing the outcomes in patients with nonconvulsive status epilepticus: Nonconvulsive status epilepticus is underdiagnosed, potentially overtreated, and confounded by comorbidity. J. Clin. Neurophysiol. 1999;16:341–352. 64. Kaplan, P. W. Nonconvulsive status epilepticus in the emergency room. Epilepsia 1996;37:643–650.
65. Kapur, J., and D. A. Coulter. Experimental status epilepticus alters gamma-aminobutyric acid type A receptor function in CA1 pyramidal neurons. Ann. Neurol. 1995;38:893–900. 66. Kapur, J., and E. W. Lothman. Loss of inhibition precedes delayed spontaneous seizures in the hippocampus after tetanic electrical stimulation. J. Neurophysiol. 1989;61:427– 434. 67. Kapur, J., and E. W. Lothman. NMDA receptor activation mediates the loss of GABAergic inhibition induced by recurrent seizures. Epilepsy Res. 1990;5:103–111. 68. Kapur, J., and R. L. Macdonald. Rapid seizure-induced reduction of benzodiazepine and Zn2+ sensitivity of hippocampal dentate granule cell GABAA receptors. J. Neurosci. 1997;17:7532–7540. 69. Kapur, J., J. L. Stringer, and E. W. Lothman. Evidence that repetitive seizures in the hippocampus cause a lasting reduction of GABAergic inhibition. J. Neurophysiol. 1989; 61:417–426. 70. Kaufman, D. M., M. H. Miller, and N. H. Steigbigel. Subdural empyema: Analysis of 17 recent cases and review of the literature. Medicine (Baltimore) 1975;54:485–498. 71. Kiessling, M., K. A. Hossman, and P. Kleihues. Pulmonary edema during bicuculline-induced seizures in rats. Exp. Neurol. 1981;74:430–438. 72. Kim, J.-M., N. Y. Walton, and D. M. Treiman. EEG patterns of high-dose pilocarpine-induced status epilepticus in rats. Epilepsia 1997;38(Suppl. 8):225–226. 73. Klapstein, G. J., and W. F. Colmers. Neuropeptide Y suppresses epileptiform activity in rat hippocampus in vitro. J. Neurophysiol. 1997;78:1651–1661. 74. Kochan, L. D., S. B. Churn, O. Omojokun, A. Rice, and R. J. DeLorenzo. Status epilepticus results in an N-methyl-aspartate receptor-dependent inhibition of Ca2+/calmodulindependent kinase II activity in the rat. Neuroscience 2000; 95:735–743. 75. Koplovitz, I., and J. P. Skvorak. Electrocorticographic changes during generalized convulsive status epilepticus in soman intoxicated rats. Epilepsy Res. 1998;30:159–164. 76. Kreisman, N. R., J. C. LaManna, M. Rosenthal, and T. J. Sick. Oxidative metabolic responses with recurrent seizures in rat cerebral cortex: Role of systemic factors. Brain Res. 1981;218:175–188. 77. Kreisman, N. R., J. C. Magee, and B. L. Brizzee. Relative hypoperfusion in rat cerebral cortex during recurrent seizures. J. Cereb. Blood Flow Metab. 1991;11:77–87. 78. Kreisman, N. R., M. Rosenthal, and T. J. Sick. Oxidative metabolic responses during recurrent seizures are independent of convulsant, anesthetic, or species. Neurology 1983;33: 861–867. 79. Krumholz, A. Epidemiology and evidence for morbidity of nonconvulsive status epilepticus. J. Clin. Neurophysiol. 1999;16: 314–322. 80. Lacroix, J., C. Deal, M. Gauthier, E. Rousseau, and C. A. Farrell. Admissions to a pediatric intensive care unit for status epilepticus: A 10-year experience. Crit. Care Med. 1994;22: 827–832. 81. Lathers, C. M., and P. L. Schraeder. Autonomic dysfunction in epilepsy: Characterization of autonomic cardiac neural discharges associated with pentylenetetrazol-induced epileptogenic activity. Epilepsia 1982;23:633–647. 82. Lewis, D. V., and W. H. Schuette. NADH fluorescence, [K+]0 and oxygen consumption in cat cerebral cortex during direct cortical stimulation. Brain Res. 1976;110:523–535.
83. Lindvall, O., M. Ingvar, and F. H. Gage. Short term status epilepticus in rats causes specific behavioral impairments related to substantia nigra necrosis. Exp. Brain Res. 1986;64: 143–148. 84. Litt, B., R. J. Wityk, S. H. Hertz, et al. Nonconvulsive status epilepticus in the critically ill elderly. Epilepsia 1998;39:1194– 1202. 85. Liu, H., A. M. Mazarati, H. Katsumori, R. Sankar, and C. G. Wasterlain. Substance P is expressed in hippocampal principal neurons during status epilepticus and plays a critical role in the maintenance of status epilepticus. Proc. Natl. Acad. Sci. U. S. A. 1999;96:5286–5291. 86. Logroscino, G., D. C. Hesdorffer, G. Cascino, J. F. Annegers, and W. A. Hauser. Short-term mortality after a first episode of status epilepticus. Epilepsia 1997;38:1344–1349. 87. Lothman, E. W., E. H. Bertram, J. W. Bekenstein, and J. B. Perlin. Self-sustaining limbic status epilepticus induced by “continuous” hippocampal stimulation: Electrographic and behavioral characteristics. Epilepsy Res. 1989;3:107–119. 88. Malone, A. J., Jr., S. Field, J. Rosman, and W. P. Shemerdiak. Neurotoxic reaction to oxacillin. N. Engl. J. Med. 1977;296: 453. 89. Maytal, J., S. Shinnar, S. L. Moshe, and L. A. Alvarez. Low morbidity and mortality of status epilepticus in children. Pediatrics 1989;83:323–331. 90. Mazarati, A. M., and C. G. Wasterlain. N-methyl--aspartate receptor antagonists abolish the maintenance phase of selfsustaining status epilepticus in rat. Neurosci. Lett. 1999;265: 187–190. 91. McDonough, J. H., Jr., and T. M. Shih. Neuropharmacological mechanisms of nerve agent-induced seizure and neuropathology. Neurosci. Biobehav. Rev. 1997;21:559–579. 92. McDonough, J. H., Jr., L. D. Zoeffel, J. McMonagle, T. L. Copeland, C. D. Smith, and T. M. Shih. Anticonvulsant treatment of nerve agent seizures: Anticholinergics versus diazepam in soman-intoxicated guinea pigs. Epilepsy Res. 2000;38:1–14. 93. Meldrum, B. S. Metabolic factors during prolonged seizures and their relation to nerve cell death. In A. V. DelgadoEscueta, C. G. Wasterlain, D. M. Treiman, and R. J. Porter, eds. Status Epilepticus: Mechanisms of Brain Damage and Treatment. Adv. Neurol. 1983;34:261–275. 94. Meldrum, B. S., and J. B. Brierley. Prolonged epileptic seizures in primates: Ischemic cell change and its relation to ictal physiological events. Arch. Neurol. 1973;28:10–17. 95. Meldrum, B. S., and R. W. Horton. Physiology of status epilepticus in primates. Arch. Neurol. 1973;28:1–9. 96. Men, S., D. H. Lee, J. R. Barron, and D. G. Munoz. Selective neuronal necrosis associated with status epilepticus: MR findings. Am. J. Neuroradiol. 2000;21:1837–1840. 97. Meldrum, B. S., and B. Nilsson. Cerebral blood flow and metabolic rate early and late in prolonged epileptic seizures induced in rats by bicuculline. Brain 1976;99:523–542. 98. Meldrum, B. S., R. A. Vigouroux, and J. B. Brierley. Systemic factors and epileptic brain damage: Prolonged seizures in paralyzed artificially ventilated baboons. Arch. Neurol. 1973; 29:82–87. 99. Mikati, M. A., A. Chronopoulos, and G. L. Holmes. Stages of kainic acid (KA)-induced status epilepticus (SE) in the prepubescent brain and response to phenobarbital (Ph). Neurology 1992;42(Suppl. 3):364. 100. Monaco, F., R. Mutani, G. P. Sech, and A. Russo. La distribuzione cerebrale di difenilidantoina nello stato di male
:
65
101.
102.
103.
104.
105.
106.
107.
108.
109. 110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
66
epilettico generalizzato e focale da penicillina nel gatto. Boll. Lega. Ital. Epilessia. 1985;51–52:243–244. Morimoto, T., M. Fukuda, Y. Suzuki, M. Kusu, and K. Kida. Sequential changes of brain CT and MRI after febrile status epilepticus in a 6-year-old girl. Brain Dev. 2002;24:190–193. Naquet, R., B. S. Meldrum, E. Balzano, and J. P. Charrier. Photically-induced epilepsy and glucose metabolism in the adolescent baboon (Papio papio). Brain Res. 1970;18:503–512. Nei, M., J. M. Lee, V. L. Shanker, and M. R. Sperling. The EEG and prognosis in status epilepticus. Epilepsia 1999;40: 157–163. Nevander, G., M. Ingvar, R. Auer, and B. K. Siesjö. Irreversible neuronal damage after short periods of status epilepticus. Acta Physiol. Scand. 1984;120:155–157. Nevander, G., M. Ingvar, R. Auer, and B. K. Siesjö. Status epilepticus in well-oxygenated rats causes neuronal necrosis. Ann. Neurol. 1985;18:281–290. Ney, G. C., C. Zimmerman, and N. Schaul. Psychogenic status epilepticus induced by a provocative technique. Neurology 1996;46:546–547. Nixon, J., D. Bateman, and T. Moss. An MRI and neuropathological study of a case of fatal status epilepticus. Seizure 2001;10(8):588–591. Nohria, V., N. Lee, R. D. Tien, et al. Magnetic resonance imaging evidence of hippocampal sclerosis in progression: A case report. Epilepsia 1994;35:1332–1336. Norman, R. M. The neuropathology of status epilepticus. Med. Sci. Law 1964;4:46–51. Nowack, W. J., and I. A. Shaikh. Progression of electroclinical changes in complex partial status epilepticus: Filling in the blanks. Clin. Electroencephalogr. 1999;30:5–8. O’Connell, B. K., J. Towfighi, W. A. Kofke, and R. A. Hawkins. Neuronal lesions in mercaptopropionic acidinduced status epilepticus. Acta Neuropathol. 1989;77:47–54. Olney, J. W., T. deGubareff, and R. S. Sloviter. “Epileptic” brain damage in rats induced by sustained electrical stimulation of the perforant path. II. Ultrastructural analysis of acute hippocampal pathology. Brain Res. Bull. 1983;10:699–712. Oxbury, J. M., and C. W. M. Whitty. Causes and consequences of status epilepticus in adults: A study of 86 cases. Brain 1971;94:733–744. Pakalnis, A., M. E. Drake, Jr., and B. Phillips. Neuropsychiatric aspects of psychogenic status epilepticus. Neurology 1991;41:1104–1106. Pakalnis, A., J. Paolicchi, and E. Gilles. Psychogenic status epilepticus in children: Psychiatric and other risk factors. Neurology 2000;54:969–970. Paydarfar, D., F. L. Eldridge, S. C. Scott, R. T. Dowell, and P. G. Wagner. Respiratory responses to focal and generalized seizures in cats. Am. J. Physiol. 1991;260:R934–R940. Perl, T. M., L. Bedard, T. Kosatsky, J. C. Hockin, E. C. Todd, and R. S. Remis. An outbreak of toxic encephalopathy caused by eating mussels contaminated with domoic acid. N. Engl. J. Med. 1990;322:1775–1780. Petsche, H., P. Rappelsberger, R. Vollmer, and O. Prohaska. Das Phänomen der Synchronisierung im Penicillinstatus und dessen Veränderung unter Clonazepam. EEG EMG Z. Elektroenzephalogr. Elektromyogr. Verwandte Geb. 1977;8:1–17. Pfleger, L. Beobachtungen über Schrumpfung und Sclerose des Ammonshornes bei Epilepsie. Allg. Z. Psychiatr. 1880; 36:359–365. Pinard, E., A. S. Rigaud, D. Riche, R. Naquet, and J. Seylaz. Continuous determination of the cerebrovascular changes
:
121.
122.
123.
124.
125.
126. 127.
128.
129.
130. 131.
132.
133.
134.
135.
136.
137. 138. 139.
140.
induced by bicuculline and kainic acid in unanaesthetized spontaneously breathing rats. Neuroscience 1987;23:943–952. Pinard, F., E. Tremblay, Y. Ben-Ari, and J. Seylaz. Blood flow compensates oxygen demand in the vulnerable CA3 region of the hippocampus during kainate-induced seizures. Neuroscience 1984;13:1039–1049. Plum, F., J. B. Posner, and B. Troy. Cerebral metabolic and circulatory responses to induced convulsions in animals. Arch. Neurol. 1968;18:1–13. Privitera, M., M. Hoffman, J. L. Moore, and D. Jester. EEG detection of nontonic-clonic status epilepticus in patients with altered consciousness. Epilepsy Res. 1994;18:155–166. Qian, J., W. F. Colmers, and P. Saggau. Inhibition of synaptic transmission by neuropeptide Y in rat hippocampal area CA1: Modulation of presynaptic Ca2+ entry. J. Neurosci. 1997;17:8169–8177. Rafiq, A., Y. F. Zhang, R. J. DeLorenzo, and D. A. Coulter. Long-duration self-sustained epileptiform activity in the hippocampal parahippocampal slice: A model of status epilepticus. J. Neurophysiol. 1995;74:2028–2042. Rechlin, T., T. H. Loew, and P. Joraschky. Pseudoseizure “status.” J. Psychosom. Res. 1997;42:495–498. Reuber, M., S. M. Enright, and P. J. Goulding. Postoperative pseudostatus: Not everything that shakes is epilepsy. Anaesthesia 2000;55:74–78. Rocha, L., J. Engel, Jr., and R. F. Ackermann. Effects of chronic naloxone pretreatment on amygdaloid kindling in rats. Epilepsy Res. 1991;10:103–110. Roger, J., H. Lob, and C. A. Tassinari. Status epilepticus. In P. J. Vinken, and G. W. Bruyn, eds. The Epilepsies. Vol. 15. New York: American Elsevier, 1974:145–188. Scholtz, W. Uber die Entstehung des Hirnbefundes bei der Epilepsie. Z. Gesamte Neurol. Psychiatr. 1933;145:471–515. Schraeder, P. L., and C. M. Lathers. Cardiac neural discharge and epileptogenic activity in the cat as an animal model for unexplained death. Life Sci. 1983;32:1371–1382. Schwob, J. E., T. Fuller, J. L. Price, and J. W. Olney. Widespread patterns of neuronal damage following systemic or intracerebral injections of kainic acid: A histological study. Neuroscience 1980;5:991–1014. Shih, T. M., and J. H. McDonough, Jr. Neurochemical mechanisms in soman-induced seizures. J. Appl. Toxicol. 1997;17: 255–264. Shih, T. M., and J. H. McDonough, Jr. Organophosphorus nerve agents–induced seizures and efficacy of atropine sulfate as anticonvulsant treatment. Pharmacol. Biochem. Behav. 1999;64:147–153. Shinnar, S., J. Maytal, L. Krasnoff, and S. L. Moshe. Recurrent status epilepticus in children. Ann. Neurol. 1992;31: 598–604. Shorvon, S. Status Epilepticus: Its Clinical Features and Treatment in Children and Adults. Cambridge, U.K.: Cambridge University Press, 1994. Shorvon, S. D. Pseudostatus epilepticus. Lancet 1989;2:485. Simon, R. P. Physiologic consequences of status epilepticus. Epilepsia 1985;26(Suppl. 1):S58–S66. Simon, R. P., M. J. Aminoff, and N. Benowitz. Changes in plasma catecholamines after tonic-clonic seizures in man: Possible role in sudden death during seizures. Neurology 1984;34:255–257. Simon, R. P., L. L. Bayne, R. F. Tranbaugh, and F. R. Lewis. Elevated pulmonary lymph flow and protein content during status epilepticus in sheep. J. Appl. Physiol. 1982;52:91–95.
141. Snodgrass, S. M., K. Tsuburaya, and C. Ajmone-Marsan. Clinical significance of periodic lateralized epileptiform discharges: Relationship with status epilepticus. J. Clin. Neurophysiol. 1989;6:159–172. 142. Söderfeldt, B., G. Blennow, H. Kalimo, Y. Olsson, and B. K. Siesjö. Influence of systemic factors on experimental epileptic brain injury: Structural changes accompanying bicuculline-induced seizures in rats following manipulations of tissue oxygenation or alpha-tocopherol levels. Acta Neuropathol. 1983;60:81–91. 143. Spehlmann, R. Special epileptiform patterns. In R. Spehlmann, ed. EEG Primer. Amsterdam: Elsevier, 1981: 309–340. 144. Sperk, G., and H. Herzog. Anticonvulsant action of neuropeptide Y: Neuropeptide Y may act as an endogenous anticonvulsant through Y5 receptors suggesting a new target for antiepileptic drugs. Nat. Med. 1997;3:728–729. 145. Sperk, G., H. Lassmann, H. Baran, S. J. Kish, F. Seitelberger, and O. Hornykiewicz. Kainic acid induced seizures: Neurochemical and histopathological changes. Neuroscience 1983;10: 1301–1315. 146. Spuler, A., and P. Grafe. Adenosine, “pertussis-sensitive” G-proteins, and K+ conductance in central mammalian neurones under energy deprivation. Neurosci. Lett. 1989; 98:280–284. 147. Striano, S., F. A. De Falco, F. Zaccaria, A. Fels, S. Natale, and G. Vacca. Paroxysmal lateralized epileptiform discharges (PLEDs): Clinical-EEG correlations in twenty cases. Acta Neurol. 1986;8:1–12. 148. Tien, R. D., and G. J. Felsberg. The hippocampus in status epilepticus: Demonstration of signal intensity and morphologic changes with sequential fast spin-echo MR imaging. Radiology 1995;194:249–256. 149. Toone, B. K., and J. Roberts. Status epilepticus: An uncommon hysterical conversion syndrome. J. Nerv. Ment. Dis. 1979;167:548–552. 150. Towfighi, J., W. A. Kofke, B. K. O’Connell, C. Housman, and J. M. Graybeal. Substantia nigra lesions in mercaptopropionic acid induced status epilepticus: A light and electron microscopic study. Acta Neuropathol. 1989;77:612– 620. 151. Towne, A. R., J. M. Pellock, D. Ko, and R. J. DeLorenzo. Determinants of mortality in status epilepticus. Epilepsia 1994;35:27–34. 152. Treiman, D. M. Electroclinical features of status epilepticus. J. Clin. Neurophysiol. 1995;12:343–362. 153. Treiman, D. M. Generalized convulsive, nonconvulsive, and focal status epilepticus. In E. Feldman, ed. Current Diagnosis in Neurology. St. Louis: Mosby–Year Book, 1994:11–18. 154. Treiman, D. M. Generalized convulsive status epilepticus. In J. Engel, Jr., and T. A. Pedley, eds. Epilepsy: A Comprehensive Textbook. Philadelphia: Lippincott-Raven, 1997:669–680. 155. Treiman, D. M. Generalized convulsive status epilepticus in the adult. Epilepsia 1993;34(Suppl. 1):S2–S11. 156. Treiman, D. M. Neocortical status epilepticus. In P. D. Williamson, A. M. Siegel, D. W. Roberts, V. M. Thadani, and M. S. Gazzaniga, eds. Neocortical Epilepsies. Adv. Neurol. 2000; 84:243–251. 157. Treiman, D. M. Status epilepticus. In J. Resor and H. Kutt, eds. The Medical Treatment of Epilepsy. New York: Marcel Dekker, 1992:183–193. 158. Treiman, D. M. Status epilepticus. Baillieres Clin. Neurol. 1996; 5:821–839.
159. Treiman, D. M. Treatment of status epilepticus. In J. Engel, Jr., and T. A. Pedley, eds. Epilepsy: A Comprehensive Textbook. Philadelphia: Lippincott-Raven, 1997:1317–1323. 160. Treiman, D. M., C. M. DeGiorgio, S. Salisbury, and C. Wickboldt. Subtle generalized convulsive status epilepticus. Epilepsia 1984;25:653. 161. Treiman, D. M., and A. V. Delgado-Escueta. Status epilepticus. In R. A. Thompson, and J. R. Green, eds. Critical Care of Neurological and Neurosurgical Emergencies. New York: Raven Press, 1980:53–99. 162. Treiman, D. M., P. D. Meyers, and the DVA Status Epilepticus Cooperative Study Group. Utility of the EEG pattern as a predictor of success in the treatment of generalized convulsive status epilepticus. Epilepsia 1991;32(Suppl. 3):93. 163. Treiman, D. M., P. D. Meyers, and N. Y. Walton. Status epilepticus in the elderly: Nosology and therapy. In A. J. Rowan and R. E. Ramsay, eds. Seizures and Epilepsy in the Elderly. Boston: Butterworth-Heinemann, 1997:207–215. 164. Treiman, D. M., P. D. Meyers, N. Y. Walton, and the DVA Status Epilepticus Cooperative Study Group. Duration of generalized convulsive status epilepticus: Relationship to clinical symptomatology and response to treatment. Epilepsia 1992;33(Suppl. 3):66. 165. Treiman, D. M., P. D. Meyers, N. Y. Walton, et al. A comparison of four treatments for generalized convulsive status epilepticus. N. Engl. J. Med. 1998;339:792–798. 166. Treiman, D. M., N. Y. Walton, and C. Kendrick. A progressive sequence of electroencephalographic changes during generalized convulsive status epilepticus. Epilepsy Res. 1990;5: 49–60. 167. Treiman, D. M., N. Y. Walton, P. D. Meyers, and the VA Status Epilepticus Cooperative Study Group. Generalized convulsive status epilepticus: A frequent complication of serious medical illness. Epilepsia 1994;35(Suppl. 8):33. 168. Trousseau, A. Lectures on Clinical Medicine Delivered at the Hotel Dieu, Paris. London: New Sydenham Society, 1868. 169. Tuxhorn, I. E., and H. S. Fischbach. Pseudostatus epilepticus in childhood. Pediatr. Neurol. 2002;27(5):407–409. 170. Vignatelli, L., C. Tonon, R. D’Alessandro, and the Bologna Group for the Study of Status Epilepticus. Incidence and short-term prognosis of status epilepticus in adults in Bologna, Italy. Epilepsia 2003;44(7):964–968. 171. Walton, N. Y. Systemic effects of generalized convulsive status epilepticus. Epilepsia 1993;34(Suppl. 1):S54–S58. 172. Walton, N. Y., and D. M. Treiman. Motor and electroencephalographic response of refractory experimental status epilepticus in rats to treatment with MK-801, diazepam, or MK-801 plus diazepam. Brain Res. 1991;553:97–104. 173. Walton, N. Y., and D. M. Treiman. Rational polytherapy in the treatment of status epilepticus. In I. E. Leppik and R. W. Homan, eds. Rational Polypharmacy. Epilepsy Res. 1996;Suppl. 11:123–139. 174. Walton, N. Y., and D. M. Treiman. Response of status epilepticus induced by lithium and pilocarpine to treatment with diazepam. Exp. Neurol. 1988;101:267–275. 175. Wasterlain, C. G. Mortality and morbidity from serial seizures: An experimental study. Epilepsia 1974;15:155–176. 176. Westmoreland, B. F., D. W. Klass, and F. W. Sharbrough. Chronic periodic lateralized epileptiform discharges. Arch. Neurol. 1986;43:494–496. 177. Wieshmann, U. C., F. G. Woermann, L. Lemieux, et al. Development of hippocampal atrophy: A serial magnetic resonance imaging study in a patient who developed epilepsy
:
67
178.
179. 180.
181.
68
after generalized status epilepticus. Epilepsia 1997;38:1238– 1241. Wijdicks, E. F., and R. D. Hubmayr. Acute acid-base disorders associated with status epilepticus. Mayo Clin. Proc. 1994; 69:1044–1046. Wilner, A. N., and P. R. Bream. Status epilepticus and pseudostatus epilepticus. Seizure 1993;2:257–260. Wilson, J. V. K., and E. H. Reynolds. Translation and analysis of a cuneiform text forming part of a Babylonian treatise on epilepsy. Med. Hist. 1990;34:185–198. Winocour, P. H., A. Waise, G. Young, and K. J. Moriarty. Severe, self-limiting lactic acidosis and rhabdomyolysis accompanying convulsions. Postgrad. Med. J. 1989;65:321– 322.
:
7
Simple and Complex Partial Status Epilepticus
, , S can assume as many forms as there are varieties of epileptic seizures. —Gastaut, 1967
Introduction The subdivision of focal seizures into simple partial seizures and complex partial seizures was adopted by the Commission on Classification and Terminology of the International League Against Epilepsy in 1981 (42). These terms were applied to status epilepticus (SE) by Gastaut in 1983 (72), with alteration of consciousness used to differentiate elementary or simple partial status epilepticus (SPSE) from complex partial status epilepticus (CPSE). Although Shorvon has recently attempted a syndromic classification of SE (191) that takes into account age, cerebral maturation, and pathophysiologic mechanisms, there is no recognized alternative to the dichotomy of simple versus complex based on altered consciousness. This chapter therefore follows the existing classification, although two types of problems are associated with it. The first is that SE of different types cannot in fact be reduced to the types of seizures of which they are composed, but are distinct clinical entities, which may be very different from the seizure types to which their names refer. The second is that a separation of SE into two large categories based exclusively on alteration of consciousness does not appear justified on any pathophysiologic, anatomic, or prognostic ground, resulting in forms of ambiguous classification such as nonconvulsive SE of frontal origin or aphasic SE. Alteration of consciousness is also notoriously difficult to define and therefore to evaluate clinically (79).
Simple partial status epilepticus SPSE is characterized by “a fixed and enduring condition” resulting from the persistence or the repetition of partial seizures with no alteration of consciousness or secondary generalization (71, 72, 182). These conditions are theoretically met when a simple partial seizure lasts more than 30 minutes (47) or when the seizures recur in such a way that there are interictal neurologic signs indicative of neuronal exhaustion in the specific cortical areas implicated in the
ictal activity. This chapter discusses in turn convulsive SPSE, which is frequent, easy to diagnose, and often carries a severe prognosis, and nonconvulsive SPSE, which is difficult to diagnose because of its rarity and its unusual clinical features. C SPSE Somatomotor SPSE Somatomotor SPSE is characterized by repeated partial motor seizures, preserved consciousness, and preserved neurovegetative regulation (71, 72, 182). The cardinal clinical finding is repeated clonic jerks with localization depending on the localization of the epileptogenic lesion in the primary motor cortex (38). Parts of the body with an extensive cortical representation are most commonly involved, particularly the thumb, the mouth, the periocular muscles, and the big toe. Frequent and successive seizures occur, characterized by segmental jerks of progressively increasing amplitude and decreasing frequency. During the interictal periods, the neurologic examination shows a progressively increasing motor deficit in the same localization as the clonic jerks. In those rare instances in which a BravaisJacksonian march occurs, the discharges spread over the motor cortex but still remain relatively localized. The clonic jerks, at times preceded by a tonic component, then spread over the side of the body, with a successive segmental involvement of each limb. Although rare, cheiro-oral propagation, or the march of myoclonic contractions from the thumb to the ipsilateral labial muscles, is characteristic (48, 71, 163). Forced adversion, initially of the eyes and then of the head, at times associated with postural manifestations, may precede the motor manifestations when the epileptic focus is located in the contralateral dorsolateral intermediate frontal region (48, 182) and must be differentiated from the oculoclonic occipital SE described by Palem et al. (160) and Kanazawa et al. (100). The electroencephalogram (EEG) shows more or less well-defined paroxysmal discharges over contralateral rolandic regions (72), often hidden by muscle artifact when the jerks involve the hemiface (Figure 7.1). In many instances, these focal seizures represent the prodromal phase of a secondarily generalized SE. The
, , :
69
F 7.1 Simple partial somatomotor status epilepticus involving the right side of the face and presenting as repeated seizures lasting 5 minutes and repeating every 8 minutes in a 58-year-old man. Facial jerks are seen as muscle artifacts in right frontal and
temporal regions, associated with a rhythmic 2-Hz spike-and-wave focus over the left central region. Interictally, there was a progressively increasing right facial weakness. The CT scan showed a left central intracerebral hemorrhage.
prognosis and implications for treatment are then those of this type of SE. Somatomotor SPSE may also develop into epilepsia partialis continua (99), with persisting myoclonic jerks replacing the discrete somatomotor seizures (Figure 7.2). Somatomotor SPSE is usually related to symptomatic or cryptogenic epilepsies of the central region. Patients whose seizures begin with this form of SE typically have acute or subacute lesions of the rolandic region, particularly of vascular or neoplastic origin (71, 72). In very rare instances, focal SE may be followed by the development of focal chronic epilepsy (20).
living in wooded areas in western Russia in association with Russian spring-summer tick-borne encephalitis (112), which later became endemic in Siberia (159). Two major forms of EPC have been described. The first (EPC 1) occurs with nonspecific lesions of the central region. The second (EPC 2) is characteristic of a rare but well-documented syndrome, Rasmussen’s chronic encephalitis (8, 183). EPC of nonspecific etiology, on EPC 1, occurs in adults and children. It is characterized by somatomotor partial seizures followed by permanent or intermittent segmental myoclonus in the same region that is resistant to medical treatment (15, 16, 38). The myoclonic jerks in EPC 1 are classically unilateral and are of variable amplitude, distribution, and rhythmicity. They occur with preservation of consciousness and are resistant to antiepileptic drugs (188), as well as to injections of botulinum toxin (202). They are thus different from the myoclonic SE that may occur in comatose patients (202). EPC 1 most frequently involves one side of the face or one upper extremity and is usually responsible for moderate
Epilepsia partialis continua According to Obeso et al. (155), epilepsia partialis continua (EPC) is defined as “spontaneous regular or irregular clonic twitching of cerebral cortical origin sometimes aggravated by action or sensory stimuli, confined to one part of the body and continuing for hours, days, or weeks.” EPC has been included in the present classification of epileptic syndromes (42) with the eponym Kojewnikow syndrome. Kojewnikow described EPC in Russian peasants
70
:
F 7.2 Epilepsia partialis continua in a 67-year-old man with a right central tumour. Persisting jerks are recorded at the left wrist (arrows) and alternate with recurring somatomotor seizures of the left upper extremity. The EEG shows rhythmic slow activity,
predominantly over the right hemisphere. The end of the seizure is marked by a 15-second afterdischarge. Recurrent jerks at the left wrist (arrows) are of lower amplitude than before because of the associated Todd’s paresis.
interference with function of the limb (Figure 7.3). In the most disabling cases there is involvement of the rolandic operculum, and these cases are characterized by velolinguopalatine epileptic myoclonus (Foix-Chavany-Marie syndrome), responsible for dysphagia, dysarthria, or anarthria (68, 154, 203, 208). In these cases, a strictly unilateral epileptic discharge of opercular origin produces bilateral motor expression because of the bilateral projections of the inferior corticonuclear pathways. A similar syndrome of idiopathic origin consists of hemifacial clonic jerks, drooling, and anarthria and may very rarely complicate the course of benign epilepsy of childhood, with centrotemporal spikes (41, 56, 64). EPC 1 is classically associated with epileptogenic lesions of the rolandic motor cortex, which may be of vascular (205), neoplastic (15, 16), infectious (36), inflammatory (17, 153), or posttraumatic (205) origin. Recent work using modern imaging methods has shown an elevated frequency of focal cortical dysplastic lesions in EPC 1 (6, 67, 121, 122, 161). Severe prolonged migrainous symptoms and prolonged partial SE, typically taking the form of EPC 1, are characteristic features of the MELAS syndrome (mitochon-
drial encephalomyopathy, lactic acidosis, and strokelike episodes) (7). Late-onset EPC may also reveal Kufs’ disease (70). EPC 1 is progressive insofar as the underlying lesion may be progressive and may respond to appropriate neurosurgical intervention. Other etiologic factors include metabolic encephalopathies, particularly nonketotic hyperglycemia (39, 194). A case of EPC 1 associated with an NADH-coenzyme Q reductase deficiency has been reported (9). More recently, three patients with lung cancer and positive anti-Hu antibodies developed EPC, which in this context was clearly related to a paraneoplastic disorder (187). Polygraphic recording in EPC 1 shows that the myoclonic jerks are characterized by cocontraction of agonist and antagonist muscles. The EEG may show continuous or intermittent low-amplitude focal abnormalities in the central regions, at times correlated with the myoclonic jerks (see Figure 7.3). Jerk-locked back-averaging studies (188, 227) may show that the latency between the cortical event and the myoclonic jerk is compatible with corticospinal transmission. This type of investigation may be improved by using a “rectified” recording of the electromyogram, and
, , :
71
F 7.3 Epilepsia partialis continua in a 22-year-old woman with symptomatic partial epilepsy and left rolandic focal cortical dysplasia. The epilepsy was characterized by right hemifacial somatomotor seizures at night, becoming secondarily generalized and epilepsia partialis continua with rapid myoclonic jerks of the right eyelid and corner of the mouth occurring daily for 2–4 hours at a time, usually at the end of the afternoon. The myoclonus is
seen as muscle artifact over the right frontal regions and in the electro-oculogram. At rest (left recording), there is associated lowamplitude irregular theta activity over the left centroparietal region. With the arms held out (right recording), epileptic negative myoclonus of the proximal part of the right upper limb is seen, with periodic loss of muscle tone associated with the epilepsia partialis continua (arrowheads).
may be complemented by topographic studies using dipole source localization (34). When the neurophysiologic results are ambiguous, functional imaging with single-photon emission computed tomography (SPECT) or positron emission tomography may clarify the situation (45, 83, 108, 203) and permit follow-up studies (200). The pathogenesis of EPC 1 has been discussed for some time. Initial studies, based on the topographic distribution of the causal lesions, suggested that there was uncoupling between subcortical structures, presumed responsible for the myoclonic jerks, and cortical structures, presumed responsible for the epileptic seizures (99). More recent studies using depth electrode recording argue for a common neocortical origin of both these clinical manifestations, with the same epileptic region being responsible for both somatomotor seizures and continuous clonic activity (37, 38, 231). EPC 2 is an independent severe and progressive neurologic disease known as Rasmussen’s encephalitis. It was discovered and extensively studied by the Montreal school (8, 156, 169). The anatomic substrate of the disease may be an autoimmune chronic encephalitis characterized by autoan-
tibodies directed against type 3 glutamatergic receptors (176). Rasmussen’s encephalitis is a devastating neurologic disease of childhood that typically begins between ages 1 and 14 years. In half of cases there is a history of recent and apparently viral infection. The central regions are preferentially involved, and the epilepsy manifests principally as simple partial seizures. The disease then progresses, with neurologic signs related to the insidious destruction of the involved hemisphere: severe epilepsy, characterized by several types of partial seizures and secondary generalized seizures; hemiparesis, which may initially be limited to a loss of fine movements of the fingers; abnormal movements; deterioration in cognitive function; and language disturbances when the dominant hemisphere is involved. EPC of variable expression is found in half of the cases. Imaging studies (Figure 7.4 and Color Plate 1) show a progressive and widespread unilateral atrophy associated with subtle signs of white matter inflammation (6, 8, 225). Findings on functional imaging and magnetic resonance imaging (MRI) spectroscopy (35) usually correlate well with the anatomic and
72
:
F 7.4 Rasmussen’s encephalitis of 3 years’ duration in a 12year-old girl. T2-weighted MR imaging shows unilateral left cortical and subcortical atrophy. Interictal HMPAO SPECT imaging
shows significant hypoperfusion of the left hemisphere, predominantly over centroparietal regions. (See Color Plate 1.)
electroclinical information (Figure 7.4). Late-onset Rasmussen’s encephalitis, beginning in adult life, is rare (142). A brain biopsy shows encephalitic changes, which may be subtle. Medical treatment is often disappointing: corticosteroids, plasmapheresis, immune globulins, intraventricular interferon, and zidovudine have been used (51, 86, 132). Functional hemispherectomy arrests the progression of the disease, leaving variable motor and cognitive deficits (224). The timing of surgery is often difficult and must be extensively discussed with the patient’s family.
patients should be documented extensively. In the personal experience of one of the authors (P.T.), among approximately 100 episodes of partial SE investigated in 10 years, only four such patients were encountered, one each with visual, auditory, somatosensory, and somatoinhibitory symptoms. Nonconvulsive SPSE is a fixed and prolonged epileptic state characterized by “elementary” ictal symptoms (72), which may be visual, auditory, somatosensory, inhibitory, vegetative, cognitive or affective, occurring without impairment of consciousness. This condition appears to be similar to prolonged simple partial seizure with elementary symptomatology (49). Aphasic SE, usually included in this group,
N SPSE Nonconvulsive SPSE is a diagnostic challenge: it is rare, the symptoms are unusual, and the
, , :
73
is discussed later in the chapter. Although intact consciousness is a diagnostic criterion for SPSE, several published cases (61, 81, 89, 141, 193, 230, 232, 236) show that this pattern may develop into CPSE and may thus represent the prodromal phase of this condition. Visual nonconvulsive SPSE may manifest with negative symptoms such as cortical blindness (13, 18, 61, 89), amounting to “status epilepticus amauroticus” (13). Positive symptomatology with simple or complex visual hallucinations may be responsible for more or less pronounced behavioral changes (43, 96, 160, 196). The EEG shows ictal occipital discharges, which are most often bilateral. In auditory nonconvulsive SPSE, only positive symptoms are thus far recognized, exemplified by a patient described by Wieser et al. (230, 233) who experienced musical hallucinations associated with continuous ictal activity in the right Heschl’s gyrus. Somatosensory nonconvulsive SPSE is rare (72, 184). We were able to identify one such patient with a parietal astrocytoma. The symptoms included somatosensory seizures with a jacksonian march characterized by paresthesias and
causalgic sensations. Eight patients with somatoinhibitory SPSE have been described in the literature (Figure 7.5). The clinical pattern in this entity is particularly misleading. It may include hemiparesis (12), hemiasomatognosia (209), or alien-hand syndrome (63), and may suggest Todd’s paralysis (213), acute stroke (209), or behavioral disturbances (63). Four cases of SPSE with vegetative symptoms have been reported (130, 193). Symptoms included prolonged “auras” characterized by episodes of rising epigastric sensations, a butterfly sensation in the stomach, and olfactory hallucinations. SPSE with cognitive symptoms is difficult to investigate. Sacquegna et al. (180) described a patient in whom extensive neuropsychological testing showed errors in reading and writing, in mental arithmetic, and in visual construction tasks. Behavior and alertness were normal. The EEG showed left temporo-occipital ictal activity. Matsuoka et al. (137) described a patient with ideational, ideomotor, and constructional apraxia, finger agnosia, left-right confusion, and agraphia associated with biparietal ictal EEG discharges. In a case report, Wieser et al. assessed cognitive
F 7.5 Right-sided somatoinhibitory SPSE in a 69-year-old woman with right frontoparietal cryptogenic partial epilepsy. Left hemiparesis, left hemihypoesthesia, left visual neglect, and left epileptic nystagmus are associated with continuous high-amplitude spike-and-wave discharges from the right centrotemporoparietal
region. Consciousness was maintained. No lesion was found on imaging studies. The clinical signs disappeared rapidly after the SE terminated, and there was no persistent neurologic deficit. (Reprinted with permission from Thomas et al. [209].)
74
:
functions with tachistoscopic tasks (232) and demonstrated impairment of lexical decision task performances during sustained left hippocampal discharges. SPSE with affective symptoms is mostly characterized by prolonged periods of ictal fear. Henriksen (89) described a patient with right mesial temporal ictal activity and SE, during which the patient “screamed as if possessed with terror.” McLachlan and Blume (141) and Zappoli et al. (236) described two similar patients exhibiting intense fear. Alteration of consciousness occurred later in the course of SE in these patients. Affective disinhibition with a pusillanimous euphoric state may also be observed in some patients with nonconvulsive SPSE of frontal origin (see below).
Complex partial status epilepticus The first case of etat de mal temporal (temporal lobe SE) was reported in 1956 by Gastaut et al. (74). The patient, a 56year-old nurse, had a prolonged amnestic fugue state during which she lived outdoors in the hills behind the coast near Marseilles, going to neighboring villages only to seek something to drink. After 1 month she was apprehended and hospitalized with severe malnutrition. The possibility of an acute psychosis was ruled out by the EEG, which showed left temporal ictal discharges occurring every 5–10 minutes, during which memory functions were disturbed. This new entity was quite unlike absence status, since the disturbance of consciousness was related to recurrent focal ictal discharges rather than to generalized ictal activity. CPSE N L R Until the mid-1980s, one of the distinguishing features of CPSE was believed to be its rarity. This is understandable if one considers that the initial reports equated CPSE with a prolonged epileptic fugue (poriomania), which was of course difficult to document with ictal EEG (138). The Xth Marseilles Colloquium of October 1962, devoted to SE, focused on generalized epilepsies, with the result that this impression of rarity was further reinforced (Roger, 1995, personal communication): of the 137 patients presented, only one had a partial epilepsy (71). The small number of cases published by 1967 explains why Gastaut, in his first classification of SE (71), did not feel it necessary to create a specific category for temporal lobe SE. In fact, in 1970, Oller-Daurella (158) could find only three adequately documented cases in the literature (31, 74, 162). Roger et al. (174) therefore wrote in 1974 that “temporal lobe SE has rarely been described electrographically and clinically.” A similar bias in case finding may also explain why Celesia (33) found only two cases of CPSE in his series of 60 patients with SE and why, 8 years later, Courjon et al. (44) found only a single patient with “nonconvulsive SE with complex partial seizures” in a series of 90 consecutive patients with SE.
Ballenger et al. (14) described eight new patients in 1983 and retained only those 17 of the previously described patients whose cases were well documented by ictal EEG out of the approximately 50 published observations over the previous 30 years (22, 46, 53, 61, 62, 74, 84, 85, 88, 94, 128, 133, 139, 140, 141, 148, 235). In 1986, Tomson et al. (215) challenged this notion of rarity. Between 1983 and 1985, there was a great increase in well-documented cases, with approximately 40 new cases being reported (1, 14, 54, 58, 145, 151, 167, 179, 186, 217, 221, 232, 234, 236). As Delgado-Escueta and Treiman (49) remarked, this impressive expansion is probably related to the widespread use of video-EEG monitoring. Nevertheless, most of the 100 observations available in 1986 were isolated case reports, and the relative incidence of CPSE is still unclear. Two studies have addressed the frequency of CPSE as a variety of nonconvulsive SE. Tomson et al. (215) found that CPSE accounted for 5 of 10 patients with nonconvulsive SE, and Rohr-Le Floch et al. (177) found 28 cases of CPSE (47%) in a series of 60 cases of nonconvulsive SE. Between 1986 and January 2000, approximately 100 new cases were published in 42 different reports (5, 10, 19, 23, 26, 40, 52, 57, 59, 66, 87, 93, 98, 105, 112, 113, 116, 118, 124–126, 129, 131, 144, 149, 150, 157, 166, 173, 175, 177, 181, 182, 185, 197, 204, 210, 214, 215, 222, 226, 236). CPSE has become almost commonplace and relatively easy to diagnose, as suggested by the number of patients recently reported from medical emergency departments (40, 57, 93, 105, 127, 177, 182, 214). Nevertheless, the approximately 200 reported cases differ widely in age at onset, clinical presentation, the course of the episodes, and the presumed etiology and localization of the underlying seizure generator. Only five studies comprising 17 patients reported depth electrode studies during CPSE occurring by chance during intensive monitoring (49, 101, 226, 232, 234). T, D, P A CPSE Following the proposed International Classification of Epileptic Seizures (72, 73), the term complex partial status epilepticus was proposed in 1978 by Markand et al. (133) and by Engel et al. in the same year (61), as well as by Mayeux and Lüders (139). This term was then almost universally adopted. Other terms, such as “temporal lobe status” (74), “psychomotor status” (31, 110, 221), “status psychomotoricus” (235), “limbic status” (232), “recurrent temporal seizures” (147) and “prolonged epileptic twilight state with automatisms” (62), have almost disappeared. In 1969, Heintel (88) proposed a definition based on the model of convulsive SE. He described only a single clinical pattern characterized by a simple series of temporal lobe complex partial seizures without interictal return to normal consciousness. This definition was modified in 1975 by Gastaut (73) and Gastaut and Tassinari (75), who described
, , :
75
two distinct clinical forms of CPSE, a discontinuous form and a continuous form. The discontinuous form was described as comprising “closely spaced temporal seizures with classic psychomotor, psychosensory, or psychoaffective symptoms with full or almost full recovery of consciousness in between.” The continuous form was described as “a continuous long lasting episode of mental confusion with or without automatic behaviour and psychosensory or psychoaffective phenomena.” Mayeux and Lüders (139) added EEG information to these definitions. The discontinuous form is characterized by recurrent ictal activity, while the continuous form is characterized by continuous ictal activity. In both cases, the ictal discharges may be localized to the temporal region either initially or secondarily. The most ambitious phenomenological classification of CPSE was proposed by Treiman and Delgado-Escueta in a series of articles published between 1974 and 1987 (49, 62, 217–219). These authors distinguished two major electroclinical types of CPSE. The first and most characteristic type was described in an initial series of 11 patients (217). Two clearly distinct electroclinical phases alternate in the course of a single such episode. The first phase is characterized by “a continuous twilight state, with partial and amnesic responsiveness, partial speech and quasi-purposeful complex reactive automatisms.” The EEG shows diffuse abnormal slow waves predominating over posterior regions, at times mixed with rapid rhythms. This phase alternates with episodes of “staring, total unresponsiveness, speech arrest and stereotyped automatisms” associated with ictal rhythmic discharge at 6–20 Hz involving initially the mesial temporal region before spreading to lateral temporal areas. The fundamental clinical characteristic of this type of CPSE, presumably related to cyclic disorganization of amygdaloid and hippocampal function, is the cyclic nature of the disturbance of consciousness. This characteristic sets it apart from absence status, in which the fluctuation of symptoms is not as regular and not as marked. Delgado-Escueta and Treiman (49) later accepted the possibility that the mesial temporal structures could be secondarily involved by discharge from an extratemporal epileptic focus in the posterior temporal neocortex, the opercular region, the occipital lobe, or the frontal lobe (49). In these cases the clinical pattern was also cyclic but included clinical features linked to early ictal involvement of these respective cortical areas. The second type of CPSE, presumably arising from ictal disorganization of frontal lobe function without involvement of mesial temporal structures, is characterized by a continuous confusional state without any marked cyclic pattern. These cases can be distinguished from absence status only by the EEG, which shows continuous or intermittent ictal discharges with a variable distribution over the scalp (49).
76
:
Although this phenomenologic approach is of great conceptual interest, its validity is open to question (190). The cyclic pattern described above and considered the most characteristic pattern accounts for only a minority of published cases. Moreover, during a single episode, the first pattern is often followed by the second, so that far from being independent clinical syndromes, the cyclic and continuous forms may represent extremes on the same continuum. In addition, depth electrode studies, though scanty (49, 230, 232, 234), show that consciousness is disturbed only when the ictal discharge involves extratemporal structures (147) or becomes bilateral (230). The cyclic disturbance of consciousness was seen in only 6 of the 16 patients studied (49, 234), who for the most part had extratemporal CPSE (234). There has also been a rather poor correlation between simultaneous depth electrode and scalp EEG recording (230, 232, 234), and thus anatomic and electroclinical correlations based on surface recording must remain speculative. In 1994, Shorvon (190) concluded that a broad and intentionally imprecise definition was the least unsatisfactory solution to the great diversity of clinical and EEG presentations. He proposed the following definition, which accounts for the majority of published cases: “CPSE is a prolonged epileptic episode in which fluctuating or frequently recurring focal electrographic epileptic discharges, arising in temporal or extratemporal regions, result in a confusional state with variable clinical symptoms.” The term CPSE nevertheless implies an alteration of consciousness, a term which is itself open to criticism: in many patients with CPSE, the clinical presentation is more suggestive of a selective dysfunction of certain neocortical associative regions rather than a diffuse and homogeneous alteration of consciousness. In many cases, it appears quite arbitrary to distinguish different clinical forms only on the basis of altered consciousness. We favor the approach adopted by Gloor (79), who suggested that the term complex partial should apply to all partial seizures characterized by disturbances of cognitive function. Indeed, as observed in partial seizures, alteration of consciousness in partial SE has no localizing value on its own (79), and a purely topographic classification of nonconvulsive SE would be without doubt more useful than a classification based solely on the electroclinical criteria currently in force (177). We illustrate these terminologic problems at the end of this chapter, in a discussion of two clinical forms of nonconvulsive SE that are difficult to classify, frontal nonconvulsive SE and aphasic SE. A, I, T F, E CPSE The age at which CPSE occurs is extremely variable. The youngest patient described was less than 1 year old (226) and the oldest was 79 years old (24). A slight female preponderance was noted by Shorvon (190).
There are no reliable data on the true incidence of CPSE. Shorvon, based on his personal experience, believes that approximately 15% of patients with partial epilepsy will have at least one episode of CPSE. The annual incidence of CPSE in adults would thus be approximately of 35 per 1 million population, representing 8,750 new cases each year in the United States (191). This incidence might therefore be higher than that of tonic-clonic SE. Most patients have a preexisting partial epilepsy, more often symptomatic than cryptogenic (221), localized to temporal or extratemporal regions and of different causes (14, 105, 182, 214). In some cases the underlying epilepsy is manifested only by tonic-clonic seizures (85). The interval between the first seizure and the first episode of SE may be quite long, 49 years in one case (177). CPSE may occur in severe myoclonic epilepsy of childhood (208) in the lateonset form of MELAS (124, 125). Risk factors for CPSE in patients with established epilepsy include stopping or changing antiepileptic drugs, alcohol use, sleep deprivation, fever, the catamenial period, anesthesia, and surgery (14, 40). CPSE more often appears at the onset of epilepsy in adults than in children (2, 140, 186). When the episode of status is related to an acute CNS lesion, the clinical findings related to the lesions may mask those related to the status, making the initial EEG and clinical evaluation difficult (93). In contrast to absence status, toxic and metabolic precipitating factors are relatively uncommon. In patients without previous epilepsy, acute or chronic causes of CPSE include crack cocaine use (157), electroconvulsive therapy (222, 228), intravenous contrast agent use (129), meningeal carcinomatosis (52), epidural metastases (197), neurosyphilis (87, 124, 166), Alzheimer’s disease (11), and drugs such as cyclosporin (10), ciprofloxacin (98), lithium (181), theophylline (116), diazepam and midazolam (paradoxic response) (3), and vigabatrin (175). The implication of tiagabine in recommended doses remains controversial (189), because in most cases, a benzodiazepine-responsive toxic encephalopathy may also be considered (65, 163, 195, 198, 220). Among unusual causes, Fujiwara et al. (66) reported a case of recurrent CPSE clearly correlated with alcohol use, and Thomas et al. (210) reported a case of CPSE during pregnancy that could only be controlled after the induction of labor and delivery. The duration of CPSE is extremely variable, ranging from 1 hour (140) to several months (40). Mikati et al. described an 11-year-old boy with “protracted epileptiform encephalopathy” lasting more than 4 months, with a benign outcome (145). Cockerell et al. (40) described a patient who was considered to persist in CPSE for 18 months despite vigorous treatment, even longer than a similar case that lasted for 7 months (173). CPSE is frequently recurrent, especially in patients with known epilepsy, found in seven of eight patients described by Ballenger et al. (14) and in 17 of 20
patients described by Cockerell et al. (40). At times recurrences are periodic and unaffected by various adjustments of medications (5, 40, 190). C C CPSE The clinical features of CPSE are extremely variable, depending on ictal disorganization of various anatomophysiologic networks, each of them with a distinct topography and epileptogenicity. Mesial temporal structures are only rarely the only areas involved. Therefore, it appears to us that any description of a typical clinical form, if one indeed exists, must be reductionist. The most typical symptoms include a more or less marked clouding of consciousness, which may be cyclic or continuous, accompanied by automatisms of variable complexity and disturbed affective function, which may at times be responsible for gross behavioral disturbances. Clouding of consciousness The alteration of consciousness is of variable intensity but is usually marked and associated with total or more often partial amnesia for the episode (177, 193). Occasional patients may be lethargic or even stuporous (126, 145). A mild clouding of consciousness, which may even be absent, and without amnesia is frequent in CPSE of frontal lobe origin (177). Detailed neuropsychological evaluation may be needed in those cases to confirm the diagnosis (177). In patients with sustained episodes of confusion, Karbowski (107) notes that the clinical presentation may be easily confused with absence status. In these patients, the ictal discharges are often continuous. In patients with cyclic periods of confusion, the deterioration in level of consciousness outside of the interictal periods makes it possible to differentiate this from a postictal encephalopathy (14, 28). Automatisms Epileptic automatisms of variable type (oroalimentary, gestural, ambulatory) and complexity (elementary, simple, complex) are almost always present during CPSE (14, 31, 177). Treiman and Delgado-Escueta (217) believe that simple oro-alimentary and/or gestural automatisms associated with altered consciousness, alternating cyclically with more or less marked confusion and reactive automatisms, are almost pathognomonic of CPSE of mesial temporal origin. This opinion is shared by Munari et al. (147) on the basis of depth electrode recordings. In contrast, in the series of Rohr-Le Floch et al. (177), 44% of temporal forms of CPSE were characterized by complex rather than simple gestural automatisms. These complex automatisms were, however, rarely as coordinated and sudden as those seen in isolated complex partial seizures (190). For these authors (177), simple gestural automatisms are nonspecific signs, also encountered in absence status and in CPSE of extratemporal origin. Prolonged fugue states are also nonspecific (177) but may allow the diagnosis to be made retrospectively (74, 138).
, , :
77
Associated signs There are several reports of tonic-clonic seizures at the onset of CPSE (14, 62, 177). Unlike absence status, CPSE only rarely ends with a convulsive seizure. Disturbances of language are usual during CPSE. These are at times limited to reduced verbal fluency with imprecise and stereotyped responses. Prolonged ictal aphasia has been classified in the literature as CPSE or aphasic SE (54, 140) and will be discussed later with intermediate clinical forms. Ideational or ideomotor apraxia (94), at times associated with a true Gerstmann’s syndrome (137) has been described with parietal lobe involvement. Clinical manifestations of CPSE may rarely be confined to isolated anterograde and retrograde global amnesia (74, 144). The amnesia may also be associated with other focal manifestations (124). Wieser (230) reported depth electrode studies in such a patient in whom the memory disturbances were associated with ictal discharge in both hippocampi. Ictal changes in the person’s emotional state, almost always unpleasant, appear to be characteristic of CPSE of temporal origin (14, 61, 107, 128, 133, 177, 221, 230, 235). In some cases the clinical picture is dominated by sustained terror (89, 141, 236). Rohr-Le Floch et al. (177) found that all the patients in their experience were uneasy, anxious, or frightened, and at times negativistic, irritable, suspicious, or frankly aggressive. Gelastic seizures have been reported in only one patient (78). Visual hallucinations (145) and complex auditory hallucinations (136, 145, 230), related to involvement of specific sensory areas, have been reported. Matsumoto et al. (136) described a patient in whom these hallucinations reappeared fleetingly 1 week after the status had stopped; they related this course to “forced normalization.” Although patients whose primary observable phenomena are motor must be excluded from the definition of CPSE, in some cases focal motor manifestations may occur. Parcellary adversive movements are frequent. They may be intermittent or sustained and may involve much of the body or be limited to the eyes (14, 22, 58, 61, 62, 84, 139, 148). Adversive movements may be ipsilateral to the ictal discharge (88) and may be associated with epileptic nystagmus (210). When the CPSE occurs in the form of serial seizures, these movements may be useful indicators of the beginning of the individual seizures (58). Low-amplitude lateralized clonic movements may be present (62). Velopalatine myoclonus may occur (60), but bilateral eyelid and facial myoclonus, typical of absence status, has not been reported. Vegetative signs such as pallor, hyperventilation, pupillary dilation, hypersalivation, burping, and changes in gastrointestinal motility are common. Three instances of an unusual presentation with confusion or memory disturbance and intermittent fever have been reported (59, 144, 185).
78
:
Focal neurologic deficits in CPSE, such as hemiparesis, hemianopsia, or hemihypesthesia, were reported by Hilkens and De Weerd (93). L E CPSE The EEG is the key to diagnosis. Only in this way can CPSE be clearly differentiated from absence status, nonepileptic behavior disturbance (54), dementia (170), or metabolic (30) or cerebrovascular disease (24, 150). Other entities in the differential diagnosis are similar to those for other nonconvulsive SE (see Thomas et al., Chapter 8, this volume). Electroencephalography The characteristic EEG sign of CPSE is focal paroxysmal activity that is continuous (Figure 7.6) or occurs in discrete recurring seizures. In the latter, the EEG is comparable to that seen in patients with isolated complex partial seizures. The seizures begin with low-voltage fast activity, which has localizing value, followed by focal rhythmic theta activity, which is gradually replaced by slow waves (49, 216). The interictal tracing can show different types and degrees of abnormality. When the paroxysmal activity is continuous, spikes, spike-and-wave complexes, or focal rhythmic or pseudorhythmic sharp and slow waves occur (133, 139, 216), often alternating with short periods of lowamplitude fast activity. The first of these patterns often evolves into the second in the course of the episode (216). The scalp distribution of the paroxysmal activity is variable. An intermittent or sustained focal discharge clearly localized to one cortical area is rare, as is a strictly temporal localization (80). In most cases the ictal abnormalities are widespread and occur over several lobes, involving frontotemporal, temporoparietal, or temporooccipital regions. Other patterns occasionally observed include intermittent widespread involvement of one or both hemispheres, ictal activity that shifts from side to side, and activity that may shift to one region of the contralateral hemisphere in the course of a single episode (61, 114). A confusional state with periodic lateralized epileptiform discharges (PLEDs) was described in elderly patients by Terzano et al. (204). This syndrome, the existence of which as an independent entity is not yet accepted, may represent a specific EEG manifestation of CPSE at the onset of a primary degenerative dementing illness. In a comatose patient with PLEDs, hyperperfusion on SPECT resolved with further aggressive treatment (4). Other laboratory examinations Transient focal abnormalities are occasionally seen on imaging studies. Hypodensity with (29) or without (114) contrast enhancement, hyperintensity in T2-weighted MR images (22, 90, 114, 123, 124), ictal hyperperfusion on SPECT (22, 212), and a clear frontal increase in lactate signal on proton magnetic resonance spectroscopy (146) have been reported. These abnormalities appear to be related to the edema and hyperperfusion
F 7.6 Continuous form of neocortical complex partial status epilepticus arising from the left temporal region in a 45-yearold woman with symptomatic left temporal partial epilepsy. She had had an arteriovenous malformation excised 20 years earlier and was noncompliant with antiepileptic drugs. Symptoms included mild confusion, aphasia of comprehension, and right visual neglect with macroptic illusions. The EEG (left recording,
average reference) shows continuous pseudorhythmic slow spike and wave activity over left anterior and midtemporal regions and low-amplitude intermittent rapid discharge in the same area. Intravenous administration of 15 mg of diazepam led to transitory slowing of the paroxysmal activity (right recording). The SE ceased without sequelae after IV phenytoin administration.
associated with the seizures (22, 90, 114, 123), but they may also be indicative of low-grade primary brain tumor (90). In our experience (212), the ictal SPECT may provide reliable localizing information and can be particularly useful in differentiating temporal from extratemporal episodes (Figure 7.7).
Figure 7.6) is much more frequent than in absence status: in the series of Granner and Lee (80), 90% of cases of generalized SE responded to IV diazepam but only 60% of cases of CPSE responded. Refractory cases always require identification and correction of the causes and immediate trigger of the status. In our experience, the greater the delay in diagnosis, the greater the likelihood of failure. Because parenteral lorazepam is not available in France, we follow a specific but classic protocol (48, 49), combining IV diazepam, 2 mg/min until the status stops or to a total dose of 20 mg, and IV fosphenytoin, 20–25 mg phenytoinequivalent per kilogram at once, at a rate no faster than 150 mg/min. Lorazepam is commonly used in Canada and the United States. Cases that are still difficult to control may require pentobarbital anesthesia, a possibility that occurred in approximately one-fifth of our personal series (unpublished observations). Propofol administered IV may also be useful (23), as well as oral topiramate (171).
E T CPSE Treating the episodes of CPSE is difficult. The response to intravenous (IV) benzodiazepines is variable. Although spectacular results may be obtained with the first injection (57, 133, 139), the necessary dose is often greater than that needed in absence status (190). When the EEG abnormalities are diffuse, IV benzodiazepine may reduce the extent of the discharge and cause the underlying epileptic focus to be better circumscribed (80). Initial failure to respond to injected benzodiazepine or recurrence of the SE within the first hour after injection (see
, , :
79
F 7.7 Ictal, then postictal HMPAO SPECT scans in a 42year-old man with de novo complex partial status epilepticus of right frontal origin, characterized clinically by affective disinhibition and mild confusion. The EEG showed continuous slow spikeand-wave activity over the right frontotemporal region. The ictal
SPECT (top series) shows right anterior frontal hyperperfusion. A SPECT study performed 72 hours after the end of the SE is normal (bottom series). MRI was normal. Investigations showed active neurosyphilis. (See Color Plate 2.)
P CPSE Although experimental partial SE of the limbic system induced using pilocarpine, kainic acid, or various protocols involving electrical stimulation (95, 115) can cause neuronal damage, the great majority of patients are successfully treated without sequelae, even after several recurrences (40, 55). Transient disturbances of memory, cognitive function, or personality are, however, common and in our experience resolve after several days to weeks. Hilkens and De Weerd (93) believe that the CPSE occurring with an acute brain lesion may cause long-term worsening of the associated neurologic dysfunction. A significant increase in neurospecific enolase, a marker of neuronal dysfunction,
has been reported in a series of eight consecutive adult patients (47). Although there is little argument that generalized SE can produce any lasting deficits, there is still debate over the morbidity of CPSE (102–104, 106). However, some rare unfavorable outcomes are well known. Patients described by Treiman et al. (49, 219) and Engel et al. (61) had severe, prolonged amnesia, which was permanent in one case. A similar unfavorable outcome was obvious in a patient with limbic CPSE of very long duration (personal observation) (Figure 7.8 and Color Plate 2). Krumholz et al. (118) reported a series of 10 consecutive patients with three
F 7.8 A 48-year-old woman with right temporal lobe epilepsy had afebrile limbic complex partial status epilepticus related to an abrupt discontinuation of previous antiepileptic treatment. Status was both underdiagnosed and undertreated and lasted 18 days, with frequent limbic seizures, either right temporal or (middle part of the figure) left temporal. The first MRI study (top series), performed 16 days after the beginning of status, showed T2 hypersignal and T1 hyposignal of both anterior part of parahip-
pocampal gyri. A lumbar puncture was normal. A polymerase chain reaction test of CSF was negative for herpes simplex. There was no finding suggestive of a paraneoplastic encephalitis. Pentobarbital anesthesia finally stopped the epileptic seizures. Long-term evolution was marked by serious memory disturbances, related on neuropsychological testing to axial amnesia. A control MRI study performed 2 years after the SE began showed bilateral hippocampal atrophy with a right-sided predominance (lower series).
80
:
, , :
81
deaths, four patients with permanent memory disturbance, which was severe in two cases, and three instances of memory and cognitive disturbances lasting longer than 3 months. Most of these patients had had mesial temporal CPSE lasting longer than 36 hours. Although the use of major IV anticonvulsants can confer morbidity (106), these reports argue in favor of early diagnosis and vigorous treatment of all patients with CPSE, especially when the limbic system is likely involved by the epileptic discharges (107).
Clinical forms intermediate between SPSE and CPSE Two clinical entities, frontal lobe nonconvulsive SE and aphasic SE, are difficult to classify. Frontal lobe nonconvulsive SE, relatively recently described, may occur in the form of SPSE or CPSE. The involvement of highly specialized association areas in aphasic SE can result in complex cognitive dysfunction; some of these cases may best be described as SPSE and others as CPSE. N F SE Nonconvulsive frontal SE is a relatively well-defined entity since the work of Williamson et al. (234), who found frontal lobe origin in five of eight patients with CPSE who were studied with depth electrodes, and by Rohr-Le Floch et al. (177), who described the principal characteristics of this syndrome based on 19 cases. Earlier reports employed terms such as “borderline cases of petit mal status” (92), “absence status with focal characteristics” (152), and “transitional petit mal status” (82). Nonconvulsive frontal SE is characterized by prolonged periods of cognitive disturbance associated with unilateral or bilateral frontopolar ictal discharges, at times accompanied by visible focal ictal signs (152, 177). In order to be diagnostic, the EEG must include an adequate number of channels and montages to record from anterior frontal regions (177). In 65 cases meeting these criteria and published since 1971 in 22 different papers (1, 27, 66, 69, 76, 92, 97, 119, 120, 126, 135, 143, 152, 164, 172, 177, 199, 201, 206, 212, 215, 234), the average age was 40 years (range, 13–84 years) and 59% of the patients were women. Patients with no previous history of epilepsy accounted for 36% of cases, and focal frontal lesions were found in 35%. Two electroclinical varieties can be described. The first is characterized by subtle disturbances of cognitive function associated with behavioral disturbances, such as disinhibition or even affective indifference with lack of spontaneous activity and emotionality (Figure 7.9). The neurologic examination shows only some perseveration and difficulty in the performance of complex motor tasks (120, 164, 177, 211, 212). The EEG shows unilateral and relatively localized
82
:
frontopolar ictal discharges. This type of frontal lobe nonconvulsive SE thus appears to be a variety of SPSE with affective or cognitive symptoms rather than a CPSE (211, 212). In the second type, a clear-cut alteration of consciousness occurs and is associated with ictal epileptiform activity involving both frontal regions simultaneously (Figure 7.10), or eventually developing into absence status from an initial frontopolar focus (1, 27, 119). The EEG then shows bilateral, asymmetric, paroxysmal activity (absence status with focal features; see Thomas et al., Chapter 8, this volume). In contrast to the first type, the electroclinical features are those of a CPSE of extratemporal origin. A SE Of the reported cases of aphasic SE (27, 32, 46, 50, 53, 77, 81, 85, 109, 111, 134, 136, 165, 168, 178, 210, 223), only a few (32, 46, 111, 178) meet the diagnostic criteria proposed in 1988 by Rosenbaum et al. (178): the patient must speak during seizures, the language produced must be aphasic (that is, nonfluent, dysnomic, or paraphasic), consciousness must be preserved, and the EEG must show a strict correlation between the ictal discharges and the aphasic episodes. In many patients (85, 210, 223, 229), the ictal episodes are characterized by negative aphasic signs consisting either of a suspension of speech or a reduction in fluency associated with abnormalities in comprehension of varying degree. The aphasic manifestations in the strict sense of the word are found only in the interictal period and appear to be a form of Todd’s paresis resulting from metabolic exhaustion of specific neuronal areas governing language (46). During the ictal period, it is often difficult to know if the suspension of language is indeed accompanied by aphasia or alteration of consciousness unless, as in the case report of Gilmore et al. (77), a test of syntactic comprehension is used. The validity of this test does not in fact depend on the ability to produce speech. Aphasic manifestations have also been reported in CPSE in the more general sense. These manifestations include periodic suspension of language, possibly representing speech arrest rather than aphasia (54, 140), expressive aphasia with intact comprehension associated with left frontotemporal ictal discharges (85), and, with left posterior temporal discharges, receptive or fluent aphasia, which may fluctuate (111) or be continuous (53). In a single case report (50), an isolated inability to vocalize was associated with right frontoparietal discharges. Such episodes have been reported with homonymous hemianopia (93, 94, 128) and even cortical blindness (61). The occurrence of a relatively pure aphasic nonconvulsive partial SE as described above, as well as the mixed syndromes, can explain at least partly why aphasic SE has been
F 7.9 Right frontal nonconvulsive SE in a 47-year-old man with symptomatic right frontal partial epilepsy related to a falx meningioma operated on 2 years earlier. Clinically, there was no confusion or alteration of awareness, only affective indifference with lack of spontaneous activity and emotion. The EEG shows
prolonged recurring trains of polyspike-and-wave discharges of progressively higher amplitude and lower frequency over the right frontal region, with phase reversals at electrode F4. Periods of flattening of the EEG indicate the beginning of a new run of discharges. Note that temporal regions are relatively untouched.
at times classified as SPSE and at other times as CPSE. According to one school of thought (72, 93, 182, 217), complete preservation of consciousness is one of the defining characteristics of aphasic SE. Another school (14, 53, 165, 177, 190) holds that when aphasic SE occurs in the form of repeated seizures with persisting disturbances of language during the interictal period, aphasic SE and CPSE are one and the same, with aphasic SE being simply one topographic variant of the other.
electroclinical correlations, followed by vigorous treatment of both seizures and causative factors, will prevent, in somatomotor SPSE, the evolution toward a life-threatening secondarily generalized SE, and in CPSE, the occurrence of serious memory or cognitive deficits. However, in this latter form, as noted by Kaplan et al. (105), a high degree of clinical suspicion is essential, especially in psychiatric or mentally retarded patients or in patients with acute cerebral lesions. It is hoped that better understanding of pathophysiologic mechanisms involved in CPSE, due to new imaging and neurophysiological techniques and neuropsychological ictal investigations, will aid in research to delineate the various anatomic networks underlying this heterogeneous but fascinating condition.
Comment Given the pleiomorphic clinical features of nonconvulsive SPSE and CPSE, these are some of the more difficult neurologic conditions to diagnose early in their course. The diagnostic cornerstone of these forms of SE remains the EEG. Emergency diagnosis of nonconvulsive SE is one of the main arguments for maintaining rapid access to EEG from the emergency department. An effective and rapid diagnostic management, allowing when necessary accurate
This work was supported in part by a grant from the Programme Hospitalier de Recherche Clinique, CHRU Nice, French Ministry of Health (P.T.). The authors thank M. J. Breloin for assistance with the figures, and Eva Paquet and Roula Vrentzos for preparing the English-languge translation.
, , :
83
F 7.10 First presentation of epilepsy in a 52-year-old woman in the form of bifrontal complex partial status epilepticus with recurring seizures. Clinically, a sustained confusional state was regularly interrupted every 5 minutes by slight turning of the head and eyes to the left, followed by complete loss of contact for 80–100 seconds. The EEG shows ictal discharges of the same duration over both frontotemporal regions. At the end of each train of
discharges, the return to the baseline confusional state was marked by an inappropriate smile. MRI was normal. Ictal SPECT showed hyperperfusion over the right frontobasal region. This instance of SE was particularly difficult to treat, requiring pentobarbital anesthesia, but the patient recovered without sequelae. (Reprinted with permission from Thomas et al. [212].)
REFERENCES 1. Aguglia, U., P. Tinuper, and G. Farnarier. Etat confusionnel critique à point de départ frontal chez le sujet âgé. Rev. EEG Neurophysiol. 1983;13:174–179. 2. Aicardi, J. Status epilepticus. In J. Aicardi, ed. Epilepsy in Children. 2nd ed. New York: Raven Press, 1996:284–309. 3. Al Tahan, A. Paradoxic response to diazepam in complex partial status epilepticus. Arch. Med. Res. 2000;31:101–104. 4. Ali, I. I., N. A. Pirzada, and B. V. Vaughn. Periodic lateralized epileptiform discharges after complex partial status epilepticus associated with increased focal cerebral blood flow. J. Clin. Neurophysiol. 2001;18:565–569. 5. Ambrosetto, G., P. Tinuper, and C. A. Tassinari. Marfan’s syndrome, recurrent complex partial status epilepticus and myoclonus: A case report. Clin. Electroencephalogr. 1988;19: 33–36. 6. Andermann, F. Epilepsia partialis continua and other seizures arising from the precentral gyrus: High incidence in patients with Rasmussen syndrome and neuronal migration disorders. Brain Dev. 1992;14:338–339. 7. Andermann, F., E. Lugaresi, G. S. Dvorkin, and P. Montagna. Malignant migraine: The syndrome of prolonged classical migraine, epilepsia partialis continua, and repeated strokes.
84
:
8.
9.
10.
11.
12.
13. 14.
A clinically characteristic disorder probably due to mitochondrial encephalopathy. Funct. Neurol. 1986;1:481–486. Andermann, F., and T. Rasmussen. Chronic encephalitis and epilepsy: An overview. In F. Andermann, ed. Chronic Encephalitis and Epilepsy: Rasmussen’s syndrome. Boston: ButterworthHeinemann, 1991:283–289. Antozzi, C., S. Franceschetti, G. Filippini, et al. Epilepsia partialis continua associated with NADH-coenzyme Q reductase deficiency. J. Neurol. Sci. 1995;129:152–161. Appleton, R. E., K. Farrell, P. Teal, S. A. Hashimoto, and P. K. Wong. Complex partial status epilepticus associated with cyclosporin A therapy. J. Neurol. Neurosurg. Psychiatry 1989; 52:1068–1071. Armon, C., G. W. Peterson, and B. H. Liwnicz. Alzheimer’s disease underlies some cases of complex partial status epilepticus. J. Clin. Neurophysiol. 2000;17:511–518. Armon, C., R. A. Radtke, and A. H. Friedman. Inhibitory simple partial (non-convulsive) status epilepticus after intracranial surgery. J. Neurol. Neurosurg. Psychiatry 2000;69:18–24. Ayala, H., and S. Stephenson. Status epilepticus amauroticus. Boll. Accad. Med. Roma 1929;55:288–290. Ballenger, C. E., D. W. King, and B. B. Gallagher. Partial complex status epilepticus. Neurology 1983;33:1545–1552.
15. Bancaud, J., A. Bonis, S. Trottier, J. Talairach, and O. Dulac. L’épilepsie partielle continue: Syndrome et maladie. Rev. Neurol. 1982;138:802–814. 16. Bancaud, J., and J. Talairach. Clinical semiology of frontal lobe seizures. In P. Chauvel, A. V. Delgado-Escueta, E. Halgren, and J. Bancaud, eds. Frontal Lobe Seizures and Epilepsy. Adv. Neurol. 1992;57:3–58. 17. Bansal, S. K., I. M. Sawhney, and J. S. Chopra. Epilepsia partialis continua in Sjögren’s syndrome. Epilepsia 1987;28: 362–363. 18. Barry, E., N. M. Sussmann, T. M. Bosley, and R. N. Harner. Ictal blindness and status epilepticus amauroticus. Epilepsia 1985;26:577–584. 19. Bartolomei, F., and J. L. Gastaut. Complex partial status epilepticus provoked by hyponatremia. Eur. Neurol. 1998; 40:53–54. 20. Bartolomei, F., J. Regis, A. Donnet, and J. L. Gastaut. Development of focal chronic epilepsy following focal status epilepticus in adult patients. Neurophysiol. Clin. 1999;29: 271–276. 21. Bauer, G. Psychische Veränderungen bei kontinuierlichen epileptischen Entladungen. Schweitz Arch. Neurol. Neurochir. Psychiatr. 1975;116:241–255. 22. Bauer, J., H. Stefan, W. J. Huk, et al. CT, MRI and SPECT neuroimaging in status epilepticus with simple partial and complex partial seizures: Case report. J. Neurol. 1989;236: 296–299. 23. Begemann, M., A. J. Rowan, and S. Tuhrim. Treatment of refractory complex-partial status epilepticus with propofol: Case report. Epilepsia 2000;41:105–109. 24. Behrens, J. M. Psychomotor status epilepticus masking as a stroke. Postgrad. Med. 1980;68:223–226. 25. Belafsky, M., S. Carwille, P. Miller, S. Waddell, J. BoxleyJohnson, and A. V. Delgado-Escueta. Prolonged epileptic twilight states: Continuous recordings with nasopharyngeal electrodes and video-tape analysis. Neurology 1978;28: 239–245. 26. Bequet, D., E. Bodiguel, J. L. Renard, and J. Goasguen. Etat de mal partiel complexe temporal. Rev. Neurol. 1990;146: 147–150. 27. Berkovic, S. F., F. Andermann, M. Aubé, R. M. Rémillard, and P. Gloor. Nonconvulsive confusional frontal status. Epilepsia 1985;26:529. 28. Biton, V., J. R. Gates, and L. De Padua Sussman. Prolonged postictal encephalopathy. Neurology 1990;40:963–966. 29. Blatt, I., S. Jackson, and R. M. Dashieff. Aphasic status epilepticus with reversible contrast enhancement on CT. Epilepsia 1992;33(Suppl. 3):S4. 30. Bogdanovic, M. D., D. Kidd, A. Briddon, J. S. Duncan, and J. M. Land. Late onset heterozygous ornithine transcarbamylase deficiency mimicking complex partial status epilepticus. J. Neurol. Neurosurg. Psychiatry 2000;69:813–815. 31. Bonduelle, M., C. Sallou, J. Guillard, and J. J. Gaussel. L’état de mal psychomoteur: Ses rapports avec les automatismes et les psychoses aiguës épileptiques. Rev. Neurol. 1964;110: 365–370. 32. Boudouresques, J., J. Roger, and H. Gastaut. Crises aphasiques subintrantes chez un épileptique temporal. Rev. Neurol. 1962;106:381–393. 33. Celesia, G. C. Modern concepts of status epilepticus. JAMA 1976;235:1571–1574. 34. Celesia, G. G., L. Parmeggiani, and M. Brigell. Dipole source localization in a case of epilepsia partialis continua without
35.
36.
37.
38.
39.
40.
41.
42.
43. 44.
45.
46.
47.
48.
49.
50.
51.
premyoclonic EEG spikes. Electroencephalogr. Clin. Neurophysiol. 1994;90:316–319. Cendes, F., F. Andermann, K. Silver, and D. L. Arnold. Imaging of axonal damage in vivo in Rasmussen’s syndrome. Brain 1995;118:753–758. Chalk, C. H., P. G. McManis, and G. D. Cascino. Cryptococcal meningitis manifesting as epilepsia partialis continua of the abdomen. Mayo. Clin. Proc. 1991;66:926–929. Chauvel, P., C. Liegeois-Chauvel, P. Marquis, and J. Bancaud. Distinction between the myoclonus-related potential and the epileptic spike in epilepsia partialis continua. Electroencephalogr. Clin. Neurophysiol. 1986;64:304–307. Chauvel, P., S. Trottier, J. P. Vignal, and J. Bancaud. Somatomotor seizures of frontal lobe origin. In P. Chauvel, A. V. Delgado-Escueta, E. Halgren, and J. Bancaud, eds. Frontal Lobe Seizures and Epilepsy. Adv. Neurol. 1992;57: 185–243. Cochin, J. P., D. Hannequin, T. Delangre, E. GueganMassardier, and P. Augustin. Epilepsie partielle continue revelatrice d’un diabete sucre. Rev. Neurol. 1994;150: 239–241. Cockerell, O. C., M. C. Walker, J. W. Sander, and S. D. Shorvon. Complex partial status epilepticus: A recurrent problem. J. Neurol. Neurosurg. Psychiatry 1994;57:835–837. Colamaria, V., V. Sgro, R. Caraballo, et al. Status epilepticus in benign rolandic epilepsy manifesting as anterior operculum syndrome. Epilepsia 1991;32:329–334. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489–501. Corin, S. Visual status epilepticus. Neurology 1974;23:434. Courjon, J., M. H. Fournier, and F. Mauguière. Les états de mal chez les épileptiques adultes suivis dans un hôpital neurologique. Rev. EEG Neurophysiol. 1984;14:175–179. Cowan, J. M., J. C. Rothwell, R. J. Wise, and C. D. Marsden. Electrophysiological and positron emission studies in a patient with cortical myoclonus, epilepsia partialis continua and motor epilepsy. J. Neurol. Neurosurg. Psychiatry 1986;49: 796–807. De Pasquet, E. G., E. S. Gaudin, A. Bianchi, and S. A. De Mendilaharsu. Prolonged and monosymptomatic dysphasic status epilepticus. Neurology 1976;26:244–247. DeGiorgio, C. M., P. S. Gott, A. L. Rabinowicz, C. N. Heck, T. D. Smith, and J. D. Correale. Neuron-specific enolase, a marker of acute neuronal injury, is increased in complex partial status epilepticus. Epilepsia 1996;37:606–609. Delgado-Escueta, A. V., and F. Enrile-Bacsal. Combination therapy for status epilepticus: Intravenous diazepam and phenytoin. In A. V. Delgado-Escueta, C. G. Wasterlain, D. M. Treiman, and R. J. Porter, eds. Status Epilepticus. Adv. Neurol. 1983;43:477–485. Delgado-Escueta, A. V., and D. M. Treiman. Focal status epilepticus: Modern concepts. In H. Lüders, and R. P. Lesser, eds. Epilepsy: Electroclinical Syndromes. London: Springer-Verlag, 1987:347–391. DeToledo, J. C., A. Minagar, and M. R. Lowe. Persisting aphasia as the sole manifestation of partial status epilepticus. Clin. Neurol. Neurosurg. 2000;102:144–148. DeToledo, J. C., and D. B. Smith. Partially successful treatment of Rasmussen’s encephalitis with zidovudine: Symptomatic improvement followed by involvement of the contralateral hemisphere. Epilepsia 1994;35:352–355.
, , :
85
52. Dexter, D. D., Jr., B. F. Westmoreland, and T. L. Cascino. Complex partial status epilepticus in a patient with leptomeningeal carcinomatosis. Neurology 1990;40:858–859. 53. Dinner, D. S., H. Lüders, R. Lederman, and T. E. Gretter. Aphasic status epilepticus: A case report. Neurology 1981; 31:888–890. 54. Drake, M. E., and J. E. Coffey. Complex partial status epilepticus simulating psychogenic unresponsiveness. Am. J. Psychiatry 1983;140:800–801. 55. Drislane, F. W. Evidence against permanent neurologic damage from nonconvulsive status epilepticus. J. Clin. Neurophysiol. 1999;14:323–331. 56. Drislane, F. W., A. S. Blum, and D. L. Schomer. Focal status epilepticus: Clinical features and significance of different EEG patterns. Epilepsia 1999;40:1254–1260. 57. Dunne, J. W., Q. A. Summers, and E. G. Stewart-Wynne. Nonconvulsive status epilepticus: A prospective study in an adult general hospital. Q. J. Med. 1987;62:117–126. 58. Egawa, I., J. Yamamoto, Y. Yamada, and Y. Hishikawa. Three epileptic patients suffering from period of frequent complex partial seizures and diagnostic criteria for epileptic status. Folia Psychiatr. Neurol. Jpn. 1984;38:111–120. 59. El-Ad, B., and M. Y. Neufeld. Periodic febrile confusion as a presentation of complex partial status epilepticus. Acta Neurol. Scand. 1990;82:350–352. 60. Emre, M. Palatal myoclonus occurring during complex partial status epilepticus. J. Neurol. 1992;239:228–230. 61. Engel, J., B. Ludwig, and M. Fetell. Prolonged partial complex status epilepticus: EEG and behavioral observations. Neurology 1978;28:863–869. 62. Escueta, A. V., J. Boxley, N. Stubbs, G. Wadell, and W. A. Wilson. Prolonged twilight state and automatisms: A case report. Neurology 1974;24:331–339. 63. Feinberg, T. E., D. M. Roane, and J. Cohen. Partial status epilepticus associated with asomatognosia and alien handlike behaviors. Arch. Neurol. 1998;55:1574–1576 [Published erratum appears in Arch. Neurol. 1999;56:24]. 64. Fejerman, N., and A. M. Di Blasi. Status epilepticus of benign partial epilepsies in children: Report of two cases. Epilepsia 1987;28:351–355. 65. Fitzek, S., S. Hegemann, D. Sauner, D. Bonsch, and C. Fitzek. Drug-induced nonconvulsive status epilepticus with low dose of tiagabine. Epileptic Disord. 2001;3:147–150. 66. Fujiwara, T., M. Watanabe, K. Matsuda, M. Senbongi, K. Yagi, and M. Seino. Complex partial status epilepticus provoked by the ingestion of alcohol: A case report. Epilepsia 1991;32:650–656. 67. Fusco, L., E. Bertini, and F. Vigevano. Epilepsia partialis continua and neuronal migration anomalies. Brain Dev. 1992; 14:323–328. 68. Fusco, L., and F. Vigevano. Reversible operculum syndrome caused by progressive epilepsia partialis continua in a child with left hemimegalencephaly. J. Neurol. Neurosurg. Psychiatry 1991;54:556–558. 69. Gall, M. V., G. Scollo-Lavizzari, and H. Becker. Absence status in the adult: New results including computerized transverse axial tomography. Eur. Neurol. 1978;17:121–128. 70. Gambardella, A., G. Pasquinelli, R. Cittadella, et al. Kufs’ disease presenting as late-onset epilepsia partialis continua. Neurology 1998;51:1180–1182. 71. Gastaut, H. À propos d’une classification symptomatique des états de mal épileptiques. In H. Gastaut, J. Roger, and H. Lob, eds. Les états de mal épileptiques. Paris: Masson, 1967:1–8.
86
:
72. Gastaut, H. Classification of status epilepticus. In A. V. Delgado-Escueta, C. G. Wasterlain, D. M. Treiman, and R. J. Porter, eds. Status Epilepticus. Adv. Neurol. 1983;34:83–92. 73. Gastaut, H. Clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1970;11:102–113. 74. Gastaut, H., J. Roger, and A. Roger. Sur la signification de certaines fugues épileptiques: A propos d’une observation électroclinique d’ “état de mal temporal.” Rev. Neurol. 1956;94: 298–301. 75. Gastaut, H., and C. A. Tassinari. Status epilepticus. In A. Remond, ed. Handbook of Electroencephalography and Clinical Neurophysiology. Vol. 13. Amsterdam: Elsevier, 1975:39–45. 76. Geier, S. Prolonged psychic epileptic seizures: A study of the absence status. Epilepsia 1978;19:431–445. 77. Gilmore, R. L., and K. M. Heilman. Speech arrest in partial seizures: Evidence of an associated langage disorder. Neurology 1981;31:1016–1019. 78. Glassman, J. N., D. Dryer, and J. R. McCartney. Complex partial status epilepticus presenting as gelastic seizures. Gen. Hosp. Psychiatry 1986;8:61–64. 79. Gloor, P. Consciousness as a neurological concept in epileptology: A critical review. Epilepsia 1986;27(Suppl. 2):S14–S26. 80. Granner, M. A., and S. I. Lee. Nonconvulsive status epilepticus: EEG analysis in a large series. Epilepsia 1994;35:42–47. 81. Grimes, D. A., and A. Guberman. De novo aphasic status epilepticus. Epilepsia 1997;38:945–949. 82. Guberman, A., G. Cantu-Reyna, D. Stuss, and R. Broughton. Nonconvulsive généralized status epilepticus: Clinical features, neuropsychological testing and long-term follow-up. Neurology 1986;36:1284–1291. 83. Hajek, M., A. Antonini, K. L. Leenders, and H. G. Wieser. Epilepsia partialis continua studied by PET. Epilepsy Res. 1991;9:44–48. 84. Hamanaka, T. Zum Problem des Status psychomotorische Anfälle. J. Clin. Psychiatry 1972;14:592–603. 85. Hamilton, N. G., and T. Matthews. Aphasia: The sole manifestation of focal status epilepticus. Neurology 1979;29: 745–748. 86. Hart, Y. M., M. Cortez, F. Andermann, et al. Medical treatment of Rasmussen’s syndrome (chronic encephalitis and epilepsy): Effect of high-dose steroids or immunoglobulins in 19 patients. Neurology 1994;44:1030–1036. 87. Heald, A., S. Connolly, and P. Hudgson. Neurosyphilis presenting as complex partial status epilepticus. Eur. Neurol. 1996;36:111–112. 88. Heintel, H. Status von tonischen Dämmerattacken. Arch. Psychiatr. Nervenkr. 1969;212:117–125. 89. Henriksen, G. F. Status epilepticus partialis with fear as clinical expression. Epilepsia 1973;14:39–46. 90. Henry, T. R., I. Drury, J. A. Brunberg, P. B. Pennell, P. E. McKeever, and A. Beydoun. Focal cerebral magnetic resonance changes associated with partial status epilepticus. Epilepsia 1994;35:35–41. 91. Hess, D. C., and K. D. Sethi. Epilepsia partialis continua in multiple sclerosis. Int. J. Neurosci. 1990;50:109–111. 92. Hess, R., G. Scollo-Lavizzari, and F. E. Wyss. Borderline cases of petit mal status. Eur. Neurol. 1971;5:137–154. 93. Hilkens, P. H. E., and A. W. De Weerd. Non-convulsive status epilepticus as cause for focal neurological deficit. Acta. Neurol. Scand. 1995;92:193–197. 94. Hojo, K., and Y. Fukushima. A case of partial status epilepticus with various neuropsychological symptoms. Folia Psychiatr. Neurol. Jpn. 1979;33:291–294.
95. Hosford, D. A. Animal models of nonconvulsive status epilepticus. J. Clin. Neurophysiol. 1999;16:306–313. 96. Huott, A. D., D. S. Madison, and E. Niedermeyer. Occipital lobe epilepsy: A clinical and electroencephalographic study. Eur. Neurol. 1974;11:325–339. 97. Inoue, Y., T. Fujiwara, K. Matsuda, et al. Ring chromosome 20 and nonconvulsive status epilepticus: A new epileptic syndrome. Brain 1997;120:939–953. 98. Isaacson, S. H., J. Carr, and A. J. Rowan. Ciprofloxacininduced complex partial status epilepticus manifesting as an acute confusional state. Neurology 1993;43:1619–1621. 99. Juul-Jensen, P., and D. Denny-Brown. Epilepsia partialis continua. Arch. Neurol. 1966;15:563–578. 100. Kanazawa, O., A. Sengoku, and I. Kawai. Oculoclonic status epilepticus. Epilepsia 1989;30:121–123. 101. Kanemoto, K., T. Tomikimi, and J. Kawasaki. Prolonged postictal confusion as a manifestation of continuous complex partial status epilepticus: A depth EEG study. Seizure 2000; 9:151–155. 102. Kaplan, P. W. Assessing the outcomes in patients with nonconvulsive status epilepticus: Nonconvulsive status epilepticus is underdiagnosed, potentially overtreated, and confounded by comorbidity. J. Clin. Neurophysiol. 1999;16:341–352. 103. Kaplan, P. W. Behavioral manifestations of nonconvulsive status epilepticus. Epilepsy Behav. 2002;3:122–139. 104. Kaplan, P. W. No, some types of nonconvulsive status epilepticus cause little permanent neurologic sequelae (or: “The cure may be worse than the disease”). Neurophysiol. Clin. 2000;30:377–382. 105. Kaplan, P. W. Nonconvulsive status epilepticus in the emergency room. Epilepsia 1996;37:643–650. 106. Kaplan, P. W. Prognosis in nonconvulsive status epilepticus. Epileptic Disord. 2000;2:185–193. 107. Karbowski, K. Status psychomotoricus: Klinische und electroencephalographische Aspekte. In K. Karbowski, ed. Status psychomotoricus und seine differential Diagnose. Bern: Verlag Hans Huber, 1980. 108. Katz, A., A. Bose, S. J. Lind, and S. S. Spencer. SPECT in patients with epilepsia partialis continua. Neurology 1990;40: 1848–1850. 109. Kirshner, H. S., T. Hughes, T. Fakhoury, and B. Abou-Khalil. Aphasia secondary to partial status epilepticus of the basal temporal language area. Neurology 1995;45:1616–1618. 110. Kitagawa, T., K. Takahashi, K. Matsushima, and R. Kawahara. A case of polonged confusion after temporal lobe psychomotor status. Folia Psychiatr. Neurol. Jpn. 1979;33: 279–284. 111. Knight, R. T., and J. Cooper. Status epilepticus manifesting as reversible Wernicke’s aphasia. Epilepsia 1986;27:301–304. 112. Kojevnikov, A. Y. A particular type of cortical epilepsy (epilepsia corticalis sive partialis continua). In F. Andermann, ed. Chronic Encephalitis and Epilepsy: Rasmussen’s Syndrome. Boston: Butterworth-Heinemann, 1991:245–262. 113. Komsuoglu, S. S., M. Ozmenoglu, C. Ozcan, and H. Gurhan. Complex partial status epilepticus. Clin. Electroencephalogr. 1988;19:167–171. 114. Kramer, R. E., H. Luders, R. P. Lesser, et al. Transient focal abnormalities of neuroimaging studies during focal status epilepticus. Epilepsia 1987;28:528–532. 115. Krsek, P., A. Mikulecka, R. Druga, Z. Hlinak, H. Kubova, and P. Mares. An animal model of nonconvulsive status epilepticus: A contribution to clinical controversies. Epilepsia 2001;42:171–180.
116. Krieger, A. C., and M. Takeyasu. Nonconvulsive status epilepticus in theophylline toxicity. J. Toxicol. Clin. Toxicol. 1999;37:99–101. 117. Krumholz, A. Epidemiology and evidence for morbidity of nonconvulsive status epilepticus. J. Clin. Neurophysiol. 1999; 16:314–322. 118. Krumholz, A., G. Y. Sung, R. S. Fisher, E. Barry, G. K. Bergey, and L. M. Grattan. Complex partial status epilepticus accompanied by serious morbidity and mortality. Neurology 1995;45:1499–1504. 119. Kudo, T., K. Sato, K. Yagi, and M. Seino. Can absence status epilepticus be of frontal lobe origin? Acta Neurol. Scand. 1995:92:472–477. 120. Kugoh, T., and K. Hosokawa. Mental dullness associated with left frontal continuous focal discharges. Folia Psychiatr. Neurol. Jpn. 1977;31:473–480. 121. Kuzniecky, R., S. Berkovic, F. Andermann, D. Melanson, A. Olivier, and Y. Robitaille. Focal cortical myoclonus and rolandic cortical dysplasia: Clarification by magnetic resonance imaging. Ann. Neurol. 1988;23:317–325. 122. Kuzniecky, R., and R. Powers. Epilepsia partialis continua due to cortical dysplasia. J. Child Neurol. 1993;8:386–388. 123. Lansberg, M. G., M. W. O’Brien, A. M. Norbash, M. E. Moseley, M. Morrell, and G. W. Albers. MRI abnormalities associated with partial status epilepticus. Neurology 1999; 52:1021–1027. 124. Lee, B. I., B. C. Lee, Y. M. Hwang, et al. Prolonged ictal amnesia with transient focal abnormalities on magnetic resonance imaging. Epilepsia 1992;33:1042–1046. 125. Leff, A. P., A. W. McNabb, M. G. Hanna, C. R. Clarke, and A. J. Larner. Complex partial status epilepticus in late-onset MELAS. Epilepsia 1998;39:438–441. 126. Lim, L., P. Yagnik, P. Schraeder, and S. Wheeler. Ictal catatonia as a manifestation of non convulsive status epilepticus. J. Neurol. Neurosurg. Psychiatry 1986;49:833–836. 127. Litt, B., R. J. Wityk, S. H. Hertz, P. D. Mullen, H. Weiss, D. D. Ryan, and T. R. Henry. Nonconvulsive status epilepticus in the critically ill elderly. Epilepsia 1998;39: 1194–1202. 128. Lugaresi, E., P. Pazzaglia, and C. A. Tassinari. Differentiation of “absence status” and “temporal lobe status.” Epilepsia 1971;12:77–87. 129. Lukovitz, T. G., C. E. Fadul, J. M. Pipas, and P. D. Williamson. Nonconvulsive status epilepticus after intravenous contrast medium administration. Epilepsia 1996;37: 1117–1120. 130. Manford, M., and S. D. Shorvon. Prolonged sensory or visceral symptoms: An under-diagnosed form of nonconvulsive focal (simple partial) status epilepticus. J. Neurol. Neurosurg. Psychiatry 1992;55:714–716. 131. Manning, D. J., and L. Rosenbloom. Non-convulsive status epilepticus. Arch. Dis. Child. 1987;62:37–40. 132. Maria, B. L., D. M. Ringdahl, J. P. Mickle, et al. Intraventricular alpha interferon therapy for Rasmussen’s syndrome. Can. J. Neurol. Sci. 1993;20:333–336. 133. Markand, O. N., G. L. Wheeler, and S. L. Pollack. Complex partial status epilepticus (psychomotor status). Neurology 1978;28:189–196. 134. Marrosu, F., A. Brundu, M. G. Rachele, and G. Marrosu. Epileptic aphasia as dynamic disturbance: A case report. Acta Neurol. (Naples) 1983;5:43–46. 135. Masnou, P., F. Salefranque, H. Megas, and J. N. Vidart. Activité critique subintrante et épilepsie frontale: Rôle dans
, , :
87
136.
137.
138. 139.
140.
141. 142.
143.
144.
145.
146.
147.
148. 149. 150.
151.
152.
153.
154.
155. 156.
88
la genèse de troubles du comportement. Epilepsies 1995;6: 235–239. Matsumoto, A., T. Takeuchi, and T. Kumagai. A case of complex partial status epilepticus: Serial EEGs and clinical symptoms change. J. Jpn. Epilepsy Soc. 1986;4:48–57. Matsuoka, H., T. Okuoma, T. Ueno, and H. Saito. Impairment of parietal cortical functions associated with episodic prolonged spike-and-wave discharges. Epilepsia 1986;27: 432–436. Mayeux, R., P. Alexander, D. F. Benson, J. Brandt, and J. Rosen. Poriomania. Neurology 1979;29:1616–1619. Mayeux, R., and H. Lüders. Complex partial status epilepticus: Case report and proposal for diagnostic criteria. Neurology 1978;28:957–961. McBride, M. C., E. C. Dooling, and E. V. Oppenheimer. Complex partial status epilepticus in young children. Ann. Neurol. 1981;9:526–530. McLachlan, R. S., and W. Blume. Isolated fear in complex partial status epilepticus. Ann. Neurol. 1980;8:639–641. McLachlan, R. S., J. P. Girvin, W. T. Blume, and H. Reichman. Rasmussen’s chronic encephalitis in adults. Arch. Neurol. 1993;50:269–274. Melamed, E., S. Lavy, Z. Argov, and M. Feinsod. Absence and automatisms associated with an orbitofrontal meningioma. J. Clin. Psychiatry 1979;40:44–45. Meo, R., L. Bilo, S. Striano, P. Ruosi, A. Estranero, and C. Nocerino. Transient global amnesia accompanied by fever. Seizure 1995;4:311–317. Mikati, M., W. Lee, and G. R. Delong. Protracted epileptiform encephalopathy: An unusual form of partial complex status epilepticus. Epilepsia 1985;26:563–571. Mueller, S. G., S. S. Kollias, A. H. Trabesinger, A. Buck, P. Boesiger, and H. G. Wieser. Proton magnetic resonance spectroscopy characteristics of a focal cortical dysgenesis during status epilepticus and in the interictal state. Seizure 2001;10:518–524. Munari, C., M. Soncini, P. Brunet, et al. Sémiologie électroclinique des crises temporales subintrantes. Rev. EEG Neurophysiol. 1985;15:289–298. Murasaki, M. Psychomotor status: Case report and proposal for classification. Folia Psychiatr. Neurol. Jpn. 1979;33:353–357. Murasaki, M., and A. Takahashi. Complex partial status epilepticus. Jpn. J. Psychiatry 1988;42:515–519. Musolino, R., L. Marabello, P. De Domenico, et al. Complex partial status epilepticus simulating an ischemic insult: Case report. Ital. J. Neurol. Sci. 1991;12:207–210. Nakada, T., H. Lee, I. L. Kwee, and A. M. Lerner. Epileptic Kluver-Bucy syndrome: Case report. J. Clin. Psychiatry 1984;45:87–88. Niedermeyer, E., F. Fineyre, T. Riley, and S. Uematsu. Absence status (petit mal status) with focal characteristics. Arch. Neurol. 1979;36:417–421. Nyquist, P. A., G. D. Cascino, and M. Rodriguez. Seizures in patients with multiple sclerosis seen at Mayo Clinic, Rochester, Minn, 1990–1998. Mayo Clin. Proc. 2001;76: 983–986. Noachtar, S., A. Ebner, O. W. Witte, and R. J. Seitz. Palatal tremor of cortical origin presenting as epilepsia partialis continua. Epilepsia 1995;36:207–209. Obeso, J. A., J. C. Rothwell, and C. D. Marsden. The spectrum of cortical myoclonus. Brain 1985;108:193–224. Oguni, H., F. Andermann, and T. B. Rasmussen. The natural history of the syndrome of chronic encephalitis and epilepsy:
:
157.
158. 159.
160.
161.
162.
163.
164.
165. 166.
167.
168.
169.
170.
171.
172.
173.
174.
175.
A study of the MNI series of forty-eight cases. In F. Andermann, ed. Chronic Encephalitis and Epilepsy: Rasmussen’s Syndrome. Boston: Butterworth-Heinemann, 1991:7–36. Ogunyemi, A. O., G. E. Locke, L. D. Kramer, and L. Nelson. Complex partial status epilepticus provoked by “crack” cocaine. Ann. Neurol. 1989;26:785–786. Oller-Daurela, L. Les crises épileptiques psychiques de longue durée. Rev. Neuropsychiatr. Infant 1970;18:548–557. Omorokov, L. I. Kojevnikov’s epilepsy in Siberia. In F. Andermann, ed. Chronic encephalitis and epilepsy: Rasmussen’s syndrome. Boston: Butterworth-Heinemann, 1991:263–270. Palem, R., L. Force, and J. Esvan. Hallucinations critiques epileptiques et délire (à propos d’un état de mal oculoclonique). Ann. Med. Psychol. 1980;2:161–190. Palmini, A., A. Gambardella, F. Andermann, et al. Intrinsic epileptogenicity of human dysplastic cortex as suggested by corticography and surgical results. Ann. Neurol. 1995;37: 476–487. Passouant, P., N. Duc, J. Cadilhac, and J. Mienvielle. Accès confusionnel de longue durée et décharge épileptique temporale au cours d’une paralysie générale. Rev. Neurol. 1957;96: 229–332. Piccinelli, P., R. Borgatti, E. Perucca, A. Tofani, G. Donati, and U. Balottin. Frontal nonconvulsive status epilepticus associated with high-dose tiagabine therapy in a child with familial bilateral perisylvian polymicrogyria. Epilepsia 2000; 41:1485–1488. Picornell Darder, I., M. Conde, and J. Carbonell. Etat de mal post-traumatique à symptomatologie uniquement psychique. Rev. EEG Neurophysiol. 1978;8:341–344. Primavera, A., G. P. Bo, and S. Venturi. Aphasic status epilepticus. Eur. Neurol. 1988;28:255–257. Primavera, A., C. Solaro, and L. Cocito. De novo status epilepticus as the presenting sign of neurosyphilis. Epilepsia 1998;39:1367–1369. Pritchard, P. B., and D. B. O’Neal. Nonconvulsive status epilepticus following metrizamide myelography. Ann. Neurol. 1984;16:252–254. Racy, A., M. A. Osborn, B. A. Vern, and G. F. Molinari. Epileptic aphasia: First onset of prolonged monosymptomatic status epilepticus in an adult. Arch. Neurol. 1980;37:419–422. Rasmussen, T., J. Olzewski, and D. L. Lloyd-Smith. Focal seizures due to chronic localized encephalitis. Neurology 1958;8:435–445. Rees, J. H., S. J. Smith, D. M. Kullmann, N. P. Hirsch, and R. S. Howard. Creutzfeldt-Jakob disease presenting as complex partial status epilepticus: A report of two cases. J. Neurol. Neurosurg. Psychiatry 1999;66:406–407. Reuber, M., J. Evans, and J. M. Bamford. Topiramate in drugresistant complex partial status epilepticus. Eur. J. Neurol. 2002;9:111–112. Rey, M., and J. J. Papy. Etats d’obnubilation critique d’origine frontale: Un diagnostic clinique difficile. Rev. EEG Neurophysiol. 1987;17:377–385. Roberts, M. A., and P. R. Humphrey. Prolonged complex partial status epilepticus: A case report. J. Neurol. Neurosurg. Psychiatry 1988;51:586–588. Roger, J., H. Lob, and C. A. Tassinari. Status epilepticus. In O. Magnus, and A. M. Lorentz de Haas, eds. Handbook of Clinical Neurophysiology. Vol. 15. The Epilepsies. Amsterdam: North Holland, 1974:145–188. Rogers, D., J. Bird, and P. Eames. Complex partial status after starting vigabatrin. Seizure 1993;2:155–156.
176. Rogers, S. W., P. I. Andrews, L. C. Gahring, et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen’s encephalitis. Science 1994;265:648–651. 177. Rohr-Le Floch, J., G. Gauthier, and A. Beaumanoir. Etats confusionnels d’origine épileptique: Intérêt de l’EEG fait en urgence. Rev. Neurol. 1988;144:425–436. 178. Rosenbaum, D. H., M. Siegel, M. A. Barr, and A. J. Rowan. Epileptic aphasia. Neurology 1986;36:822–825. 179. Russell, D., I. M. Anke, R. Nyberg-Hansen, O. Slettnes, O. Sortland, and T. Veger. Complex partial status epilepticus following myelography with metrizamide. Ann. Neurol. 1980;8: 325–327. 180. Sacquegna, T., P. Pazzaglia, A. Baldrati, P. De Carolis, R. Gallassi, and M. Maccheroni. Status epilepticus with cognitive symptomatology in a patient with partial complex epilepsy. Eur. Neurol. 1981;20:319–325. 181. Schindler, B. A., and D. Ramchandani. Partial complex status epilepticus in a lithium-toxic patient. Psychosomatics 1993;34: 521–524. 182. Scholtes, F. B., W. O. Renier, and H. M. Meinardi. Nonconvulsive status epilepticus: Causes, treatment, outcome in 65 patients. J. Neurol. Neurosurg. Psychiatry 1996;61:93–95. 183. Schomer, D. L. Focal status epilepticus and epilepsia partialis continua in adults and children. Epilepsia 1993;34(Suppl. 1):S29–S36. 184. Scott, J. S., and R. L. Masland. Occurrence of “continuous symptoms” in epileptic patients. Neurology 1952;2:297–301. 185. Semel, J. D. Complex partial status epilepticus presenting as fever of unknown origin. Arch. Intern. Med. 1987;147: 1571–1572. 186. Shalev, R. S., and N. Amir. Complex partial status epilepticus. Arch. Neurol. 1983;40:90–92. 187. Shavit, Y. B., F. Graus, A. Probst, R. Rene, and A. J. Steck. Epilepsia partialis continua: A new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis. Ann. Neurol. 1999;45:255–258. 188. Shibasaki, H., Y. Yamashita, S. Tobimatsu, and R. Neshige. Electroencephalographic correlates of myoclonus. Adv. Neurol. 1986;43:357–372. 189. Shinnar, S., A. T. Berg, D. M. Treiman, W. A. Hauser, D. C. Hesdorffer, J. C. Sackellares, I. Leppik, M. Sillanpää, and K. W. Sommerville. Status epilepticus and tiagabine therapy: Review of safety data and epidemiologic comparisons. Epilepsia 2001;42:372–379. 190. Shorvon, S. Complex partial status epilepticus. In S. Shorvon, ed. Status Epilepticus: Its Clinical Features and Treatment in Children and Adults. Cambridge, U.K.: Cambridge University Press, 1994:116–130. 191. Shorvon, S. Definition, classification and frequency of status epilepticus. In S. Shorvon, ed. Status Epilepticus: Its Clinical Features and Treatment in Children and Adults. Cambridge, U.K.: Cambridge University Press, 1994:21–30. 192. Shorvon, S. Epilepsia partialis continua. In S. Shorvon, ed. Status Epilepticus: Its Clinical Features and Treatment in Children and Adults. Cambridge, U.K.: Cambridge University Press, 1994:84–98. 193. Shorvon, S. Nonconvulsive simple partial status epilepticus. In S. Shorvon, ed. Status Epilepticus: Its Clinical Features and Treatment in Children and Adults. Cambridge, U.K.: Cambridge University Press, 1994:110–116. 194. Singh, B. M., and R. J. Strobos. Epilepsia partialis continua associated with nonketotic hyperglycemia: Clinical and biochemical profile in 21 patients. Ann. Neurol. 1980;8:155–160.
195. Skodda, S., I. Kramer, J. F. Spittler, and W. Gehlen. Nonconvulsive status epilepticus in two patients receiving tiagabine add-on treatment. J. Neurol. 2001;248:109–112. 196. Sowa, M. V., and S. Pituck. Prolonged spontaneous complex visual hallucinations and illusions as ictal phenomena. Epilepsia 1989;30:524–526. 197. Steg, R. E., A. R. Frank, and D. M. Lefkowitz. Complex partial status epilepticus in a patient with dural metastases. Neurology 1993;43:2389–2392. 198. Steinhoff, B. J., and K. M. Eckardt. Clinical and EEG findings in complex partial status epilepticus with tiagabine. Seizure 1999;8:197. 199. Striano, S., F. Barbieri, L. Bilo, P. Ruosi, and M. Soricellis. Recurrent frontal status epilepticus with polymorphic clinical features: A case report. Acta Neurol (Naples) 1990;12:193–199. 200. Sztriha, L., L. Pavics, and E. Ambrus. Epilepsia partialis continua: Follow-up with 99mTc-HMPAO-SPECT. Neuropediatrics 1994;25:250–254. 201. Takeda, A. Complex partial status epilepticus of frontal lobe origin. Jpn. J. Psychiatry 1988;42:525–530. 202. Tarsy, D., and S. C. Schachter. Botulinum toxin treatment is not effective for epilepsy partialis continua. Mov. Disord. 1995;10:357–358. 203. Tatum, W. O., M. R. Sperling, and J. G. Jacobstein. Epileptic palatal myoclonus. Neurology 1991;41:1305–1306. 204. Terzano, M. G., L. Parrino, A. Mazzuchi, and G. Moretti. Confusional states with periodic lateralized epileptiform discharges (PLEDs): A peculiar epileptic syndrome in elderly. Epilepsia 1986;27:446–457. 205. Thomas, J. E., T. J. Reagan, and D. W. Klass. Epilepsia partialis continua: A review of 32 cases. Arch. Neurol. 1977;34:266–275. 206. Thomas, P., and F. Andermann. Absence status in elderly patients is most often situation-related. In A. Malafosse, P. Genton, E. Hirsch, C. Marescaux, D. Broglin, and R. Bernasconi, eds. Idiopathic Generalized Epilepsies: Clinical, Experimental and Genetic Aspects. London: John Libbey, 1994:95–109. 207. Thomas, P., P. Barrès, and M. Chatel. Complex partial status epilepticus of extra-temporal origin: Report of a case. Neurology 1991;41:1147–1149. 208. Thomas, P., M. Borg, G. Suisse, and M. Chatel. Opercular myoclonic-anarthric status epilepticus. Epilepsia 1995;36: 281–289. 209. Thomas, P., K. Giraud, H. Alchaar, and M. Chatel. Ictal asomatognosia with hemiparesis. Neurology 1998;51:280–282. 210. Thomas, P., B. Kullmann, and M. Chatel. Etat de mal épileptique à expression aphasique. Rev. Neurol. 1991;147: 246–250. 211. Thomas, P., and Y. Mottin. Etat de mal frontal non convulsif. Rev. Neurol. 1997;153:421–426. 212. Thomas, P., B. Zifkin, O. Migneco, C. Lebrun, J. Darcourt, and F. Andermann. Nonconvulsive status epilepticus of frontal origin. Neurology 1999;52:1174–1183. 213. Tinuper, P., U. Aguglia, S. Laudadio, and H. Gastaut. Prolonged ictal paralysis: Electroencephalographic confirmation of its epileptic nature. Clin. Electroencephalogr. 1987;18:12–14. 214. Tomson, T., U. Lindbom, and B. Y. Nilsson. Nonconvulsive status epilepticus in adults: Thirty two consecutive patients from a general hospital population. Epilepsia 1992;33: 829–835. 215. Tomson, T., E. Svanborg, and J. E. Wedlund. Nonconvulsive status epilepticus: High incidence of complex partial status. Epilepsia 1986;27:276–285.
, , :
89
216. Treiman, D. M. Electroclinical features of status epilepticus. J. Clin. Neurophysiol. 1995;12:343–362. 217. Treiman, D. M., and A. V. Delgado-Escueta. Complex partial status epilepticus. In A. V. Delgado-Escueta, C. G. Wasterlain, D. M. Treiman, and R. J. Porter, eds. Status Epilepticus. Adv. Neurol. 1983;34:69–81. 218. Treiman, D. M., and A. V. Delgado-Escueta. Status epilepticus. In R. A. Thompson, and J. R. Green, eds. Critical Care in Neurologic and Neurosurgical Emergencies. New York: Raven Press, 1980:53–99. 219. Treiman, D. M., A. V. Delgado-Escueta, and M. A. Clark. Impairment of memory following complex partial status epilepticus. Neurology 1981;31(Suppl. 4):S109. 220. Trinka, E., T. Moroder, M. Nagler, W. Staffen, W. Loscher, and G. Ladurner. Clinical and EEG findings in complex partial status epilepticus with tiagabine. Seizure 1999;8: 41–44. 221. Van Rossum, J., and A. A. W. Groeneveld-Ockhuysen. Psychomotor status. Arch. Neurol. 1985;42:989–993. 222. Varma, N. K., and S. I. Lee. Nonconvulsive status epilepticus following electroconvulsive therapy. Neurology 1992;42: 263–264. 223. Vernea, J. Partial status epilepticus with speech arrest. Proc. Austr. Assoc. Neurol. 1974;11:223–228. 224. Villemure, J. G., F. Andermann, and T. Rasmussen. Hemispherectomy for the treatment of epilepsy due to chronic encephalitis. In F. Andermann, ed. Chronic Encephalitis and Epilepsy: Rasmussen’s Syndrome. Boston: ButterworthHeinemann, 1991:235–244. 225. Vining, E. P., J. M. Freeman, J. Brandt, B. S. Carson, and S. Uematsu. Progressive unilateral encephalopathy of childhood (Rasmussen’s syndrome): A reappraisal. Epilepsia 1993;34: 639–650. 226. Wakai, S., M. Ikehata, H. Nihira, et al. “Obtundation status (Dravet)” caused by complex partial status epilepticus in a patient with severe myoclonic epilepsy in infancy. Epilepsia 1996;37:1020–1022. 227. Watanabe, K., Y. Kuroiwa, and Y. Toyokura. Epilepsia partialis continua: Epileptogenic focus in motor cortex and its participation in transcortical reflexes. Arch. Neurol. 1984;41: 1040–1044. 228. Weiner, R. DECT-induced status epilepticus and further ECT: A case report. Am. J. Psychiatry 1981;138:1237–1238. 229. Wells, C. R., D. R. Labar, and G. E. Solomon. Aphasia as the sole manifestation of simple partial status epilepticus. Epilepsia 1992;33:84–87. 230. Wieser, H. G. Temporal lobe or psychomotor status epilepticus: A case report. Electroencephalogr. Clin. Neurophysiol. 1979; 48:558–572. 231. Wieser, H. G., H. P. Graf, C. Bernouilli, and J. Siegfried. Quantitative analysis of intracerebral recordings in epilepsia partialis continua. Electroencephalogr. Clin. Neurophysiol. 1977;44: 14–22. 232. Wieser, H. G., S. Hailemariam, M. Regard, and T. Landis. Unilateral limbic epileptic status activity: Stereo EEG, behavioural and cognitive data. Epilepsia 1985;26:19–29. 233. Wieser, H. G., H. Hungerbüler, A. M. Siegel, and A. Buck. Musicogenic epilepsy: Review of the literature and case report with ictal single photon emission tomography. Epilepsia 1997;38:200–207. 234. Williamson, P. D., D. D. Spencer, S. S. Spencer, et al. Complex partial status epilepticus: A depth electrode study. Ann. Neurol. 1985;18:647–654.
90
:
235. Wolf, P. Zur Klinik und Psychopathologie des Status psychomotoricus. Nervenartz 1970;41:603–610. 236. Zappoli, R., G. Zaccara, L. Rossi, G. Arnetoli, and A. Amantini. Combined partial temporal and secondary generalised status epilepticus: Report of a case with fear bouts followed by prolonged confusion. Eur. Neurol. 1983;22: 192–204.
8
Absence Status
, ,
Introduction Status epilepticus may be classified for practical purposes into convulsive status epilepticus, which must be rapidly stopped to prevent death or neurologic sequelae, and nonconvulsive status epilepticus (NCSE), in which the diagnosis is not obvious and must be confirmed by urgent electroencephalography (EEG). NCSE may be further classified into nonconfusional and confusional forms (100, 183). Nonconfusional NCSE is characterized by various somatosensory, visual, auditory, psychic, or vegetative symptoms that by definition occur without any impairment of consciousness. Confusional NCSE, by contrast, is characterized by some degree of clouding of consciousness. NCSEs are classically also divided on the basis of the ictal EEG into absence status epilepticus (ASE) and complex partial status epilepticus (CPSE). CPSE is characterized by continuous or rapidly recurring complex partial seizures that may involve temporal or extratemporal regions, or both (see Thomas et al., Chapter 7, this volume). ASE is the most frequent form of NCSE and often constitutes a diagnostic challenge. By definition, it is accompanied by predominantly symmetric synchronous ictal discharges and has heterogeneous clinical and EEG manifestations.
Historical perspective Well before the advent of EEG, nonconvulsive confusional states were recognized as epileptic by Pritchard, Trousseau, Jackson, Wilks, Colman, and Clark and Prout (166). In one of his Tuesday lectures in January 1888, Charcot described a healthy 37-year-old deliveryman with episodes of prolonged automatisms during which he walked from place to place throughout Paris. Charcot believed that this “poriomania,” or prolonged ambulatory fugue state, was related to an epileptic breakdown of consciousness (33, 74) and later proposed a trial of potassium bromide, an early antiepileptic drug. In 1927, Ratner described for the first time a confusional state lasting several hours in a child with pyknoleptic absence (93). Ratner recognized the ictal nature of this confusion and considered it a form of SE. In 1938, several years after the introduction of the EEG, W. G. Lennox recorded periods of continuous spike-and-wave discharges and altered level of consciousness, after insulin-induced hypoglycemia in one of his cousins, a child with absence epilepsy. Lennox
believed that this represented very brief absences in rapid succession without a return to the usual level of consciousness, and in 1945 he suggested the term Petit Mal status to describe this pattern (113, 114). The first case of ASE documented in a young adult had been published three years earlier by Putnam and Merritt in 1941 (150).
Concepts of absence status and problems in terminology and classification P M S For about a decade following the original description by Lennox, the term Petit Mal status was used without further qualification in several isolated case reports (17, 71, 103, 125, 153). Interest in this syndrome then appeared to wane until the work of Niedermeyer and Kalifeh (130), who reported that during ASE, the alteration of consciousness seemed to be less profound than that noted during typical absence attacks. Similarly, the EEG expression of these was also atypical, consisting of spike-and-wave discharges that were neither as regular nor as continuous as those of absence seizures. Also, these epileptic confusional states could appear in patients with severe epilepsy associated with mental retardation. These authors preferred the less specific and more descriptive term spike-wave stupor rather than Petit Mal status. Lob expressed similar reservations in his doctoral thesis (120, 121). The term Petit Mal status suggested that the patient had a preexisting but well-characterized type of epilepsy, the “Petit Malabsence,” now described as childhood absence epilepsy (36). However, it became clear that these forms of SE could occur in patients whose epilepsy manifested with seizure types other than absence seizures and who had no history of idiopathic generalized epilepsy, and even in patients with no history of epilepsy. Moreover, the term Petit Mal status implied, according to Lennox’s original description, a clinical pattern limited to prolonged or serial typical absence attacks that were sufficiently close together to give rise to a prolonged disturbance of consciousness, and an EEG pattern limited to the classic ictal 3-Hz spike-and-wave pattern. The problems arising from use of the term Petit Mal status, the variety of clinical presentations, the etiologic and pathogenic questions raised by these events, and the lack of precise definitions of the terms used may explain the extraordinary development in the 1950s and 1960s of new names for what were very similar clinical entities. Shorvon
, , :
91
(164, 165) referred to this situation as a “nosographic labyrinth.” Some of these terms included “prolonged epileptic twilight state with almost continuous wave-spikes” (201), “prolonged alterations in behavior associated with a continuous EEG spike-and-dome abnormality” (24), “epilepsia minoris continua” (59), “simple epileptic confusional state” (66), “prolonged behavioral disturbance as ictal phenomena” (75), “spike-wave stupor, ictal stupor” (130), and “minor status epilepticus” (28). T A A S In an attempt to unify the concept, the Commission on Classification and Terminology of the International League Against Epilepsy in 1970 retained the term absence status, which Gastaut, Roger, and Lob had proposed in October 1962 during the Xth Marseilles Colloquium (63–65). This term was also adopted by the expert committee of the World Health Organization in the Dictionary of Epilepsy (66). The definition of absence status was intentionally loose: a prolonged or repeated absence seizure, thus representing status epilepticus. Clinically, AS is essentially or exclusively characterized by impairment of consciousness of varying intensity, persisting hours to days, occasionally leading to an epileptic fugue. The EEG findings exceptionally consist of continuous or discontinuous rhythmic 3 Hz SW discharges similar to those encountered in typical absence seizures; more often one finds more or less rhythmic SW or polyspike-wave (PSW) discharges sometimes interrupted by slow background activity.
Unfortunately, despite Gastaut’s efforts at unification, terminological confusion continued. Although many authors adopted the term absence status without reservation (7, 32, 61, 68, 76, 109, 124, 129, 132, 152, 164), semantic disorder persisted, and many new terms appeared after 1970, among them “centrencephalic condition of prolonged disturbance of consciousness” (81), “ictal psychosis” (197), “prolonged confusion as an ictal state” (52), “acute prolonged ictal confusion” (188), and “generalized nonconvulsive status epilepticus” (79). Although the Commission on Classification and Terminology (63–65) advised against use of the term Petit Mal status, it continued to be widely used in scientific reports (8, 14, 45, 49, 69, 70, 87, 102, 134, 136, 155, 160, 171, 192). This term has become familiar and is encountered to the present day, especially informally among neurologists. Finally, a third group of authors took an approach to definition that was diametrically opposed to that of Gastaut and used the term absence status literally, reserving it only for those episodes of SE made up of a succession of typical absence attacks, and used other terms, such as Petit Mal status (145), spike-wave stupor (11, 37, 156), or generalized nonconvulsive status epilepticus (79), to describe any other electroclinical forms. This only led to greater difficulties in terminology and classification.
92
:
In a further attempt at clarification, Gastaut suggested at the 1983 Santa Monica Colloquium a new classification of AS (65), distinguishing “typical” AS, with an excellent prognosis, occurring in patients with idiopathic generalized epilepsy and characterized by a simple confusional state with rhythmic 3-Hz spike-and-wave discharges, and “atypical” absence status, occurring mainly in patients with symptomatic and/or cryptogenic generalized epilepsy. This atypical variety could be conceptualized as a transient exacerbation of the epileptic symptomatology superimposed on a chronic epileptogenic encephalopathy, such as the Lennox-Gastaut syndrome (13). Episodes of atypical AS were characterized by periods of confusion accompanied by more marked motor manifestations and associated with spike-and-wave discharges slower than 3 Hz, with a variable rhythmicity and regularity (65). Moreover, these atypical AS episodes were clearly distinguishable from typical AS episodes by their associated clinical features, including pseudoataxia and/or pseudodementia, their prolonged duration (several days or several weeks), their tendency to recur, and their pronounced resistance to treatment, benzodiazepines usually being ineffective (44, 60, 137, 169). Gastaut thus suggested the clinical and nosographic limits of these two types of AS, but the two forms could at times occur in the same patient. This was further described by Beaumanoir et al. (13) in the Lennox-Gastaut syndrome and by Brotkorb et al. (30) in mentally retarded adults, leading to further attempts at subclassification of atypical AS, which have unfortunately been little used since (163, 164). N C U C Newly reported cases that could not be correctly classified added yet further difficulties. New terms were again proposed by several authors: “borderline petit mal status” (87), “transitional petit mal status” (164), and “absence status with focal characteristics” (129). These events were occasionally encountered in patients with localization-related epilepsy and were characterized by EEG patterns with focal features that were considered too significant to justify their classification within the group of generalized epilepsies (61, 87, 129). This “imperfectly generalized” ictal pattern was compared to the focalictal discharges of CPSE (see Thomas et al., Chapter 7, this volume) and helped blur the distinctions between the two entities. New theoretical pathophysiologic mechanisms were discussed, mainly based on the works of Tükel and Jasper in Montreal and on stereo-EEG (depth electrode) studies by Bancaud and Talairach in Paris, who demonstrated that a single epileptic focus could give rise to secondary bilaterally synchronous discharges, particularly when this focus involved mesial-frontal structures (10, 138, 186). Several authors had indeed emphasized the similarities between certain forms of AS and CPSE of frontal origin (3,
61, 155, 176, 179). These similarities are probably not fortuitous: several reports show the transformation from CPSE with frontopolar focal ictal discharges into an AS with a perfectly bilateral and symmetric EEG pattern (2, 19, 109, 129, 157, 172, 176). These occasional but well-documented reports may explain the development of AS with “generalized” discharges during the course of an extratemporal localization-related epilepsy, especially of frontal lobe origin (9, 109, 176). “D N” A S L O A further group of patients was described in which AS first occurred in elderly subjects with no previous history of seizures. In 1964, Shev underlined the rarity of AS in adults (162). Isolated cases were described by Elian (51) and by Amand (5). In 1971, Schwartz and Scott (161) published four cases of AS appearing “de novo” in middle-aged or elderly adults with no previous history of seizures. They suggested that these cases could represent “the extreme end of a continuum of petit mal epilepsy extending from childhood to middle age.” However, later observations showed that this is not usually so. Since 1971, about 100 such patients have been described in the literature (11, 26, 37, 48, 52, 54, 55, 70, 76, 86, 109, 110, 114, 133, 146, 148, 152, 156, 172, 173, 175, 178, 179, 186–190, 193, 196, 197). Different designations have been used: “isolated petit mal status presenting de novo in middle age” (85, 160), “senile petit mal epilepsy” (133), “de novo minor status epilepticus of late onset” (11), “toxic ictal confusion in middle age” (186, 187), and “de novo absence status of late onset” (55, 172, 173, 175). The average age of the patients is in the sixth decade, and there is a clear preponderance of women. Many of the subjects have preexisting psychiatric symptoms. In three-quarters of the cases, the AS occurs with a toxic or metabolic systemic disorder (173, 187). Among triggering factors, psychotropic drugs seem to be prominent and were present in 39 individuals in a series of 79 such patients (172). The AS may occur with high doses of psychotropic drugs or with a sudden withdrawal of the medication: several reports have emphasized the role of benzodiazepine withdrawal (48, 94, 175). A combination of factors such as a simultaneous toxic and metabolic encephalopathy is characteristic. These data indicate that “de novo” AS is more often an acute symptomatic seizure rather than the late resurgence of a hypothetical childhood absence epilepsy. This clinical entity is thus probably best designated situation-related AS and should be included in the current syndromic classification of the epilepsies (36) among the “special syndromes—situation-related seizures” (165, 173, 186). C C A S The pathophysiology of ASE is not well understood, and it would
therefore be misleading to classify these events according to rigid clinical criteria. Like absence seizures, ASE can occur within a broad neurobiologic continuum and can complicate virtually any epileptic syndrome (1, 18). We believe that it is preferable to conceptualize the different forms of ASE as individual events within the natural history of a particular form of epilepsy, although certain forms may represent the beginning of an encephalopathy that manifests clinically with episodes of ASE. The prognostic implications of ASE are thus related more to the epileptic syndrome within which they occur than to the electroclinical characteristics of the episodes themselves. We believe that four types of ASE may be recognized (Figure 8.1): typical absence status (or Petit Mal status), atypical absence status (or spike-wave stupor); de novo absence status of late onset (situation-related nonconvulsive status epilepticus), and absence status with focal features. However, it must be clearly recognized that the vast majority of cases appear to be transitional forms between these better defined clinical entities. Typical absence status Typical AS occurs as part of an idiopathic generalized epilepsy most often characterized by absences. Isolated impairment of consciousness, at times with subtle jerks of the eyelids, is the essential symptom. The EEG correlates with repetitive absence seizures and shows symmetric and bilaterally synchronous spike-and-wave or polyspike-and-wave complexes faster than 3 Hz (Figure 8.2), but this pattern is often not strictly maintained as the event continues. The immediate prognosis is excellent: intravenous (IV) benzodiazepine injection stops the AS. Atypical absence status Atypical AS occurs in patients with symptomatic or cryptogenic epilepsies and is characterized by a fluctuating confusional state with more prominent tonic and/or myoclonic and/or lateralized ictal manifestations than occur in typical AS (138). The EEG shows continuous or intermittent diffuse irregular slow spike-and-wave or polyspike-and-wave complexes (Figure 8.3). The immediate prognosis is guarded, as these episodes tend to recur and to be resistant to medication. De novo absence status of late onset This condition is characterized by toxic or metabolic precipitating factors leading to seizures in middle-aged or elderly subjects with no previous history of attacks. Patients often have a history of psychiatric illness with multiple psychotropic drug intake. The electroclinical characteristics (Figure 8.4) and the immediate prognosis are variable. These episodes of AS generally represent acute symptomatic seizures and may not recur if the triggering factors can be controlled or corrected. Long-term antiepileptic drugs thus may not be needed.
, , :
93
F 8.1 The nosography of absence status. Most cases represent transitional forms between the four distinct and well-defined clinical entities.
Absence status with focal features This condition occurs in subjects with a preexisting or newly developing localizationrelated epilepsy, most often of extratemporal origin. The EEG shows bilateral but often asymmetric ictal discharges (Figure 8.5). Many of these cases may represent CPSE of frontal lobe origin (176), and the EEG may not conclusively distinguish these from AS, especially late in the episode. The immediate prognosis is variable but is reportedly poor in critically ill elderly patients (116).
Epidemiology Lob et al. (121) found that of 148 patients collected by 1962, 93% had preexisting epilepsy, and 92% of these patients had a form of idiopathic generalized epilepsy. Nevertheless, only 16% of these had only absence seizures. Only 11 patients had
94
:
no history of epilepsy. Porter and Penry (146) found that 85% of patients had preexisting epilepsy. Of the patients discussed by Rohr-Le Floch et al. (156), 78% had preexisting epilepsy, and all of these had idiopathic generalized epilepsy. Dalby (40) found that 6.2% of patients with idiopathic generalized epilepsy had had episodes of AS. Patients with absences more often had AS (9.3%) than those who did not (3.4%). In patients with childhood- and adolescence-onset absence epilepsy, the incidence of AS has varied: 5.8% of patients according to Loiseau and Cohadon (122), 9.9% for Livingston et al. (118), 28.3% for Lorentz de Haas and Magnus (123), 37.7% for Oller-Daurella (140). However, with a 100 per million prevalence of absence epilepsy and a 1% occurrence of AS in these patients, Shorvon estimated the annual incidence of typical AS to be very low, occurring in about 1 per million persons in the general population (164).
F 8.2 Typical absence status in a 15-year-old girl with juvenile absence epilepsy. AS followed withdrawal of valproate and administration of carbamazepine. The only clinical signs were cognitive slowing and subtle eyelid myoclonus. The EEG shows bursts
of 3-Hz polyspike-and-wave activity organized in brief absences lasting 4–6 seconds. The EEG was almost normal between these bursts.
AS has been reported in SCGE such as the LennoxGastaut syndrome in 15%–40% of patients (46, 140). Other studies (13, 47) show that almost all these patients have periods of epileptic confusional states at one time or another. In a mentally handicapped population, the annual incidence of NCSE is estimated at 100–200 cases per million (166). No reliable data are available to estimate the occurrence of de novo AS of late onset. Studies from emergency wards of general hospitals in which EEG is immediately available, generally in cities of 1 million or more, describe two to five new cases per year (155, 158, 178, 179).
in some patients with CPSE of presumed amygdalohippocampal origin (181).
Clinical features The cardinal clinical sign of AS is variable clouding of consciousness, ranging from subtle subjective impairment of thought processes to severe stupor with incontinence. Subtle motor signs are seen in half the patients. In 90% of cases the confusional symptoms fluctuate, this fluctuation being most marked when the level of consciousness is relatively well preserved (155). This fluctuation is an important factor in favor of the ictal nature of the confusional state. However, impairment of consciousness in AS is never clearly organized in a cyclic and a discontinuous way, as may be observed
C C Although the alteration of consciousness in AS is best represented by a continuum (7), recognition of four grades of severity in disturbance of consciousness (120, 154, 164) may be useful in clinical practice. This classification was based on the largest series of AS, the 148 cases collected at the time of the 1962 Marseilles Colloquium (62). Slight clouding Slight clouding of consciousness is present in 19% of cases. This consists of simple slowing of thought processes and expression, often so subtle that only the patient himself can recognize it. There is no true mental confusion (8, 144). Patients with recurrent AS may learn to recognize these periods, which may be defined as “bad days” or described as “a lack of efficiency” or “the inability to perform at a normal level” (7). Lennox (113) reported the case of a physician who continued his work but felt himself unable to make difficult diagnoses during his episodes. Dongier (43) described a businessman who was able to drive his car but recognized that he was unable to brake soon enough before an obstacle.
, , :
95
F 8.3 Atypical absence status in a 15-year-old boy with Lennox-Gastaut syndrome. His head and eyes were slightly turned to the right and he was moderately confused, with periocular myoclonia and hypersalivation. The EEG shows almost continuous
irregular bilateral 2-Hz spike-and-wave complexes with left centrotemporal predominance. IV benzodiazepines and phenytoin were ineffective. Only high-dose IV methylprednisolone (5 mg/kg) led to cessation of the episode. This AS episode lasted 16 days.
Patients with the mildest degree of disturbance have no apparent psychological disturbance, are oriented in time and space, and are able to speak fluently. They are aware of what is happening to them and are not amnestic for their periods of AS. Shorvon (164) noted the frequent and striking dissociation between these mild clinical manifestations and the impressive ictal EEG abnormalities. Although these patients are able to carry on with typical activities of daily living, they are unable to normally perform complex intellectual tasks involving choices, strategy, planning, or initiative. A patient described by Rigal et al. (154) attempted to take the bus to work despite a transport strike, eventually reached her office, and worked throughout the morning. The only unusual thing her colleagues noted was that she did not stop for lunch at noon. Some of the mild
manifestations of intellectual dysfunction may be expressed as somatic symptoms, particularly headache: one of our patients reported a 2-day history of unusual moderate frontal tension-like headache that immediately disappeared when her AS ceased with IV benzodiazepine (unpublished personal observation). Formal neuropsychological testing, in one report including dichotic listening (57), may be necessary to document mild degrees of altered consciousness in AS (133, 196). In our experience, the Stroop test, which requires sustained attention, is sensitive and quickly administered (75). Roger, Lob, and Tassinari (155) noted that the most sensitive neuropsychological tests in AS were those requiring sustained attention, sequencing of tasks, and spatial ability. Neuropsychological deficits may also suggest a more localized
96
:
F 8.4. De novo AS in a 50-year-old man with no history of epilepsy, occurring after withdrawal of benzodiazepines (clorazepate, 200 mg/d; lorazepam, 12.5 mg/d; triazolam, 2 mg/d). He
was stuporous and confused, with eyelid myoclonia. The EEG shows continuous slow diffuse irregular polyspike-and-wave complexes. AS stopped 12 hours after a 50-mg oral dose of clorazepate.
disturbance (69, 164), typically with sparing of language, unlike some cases of CPSE. Vuillemier et al. (196) described a patient with pronounced isolated pure retrograde amnesia.
clumsily and slowly, and sequential tasks are usually interrupted more because of attention difficulties than because of a true apraxia. Automatic behavior of variable complexity may occur during these periods of confusion, which are otherwise marked by a global reduction of activity. Simple gestural automatisms are frequent. More elaborate motor patterns, which appear to represent a combination of complex automatisms and the behavioral disturbance caused by the clouding of consciousness, are associated with perseverative and compulsive features, a highly suggestive feature of AS. One of our patients repeatedly tried to put her fingers into electrical outlets. Another patient began his episode of AS while leaving the psychiatric ward; as a gesture of farewell, he repeatedly kissed his nurse on the cheek over 15 times. These complex automatisms may occasionally be responsible for prolonged fugue states (poriomania) which may
Marked clouding of consciousness Marked clouding of consciousness is most typical and is reported in 64% of cases. A frank confusional state occurs, with disturbance of alertness, attention, memory, judgment, and language, and with some agnosia and apraxia. The patients are severely disoriented. They are usually calm, immobile, and indifferent, with little or no spontaneous language or motor activity. Simple commands are obeyed only after repeated requests, often correctly but very slowly and after some delay. Patients are usually unable to follow more complex commands. Language is reduced to fragmented, hesitant, and at times irrelevant responses interrupted by long pauses. Echolalia and palilalia may be present. Motor tasks are performed
, , :
97
F 8.5. AS with focal characteristics, possibly frontal CPSE, in a 55-year-old woman with cryptogenic left frontocentral epilepsy. She was moderately confused, with some emotional disinhi-
bition, echolalia, and palilalia. The EEG shows bilateral 1.5-Hz slow spike-and-wave complexes with clear left frontotemporal predominance.
sometimes have an explicit goal. A patient of Friedlander and Feinstein (60) suddenly left his home and went directly to the EEG laboratory. At times some of these behaviors may cause legal problems; examples include compulsive masturbation (92), episodes of disrobing in public (59), and destructive behavior (7). In these cases there is a variable degree of amnesia for the confusional episode. When the AS is characterized by marked fluctuations, the patient can often report fragmented memories of events during the episode.
A S Myoclonus Myoclonus is the most frequent and most suggestive associated sign, occurring in about half of cases (155, 156). It is an important diagnostic clue, as it does not occur in CPSE (156). A history of myoclonic episodes associated with confusion can suggest a retrospective diagnosis of AS, especially in patients with preexisting IGE. The myoclonus of AS is characterized by bilateral jerks of the eyelids or face, most often subtle and intermittent, and more easily diagnosed with the patient’s eyes closed. Mann and Leslie (126) emphasized “vibration of the eyelashes.” Myoclonic jerks may occasionally involve the arms and hands. This may be asymmetric, falsely suggesting a localization-related SE (155). Rarely, they may be so marked as to dominate the presentation, overlapping clinically with myoclonic SE (171, 185). Two episodes of AS documented in patients with juvenile myoclonic epilepsy were characterized by myoclonus just like the patients’ typical morning myoclonic jerks (106). Epileptic negative myoclonus may also be intermingled with the positive myoclonic jerks (unpublished personal observation).
Profound clouding of consciousness Profound clouding of consciousness is reported in 7% of cases. Even with vigorous stimulation, only very brief and limited motor or verbal responses can be elicited. The patients remain motionless. They are frequently incontinent, cannot move without help, and are unable to feed themselves. Lethargic stupor Lethargic stupor is reported in 8% of cases. This resembles catatonic stupor with apparent suspension of all psychic activity. Patients are motionless, with eyes turned upward, and are incontinent of urine and stool. They are completely dependent and react only to strong, painful stimulation.
98
:
Other clinical manifestations Psychiatric manifestations have been reported in atypical AS. These include aggressive behavior, hallucinations, illusions, experiential phenomena, and psychotic depression (7, 43, 56, 75, 89). These symptoms are very unusual and, if present, are never as marked as those that occur in CPSE (156).
Establishing the diagnosis When a reliable clinical history can be obtained and the beginning of the confusional state is reportedly sudden, its epileptic nature may be suspected. However, for obvious reasons, continuous EEG documentation prior to hospitalization is very rare. Primary or secondarily generalized tonic-clonic seizures may appear at the beginning (7, 12, 54, 79) or more classically at the end of ASE. When the seizures occur at the onset, the unusually long duration of the presumed postictal confusional period should raise a suspicion of the diagnosis, and EEG should therefore be performed urgently. Convulsive seizures may also occur during the course of an episode of ASE (7). The delay in diagnosis is often long. Rohr-Le Floch et al. (156) found that the correct diagnosis was made at the time of initial clinical examination in only 4 of 60 cases (7%). In 18 (30%) of 60 cases, the diagnosis was a prolonged postictal state. In recent series (95, 172), delays in diagnosis ranged from 8 hours to 4 days. As noted by Kaplan (100), the altered mental status of ASE may be attributed to a metabolic disturbance or to excessive psychotropic drug use or withdrawal, each of which may also induce AS. In these cases, impaired consciousness can result in a combination of ASE and encephalopathy, and it may be impossible to assess the relative part played by these two factors. Furthermore, in SCGE, subtle worsening of cognitive impairment may be difficult to discern in a patient with mental retardation. In most cases, nonictal events are first suspected before the diagnostic EEG is obtained. Even when NCSE is suspected, ASE may be clinically indistinguishable from CPSE, especially of frontal lobe origin. The most frequent initial diagnoses have included prolonged postictal confusion, prolonged postictal encephalopathy, various psychiatric diagnoses such as depression, acute or interictal psychoses, Ganser’s syndrome, puerperal psychosis, and hysteria; medication overdose or idiosyncratic reaction to antiepileptic drugs, toxic or metabolic encephalopathy, overdose of psychotropic drugs, psychotropic drug withdrawal, amnesia or automatisms related to a short-acting benzodiazepine, transient global amnesia, frontal lobe stroke, aphasia, and transient unresponsiveness in the elderly (23, 80, 84, 95, 156, 158, 178, 179). A catatonic state clinically similar to ASE and reversed by IV benzodiazepines, but without EEG abnormalities, and a similar state during ifosfamide-induced
confusion were reported by Louis and Pflaster (123) and by Simonian et al. (166), respectively. In recent years, several papers in the literature have tended to lump together NCSE, subtle SE, myoclonic SE, and EEG patterns suggestive of SE in comatose patients (93, 108). For instance, Mayer et al. included seven patients with “nonconvulsive status epilepticus” in “comatose or obtunded patients” (127), and among the patients studied by Towne et al. (180), 8% of comatose patients had “an EEG pattern suggestive of SE,” a pattern whose validity has been challenged by Benbadis et al. (15). This conceptual extension appears to have been caused by some degree of misinterpretation of EEG findings. Prominent generalized paroxysmal activity in comatose patients is usually the expression of a very severe encephalopathy rather than of NCSE (131). As proposed by Kaplan (98, 101), the term electrographic SE in coma is more appropriate, in its neutrality, to characterize generalized seizure activity in deeply obtunded patients with severe brain injury. Similarly, “subtle” SE (182), the extreme end of an untreated or insufficiently treated generalized tonic-clonic SE with minimal clinical expression, cannot and must not be confused with NCSE because the context of occurrence, clinical features, prognosis, and treatment are dramatically different. Severe mental confusion in ASE may express itself as catatonia, but this presentation is radically different from a comatose state.
EEG, therapeutic trial of benzodiazepines, and immediate use of other drugs Emergency EEG is the key to confirmation of the diagnosis of AS. EEG confirms the ictal nature of the confusion and settles issues of differential diagnosis. The main practical problem is to think of the diagnosis and to rapidly obtain the EEG: Kaplan notes that in most instances, “the diagnosis was all too evident in retrospect, and frequently missed or delayed initially” (100). Timely diagnosis of NCSE is one of the main reasons for maintaining rapid access to EEG from the emergency ward (104). EEG C A S The essential EEG feature of AS is a bilateral, synchronous, symmetric paroxysmal activity that is unreactive to sensory stimulation. The most characteristic tracings show continuous trains or frequently repeated bursts of polyspike-and-slow-wave complexes or slow spike-and-wave complexes that are diffuse, rhythmic, and nonreactive (179). The EEG manifestations may nevertheless be so variable that, as Porter and Penry (145) noted, “virtually any generalized continuous or nearly continuous abnormality could be a substrate for this syndrome.” Roger, Lob, and Tassinari (154) found that half of the cases of ASE in patients with idiopathic generalized
, , :
99
epilepsy had continuous, usually rhythmic, bilaterally synchronous and symmetric spike-and-wave or polyspike-andwave discharges with a bifrontal predominance and a frequency between 1.5 and 3 Hz. More rarely, the discharges were discontinuous and broken up into bursts separated by more or less normal background rhythms. Continuous spikeand-wave activity could also become discontinuous during the same EEG recording. Only rarely does the spike-and-wave activity occur at precisely 3 Hz. In 80% of cases it ranges from 1 to 2.5 Hz. Granner and Lee (77) reported on 59 patients with ASE whose paroxysmal activity ranged in frequency from 1.0 to 3.5 Hz, with a mean of 2.2 ± 0.6 Hz. Only 7% had an ictal EEG pattern of typical absence. One-fourth of the patients showed some focal predominance of their paroxysmal activity. More rarely, the spike-and-wave activity may be unusually rapid, from 4 to 6 Hz (61), or unusually slow, slower than 1 Hz (87). Other variants of the ictal epileptiform activity include irregular slow spike-and-wave activity (17), slow waves with sporadic spike-and-wave complexes (154, 177), rhythmic triphasic slow waves (160, 198), and a polyspike
F 8.6 A positive diagnostic and therapeutic trial of IV benzodiazepines in an 82-year-old woman with de novo AS. The EEG shows continuous irregular polyspike-and-slow-wave activity which
100
10–20 Hz recruiting rhythm (113, 151). Polygraphic recording in patients with SCGE (167) shows that this last variant may also occur with subtle tonic SE associated with confusion. In these unusual EEG presentations, correct identification of AS is a challenging problem, given the fact that any rhythmic EEG activity recorded during a confusional state does not inevitably correspond to AS (15). There is no clear correlation between the degree of altered consciousness and the EEG. Stupor may, however, be more frequently associated with the pattern of continuous rhythmic 3-Hz spike-and-wave activity (164). T T B The IV injection of a benzodiazepine during the EEG recording is mandatory in order to confirm the ictal nature of the episode (Figure 8.6). There may indeed be difficulties in distinguishing true ictal epileptiform EEG patterns from interictal or nonictal EEG discharges (101), such as, for example, runs of triphasic sharp waves in hepatic encephalopathy (Figure 8.7). We use 10-mg ampules of diazepam or 1-mg ampules of clonazepam (not available in the United States). The injection must be given slowly in successive boluses over
stops 140 seconds after injection of 1 mg of clonazepam. Her level of consciousness returned to normal.
:
F 8.7 A false diagnosis of absence status in a 43-year-old stuporous woman with idiopathic generalized epilepsy and posthepatitic cirrhosis. The correct diagnosis was acute hyperammonemic encephalopathy (arterial ammonia, 453 mmol/L) related to valproate and preexisting chronic hepatic failure. The EEG
shows rapid generalized spike-and-wave discharges on a background of diffuse rhythmic runs of 2-Hz triphasic slow waves. IV benzodiazepines had no effect on the EEG and the clinical condition. Discontinuation of valproate led to total recovery without sequelae.
30–60 seconds each and must produce rapidly progressive disappearance of the paroxysmal activity, leading to normalization of the EEG; spike-and-wave or polyspike-andwave discharges are typically replaced by low-amplitude diffuse beta activity (see Figure 8.6). The effective doses are usually relatively low. An average of 3.8 mg of diazepam has been reported (77). Normalization of the EEG must also be associated with disappearance of the confusion, which may be dramatic when immediate or may take minutes or even hours in elderly patients. For a therapeutic trial to be considered successful, both EEG and clinical normalization must occur. Recording must be continued for at least 60 minutes after EEG normalization to detect any early recurrence of ASE, and follow-up recording is needed if there is any later alteration of consciousness, to diagnose any possible recurrence of ASE. The clinical improvement is usually clear-cut and remarkable. In cases with very mild clouding of consciousness, we
recommend administering two sets of cognitive tasks, one prior to injection and the second 60 minutes later. We used a standardized battery of tasks that can be performed in less than 20 minutes, including orientation in time and place, personal information, digit span, serial 7s subtraction, the Stroop test, copy and recall of the Rey-Osterreith Complex Figure, and reproduction of rhythmic alternative drawings inspired by some of Luria’s figures (174). Each subtest is semiquantitatively scored from 0 to 5. A significant improvement should occur following benzodiazepine injection. If IV access is not available, or if there is a high risk of respiratory depression in an elderly patient, a single oral dose of 1 mg/kg of clobazam, a rapidly absorbed benzodiazepine, has been proposed as an alternative (67), though we have also used lower doses (Figure 8.8). With this regimen, clinical and EEG improvement is often noticeable after approximately 10 minutes and complete cessation of the AS usually occurs within 15–30 minutes. There are usually
, , :
101
F 8.8 A positive diagnostic and therapeutic trial of oral clobazam, 0.5 mg/kg, in an 81-year-old woman with AS and respiratory insufficiency. The EEG shows arrhythmic generalized
polyspike-and-slow-wave activity that stopped 90 minutes after the oral intake of a single 30-mg dose of clobazam.
no noticeable effects on vigilance, and respiratory depression does not occur. Other antiepileptic drugs may be used with similar results, including IV lorazepam (95), parenteral valproate (34, 72, 97), phenytoin (6), phenobarbital (120), and propofol (38). The prolonged use of propofol may, however, cause severe or lethal systemic complications in children and must be avoided (16, 27, 82). IV valproate may avoid some of the morbidity of repeated doses of a benzodiazepine or prolonged infusions of propofol: for children in AS, a loading dose of 20 mg/kg has been suggested, followed by maintenance infusion of 1 mg/kg/hr in noninduced patients and 2 mg/kg/hr in those taking multiple drugs (88). The potential neurologic morbidity of ASE, which is most often a relatively benign event, especially with typical ASE, must be weighed against the possible morbidity of IV antiepileptic drugs, and overtreatment must be avoided (98). AS may recur following IV benzodiazepine. This may be treated by a further dose of benzodiazepine or with a second antiepileptic drug (IV valproate, phenytoin, or fosphenytoin). In our personal series, as also noted by Granner and Lee, recurrence seems more frequent when the ASE is associated with asymmetric EEG manifestations, suggesting the
possibility of secondary bilateral synchrony with an initial localized onset (77, 172). A paradoxical worsening of the electroclinical picture has been reported in the atypical ASE of the Lennox-Gastaut syndrome after benzodiazepine injection (117).
102
Etiologic factors in absence status Endocrine factors appear important in women of childbearing age. The catamenial period (120, 128), pregnancy (49), the immediate postpartum period (14, 37), and menopause (154) have all been implicated. Drug-related factors are clearly important in many cases, particularly but not exclusively in de novo ASE of late onset. Many authors (48, 79, 95, 96, 146, 172, 186) suggest an etiologic role for psychotropic medication either taken in excess, alone or in association with other drugs, or during rapid drug withdrawal (55). Many psychotropic drugs have been implicated, in order of frequency and probable causality: benzodiazepines, neuroleptics (especially butyrophenones), tricyclic antidepressants, lithium, meprobamate, viloxazine, methaqualone, barbiturates, and monoamine oxidase inhibitors. In a patient whose ASE had been caused by with-
:
drawal of several psychotropic medications, including a benzodiazepine, the injection of flumazenil led to a transient worsening of the AS (173). Many cases have also been reported to occur in relation to other drugs. Only some of these are known to lower the convulsive threshold: bemegride and metrazol (120), theophylline (190), cyclosporin (42), ifosfamide (166, 198), baclofen (200), metformin (26, 79), cimetidine (186), ceftazidine (106), diuretics (26), and piperazine (58). Cases have been reported with the use of antiepileptic drugs, including one during a valproate-related encephalopathy that was partially reversed by flumazenil (168). Therapeutic concentrations of carbamazepine and/or phenytoin may exacerbate idiopathic generalized epilepsy in the specific form of AS (140). This paradoxical response seems to be a particular risk for patients with absences, underscoring the value of an adequate syndromic approach (29, 140). More recently, tiagabine has been implicated in episodes of atypical AS in patients with intractable partial seizures: excess GABA-mediated thalamic inhibition has been proposed to explain this, with GABA receptors playing a critical role, as shown by the ability of baclofen to induce AS (50, 53, 200). However, in most cases, EEG data were not really convincing of the ictal nature of the disorder, and this issue remains controversial (162). True syndromic aggravation related to tiagabine use has also been associated with typical AS in IGE (107). Metabolic disturbances, either isolated or associated with drugs, are frequently reported: hyponatremia (26, 52), hypocalcemia (21, 191), hypoglycemia (79, 113), hypokalemia (26), decompensated chronic renal or hepatic failure (21, 52, 192), psychogenic polydipsia with metabolic imbalance (52), and cobalamin deficiency (2). Metrizamide deserves special mention. Five cases of AS have been reported following the use of this agent during myelography (4, 135, 148, 193), and one case after carotid angiography (190). A single case was recently described after intrathecal fluorescein injection (35). Other nonspecific triggering factors have also been reported occasionally and the mechanism by which they lead to AS is speculative: alcohol (52, 86, 186), antiepileptic drug withdrawal (110), hyperventilation (25, 68, 83, 112), intermittent photic stimulation (112), television (112), and electroconvulsive therapy (78, 120). Cases following surgery (7, 39), mild head trauma (7, 115), severe head trauma (79), fever (79), cancer (52, 152), neurosyphilis (147), stress, grief, or fatigue were typically associated with disturbances of the sleep-wake cycle (7, 79, 120). Genetic factors may also be implicated (29). In contrast to the number and variety of possible etiologic factors, no focal lesions have ever been seen in AS on imaging studies. However, elderly patients often show mild to moderate cortical-subcortical atrophy with frontal pre-
dominance, presumably of vascular or degenerative origin. It has been suggested that various toxic and/or metabolic factors may express themselves more easily in brains structurally damaged by such nonspecific lesions (61). An isolated case report of atypical AS has been reported in the context of a syndrome of increased intracranial pressure and transient MRI abnormalities (31). Another patient with newonset AS had unilateral frontal hyperperfusion on ictal single-photon emission computerized tomography (172). AS has been associated with other neurologic syndromes. Inoue et al. (91), reported six cases of ring chromosome 20 (RC 20) and epilepsy with prolonged confusional states resistant to antiepileptic drugs associated with bilateral highvoltage ictal slow waves, occasionally beginning with focal frontal EEG activity. They proposed that this constituted a new syndrome (90). In a recent video-EEG study of three patients with RC 20, bifrontal rythmic sharp or slow waves was the main EEG pattern (143). AS was also recently described in a child with the congenital bilateral perisylvian syndrome (170), in patients with “eyelid myoclonia with absences” syndrome (195), in the “perioral myoclonias with absences” syndrome (22, 141, 198), and in another syndrome of “idiopathic generalized epilepsy with phantom absences” of undetermined onset (142).
Natural history of absence status and long-term treatment The spontaneous duration of each episode of AS is variable and ranges from about half an hour to several weeks (7, 66, 95). Most episodes last from 6 to 72 hours, only exceptionally exceeding 1 week (39, 66). In most typical cases, spontaneous cessation of the ASE is sudden, with striking clinical improvement. Some patients fall asleep and awaken normal. However, the episode most often ends in a tonic-clonic convulsion. ASE generally has no effect on the natural history of any preexisting epilepsy, though Wirrell et al. suggest that it is a factor predicting that childhood absence epilepsy will not remit (201). In idiopathic generalized epilepsy, the occurrence of ASE appears to have no appreciable effect on subsequent seizure frequency, and the patients’ cognition and mentation remain normal, as recently reviewed by Drislane (47, 97). The influence of ASE on the cognitive prognosis in SCGE is not as clear. In most instances AS does not appear to have any significant effect (118, 154). This is, however, a subject of debate. Doose and Völzke believe that repetitive ASE may aggravate intellectual deterioration in children with myoclonic-astatic epilepsy (45). Manning and Rosenbloom described 13 children with atypical ASE followed by a deterioration in their mental handicap, suggesting aggressive treatment for their epilepsy (127). Some adult patients were
, , :
103
reported to show significant increases in neurospecific enolase, a marker of neuronal damage (41, 150). ASE has an inconsistent tendency to recur. Most patients do not have recurrent ASE, some have a few episodes, and others have a marked tendency to experience recurrence despite antiepileptic drugs. Andermann and Robb described a man with idiopathic generalized epilepsy who had had more than 500 episodes of ASE between the ages of 40 and 65 years (7). When ASE occurs with a preexisting idiopathic generalized epilepsy, the drug of choice to prevent recurrence is valproate (20, 89): in a series of 18 patients with idiopathic generalized epilepsy, the rate of recurrent attacks during a 4.4-year period was reduced with valproate from 5.7 to 0.6 attacks per year (20). Trimethadione, ethosuximide, phenytoin, barbiturates, and carbamazepine have also been used, with less favorable results (7, 145). The long-term prognosis is clearly guarded in epileptic patients with SCGE or evidence of EEG focalization. However, in elderly patients, the identification and correction of probable triggering factors may be sufficient to prevent recurrence (173). This work was supported in part by a grant from the Programme Hospitalier de Recherche Clinique, CHRU Nice, the French Ministry of Health. The authors thank Eva Paquet and Roula Vrentzos for preparing the English translation of the text.
REFERENCES 1. Agathonikou, A., C. P. Panayiotopoulos, S. Giannakodimos, and M. Koutroumanidis. Typical absence status in adults: Diagnostic and syndromic considerations. Epilepsia 1998;39: 1265–1276. 2. Aguglia, U., A. Gambardella, R. L. Oliveri, G. De Sarro, M. Zappia, and A. Quattrone. De novo epileptic confusional status in a patient with cobalamin deficiency. Metab. Brain Dis. 1995;10:233–238. 3. Aguglia, U., P. Tinuper, and G. Farnarier. État confusionnel critique à point de départ frontal chez le sujet âgé. Rev. EEG Neurophysiol. 1983;13:174–179. 4. Ahmed, I., R. Pepple, and R. P. Jones. Absence status epilepticus resulting from metrizamide and Omnipaque myelography. Clin. Electroencephalogr. 1988;19:37–42. 5. Amand, G. États d’absence et états confusionnels prolongés au delà de 60 ans. Rev. EEG Neurophysiol. 1971;13:174–179. 6. Amit, R., M. Rottem, and S. Yatziv. Termination of absence status and suppression of inter-ictal bursts with phenytoin: Case report. Clin. Electroencephalogr. 1986;17:173–175. 7. Andermann, F., and J. P. Robb. Absence status: A reappraisal following review of thirty-eight patients. Epilepsia 1972;13: 177–187. 8. Assael, M. I. Petit mal status without impairment of consciousness. Dis. Nerv. Syst. 1972;33:526–528. 9. Bancaud, J., and J. Talairach. Clinical semiology of frontal lobe seizures. In P. Chauvel, A. V. Delgado-Escueta, E. Halgren, and J. Bancaud, eds. Frontal Lobe Seizures and Epilepsy. Adv. Neurol. 1992;57:3–58.
104
10. Bancaud, J., J. Talairach, P. Morel, et al. “Generalized” epileptic seizures elicited by electrical stimulation of the frontal lobe in man. Electroencephalogr. Clin. Neurophysiol. 1974;37:275–282. 11. Bateman, D. E., J. C. O’Grady, C. J. Willey, B. P. Longley, and D. D. Barwick. De novo minor status epilepticus of late onset presenting as stupor. BMJ 1983;287:1673–1674. 12. Bauer, G., F. Aichner, and U. Mayr. Nonconvulsive status epilepticus following generalized tonic-clonic seizures. Eur. Neurol. 1982;21:411–419. 13. Beaumanoir, A., G. Foletti, M. Magistris, and D. Volanschi. Status epilepticus in the Lennox-Gastaut syndrome. In E. Niedermeyer, and R. Degen, eds. The Lennox-Gastaut Syndrome. New York: Alan R. Liss, 1988:283–299. 14. Beaumanoir, A., P. Jenny, and M. Jekiel. Étude de quatre “petit mal status” post-partum. Rev. EEG Neurophysiol. 1980; 10:381–385. 15. Benbadis, S. R., W. O. Tatum, IV, A. R. Towne, E. J. Waterhouse, and L. Garnett. Prevalence of nonconvulsive status epilepticus in comatose patients. Neurology 2000;55: 1421–1423. 16. Bendiksen, A., and L. M. Larsen. Convulsions, ataxia and hallucinations following propofol. Acta Anaesthesiol. Scand. 1998;42:739–741. 17. Bendix, T. Petit mal status. Electroencephalogr. Clin. Neurophysiol. 1964;17:210–211. 18. Berkovic, S. F., F. Andermann, E. Andermann, and P. Gloor. Concepts of absence epilepsies: Discrete syndromes or biological continuum? Neurology 1987;37:993–1000. 19. Berkovic, S. F., F. Andermann, M. Aubé, R. M. Rémillard, and P. Gloor. Nonconvulsive confusional frontal status. Epilepsia 1985;26:529. 20. Berkovic, S. F., F. Andermann, A. Guberman, D. Hipola, and P. F. Bladin. Valproate prevents the recurrence of absence status. Neurology. 1989;39:1294–1297. 21. Berkovic, S. F., and P. F. Bladin. Absence status in adults. Clin. Exp. Neurol. 1982;19:198–207. 22. Bilgic, B., B. Baykan, C. Gurses, and A. Gokyigit. Perioral myoclonia with absence seizures: A rare epileptic syndrome. Epileptic Disord. 2001;3:23–27. 23. Biton, V., J. R. Gates, and L. de Padua Sussman. Prolonged postictal encephalopathy. Neurology 1990;40:963–966. 24. Bornstein, M., D. Coddon, and S. Song. Prolonged alterations in behavior associated with a continuous EEG (spike and dome) abnormality. Neurology 1956;6:444–448. 25. Boudin, G., J. Barbizet, and S. Masson. Étude de la dissolution de la conscience dans trois cas de petit mal avec crises prolongées. Rev. Neurol. 1958;99:483–487. 26. Bourrat, C., P. Garde, M. Boucher, and A. Fournet. États d’absence prolongés chez des patients âgés sans passé épileptique. Rev. Neurol. 1986;142:696–702. 27. Bray, R. J. Propofol infusion syndrome in children. Paediatr. Anaesth. 1998;8:491–499. 28. Brett, E. M. Minor epileptic status. J. Neurol. Sci. 1966;3:52–75. 29. Brinciotti, M., C. Mazzei, F. Galletti, and M. Matricardi. Genetic aspects of nonconvulsive status epilepticus. Eur. Neurol. 1991;31:384–387. 30. Brodtkorb, E., T. Sand, A. Kristiansen, and T. Torbergsen. Non-convulsive status epilepticus in the adult mentally retarded: Classification and role of benzodiazepines. Seizure 1993;2:115–123. 31. Callahan, D. J., and M. J. Noetzel. Prolonged absence status epilepticus associated with carbamazepine therapy, increased
:
32. 33. 34.
35.
36.
37.
38.
39.
40. 41.
42.
43.
44.
45. 46.
47.
48.
49. 50.
intracranial pressure, and transient MRI abnormalities. Neurology 1992;42:2198–2201. Cascino, G. D. Nonconvulsive status epilepticus in adults and children. Epilepsia 1993;34(Suppl. 1):S21–S28. Charcot, J. M. Clinical Lectures on the Diseases of the Nervous System (T. Savill, trans.). London: New Sydenham Society, 1889. Chez, M. G., M. S. Hammer, M. Loeffel, C. Nowinski, and B. T. Bagan. Clinical experience of three pediatric and one adult case of spike-and-wave status epilepticus treated with injectable valproic acid. J. Child Neurol. 1999;14:239–242. Coeytaux, A., A. Reverdin, P. Jallon, and A. Nahory. Nonconvulsive status epilepticus following intrathecal fluorescein injection. Acta Neurol. Scand. 1999;100:278–280. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389–399. Courjon, J., M. H. Fournier, and F. Mauguière. Les états de mal chez les épileptiques adultes suivis dans un hôpital neurologique. Rev. EEG Neurophysiol. 1984;14:175–179. Crouteau, D., M. Shevell, B. Rosenblatt, M. E. Dilenge, and F. Andermann. Treatment of absence status in the LennoxGastaut syndrome with propofol. Neurology 1998;51:315–316. D’Agostino, M. D., F. Andermann, F. Dubeau, M. Fedi, and A. Bastos. Exceptionally long absence status: Multifactorial etiology, drug interactions and complications. Epileptic Disord. 1999;1:229–232. Dalby, M. A. Epilepsy and 3-per-Second Spike and Wave Rhythms. Copenhagen: Munksgaard, 1969. DeGiorgio, C. M., C. N. Heck, A. L. Rabinowicz, P. S. Gott, T. Smith, and J. Correale. Serum neuron-specific enolase in the major subtypes of status epilepticus. Neurology. 1999;52: 746–749. Delpont, E., P. Thomas, J. Gugenheim, R. M. Chichmanian, M. H. Mahagne, G. Suisse, and C. Dolisi. Syndrome confusionnel critique au cours d’un traitement par cyclosporine. Neurophysiol. Clin. 1990;20:207–215. Dongier, S. À propos des états de mal généralisés à expression confusionnelle: Étude de la déstructuration de la conscience au cours del’état de petit mal. In H. Gastaut, J. Roger, and H. Lob, eds. Les états de mal épileptiques. Paris: Masson, 1967:10–118. Doose, H. Nonconvulsive status epilepticus